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Issues 
 
 Amyloid plaques are one of the hallmarks in the brain of Alzheimer’s disease (AD). 
These plaques are made of an aggregated peptide called amyloid-β (Aβ). Metal ions, more 
particularly Cu and Zn, are found in high amount in those plaques and have been proposed to 
play a major role in AD. Underlying processes of amyloid plaques formation and impacts of 
metal ions remain unclear. Nevertheless, evidence accumulate suggesting that Aβ peptide and 
metal ions interactions could be of paramount significance in AD. For instance, natively 
occurring Aβ sequence alterations of Aβ (truncation, mutation, etc) enhance AD and metal 
ions brain distribution correlate with amyloid plaques prone regions. This could be explained 
by the hypothesis that altered Aβ may be more toxic than native Aβ due to an aberrant 
coordination of Cu and that metal ions seem to modulate Aβ aggregation. In this context, the 
present manuscript follows these two researches axes. In the first one, named "coordination", 
we focused on the influence of Aβ sequence alterations to Cu coordination. In the second one, 
named "aggregation", we investigated the role of metal ions on the aggregation process with 
means of model peptides.  
 
 In the following chapters, we will try to reply to the following questions: 
 
Coordination 
 
- What is the coordination sphere of Cu(II) in Aβ and in its modified forms? 
- How Cu(II) coordination depends on pH ?   
- How mutations linked to early AD onset and truncations of Aβ disturb Cu(II) 
coordination?  
- How the peptide sequence alterations affect Cu(II) affinity and coordination?  
 
Aggregation 
 
- Do Cu and Zn have the same effect on aggregation? 
- How Cu and Zn modulate aggregation? 
- Is Zn-induced aggregation pH dependent? 
- Is transient Zn pool able to influence peptide aggregation? 
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 I- AD 
I. 1- Society  
Alzheimer’s disease (AD) is the major dementia (~70% of dementia are AD) which 
affected more than 35 million people worldwide. In the US, it is the sixth cause of death. As 
the disease is age-dependent (1 over 20 older than 65 year old, 1 over 5 older 85 year old), 
countries with high income and long life expectancy are more concerned. Nevertheless, 
extension of life expectancy is a phenomenon which occurs worldwide. In the coming 
decades, the number of Alzheimer’s patients from the rich countries will be largely lower than 
the ones from other countries (see Figure 1). So, Alzheimer’s disease generally considered as 
a rich people disease, is becoming an 
essential issue which need to be solved 
for the whole humanity. It is pointed 
out by the fact that dementia cost 1% of 
world’s gross product. In spite of this 
crucial importance, AD remains, so far, 
an uncured disease. 
 
Figure 1: Expected number of people with dementia from low and middle (red) or high 
(orange) income countries on the next decades (from www.alz.co.uk/research/statistics). 
I. 2- Symptoms  
a- External 
AD is characterized by a progressive lost of cognitive functions. The first noticeable 
symptom is the short-term memory loss. Then appear other disorders, difficulties to speak and 
to move. Recognition of people is also a faculty which is affected. In a later stage, the mood 
of AD patient becomes unstable. The patient may be aggressive, crying or laughing without 
reasons. At the terminal stage, patient do not show any emotions and the language is 
considerably reduced.  
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b- Internal 
Brain’s Volume 
In AD, the size of the brain is notably reduced compared to a normal brain. A highly 
affected region is the hippocampus (brain’s region related to information’s acquisition). The 
decrease of the volume is concomitant with disease’s progression. Methods used to 
investigate brain’s anomalies are Position Emission Tomography (PET), Magnetic Resonance 
Imaging (MRI) and X-ray computed tomography. Nevertheless, differences in brain activity 
or in size at early stage of disease are too weak to be effectively used for diagnoses. Definitive 
diagnosis is made post mortem by showing the presence of the two hallmarks, amyloid 
plaques and neurofibrillary tangles. 
Amyloid-plaques: aggregates of amyloid-β 
Major hallmarks of AD are amyloid plaques and they were the first internal anomaly 
discovered by Alois Alzheimer more than a century ago. These plaques are found in the 
extracellular media of AD brain, and appear firstly in most affected brain’s regions (i.e the 
hippocampus). They are constituted by aggregates of a peptide called Amyloid-β (Aβ). Aβ is 
mainly a 40 to 42 residue length peptide (see structure in annexe) issued from APP 
metabolism (see § I.4.a-Amyloid cascade). The function of Aβ is unclear. Due to its polar N-
terminal and its apolar C-terminal parts, Aβ is amphiphilic (see sequence in § I.4.e-Metal ions 
Coordination to Aβ). Its tendency to aggregate is pretty high and Aβ forms in vitro similar 
type of aggregates like those formed in vivo (amyloid plaques). The aggregates could have a 
defined 3D structure, so called amyloids, which are often identified by the use of specific dyes 
such as Thioflavin T (see structure in annexe). 
Neurofibrillary tangles: aggregates of Tau’s proteins 
Neurofibrillary tangles are the other major hallmark of AD but also appear in Pick’s 
diseases. Neurofibrillary tangles consist of aggregated intraneuronal hyper-phosphorylated 
Tau proteins.1 Tau proteins are highly expressed in neurons and their function is to stabilize 
long microtubules. Microtubules are essential to maintain the structure of the cell and to 
cellular transport. In neurones, long microtubules are required for neurotransmitter transport. 
In AD, Tau proteins are hyper-phosphorylated, which leads to incapacity to stabilize the 
microtubules. Consequently, microtubules are disrupted and the neuron becomes non-
functional.  
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c- Predisposition and Risk Factors 
Gender 
Some studies suggest that women are more prone to develop AD than men (even when 
differences in life expectancy are taken into account). An explanation could be the decrease of 
steroids hormones in women due to menopause. Clinical trials by hormones supplement and 
genetic analysis of estrogens biosynthesis linked to AD seem to confirm this hypothesis and 
suggest estrogens play an important role in AD.2
Cholesterol 
In spite of controversal studies, high level of cholesterol seems to enhance AD. It has 
been proposed that cholesterol increases Aβ concentration by promoting β-secretase at the 
expense of the α-secretase pathway (see scheme 1). Indeed, cholesterol is a membrane 
constituent and can modulate the enzymatic cleavage.3
Down’s syndrome and Gene’s mutations  
Down’s syndrome or trisomy 21 is characterized by a mental retardation, stunted 
growth and typical morphology. The APP gene is located on chromosome 21 and is 
consequently over-expressed resulting to early events of amyloid plaques formation and a 
type of AD development. Many mutations or polymorphisms on APP (precursor of Aβ), 
Presenilin (part of γ-secretase) and Apolipoprotein E (involved in clearance of Aβ)4 genes 
have been pointed out to be at the origin of early AD onset.5 These proteins are directly 
related to Aβ regulation and, as explained above, their metabolism is disrupted in AD. This in 
line with the amyloid cascade hypothesis stated below. 
I. 3- Metal ions 
a- Presence in the body 
Fe, Zn and Cu are the most common transition metal ions in the body. Nevertheless, 
their quantities are rather low. Fe and Zn contribute for 4 g and 2 g to human weight, 
respectively. Cu is less present (70 mg). Other metals such as Mo or Co are found in low trace 
amount. They are involved in metabolism as essential cofactors.  
b- Use of metals 
Metals ions are involved in many tasks in the human body. Fe is well-known as 
dioxygen carrier in red blood cells. Fe has also other roles, for instance as oxidant catalyst in 
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cytochrome P450, for electron transfer in with the Iron-Sulfur cluster in complex III or 
hydrogen peroxide regulation in Catalase. In spite of its lower quantity, Cu is crucial. It is 
typically used for its redox chemistry. Cu can activate dioxygen for diverse enzymatic 
purposes.6 Cu is involved in the respiratory chain as dioxygen reductant partner. Cu is also 
important in Fe metabolism (Ceruloplasmin) or in ROS management with Superoxide 
Dismutase (SOD). Zn is redox inactive (contrary to Cu or Fe) but can act as protein structures 
modulator or as Lewis-acid catalyst. It plays a major role in DNA transcription regulated by  
Zn finger proteins. Indeed, a secondary structure modification required for DNA interaction is 
induced by Zn coordination. Some proteases are Zn based. In those proteases, Zn destabilizes 
peptide-bond prior to the nucleophilic attack of water / hydroxide ion. 
c- Metal Homeostasis 
As explained above, metals, on one hand, are present at trace level in the body, and on 
the other hand, are essential in many pathways required for life. Those two parameters are 
absolutely vital because an overload is toxic and a lack is insufficient to maintain life’s 
chemistry. Wilson’s disease is a genetic disease which induced a mutation on an ATPase Cu 
efflux protein. The deficiency of this pump caused a Cu overload which lead to death without 
treatments. At the opposite, Menkes disease is characterized by the lack of Cu due to a 
mutation on an ATPase Cu influx. It causes severe development retardation and reduces life 
expectancy to five years. These two examples show how metals are necessary to life and how 
toxic they can be if in overload (see figure 2). So, metals homeostasis needs to be as tight as 
possible in a time and localization specific manner. 
 
Figure 2: Tight regulation of metal ions is needed to maintain life 
 
In human, brain represents 2% of the body weight, consumes 20% of dioxygen and 
contains 8% of total Cu (as pictured in figure 3). Considering those numbers and the fact that 
Cu is an efficient dioxyen activator,6 it makes sense that the brain is highly sensible to 
Reactive Oxygen Species (ROS) and oxidative stress. In AD, metal homeostasis disruption 
has been proposed as an important parameter.7  
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Figure 3: Brain’s features which make it prone to oxidative stress. 
 
I. 4- Amyloid-β peptide and Metals ions  
a- Amyloid cascade 
As explained above, Aβ peptide are found in AD brain as the main constituent in 
amyloid plaques and these amyloid plaques are a key evidence of the disease. Thus Aβ has 
been proposed to be crucial and may be involved in the aetiology of AD according to the 
amyloid cascade hypothesis (scheme 1).8
The Amyloid-β Precursor Protein (APP) is a transmembrane protein (major form has 
695 amino acids) predominantly expressed in the brain with a large extracellular N-terminal 
domain. While its function remains unclear, its metabolism is well-known. APP could be 
cleaved by two pairs of proteases, either the α and γ or the β and γ secretases. By the first pair 
of enzymes, the resulting parts of the protein are not deleterious. If APP is cleaved by the β 
and γ secretases, one of the resulting part is the Aβ peptide.9 Aβ is normally present in healthy 
brains but can accumulate and undergo “aggregation” in AD brains via a multistep process 
(see § I.4.b-Aggregation) resulting in amyloid plaques. The origins of accumulation and 
aggregation (via conformational change) in non-genetic AD are not clear. Various 
explanations have been proposed: metal ions interaction, overload of Aβ, reduction of Aβ 
degrading enzyme (such as Insulin-degrading enzyme)…10  
Few years ago, amyloid plaques were believed to be the harmful species. Now, studies 
show no direct correlation between learning deficit and amyloid plaques, suggesting other 
forms of Aβ are much more toxic.11 Aβ oligomeric species (Aβ forms between monomeric Aβ 
and amyloid plaques) are nowadays consider as the most deleterious compounds.12
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Pathways by which Aβ oligomers are toxic to neurons and can trigger AD have been 
investigated. Several deleterious interactions with neurons have been proposed without 
consensus. Aβ oligomers may destabilize neuronal membranes and increase membrane 
permeability or interact with receptors.13, 14
 
Scheme 1: Amyloid cascade pathway from APP to AD 
b- Aggregation of Aβ 
The major difference between peptides and proteins is the number of amino-acid. Due 
to this smaller number, peptides seem easier to look at compared to proteins. Here comes the 
tricky part, less amino-acids means less intermolecular interactions and thus less structured 
(or poorer 3D stability). Indeed, usually peptides are unfolded and so they have a wide range 
of possible 3D structures compared to proteins which are generally well-folded. This intrinsic 
structural instability gives to peptide tendency to seek for a lower free enthalpy (see figure 2 
in ref 15). Here begins the aggregation process. 
There are two kinds of aggregates, amorphous and ordered (or amyloids). Specific 
dyes can be used to distinguish between amorphous and amyloids.16 The major difference 
between those two types of aggregates is the well-defined 3D structures in case of amyloids. 
In AD, amyloid plaques are made of fibrils amyloids. Amyloid fibrils are constituted 
of Aβ peptides with a high content of β-sheets (see figure 1 in ref 15). Aβ and many of its 
derivatives could form amyloid fibrils under certain conditions. The rate, the amount and the 
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type of aggregates are highly dependent of various of parameters (pH, peptide sequence, 
concentration, metal ions…).  
The mechanism of amyloid fibrils formation occurs in three basic steps: nucleation, 
elongation and termination (see figure 4).17 The first step of the process, nucleation, is the rate 
limiting step. Indeed, this step needs several peptides in specific assembly modes. When the 
number and / or the shape of the nucleus are reached, elongation phase takes place. 
Elongation is similar to a non-covalent polymerisation. Monomeric peptides from the bulk are 
taken-up to extend the fibril. When the monomeric peptides concentration drops under a 
threshold, elongation stops. The quantity of fibrils remains stable, this is the plateau. The 
shape of amyloid formation kinetic is a sigmoid. Thus, fibrils aggregation can be fitted by 
mathematical model. Values found by the fitting equation give access to kinetic parameters 
(such as half-time) and allow comparing kinetic measurements.18
 
Figure 4: Formation of Amyloid fibrils: a three-step process. 
 
c- Reactive Oxygen Species 
Since O2 is essential for many living organisms, these biological systems are exposed  
to Reactive Oxygen Species (ROS), a native byproduct of O2 metabolism. In the presence of 
reducing agents, ROS can be produced via reduction of dioxygen. ROS include among others 
O2▪-, H2O2 and ▪OH. These molecules are reactive (or precursor of reactive molecules) that 
react with cell components such DNA, proteins or cell membranes. Modifications induced by 
ROS are harmful to life (damages, proteins inactivation or lipids peroxydation). In order to 
prevent such events, cell has mainly several protecting mechanisms, including the two 
enzymes, SOD and catalase. Increased ROS production leading to oxidative stress seems to 
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occur in AD. The reasons are ill defined, but for instance the modulation of the expression 
level of SOD and catalase may occurs in AD.19
d- Metals ions and Revised Amyloid Cascade 
The hypothesis of implication of metal ions in AD is based on numerous facts. Firstly, 
Cu, Zn and Fe are highly accumulated in amyloid plaques.20, 21 Secondly, AD brains show a 
dyshomeostasis of metal ions.22,23 Also, brain’s Zn distribution match with regions most prone 
to amyloid deposition (i.e hippocampus, amygdale and parietal lobe).24 Thirdly, a large body 
of in vitro and in vivo experimental evidence supports metal ions implication in AD. Indeed, 
in vitro studies show that Cu and Zn can modulate Aβ aggregation.25, 26 Chelators increase the 
resolubilisation of Aβ from isolated human amyloid plaques. In vivo, clioquinol chelator can 
dissolve amyloid deposit in transgenic mice’s brains,27 by metal chelation.28 Zn transport 
knock-out transgenic mice show markedly reduced amyloid deposit.29 Those examples 
demonstrate the importance of Cu and Zn in AD .  
Metal ions, especially Cu, can be pretty efficient to catalyze ROS formation (see § 
I.3.b-Use of metal). This depends on its environment, i.e. the coordination chemistry. “Free” 
Cu or loosely bound Cu are efficient in ROS production. In contrast most Cu-proteins like 
cytochrome c oxidase are designed to minimize ROS production. Biological reductants react 
very poorly with dioxygen. In presence of Cu(II) and biological reductant (Glutathione, 
Ascorbate…), Cu(II) is reduced to Cu(I) and rapidly passes on its electron to dioxygen in 
solution to form superoxide (see scheme 2). This cycle goes on as long as the quantity of 
reductant is sufficient. The reaction produces also hydrogen peroxide and hydroxyl radical.  
 
Scheme 2 : Cu catalysed ROS production adapted from ref 24 
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Oxidative stress present reported in AD could be explained by metal induced ROS 
production.30 In this way, lossely bound Cu seems to correlate with AD’s brain oxidative 
damages7 and cell experiments have shown the toxicity of Aβ-Cu under reductive condition.31 
Moreover, transgenic mice with reduced level of MnSOD display more amyloid plaques and 
higher level of Aβ.32 This indicates that oxidative damages can accentuate AD hallmarks, and 
thus ROS may be considered as a vicious circle in AD. 
Overall, metal ions and Aβ are two actors of AD. Aβ can bind these metal ions and it 
has been proposed that Aβ-metal ions interactions could be a key event in AD. Amyloid 
cascade (see above scheme 1) shows the pathway from Aβ monomer to amyloid plaques. A 
trigger of this event may be metal ions coordination to Aβ. Another point is that Aβ-Cu 
complexes can produce ROS in presence of physiological reductant such as ascorbate. Aβ-
metal mediated ROS production could explain oxidative damages found in AD brain and may 
be a central event of the disease. Thus, studies of Aβ-metal ions interactions are of paramount 
interest to explain both Aβ-aggregation and ROS production induced by metal ions. 
e- Metal ions Coordination to Aβ 
Aβ Sequence 
As explained above, metal ions coordination to Aβ may help to understand molecular 
process linked to AD. Below, the figure 5 shows the sequence of Aβ1-42 (see also Aβ1-40 
developed sequence in annexe), two parts can be clearly distinguished: in one side, the N-
terminal part, polar and charged with several potential metals ligands; in the other side, the C-
terminal part, largely hydrophobic. Because of this second part, the peptide is only soluble at 
very low concentrations (i.e. µM). This poor solubility is at the origin of aggregation but 
precludes the application of many spectroscopies, that require higher concentration in the 
soluble state. By looking at Figure 5, it is relatively clear that main binding sites of metal ions 
are located on the Aβ1-16 part rather than on the Aβ17-42 part. Therefore, in order to 
investigate metal coordination to Aβ at higher concentration, Aβ1-16 can be used due to its 
much higher solubility. However, Aβ1-16 does not form amyloid type aggregates, but it is 
clearly a valuable model for the soluble monomeric metal-Aβ1-40/42.33
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Figure 5a: Primary sequence of Aβ1-42 emphasizing the carboxylic acid functions (red), 
amine and imidazole (blue) and hydrophobic residues (bold). 
 
 
 
 
Figure 5b: Developed sequence of Aβ1-16 with the corresponding letter code amino-acid 
residues.  
Fe(II)-Aβ 
The most common oxidation states of Fe in body are Fe(III) and Fe(II). Nevertheless, 
the presence of the complex Aβ-Fe(III) is unlikely. The affinity of Aβ for Fe(III) is too low to 
compete with the formation of Fe(OH)3 at physiological pH (pKs ~ 38).34 An in vitro study 
conducts under strictly anaerobic conditions has shown that Fe(II) interact with Aβ1-16 and 
Aβ1-40.34 It is worth noting that Met35 often suggested as a potential ligand was not involved 
in coordination. Based on NMR data, Bousejra-El-Garah et al. proposed the binding site 
depicted in Figure 6.  
 
Figure 6: Proposed coordination of Fe(II) to Aβ1-16/40 from ref 27 
 
Zn(II)-Aβ 
Zn ion only exists as Zn(II). Its electronic structure (d10) precludes many spectroscopic 
studies (EPR, CD or UV-vis). The Zn-Aβ coordination site has been studied by NMR (peptide 
chemical shift induced by Zn coordination) and by EXAFS.35,36 Measurements of Zn(II) 
affinity on Aβ fragment by Isothermal Calorymetry (ITC) is also useful to recognize residues 
involved in Zn coordination.37 In spite of a real consensus, several residues have been pointed 
out: Asp1 (N-terminal amine or side chain), Glu11 and His6-13-14.38 Based on preliminary 
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results we obtained by NMR and XAS on Aβ and several mutants, we proposed the 
coordination shown below in Figure 7. Ligands proposed are His6; His13; Glu11 and Asp1 
with COO- and NH2 depending on the pH. 
 
 
Figure 7: Proposed coordination of Zn(II) to Aβ 
Cu(II)-Aβ 
Cu(II) coordination to Aβ has been widely studied by many techniques.39 Recently, a 
consensus has been found by advanced EPR and NMR spectroscopic methods.40, 41 Aβ-Cu(II) 
coordination is pH dependent and display two kinds of coordination (species) around 
physiological pH (Figure 8). Interestingly, Aβ from murine show three mutations compared to 
human Aβ, R5G-Y10F-H13R, and do not develop AD. Interestingly, Cu coordination greatly 
differs between human and murin (see Figure 7). This may be one of the reasons why mice 
are preserved from AD.42
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Figure 8: Cu(II) coordination to human and murin Aβ peptides and their pH dependence. 
 
Cu(I)-Aβ 
Like Zn(II), the electronic structure of Cu(I) is d10. Its coordination to Aβ have been 
investigated by 1H-NMR and by XANES.43 Those spectroscopic data suggest that Cu(I) is 
coordinated to Aβ via two His in a diagonal geometry. The binding involves all 3 histidines, 
which are in equilibrium with the preferential His diad of His13 and His14 as depicted in 
Figure 8.  
 
 
Figure 9 : Proposed Cu(I) coordination to Aβ adapted from ref 43. 
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Abstract 
The mechanistic understanding of peptides self-assembly mediated by metallic ions into 
amyloid or other structures has gained a lot of interest, mainly due to their importance in 
several neurodegenerative diseases. The use of short, easy-to-handle peptides has contributed 
to a better understanding of structure and mechanisms that are also relevant for the native and 
longer peptides involved in the neurodegenerative diseases. Here, we review the results 
obtained with such “model systems” with the aim to identify and discuss fundamental 
parameters determining the self-aggregation with a special focus on the role of metallic ions 
in this process.  
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I) General principles of amyloid formation 
I.1) Importance of the metal-peptide interaction in aggregation: 
 Peptide/protein aggregation occurs in many diseases, especially neurodegenerative 
diseases. For instance, amyloid-β peptides (Aβ), prion and α-synuclein proteins are involved 
in Alzheimer's disease (AD), Prion diseases and Parkinson's disease, respectively. Metallic 
ions are found in high concentration in the deposits of amyloidogenic peptides/proteins linked 
to these diseases and a large body of evidence suggests that metallic ions (mostly Cu, Zn and 
Fe) are involved in these diseases via various processes, including modification of the 
aggregation pathway.1-4 This has led to numerous in vitro studies in order to delineate the 
effects of metallic ions on the aggregation of these peptides (for recent reviews see e.g. 4-7). 
 More recently, aggregation of peptides into amyloid fibrils has also stimulated 
investigations in the field of material science, as a scaffold of fibrils with embedded metallic 
ions.8, 9 
 
I.2) Interest in short “model” peptides:  
 It is clear that for material science the use of short, and thus cheaper and easy-to-
handle peptides is an advantage. Short model peptides are also widely studied with the aim to 
learn about basic and general mechanisms on peptides aggregation. Also here, shorter 
peptides can be an advantage for a better reproducibility and accumulation of structural and 
mechanistic data (see for instance, 8-10). This holds also for the interaction of a metallic ions 
with amyloidogenic peptides, which is the focus of the present review. Thus the review aims 
to reveal fundamental and general principles gained on short peptides regarding the impact of 
transition metallic ions (mostly Cu(II) and Zn(II)) on peptides aggregation  into amyloids. 
 
I.3) Amyloid versus non-amyloid aggregates:  
 Proteins or peptides can aggregate into different structures, going from completely 
unordered amorphous aggregates up to crystalline forms, which are highly ordered. Amyloids 
are ordered structures or at least have an ordered part, but are not crystalline. They form 
normally fibers/fibrils of about 10 nm diameter and can have a length up to several hundreds 
of µm. Therefore they are also often called amyloid fibrils. Amyloids consist of β-sheets that 
pile up to some extent.11 This requires two principal interactions: i) one that makes the 
classical β-sheet, i.e. hydrogen bonds between the backbone amide groups. As this interaction 
is between the backbones only (average distance 4.8 Å), it can be adopted by all 
peptides/proteins; ii) to pile up the β-sheets, interactions between side chains are needed that 
 
 
depend on the protein/peptide sequence. Interactions can be salt-bridges, H-bonds, and/or 
hydrophobic interactions. The average distance between the β-sheets is around 11 Å (Figure 
1). The observation of these two distances by x-ray diffraction is one of the identification 
parameters of amyloids, together with the high content of β-sheet structure that can be 
determined by FTIR, RAMAN or CD, via the interaction with specific dyes (mostly 
Thioflavin T (ThT) and congo red) and by microscopy (TEM or AFM) for fibrillar forms. 
Another, important feature of amyloids is the seeding capacity: addition of a low amount of 
preformed amyloids triggers the aggregation of monomers rapidly, as they serve as templates 
for the aggregation (see also below). 
 In contrast to that, amorphous aggregates are supposed to be unordered and do not 
show the characteristic features mentioned above. "Unordered" means here a non-regular 
organisation of the peptide or protein. However, a protein can be structured (e.g. as α-helix or 
β-sheet) and aggregated by keeping at least part of its structure. On the other hand, amyloids 
can also have a part of the peptide/protein in a non-amyloid structure, which is e.g. the case of 
amyloid-β, where only 2/3 of the peptide (C-terminal part) is structured as amyloid, and the 
N-terminus part is unstructured.11 Thus it is not always easy to recognize amyloid structures 
by electron microscopy only.  
 
 
 
 Figure 1. Top: Scheme of amyloid structure: amyloid structure can be parallel or, as shown 
here, anti-parallel β-sheet structure. Only the back-bone is shown in the first sheet. The red 
arrow indicates the direction of the backbone. The hydrogen bonds between the backbones are 
parallel to the fiber axis. The side chains are omitted for clarity but would point perpendicular 
to the paper sheet (to the front and to the back). Bottom: β-sheet turned by 90°. The side 
chains of the amino-acid residues are now shown and are above or below the plane made by 
the β-sheet structure. The same R is used here for clarity. 
 
 
  
Figure 2. Diagram showing a scheme of the folding landscape with the respective energies of 
the various possible states of peptide/protein folding. Adapted from ref. 12. 
 
I.4) Formation of amyloids:  
 To form amyloids, the monomeric peptides have to change their structure into β-sheet. 
In the case of a peptide in a random coil structure, i.e. of an unfolded peptide (Figure 2), it can 
transform directly into an amyloid1. In contrast, in a peptide/protein with a defined 3D 
structure (left part in Figure 2), it has first to unfold (at least partially) before it forms the β-
sheets of the amyloid structure. 
 In general, it is admitted that the aggregation process consists of a nucleation and an 
elongation phases (Figure 3). In this mechanism, the nuclei are the highest energetic state 
(Figure 2, right) and hence the lowest populated one. Once this state is reached, the further 
aggregation is energetically favoured (elongation phase). As the assembly from the monomer 
to the nuclei is energetically unfavoured, it is very slow and rate-determining. This is the basic 
mechanism. Extensions of this mechanism have been suggested, including (i) fragmentation, 
                                                 
1 Of course there could be other intermediates between the random coil structure and the β-sheets in the amyloid. 
E.g. Teplow and coll. showed that Aβ forms a partially alpha-helical intermediate from random coil to β-sheets. 
 
 
i.e. break-down of amyloids, which increases the number of templates for elongation, and 
hence accelerates aggregation. This has been reported to improve the description for several 
systems ;13 (ii) an additional conformational change, i.e. to formation of a nucleus involves a 
conformational change from its immediate precursor state. In this case the conformational 
change is the rate determining step, as elongation afterwards is fast.14   
Figure 3. Basic view of the aggregation process of an unstructured peptide.   
 
 Amyloid formation is concentration dependent. Below a certain concentration (called 
critical concentration) no nuclei are formed and no amyloid formation occurs.15 Above the 
critical concentration, aggregation occurs spontaneously but is often very slow due to 
formation of the nuclei (Figure 3). It can be accelerated by seeding with a preformed amyloid 
(Figure 4). 
Figure 4. Theoretical curve of the aggregation process (dotted lines), which shows the typical 
sigmoid shape, due to nucleation, elongation and termination phases. Impact of adding a seed 
 
 
(seeding experiment), i.e. adding a preformed amyloid that serves as a template for the 
addition of monomers and hence results in a immediate elongation (solid line).  
 
II) Role of transition metallic ions in peptide aggregation 
II.1) Introduction 
 Transition metal ions bind to peptides mostly through side chains of the amino-acid 
residues but backbone binding, via either carbonyl or deprotonated amide functions can also 
occur mainly in the case of Cu(II) ions. The main binding sites for Cu(II) and Zn(II) (but also 
Fe(II) and Cu(I)) are side chains of  His and Cys and the N-terminal amine. The COO- groups 
of Asp and Glu residues are also often encountered as well as the side-chain of Met. Metal 
binding to the side chains can directly interfere with the stacking between side chains (Figure 
1, bottom). Interference with the β-sheet formation is also possible, either indirectly via side-
chain binding or directly via binding to the backbone. The binding to the backbone often 
involves the N-terminus and adjacent metallacycle with backbone functional groups. Amides 
next to His are also involved, as His are a good anchor for metals.16 Conceptually, the metal 
ions can induce aggregation by bridging two peptides, by inducing a more aggregation prone 
conformation or by reducing the overall charge. In contrast, they can impede aggregation into 
amyloids by inducing or stabilizing a less aggregation prone conformation or by increasing 
the overall net charge.  
Figure 5. A, B: The metal ion bridges two peptides. In A, two metal ion binding sites are 
shared between two peptides leading to a 1:1 peptide:metal ion stoichiometry; in B  the metal 
ion binding site is shared between two peptides leading to a 1:0.5 peptide:metal ion 
stoichiometry. C: Metal ion binding leads a peptide conformation more prone to aggregation. 
 
 
 
 
 
 In order to describe the effect of metal ions on the aggregation of amyloidogenic 
peptides, the following parameters are important:  
 (i)  Where do the metal ions bind, i.e. what are their ligands?  This depends of the type 
of amino acids and of their respective position in the sequence, and in case of structured 
peptides/proteins from their spatial organisation.  
 (ii) What metal ion is considered? Different metal ions have different coordination 
chemistry (preferences in geometry and type and number of ligands).   
 (iii) The affinity of the metal ion for the peptide. This determines occupancy and is 
linked to exchange rates. 
 (iv)  Structural and overall charges changes induced by metal ion binding.  
 (v) Peptide to metal ratio.  
These parameters are discussed in more detail in the following sections. 
 
II.2) Primary Sequence as overall parameter 
 It is generally supposed that almost all peptides and proteins can adopt the amyloid 
structure. Above a certain concentration (often physiologically relevant) the amyloid structure 
becomes the most stable structure because it allows the maximal number of H-bonds between 
the backbone amides (Figure 1).17 For unstructured (random coil) peptides, the formation is 
only dependent on the length of the peptide and on the type and position of the side chains. 
For peptides with 3D structure, the unfolding has to be considered as well. The importance in 
the side chains lies in their interactions with adjacent β-sheet that can be stabilized by 
electrostatic and hydrophobic interactions. The position of the amino acids in the sequence is 
thus important to match/interact with the amino acids from the other sheet. In a simple way, 
polyArg would not adopt a very stable amyloid structure (at neutral pH) since the charged 
side chains would induce strong electrostatic repulsion. In contrast poly-Gln can form 
amyloids (e.g. in Huntington disease)18 because two neighbouring Gln side chains can form 
H-bonds. During the last years a lot of progress has been made on the identification of 
amyloidogenic peptides or stretches in protein by algorithms as well as in their design.19 
  
 In terms of metal-binding, the strongest interactions with transition metal ions 
(particularly Cu, Zn, Fe, Co, Ni,) are with side chains of  His, Cys and the N-terminal amine 
functions, as stated above. There is not much freedom for “design” concerning N-terminal 
amine, either it is there (at the same position) or not (often acetylation is used). Mostly used 
 
 
are His (see Table 1), because His are an intermediate base (in the HSAB theory) and thus it 
can bind strongly most of the transition metal ions. His are also the most important ligands in 
physiologically relevant peptides, like amyloid-β, prion protein, α-synuclein etc. Cys has 
often a stronger interaction with softer metal ions but it can be easily oxidized into disulfide 
bonds, and then the metal ion is released. In other words, experiments would have been done 
under anaerobic conditions. The other important ligands, but often of lower affinities are the 
carboxylates (Asp, Glu, C-terminus) and Met (for softer metal ions). Side chains of amino 
acids like Tyr, Ser, Lys, that are often found to bind metal ions in proteins due to a 3-D 
preorganization, but they are very rare in cases of unfolded peptide as their pKa are relatively 
high. They might only bind in absence of the stronger ligands. 
 
II.3) Secondary Structure (In)Stability. 
 In the case of random coil peptides or proteins (often the case for short peptides, but 
also for some proteins) the main parameter  to consider is where the ligands are positioned in 
the sequence, the induced structure around the metal site and the formation of amyloids (see 
above). In the case of peptides/proteins with a defined 3D-structure, formation of the 
amyloids includes a partial unfolding step. The metal ion binding can stabilize or destabilize 
the initial non-amyloid structure, and hence decrease or increase amyloid formation. For 
instance, Zn stabilizes the non-amyloid form of islet amyloid polypeptide linked to type II 
diabetes but promotes aggregation of amyloid-β.20  
 In general, the peptide/protein secondary structure could be a mixture of random coil, 
α-helix or β-sheet. The group of Koksch has established an interesting system to study this 
question. They used short model peptides that can adopt a coiled coil structure with a high α-
helical content. Thus the conversion from α-helices to β-sheets (or not) can be monitored as 
well as the interaction with Cu(II) or Zn(II). For the peptide CCM (Table 1) an immediate 
formation of β-sheet was observed, in line with fast amyloid formation.{Pagel, 2005 #442} 
The β-sheet formation was slowed down by the addition of 40% TFE (Tri-Fluoro-Ethanol), a 
known inducer/stabilizator of α-helical structures that induced a conversion from a more α-
helical structure to β-sheet. Addition of Zn(II) or Cu(II) in the presence of 40% TFE 
accelerated the conversion to β-sheet. This suggests that binding of Zn and Cu destabilized 
the α-helical structure and promoted the conversion to β-sheet and amyloid formation.21 
 
 
 
 
II.4.)   Metal Specificity 
 The metallic ions have specific coordination chemistry, i.e. preference for number and 
nature of ligands and geometry. In a very sensitive system like amyloid formation, each metal 
ion is thus expected to have a different impact (on kinetic, amount, structures of aggregates). 
Thus aggregation behaviour depends on nature, and hence, on the coordination specificity of 
the metal ion. The most studied ions, namely Cu(II) and Zn(II), are different. They differ by 
their electronic structure, Cu(II) is d9 while Zn(II) is d10. This one-electron difference is 
responsible for a main change in the coordination behaviour. Cu(II) prefers to be square 
planar (with one or two remote apical ligands) while Zn(II) is more usually tetrahedral or 
distorted pentacoordinated. Another main difference is that Cu(II) is a stronger Lewis acid 
than Zn(II). Cu(II) is strong enough to bind to backbone, as it can induce amide deprotonation 
from peptide bonds when stable metallacycle are formed with adjacent His side chain or N-
terminal amine function.16 Indeed, in all the studies published (Table 1) differences in the 
impact of these two metal ions have been reported. In general, Zn(II) is more potent in 
amyloid induction than Cu(II). The two exceptions are (i) : Zn(II) can inhibit the aggregation 
of the peptide iAPP, which is linked to type II diabetes;22 (ii): on a coiled coil peptide called 
i+7 (Table 1). The aggregation kinetics of apo- i+7 and holo-i+7 with Cu(II) was similar, but 
Zn inhibited its conversion into β-sheet. The structural reasons are not known, but it was 
proposed that α-helical structure was stabilized by Zn binding to the two His (which are close 
in the α-helical structure). Cu would bind only one His, and hence does not stabilize the α-
helical structure, but might in contrast stabilize the β-sheet.21 
 In the peptide Aβ11-28, the metal specificity has been studied in more detail, as the 
Cu(II) and Zn(II) binding sites have been determined. Cu(II) binds via the well-known 
NH2-Xxx-Xxx-His motive (ATCUN), which included two deprotonated amide ligands 
between the N-terminal amine and the His side chain leading to a very stable arrangement of 
three metallacycles. Thus the peptide wraps around Cu(II) and that disturbs the alignment  
required to form β-sheet and amyloid (see Figure 6).23 Zn(II) is not able to bind in the 
ATCUN motive, due to its lower Lewis acidity and lack of preference for the square planar 
geometry. Structural studies suggest that Zn(II) binds in between two peptides by the two 
carboxylates of Glu11 and the side chain of His14, and hence stabilizes interaction between 
peptides without disturbing too much the β-sheet alignment (see Figure 6).24  
 
 
 
Figure 6: Modulation of Cu(II) (blue circles) and Zn(II) (orange circles) on the aggregation 
of the Aβ11-28 peptide. Cu(II) decreases fibril formation due to the lowering of H-bonds 
induced by formation of the Cu-ATCUN motif at the N-term part of the peptide. 0.5 equiv. of 
Zn(II) increases fibril formation via bridging two peptides. At low pH, coordination of the 
Zn(II) is more prone to formation of β-sheet than at pH 8.5. 1 equiv. of Zn(II) also increases 
fibril formation, but to a lesser extent due to unspecific binding and induced lowering of H-
bonds.       
  
 The results obtained with the peptides Aβ13-20K16A and AcAβ13-20H14A can be 
explained in a similar manner.25, 26 In the case of Aβ13-20K16A, Cu(II) inhibited aggregation, 
in contrast to AcAβ13-20H14A, where Cu(II) enhanced aggregation. For both peptides, it was 
proposed that Cu(II) bridges two peptides but with a different coordination site. Aβ13-
20K16A binds Cu(II) by the two N-terminal His13/14 (N-terminal NH2, the deprotonated 
amide between the two His and the Nδ of the imidazole ring of His14). This might diminish 
the H-bonds number (like in the case of Cu(II)-Aβ11-28). However, for Cu(II)-Aβ13-20K16A 
one equatorial position remains free (in contrast to Cu-Aβ11-28), and could be occupied by 
the His side-chain of another peptide to form a Cu-bridged dimer. Why such a Cu(II)-bridged 
dimer of Aβ13-20K16A does not promote amyloid formation is not clear, but could be due to 
structural reasons or to the relative low affinity of the monodentate ligand.27 For Ac-Aβ13-
20H14A, the only strong Cu(II) ligand available is the side chain His13. It was hypothesized 
that formation of Cu(II)-bridged dimers is increased and hence  aggregation is favoured.25 
 
 
 
 
 
II.5) Charge changes due to metal-binding  
 The overall charge is an important parameter for aggregation, as generally aggregation 
is faster when the overall charge approaches 0. Metal ion binding can induce changes in the 
overall charge. One has to consider two points: i) the metal ion carries a charge, like +2 for 
Cu(II) and upon binding to a peptide this charge has to be added, ii) metal ions can also 
induce the release of H+ which has to be taken into account. For instance Cu(II) binding to the 
Aβ11-28 in the ATCUN motive releases about 3 protons at pH 7, and hence the overall 
change of the charge is -1. Thus the change in the overall charge due to the metal and the 
removed protons has to be taken into account for the differences between different metal ion 
like Zn and Cu.7, 24, 28, 29 However, so far no study reported the isolated impact of the change 
in charge on peptide aggregation, as one would have to ascertain that two metal ions with 
different charge bind exactly with the same coordination. 
 For short peptides in the absence of metal ions, it has been proposed that amyloid 
formation is more efficient if the net charge is close to 0 but not exactly 0.30 In line with that, 
on the system Zn-Aβ11-28, it was proposed that at net charge 0, aggregation is very fast and 
favours the formation of amorphous aggregates over fibrils. However, with time, a transition 
towards amyloids occurs. This indicates that too fast and massive aggregation will favour 
amorphous type aggregates, even when the amyloid structure is the thermodynamic more 
stable form.{Alies, 2012 #435}    
 
II.6) pH dependence: changes in charge and metal coordination 
 pH dependence of peptides/proteins is a general feature, in the presence or absence of 
metal ions. For the peptide only (apo-peptide), this is due to the change in charge of the 
peptides/proteins induced by (de)protonation of side-chains and N/C-term parts. This changes 
the overall charge. As mentioned above, the more the overall charge approaches 0, or in other 
words the closer the pH is to the pI, the faster the aggregation is. In addition, in case of a 
structured peptide/protein such protonation changes can induce structural modification, and 
hence influence the aggregation (e.g. lowering the pH destabilizes often folded proteins which 
become then more prone to aggregation into amyloids). 
 In the case of holo-peptide, on top of the change of the protonation state described 
above, one has also to consider that the metal ion coordination to peptides (but also proteins, 
although to a lesser extend) are pH dependent. For instance, it has been proposed that a 
change of Zn coordination due to pH (coordination of N-terminal amine at higher pH) is 
 
 
partially responsible for the slowdown of the amyloid formation at higher pH in case of the 
Aβ11-28 peptide (Figure 6).28   
 
II.7)  Affinity and Metal exchange 
 The apparent affinity (Ka at a given pH in a given buffer, i.e. the conditional Ka in 
presence of a competitor) of peptides/proteins has two-fold impact: i) it determines the 
occupation of the binding site, i.e. how much of the metal ion is bound to the peptide and ii) is 
related to the metal exchange, since Kd = koff/kon, where koff is the dissociation rate of the 
metal-peptide complex and kon the association rate, often considered as limited by diffusion 
process, for Cu and Zn peptide complex.31  
 Occupation: Dissociation constants of Cu(II) and Zn(II) for peptide cover several 
order of magnitude, with Kdcond from fM (Cu(II)-ATCUN motive 27) to µM  (typical value for 
Zn-Aβ,32). Peptides without His, Cys and N-terminal amine might have a much weaker 
affinity.33 Generally, the affinity follows the Irving Williams series, and hence Cu(II) has a 
higher affinity than Zn(II) for peptides. At typical µM concentration of peptide with apparent 
Kd in the µM range leads to a substantial fraction of unbound metal ion. This is the case for 
most of the peptides studied when bound to Zn(II), but to a much lesser extent when bound to 
Cu(II) (Table 1).  
 Affinity between monomeric and aggregated form: Does metal affinity to peptide 
differ between monomeric and aggregated forms ? In a recent study,34 it has been shown for a 
specific peptide that affinity for Zn(II) was much higher with a peptide pool under β-sheet 
conformation. Indeed, in this peptide β-sheet formation allows to create a new Zn(II) binding 
site (due to vicinity of  two His). Thus, metal ion affinity may be modified by the aggregation 
process. Also, Kozin et al. measure Zn(II) affinity to several Aβ portion by ITC and find that 
a shorter portion of a peptide could have better affinity than the peptide itself. It was 
rationalized by the fact salt bridge may involved important coordinating amino-residue side 
chain (such as glutamate or aspartate) which are not available to coordinate Zn in the full-
length peptide but available in the shorter version of the peptide.35 Nevertheless, for the full-
length Aβ peptide, it seems not to be  the case, since the affinity of Cu or Zn to peptide Aβ  
remains on the same order of magnitude in monomeric and aggregated forms.36, 37 
 Exchange: In general, binding of Cu(II) and Zn(II) to unstructured peptides is very fast 
and often diffusion controlled (~10-9 M-1 s-1).31 As a consequence, the koff is also relatively 
fast, e.g. in the second to sub-second region for an apparent Kd  in the nM to the µM region. 
In other words, for all the Zn-peptides studied and most of the Cu(II)-peptides (an exception 
 
 
is the ATCUN motive) the metal bonds are labile and the exchange is quite fast, at least faster 
than the aggregation time scale and could hence affect the aggregation.   
 In line with this, in a very recent work,24 we have shown that substoichiometric 
amounts of Zn(II) dramatically increase the rate of  Aβ11-28 aggregation. It was proposed 
that Zn(II) is able to rapidly initiate the aggregation by forming a dimeric species inducing 
aggregation of the entire peptide pool due to fast exchange of Zn(II) between the aggregates 
formed and the remaining monomeric peptide. In other words, a transient binding of Zn was 
enough to induce aggregation of Aβ11-28. The fact that transient, substoichiometric Zn 
binding is enough to trigger aggregation of Aβ11-28 is of importance for the Zn-Aβ 
interaction in AD, because in glutamatergic neurones Zn(II) is transiently released into the 
synaptic cleft where Aβ can be localized. This could be enough to induce aggregation or 
secondary structure modification of the extracellular Aβ. Also, Zn(II) found in senile plaques 
of AD patients may act as a labile pool of Zn(II). 
 
 
Figure 7. Substoichiometric Zn(II) triggering the Aβ11-28 aggregation. Zn(II) (red circle) 
binds to monomeric peptide and forms a transient Zn-bridged peptide dimer. This nucleates 
the aggregation. Zn(II) can leave this aggregated form and bind to other monomeric peptide to 
induce another nucleus for aggregation. The fast exchange of Zn(II) enables the formation of 
several nuclei, in contrast to the case when Zn(II) would be kinetically trapped in the 
aggregate. In the present case, Zn(II) can be considered as a catalyst of aggregation.  
 
II.8) Stoichiometry 
 The stoichiometry or the metal/peptide ratio has also a significant impact. It was 
shown to affect fibrils formation of amyloid-involved disease’s peptides.22, 38 The 
stoichiometry has been also investigated on model peptides.24, 26 Results show that Zn/peptide 
ratio modulate peptide aggregation in several ways, including kinetics, type of aggregates and 
shape of fibrils. In general, at metal/peptide ratios above 1 more amorphous type aggregates 
 
 
are formed, in line with a more unspecific binding of the second metal ions favouring 
bridging of two peptides. This is the reason why an accurate determination of the peptide 
concentration is absolutely crucial, and parameters like counter ion or water content have to 
be taken into account when concentrations are determined by weight.39 
 Below the 1:1 ratio, the complexes formed can depend on the ratio, with formation of 
1:1 or 1:2 metal:peptide complexes. Hence in the latter case, the aggregation will also 
depends on the metal:peptide ratio. This was observed for Zn-Aβ11-28 peptide. The amyloid 
formation was increased in kinetics and intensity (as determined by thioflavin T assay) for Zn 
/ Abeta11-28 ratio from 0 to 0.5, but decreased from ratio 0.5 to 1. This was explained by the 
formation of a Zn1-(Aβ11-28)2 complex that aggregated rapidly into amyloids, and further Zn 
binding yielded a Zn1-(Aβ11-28)1 that formed more amorphous aggregates (Figure 6).24 
 Difference in stoichiometry contributes to a wide range of effects seen on metal-
induced aggregation studies, but unfortunately, metal/peptide ratio is often not systematically 
varied and rigorously determined. 
 
Conclusions 
 The use of small model peptides contributed much to the fundamental understanding 
of peptide self-assembly to form amyloid or other aggregates in the past years.  
 Several key parameters were determined: 
1) Normally the binding site of flexible peptides are metal specific, i.e. Zn(II) binds 
differently than Cu(II). As a consequence, the structure is different, which has an impact on 
the self-assembly and amyloid formation.   
2) Metal ion binding to peptides has an impact on the overall charge of the complex and this 
effect is pH-dependent. 
3) Different metal to peptide stoichiometry can lead to different complexes. This can have a 
dramatic impact on the aggregation behaviour. An excess of metal ions may preferentially 
lead to unspecific amorphous aggregates.  
4) Most metal bound to peptides are labile with a rapid metal exchange between peptides. 
This can have an important impact on aggregation, as the metal ions can be considered as a 
triggering/catalytic agent. 
 What can be learned from these model systems for more physiologically relevant 
peptides or proteins? The above mentioned studies revealed general principles and determined 
important parameters in the role of metal ions in amyloid formation. These insights will help 
significantly to the better understanding of the more complex native systems.  This does not 
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mean that the more complex native systems behave exactly like the more simple shorter 
peptides discussed here. The native systems have to be studied separately as the impact of 
metal ion binding might be different for each peptide/proteins, but the principles and 
parameters discussed here will be very helpful tools for the more complicated systems. 
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La maladie d’Alzheimer (MA) est caractérisée entre autres par la présence de plaques 
amyloïdes retrouvées dans le cerveau des patients. Elles sont constituées d’agrégats de 
peptides Aβ dans lesquels est retrouvée une forte concentration d’ions Cu et Zn. Les ions 
métalliques peuvent être placés au cœur de la MA via la modulation de l’agrégation du 
peptide Aβ et/ou la production de d’espèces réactive de l’oxygène ROS (O2▪- ; H2O2 ; HO▪) 
délétères pour les neurones.1,2,3 Il existe des formes génétiques de la MA, dans lesquelles la 
maladie se déclenche précocement. Certaines d’entre elles présentent des mutations sur le 
gène de l’APP (Amyloid Precusor Protein) conduisant à différents mutants du peptide Aβ tels 
que H6R-Aβ ou D7N-Aβ .4  
Récemment, une autre modification du Aβ a été découverte. Il s’agit de formes 
tronquées sur la partie N-terminale et commençant, soit par le glutamate 3 (Aβ3), soit par la 
forme pyroglutamate correspondante (Aβp3). Ces peptides sont particulièrement intéressants. 
D’une part, ils sont retrouvés en forte proportion in vivo (représentant jusqu’à 25% du contenu 
en peptide Aβ des plaques).5, 6 D’autre part, leur présence semble promouvoir la maladie.7 On 
peut envisager l’hypothèse suivante pour expliquer la toxicité accrue de ces formes modifiées. 
Il est possible qu’une coordination différente des ions Cu à ces peptides entrainent la 
formation de plus de ROS ou/et conduisent à une agrégation des peptides plus néfaste pour les 
neurones. 
La coordination du Cu(II) diffère-t-elle entre le peptide Aβ complet et ses formes 
modifiées considérées comme plus délétères ? Afin de répondre à cette question, nous nous 
sommes intéressés à la coordination du Cu(II) à ces différents peptides. 
 
II- Coordination du Cu aux différentes formes du peptide Aβ 
II. 1- Introduction 
a- Coordination de [Cu(II)-Aβ] 
Après de nombreuses études et controverses, la coordination ou plutôt les modes de 
coordination du Cu(II) sur Aβ semble aujourd’hui bien établie.4 En effet, le peptide Aβ1-16, 
tronqué en position C-terminale (modèle du Aβ1-40/42 utilisé pour étudier la coordination du 
Cu, en raison de sa plus grande solubilité) présente deux types de coordination (notés 
composants I et II) autour du pH physiologique (i.e. pH 7.4). La géométrie du complexe est 
plan carré, néanmoins la possibilité d’un ligand apical COO- (ou molécule d'eau) n’est pas 
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exclue. Dans le plan équatorial du composant I, le Cu(II) est lié par l'amine terminale de 
l'Asp1, la fonction carbonyle adjacente de la liaison peptidique Asp1-Ala2, le noyau 
imidazole de l'His6 et de l'His13 ou de l'His14 en équilibre. Dans le composant II, la 
déprotonation de la liaison peptidique Asp1-Ala2 entraine la coordination de la fonction 
amide correspondante, de la fonction carbonyle adjacent (Ala2-Glu3) et la décoordination 
d'un des deux noyaux imidazole d'une His (Schéma 1). Ces modes de coordinations ont été 
établis par différentes spectroscopies: DC, XAS, RMN,8 et RPE pulsée couplée à l'utilisation 
de peptides marqués isotopiquement.9 
Plus récemment, nous avons montré que le complexe Cu(II)-Aβ16 présente d’autres 
espèces (notées III, IV) à des pH plus élevés. Ces espèces (III, IV) correspondent à la 
déprotonation d’un NH amide (espèce III) puis de deux amides (espèce IV) supplémentaire. 
Ainsi, dans l’espèce III, le Cu(II) est lié par l'amine terminale, 2 fonctions amides déprotonées 
(des liaisons Asp1-Ala2 et Ala2-Glu3) et un noyau imidazole d'His. Dans l’espèce IV, le 
Cu(II) est lié par l'amine terminale, 3 fonctions amides déprotonées (des liaisons Asp1-Ala2, 
Ala2-Glu3 et Glu3-Phe4). Les pKa correspondant aux transitions I/II, II/III, III/IV sont de 7,8 
; 9,3 ; 10,1, respectivement (voir schéma 1 ci-dessous).  
 
 
Schéma 1 : Modes de coordination du Cu(II) par le peptide Aβ1-16 en fonction du pH  
b- Coordination de [Cu(II)-AcAβ] 
Dans le cas du [Cu(II)-AcAβ1-16], où AcAβ1-16 correspond au peptide Aβ1-16 dans 
lequel l'amine terminale a été acétylée, nous avons montré que la coordination du Cu(II) 
diffère de celle du Aβ1-16. En effet, l’acétylation de l’amine  empêche sa coordination. La 
coordination du Cu(II) dans le complexe Cu-AcAβ1-16 dépend aussi du pH et présente 
différentes espèces en fonction du pH, notées II’, III’, IV’. La coordination de Cu(II) dans ces 
espèces implique respectivement une, deux et trois fonctions amides déprotonées. Le plan de 
coordination équatorial des ions Cu(II) est complété par des noyaux imidazole d'His et/ou des 
fonctions CO de liaisons peptidiques. 
 24
Dès lors, on peut se demander : quel impact ont les modifications annoncées dans 
l’introduction sur la coordination du Cu(II) ? 
c- Séquence des formes tronquées en N-terminal (Aβ3-16 & p3-16)  
Ci-dessous, les séquences des peptides Aβ1-42, Aβ1-16, Aβ3-16, Aβp3-16 et 
AcAβ1-16 sont présentées. On remarque que les peptides Aβ1-16 et Aβ3-16 possèdent les 
mêmes ligands : l'amine terminale, 3 groupes imidazoles des residus His, 4 (resp. 3) fonctions 
carboxylate des residus Asp et Glu.  Au contraire, l'amine terminale n’est plus disponible sur 
le peptide Aβp3-16 dû à la formation du cycle pyroglutamate qui bloque également la 
fonction COO- du glutamate. Le peptide AcAβ1-16, lui non plus, ne dispose pas de l'amine 
terminale et sera donc utilisé comme contrôle de l’influence du NH2 terminale. 
 
Aβ1-42   NH2-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-COOH 
 
Aβ1-16            NH2-DAEFRHDSGYEVHHQK-COOH 
Aβ3-16                  NH2-EFRHDSGYEVHHQK-COOH 
Aβp3-16                       pEFRHDSGYEVHHQK-COOH 
AcAβ1-16   AcNH-DAEFRHDSGYEVHHQK-COOH 
Figure 1 : Séquences primaires des peptides Aβ1-42, Aβ1-16, Aβ3-16, Aβp3-16 et 
AcAβ1-16 (utilisant le code à une lettre), qui souligne leur origine commune, les ligands 
potentiels et les chaines latérales hydrophobes. Ligands azotés en bleu ; ligands oxygénés en 
rouge ;  chaines latérales hydrophobes en gras. 
 
II. 2- Méthodes et Techniques 
a- Dichroïsme Circulaire (DC) 
Le DC est une spectroscopie optique qui nécessite deux conditions pour être utilisée : 
de l’absorbance et de la chiralité. Cette technique présente l’avantage majeur de pouvoir 
sonder les modifications structurales au-delà de la première sphère de coordination 
(contrairement à la RPE). De plus, elle est généralement plus informative qu’un spectre 
UV-vis, car le signal peut être positif ou négatif (d’où une meilleure résolution des bandes 
d’absorbance).10   
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b- Résonance Paramagnétique Electronique (RPE) 
La RPE est une technique de choix pour étudier la première sphère de coordination du 
Cu(II), de configuration électronqiue d9. En effet, l’électron célibataire est sensible à la nature 
des ligands équatoriaux du Cu(II). Les paramètres RPE reflètent la nature des atomes 
coordinés et la géométrie du complexe. Dans notre cas, la RPE permet le suivi des espèces en 
fonction du pH de façon évidente.    
c- Résonance Magnétique Nucléaire (RMN) 13C et 1H 
La RMN  permet de visualiser les atomes impliqués dans la coordination du Cu(II). Le 
Cu(II), paramagnétique, sera utilisé en quantité sub-stœchiométrique afin d’élargir 
spécifiquement le signal des atomes impliqués dans sa coordination. La RMN 13C est 
particulièrement efficace pour les sonder la déprotonation d’un amide, notamment via la perte 
des signaux du Cα et CO adjacents. Le Cu(I) étant diamagnétique, les signaux sont déplacés 
par sa présence. Dans ce cas, la RMN 1H est suffisante pour étudier la coordination du Cu(I) 
aux peptides. La difficulté majeure, d'un point de vue expérimental, est de garder le Cu sous 
sa forme réduite. 
 
II. 3- Etude comparative et structurale 
a- DC  
La comparaison des spectres DC des complexes Cu(II)-Aβ1-16, Cu(II)-Aβ3-16, 
Cu(II)-Ac-Aβ1-16 et Cu(II)-Aβp3-16 en fonction du pH  est intéressante. Dans la figure 2, on 
remarque de grandes similitudes entre les signatures spectroscopiques des complexes 
Cu(II)-Aβ3-16 et Cu(II)-Aβ1-16 ainsi qu’entre celles des complexes Cu(II)-Aβp3-16 et 
Cu(II)-AcAβ1-16. Dans le panneau A (Cu(II)-Aβ3-16 et Cu(II)-Aβ1-16), la forme des bandes 
d-d et de la bande négative à ~280nm correspondant à la transition LMCT –NH2 est 
globalement la même. Néanmoins, on note quelques différences, une bande de faible intensité 
positive à ~650nm dans le cas du complexe Cu(II)-Aβ1-16 qui n’est pas présente chez le 
Cu(II)-Aβ3-16. De plus, sur le spectre du complexe Cu(II)-Aβ3-16, on observe un 
déplacement de la transition à 325nm (vers 315nm) correspondant à une bande de transfert de 
charge N- vers Cu(II), et de la transition à 285nm (vers 275nm) correspondant à une bande de 
transfert de charge NH2 vers Cu(II). Ce déplacement n’est pas présent sur le spectre du 
complexe Cu(II)-Aβ1-16. Dans le panneau B, on remarque que les signatures des complexes 
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Cu(II)-Aβp3-16 et Cu(II)-Ac-Aβ1-16 sont hautement identiques. Par ailleurs, comme attendu, 
la transition de transfert de charge NH2 vers Cu(II) n'est pas détectée. Cette très grande 
ressemblance entre les signatures des complexes Cu(II)-Ac-Aβ1-16 et Cu(II)-Aβp3-16 et des 
complexes Cu(II)-Aβ1-16 et Cu(II)-Aβ3-16, confirme l'implication de l’amine N-terminale  
dans la coordination du Cu aux peptides Aβ1-16 et Aβ3-16. 
 
 
Figure 2 : Spectres de DC de Cu(II)-Aβ3-16 (panneau A) et Cu-Aβp3-16 (panneau B) 
en fonction du pH (d’acide bleu à basique rouge). En cartouche, les spectres DC de Cu(II)-
Aβ1-16 (panneau A) et de Cu(II)-Ac-Aβ1-16 (panneau B). Conditions : [Cu-peptide] = 
0.45mM ; ℓ=1cm ; T = 25°C. 
 
Ainsi, on peut donc d’ores et déjà observer deux groupes de complexes. Le premier, 
dans lequel l’amine N-terminale est liée au Cu(II) (Cu(II)-Aβ1-16 et Cu(II)-Aβ3-16) et le 
second, dans lequel l’amine N-terminale étant bloquée, elle ne peut intervenir dans la 
complexation du Cu(II) (Cu(II)-Ac-Aβ1-16 et Cu(II)-Aβ3-16). 
b- RPE 
La figure 3 présente les complexes Cu(II)-peptide à différents pH organisés selon les 
groupes définis ci-dessus : l’un avec les peptides Aβ1-16 et Aβ3-16 (amine terminale libre) 
sur le panneau A, l’autre avec les peptides AcAβ1-16 et Aβp3-16 (amine terminale bloquée) 
sur le panneau B.  
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Figure 3 : Spectre RPE des complexes Cu(II)-peptides à une selection de pH. Panneau 
A, Cu(II)-Aβ1-16 (noir) et Cu(II)-Aβ3-16 (gris). Panneau B, Cu(II)- AcAβ1-16 (noir) et 
Cu(II)-Aβp3-16 (gris). [Cu(peptide] = 1 mM, T = 110 K, v = 9.5 GHz. 
 
Sur le panneau A, on constate que les complexes Cu(II)-Aβ3-16 et Cu(II)-Aβ1-16 
présentent les mêmes signatures spectroscopiques, mais à des pH différents. En particulier, 
l’espèce III est nettement plus visible sur le spectre du complexe Cu(II)-Aβ3-16 que sur celui 
de Cu(II)-Aβ1-16 (données non montrées). Cela est dû à sa présence sur une grande plage de 
pH (voir tableau 1). Le pKa de  I / II est vue à ~ pH 7,0 dans le cas du peptide Aβ3-16 et à 
~ pH 7,8 ans le cas du peptide Aβ1-16 (voir le panneau A de la Figure 3). 
Dans le panneau B, à l’instar du DC, les spectres RPE des complexes Cu(II)-AcAβ1-
16 et Cu(II)-Aβp3-16 sont hautement semblables. En effet, les différents modes de 
coordination du Cu(II) sont observés pour des pH très proches (voir tableau 1). Le DC et la 
RPE suggère donc que les modes de coordination du Cu(II) par les peptides Aβp3-16 et 
AcAβ1-16 sont similaires, tout comme leur dépendance en fonction du pH. 
Il faut noter ici que l’utilisation de la RPE, comme unique technique, et sur une plage 
de pH réduite  peut conduire à des erreurs d’interprétation. En effet, les espèces II’ et III’ 
possèdent des paramètres RPE très proches des espèces I et II, respectivement. Cette erreur 
fut commise dans les travaux de Drew et al., où il fut conclu que la coordination du Cu(II) aux 
peptides Aβ3-16 et Aβp3-16 était semblable (puisque les complexes Cu(II)-AcAβ1-16 et 
Cu(II)-Aβp3-16 présentent les mêmes signatures RPE) et par conséquent que la fonction NH2 
terminale n’était pas impliquée dans la coordination du Cu(II) par les deux peptides.11 
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Peptide pKa I / II pKa II / III pKa III / IV 
Aβ1-16 7.8 9.3 10.1 
Aβ3-16 7.0 7.5 10.0 
 pKa I’ / II’ pKa II’ / III’ pKa III’ / IV’ 
Aβp3-16 5.3 7.6 8.8 
AcAβ1-16 5.2 7.5 8.7 
Tableau 1 : Valeurs des pKa des complexes  Cu(II)-Aβ1-16,  Cu(II)-Aβ3-16,  Cu(II)-
Aβp3-16 et  Cu(II)-AcAβ1-16 basées sur la spéciation des signatures RPE des différentes 
espèces en fonction du pH 
c- RMN  13C  
Afin d’aller plus loin dans l’exploration de la sphère de coordination du Cu(II), et en 
particulier pour identifier les résidus impliqués dans la coordination du Cu(II), nous avons 
utilisé la RMN du 13C en absence et en présence de Cu(II). 
Cu(II)-Aβ3-16 
 
 
Figure 4 : RMN 13C centré sur les Cα  du peptide Aβ3-16 à pH 6,0 (panneau A) et à 
pH 8,6 (panneau B) en absence (noir) et en présence (gris) de Cu(II). Les lignes en pointillés 
indiquent les résidus affectés par l’ajout de Cu(II). Condition : [Aβ3-16] = 10 mM, T = 25 °C, 
[Cu(II)]=200µM à pH 6,0 ; [Cu(II)]=3mM à pH 8,6, ν = 125,.8 MHz.  
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Dans la figure 4, on observe le spectre  RMN 13C du peptide Aβ3-16 dans la zone des 
Cα à pH 6,0 (panneau A) et pH 8,6 (panneau B) avec (gris) et sans (noir) Cu(II). Le but est de 
comparer la coordination du Cu(II) dans l’espèce I et dans l’espèce II de Cu(II)-Aβ3-16. Il 
faut noter que lorsque le Cu(II) est lié par deux fonctions amides déprotonées ou plus,  il n'y a 
plus d'échange du Cu(II) entre peptide et, en conséquence,  le signal du peptide  est totalement 
effacé. Le signal restant est donc celui du peptide libre ou du peptide lié au Cu(II) dans 
l'espèce II. Ainsi, en se plaçant à pH 6,0 et pH 8,6, la coordination reflétée par la RMN sera 
celle de l’espèce I et de l’espèce II, respectivement. On constate qu’aux deux pH, le signal Cα 
du Glu3 est largement affecté par l'ajout de Cu(II), ce qui est attribué à la coordination du 
NH2 terminal (celui-ci étant adjacent au Cα du Glu3). On remarque aussi que le signal du Cα 
de la Lys16 (adjacent au COO- terminal) est affecté. Les groupements carboxylates sont 
généralement très affectés par l’addition du Cu(II). En effet, ils sont flexibles et peuvent 
intervenir dans la coordination du Cu(II) comme ligand apical ou lors de l’échange rapide du 
Cu(II) entre les peptides. Cet élargissement n'est donc pas spécifique. Par ailleurs, le groupe 
COO- de la Lys16 n'est pas pertinent d'un point de vue biologique puisqu'il n'existe pas dans le 
peptide complet. A pH 8,6, on constate que le signal du Cα de la Phe4 est particulièrement 
affecté en présence de Cu(II). Cela indique la déprotonation de la fonction amide de la liaison 
Glu3-Phe4 dans l’espèce II du Cu(II)-Aβ3-16. Les signaux du Cα ainsi que du CO (non 
montré) de His6 sont aussi élargis par l'addition de Cu(II). 
Cu(II)-Aβp3-16 
Ci-dessous, la figure 5 présente le spectre RMN 13C du peptide Aβp3-16 en présence 
(gris) et en l’absence de Cu(II) (noir) dans deux zones d’intérêt: Cα (panneau A) et CO 
(panneau B). Les signaux Cα des groupements COO- sont affectés pour les raisons évoquées 
précédemment. Comme attendu, le signal Cα du pyroGlu3 n’est pas affecté puisqu’il 
n’intervient pas dans la coordination du Cu(II). Les différents signaux des résidus His 6, 13, 
14 sont, quant à eux, largement affectés. Cependant, on notera que les signaux Cα et CO des 
His13 et 14 sont plus touchés que ceux de l’His6 par l’ajout du Cu(II). 
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Figure 5 : RMN 13C centré sur les Cα (panneau A) et les CO (panneau B) du du 
peptide Aβp3-16 à pH 7,0 en absence (noir) et en présence (gris) de Cu(II). Condition : 
[Aβp3-16] = 5 mM, [Cu(II)]=250µM, T = 25 °C, ν = 125,8 MHz. 
d- Cu(I) & RMN  1H  
Dans l’hypothèse de la toxicité du complexe Cu-Aβ via la formation de ROS, le Cu(I) 
est essentiel. En effet, la production de ROS nécessite le cycle redox Cu(II)/Cu(I). Dans ce 
contexte, nous nous sommes intéressés à la coordination du Cu(I) aux peptides Aβ. 
 
Afin d’étudier si la coordination du Cu(I) diffère entre les différents peptides Aβ1-16, 
Aβ3-16 et Aβp3-16, nous nous sommes basés sur la méthode et les conditions décrites dans 
une précédente publication de l’équipe.12 Grâce aux spectres  RMN 1H des peptides avec et 
sans Cu(I), nous avons pu identifier les résidus impliqués dans la coordination du Cu(I) (non 
montré). Les signaux des résidus His subissent une modification en présence de Cu(I). La 
manière dont ces signaux sont déplacés et élargis par l'ajout de Cu(I) sur les peptides Aβ3-16 
et Aβp3-16 est hautement semblable aux modifications observées pour le peptide Aβ1-16. 
Ces informations suggèrent que la coordination du Cu(I) est inchangée entre les peptides 
Aβ1-16, Aβ3-16 et Aβp3-16. Il a été proposé que le Cu(I) est lié par le peptide Aβ1-16 via un 
couple préférentiel d’His (His13/14) en équilibre avec d’autres modes de coordination : 
couples d'His6/14 ou His6/13 ou via transitoirement les trois histidines.12 Le comportement 
par RMN 1H des peptides Aβ3-16 et Aβp3-16 en présence de Cu(I) étant identique à celui du 
peptide Aβ1-16, nous proposons donc la même coordination du Cu(I) pour les peptides 
Aβ1-16, Aβ3-16 et Aβp3-16 (voir § I.4.e-Metal ions Coordination to Aβ Cu(I) figure 8). 
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III. 4- Affinité 
La connaissance de l’affinité d’un ion métallique pour un peptide est une donnée 
importante. En effet, ci-celle détermine si l’interaction ions métalliques – peptides est possible 
dans le vivant, indique le sens des équilibres entre peptides en compétition et permet de 
quantifier la fraction liée et la fraction libre. De plus, l’affinité est hautement dépendante de la 
coordination. Aussi, d’importantes modifications dans l’affinité suggère une coordination 
différente (et réciproquement).  
 
Peptide Cu(II) Affinité (1010 M-1) Cu(I) Affinité (106 M-1) 
Aβ1-16 1.1 ± 0.1 7.5 ± 1.0 
Aβ3-16 0.33 ± 0.02 9.2 ± 0.9 
Aβp3-16 0.008 ± 0.001 6.5 ± 0.5 
AcAβ1-16 0.01 ± 0.001 12 ± 1.3 
Tableau 2 : Valeurs d’affinité conditionnelle (i.e. affinité absolue à un pH, donné ici 
pH 7.4) des ions Cu(II) et  Cu(I) pour les peptides étudiés.  
a- Cu(I) 
Les valeurs d’affinité du Cu(I) pour les peptides Aβ1-16, Aβ3-16, Aβp3-16 et 
AcAβ1-16 ont été obtenues par compétition avec la ferrozine suivant la procédure décrite 
dans la ref 13. Les valeurs d'affinité obtenues sont similaires pour les quatre peptides et 
comprise entre ~7-12 x106M-1 (voir tableau 2). Ces valeurs proches sont en accord avec une 
coordination du Cu(I) identique pour les quatre peptide Aβ1-16, Aβ3-16, Aβp3-16 et 
AcAβ1-16. 
b- Cu(II) 
 Les affinités conditionnelles ont été obtenues par compétition des complexes 
peptidiques avec de la glycine (chélateur du Cu(II) de faible affinité) suivie par dichroïsme 
circulaire. Dans la figure 6, on observe la décroissance de la concentration en complexes avec 
l’augmentation de la concentration en glycine. Les courbes simulées selon la ref 14 permettent 
obtenir les valeurs de l’affinité conditionnelle indiquées dans le tableau 2. On constate que 
l’ordre d’affinité est le suivant : Aβ1-16 > Aβ3-16 >> Aβp3-16 ~ AcAβ1-16.  Les affinités 
relatives du Cu(II) pour les peptides Aβ1-16, Aβ3-16, Aβp3-16 ont été calculées par 
différentes méthodes (données non montrées) et ont donné des résultats en accord avec les 
affinités conditionnelles mesurées. Il apparait clairement que la protection de l'amine 
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terminale que ce soit par acétylation ou par formation d'un cycle pyroglutamate diminue 
significativement l'affinité des peptides pour le Cu(II) en accord avec les modes de 
coordination précédemment déduits des études spectroscopiques.  
 
Figure 6 : Concentration en complexe déterminé par DC en fonction de la 
concentration en glycine. Les points proviennent de l’expérience, les courbes sont simulées à 
partir des valeurs d'affinité reportées dans le tableau 2.  Condition : [peptide-Cu] = 500µM ; 
[HEPES] = 100mM pH 7,4 ; ℓ=1cm ; les longueurs d’ondes en DC utilisées pour mesurer la 
concentration en complexe sont 315nm pour Cu(II)-Aβ1-16, 282nm pour Cu(II)-Aβ3-16, 
280nm pour Cu(II)-Aβp3-16 et Cu(II)-AcAβ1-16. 
 
II. 5- Coordination du Cu(II) sur Aβ3-16 et Aβp3-16 
a- Cu(II)-Aβp3-16 
Les différentes expériences décrites ci-dessus suggèrent que la coordination du Cu(II) 
aux peptides Aβp3-16 et AcAβ1-16 sont similaires (DC, RPE, affinité). De plus, l'effet du 
Cu(II) sur les spectres RMN 13C du peptide Aβp3-16 montre l’implication de préférentielle 
des His13 et His14. Les paramètres RPE de l’espèce II’ sont en adéquation avec une 
coordination de type ( N-, 2His, N/O ). Moins d’informations sont disponibles pour l’espèce 
III’ du Aβp3-16. Néanmoins, la formation d’un metallacycle étant plus favorable en direction 
du N-terminal,4 la déprotonation de la fonction amide de l'His13 est probable. Basé sur ces 
arguments, les coordinations du Cu(II) lié par le peptide Aβp3-16 sont proposées dans le 
schéma 2.  
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b- Cu(II)-Aβ3-16 
L'étude par RPE en fonction du pH du complexe Cu(II)-Aβ3-16 (figure 3) présente des 
similitudes avec celle de Cu(II)-Aβ1-16, néanmoins les différences importantes des valeurs de 
pKa entre les différentes espèces suggèrent une coordination non semblable à un pH donné 
(voir tableau 1). De plus, l’apparition de la bande DC à 330 nm sur une plage de pH ~7.5 - 10 
laissant place à une bande DC à 310 nm entre pH 10 – 12 suggère que la coordination du 
Cu(II)-Aβ3-16 diffère de celle de Cu(II)-Aβ1-16 pour les espèces II et III (figure 2). En effet, 
le Cu(II)-Aβ1-16 présente la bande DC à 310nm sur une plage de pH 7.5-12. La valeur du 
pKa déterminée en DC (330nm vers 310nm) pour le passage de l’espèce absorbant à 330 nm à 
celle absorbant à 310 nm est de 9,8, ce qui est très proche de la valeur du pKa(III / IV) 
déterminée par RPE. Ces données indiquent donc un « retour » du Cu(II)-Aβ3-16 vers une 
coordination semblable à celle de Cu(II)-Aβ1-16 pour l’espèce IV. A pH 7,4, l’affinité du 
Cu(II) pour le peptide Aβ3-16 est environ trois fois plus faible que celle du peptide Aβ1-16. 
Ceci est un argument supplémentaire qui soutient une coordination du Cu(II) différente 
(tableau 2) entre les deux peptides. Grâce à la RMN 13C qui montre que les siganux du Cα et 
du CO de l’His6 sont préférentiellement affectées dans l’espèce II et aux autres arguments 
énoncés ci-dessus, les modes de coordinations du Cu(II)-Aβ3-16 sont proposées dans le 
schéma 2. Pour l'espèce I, tout comme dans le cas du peptide Aβ1-16, le site du Cu(II) fait 
intervenir, l'amine terminale, la fonction carbonyle adjacente et deux noyaux imidazole de 
deux His. Pour les espèces II et III, la formation d'un second métallacycle, non-adjacent au 
metallacycle en position N-terminale est proposée, métallacycle qui fait intervenir le noyau 
imidazole de l'His6 et le groupement CO ou la fonction amide deprotonée de la liaison His6-
Asp7 dans les espèces II et III, respectivement. Dans l'espèce IV, on retrouve une 
coordination de type Aβ1-16 avec la formation de trois métallacyle consécutifs centrés sur la 
partie N-terminale.    
 
Cette forte modification de coordination pour les espèces II et III du complexe Cu(II)-
Aβ3-16 comparativement au complexe Cu(II)-Aβ3-16 est probablement dû à l’Arg5. En effet, 
il a été montré que la mutation de l'Arg5 du peptide Aβ1-16 en Gly favorise la déprotonation 
de la fonction peptidique Gly5-His6 au lien de la déprotonation de la liaison peptidique Asp1-
Ala2 dans le peptide non muté.15 Aussi, l’arginine, résidu encombrant et chargé pourrait gêner 
l’approche du Cu(II), empêchant une coordination proche de l’Arg5 dans les espèces II et III 
du complex Cu(II)-Aβ3-16. A plus haut pH dans l’espèce IV,  la formation de trois 
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metallacycles deviennent suffisamment favorable pour un retour vers une coordination 
semblable à celle du Cu(II)-Aβ1-16. 
Outre la différence de sites pour les espèces II et III. La valeur du pKa(I / II) est 
également significativement différente. Ceci est du à une stabilisation moins grande de la 
fonction amide dans la liaison Glu3-Phe4 (peptide Aβ3-16) par rapport à Asp1-Ala2 (peptide 
Aβ1-16) due à une  interaction de type hydrogène moins forte entre le groupement COO- du 
Glu3 et de la fonction amide adjacente (formation d'un cycle à 7) par rapport à celle formée 
entre le groupement COO- de l'Asp1 et de la fonction amide adjacente (formation d'un cycle à 
6).        
Ainsi, bien que les ligands disponibles soient les mêmes entre les peptides Aβ1-16 et 
Aβ3-16, la coordination à pH physiologique est radicalement différente. L'étude de la 
coordination du Cu(II) au peptide Aβ3-16 illustre donc parfaitement le fait que des résidus 
n'intervenant pas directement dans la coordination du Cu(II) peuvent néanmoins avoir un effet 
majeur sur celle-ci.    
 
 
 
Schéma 2 : Coordination du Cu(II) pour les complexes Cu(II)-Aβ3-16 (A) et 
Cu(II)-Aβp3-16 (B) en fonction du pH. 
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II. 6- H6R-Aβ, D7N-Aβ et autres mutants 
a- pKa  
Basé sur le même type d’approche, nous nous sommes intéressés à la coordination du 
Cu(II) sur une série de mutants dont les mutants familiaux H6R-Aβ et D7N-Aβ responsables 
d’un déclenchement précoce de la maladie d’Alzheimer.  
 
Peptide pKa I / II pKa II / III pKa III / IV 
Aβ1-16 7.8 9.3 10.2 
D1N-Aβ 6.0 9.0 10.3 
D7N-Aβ 7.7 9.1 10.6 
E3Q-Aβ 7.6 8.5 9.7 
E11Q-Aβ 7.5 9.3 10.1 
H6A-Aβ 7.3 9.6 
H6R-Aβ 7.2 9.7 
H13A-Aβ 7.5 9.5 10.2 
H14A-Aβ 7.5 9.6 10.4 
Tableau 3 : Valeurs des pKa des différentes espèces Cu-peptides pour Aβ1-16 et ses mutants, 
basées sur la spéciation des signatures RPE des différentes espèces détectées en fonction du 
pH.   
 
Parmi les différents mutants étudiés, certains ont une influence sur les répartitions des 
espèces, i.e. la valeur des pKa entre les différentes espèces (voir tableau 3). Les mutants 
H13A et H14A ont pour effet de favoriser la formation de l’espèce II. En effet, l’espèce II 
requiert une histidine de moins que l’espèce I (voir schéma 1). Les complexes Cu(II)-D1N-Aβ 
et le Cu(II)-E3Q-Aβ présentent notamment des valeurs de pKa(I / II) (mutant D1N) et 
pKa(II / III) (mutant E3Q) fortement différentes de celles du complexe Cu(II)-Aβ1-16. Ces 
grands écarts de pKa peuvent être expliqués par la présence (Aβ1-16) ou l’absence (E3Q-Aβ 
et D1N-Aβ) des liaisons hydrogènes stabilisantes entre les fonctions carboxylates et les NH 
d’amides à déprotoner selon le schéma ci-dessous :  
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 Schéma 3: Influence des liaisons H sur les valeurs de pKa(I/II) et pKa(II/III). 
b- H6R et D7N 
D7N : Les valeurs des pKa des espèces du complexe Cu(II)-D7N-Aβ et les donnés DC 
diffèrent peu par rapport à celles du complexe Cu(II)-Aβ1-16. Il est donc raisonnable de 
penser que la coordination du Cu(II) par le D7N-Aβ ne sera significativement différente de 
celle par le peptide Aβ1-16.  
H6R : Les complexes Cu(II)-H6R-Aβ et Cu(II)-H6A-Aβ, quant à eux, montrent de 
grandes différences de pKa(I / II) comparativement au complexe Cu(II)-Aβ1-16 (voir 
Tableau 1) et un passage direct entre espèces II et IV. Les différences des spectres DC en 
fonction du pH entre les complexes Cu(II)-Aβ1-16 et Cu(II)-H6R-Aβ, suggèrent l’implication 
simultanée des His13 et His14 dans le dernier cas. De plus, les spectres RMN 13C du peptide 
H6R-Aβ en présence ou en absence de Cu(II), suggèrent la coordination de l’amine terminale, 
des His13 et His14 et l’implication du CO de l'His13 dans l’espèce I. La formation de 
l'espèce I du complexe Cu(II)-H6R-Aβ nécessite deux histidines, or l'His6 est maintenant 
remplacée par une Arg, laissant seulement His13 et His14 disponibles. Au delà de pH 7,3, la 
RPE et le DC indique la déprotonation d’une fonction amide et l’implication d’une seule 
histidine. Si le pH augmente encore (i.e. pH > 9.7), on retrouve par DC et RPE, les signatures 
d’une coordination semblable à l’espèce IV du Cu(II)-Aβ (voir schéma 1). Le passage direct 
de l'espèce II à l'espèce IV est du à la décoordination simultanée du noyau His et de la 
fonction carbonyle adjacente formant un metallacycle. La coordination proposée pour le 
complexe Cu(II)-H6R-Aβ autour du pH physiologique vous est présentée dans le schéma 4 ci-
dessous. Cette coordination largement différente de celle obtenue avec le peptide Aβ1-16 
semble avoir les répercussions sur les propriétés d’agrégation et redox du complexe.16 
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Schéma 4:    Espèces I et II proposées pour le complexe Cu(II)-H6R-Aβ autour du pH 
physiologique  
 
II. 7- Conclusion 
Par ces résultats nous avons montré que : 
- la coordination du Cu(II)-Aβ présente différentes espèces en fonction du pH 
- la fonction N-terminale a un rôle majeur dans la coordination du Cu(II) et son blocage 
change considérément la coordination et diminue fortement l’affinité pour le Cu(II) 
- la seconde sphère de coordination joue un rôle majeur sur la première sphère de coordination 
du Cu(II) (influence de l'Arg5, mutation D1N) 
- la coordination du Cu(II) est très sensible à de faibles modifications de la séquence du 
peptide amyloïde β 
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’ INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly population with an estimated prevalence
of 30 million people worldwide, a number that is expected to
quadruple in 40 years.1 AD is a complex multifactorial neurode-
generative disease in which many genetic and environmental
factors are involved. The underlying mechanisms of AD are not
clear, but there is evidence and a relatively wide agreement that
the so-called amyloid cascade is a key and early event in the
development of AD. This hypothesis proposes an increased
extracellular accumulation of a peptide, called amyloid-β (Aβ),
which leads to its aggregation, first into oligomers, then into
protofibrils and last into amyloid plaques, a hallmark of AD. This
hypothesis suggests that the mismetabolisms of Aβ and of its
precursor protein are initiating events in AD pathogenesis.
Formation of Aβ aggregates would further instigate pathological
events, including formation of intracellular neurofibrillary tangles
(another hallmark of AD), disruption of synaptic connections,
ultimately leading to neuronal cells death and dementia.16 Aβ is
typically a 3943 residue polypeptide and consists of a hydro-
philic N-terminal domain (128) and a C-terminal hydrophobic
domain (2939/43). In vivo, the most prevalent forms of Aβ
consist of 40 (Aβ40) and 42 amino acids (Aβ42). The longer
form Aβ42 is more prone to aggregation and more toxic to
neurons than Aβ40, in agreement with the amyloid cascade
hypothesis. Metal ions (Cu, Fe, Zn) have been proposed to play a
key role in the development of AD. In vivo, in cello, and in vitro
experiments strongly suggest that metal ions and in particular Cu
ions are involved in AD. Cu ions can bind to Aβ and modulate its
aggregation. Furthermore [Cu(Aβ)] oligomeric forms can cat-
alyze the production of ROS (reactive oxygen species) in
presence of physiological reducing agents (e.g., ascorbate), which
finally leads to neuronal cells death (for reviews, see refs 714).
Copper coordination to the Aβ peptides has been proposed as
an important event in the amyloid cascade and deciphering the
Cu environment when bound to Aβ peptides is still a burning and
controversial topic. At physiological pH, two equatorial binding
modes coexist. The one predominant at lower pH is constituted
of two equivalent sets of ligands (noted Ia and Ib), where the
terminal NH2 (from Asp1), the CO from the Asp1Ala2
peptide bond, a N from imidazole ring of His6 and from His13
(component Ia) or fromHis14 (component Ib) are involved.1519
The two components have been proposed to be in equilibrium in
1:1 ratio,15,17 and thus in the following the mixture of Ia and Ib
will be noted component I. However, a recent study reported
Received: August 10, 2011
ABSTRACT: Copper ions have been proposed to intervene in
deleterious processes linked to the development of Alzheimer’s
disease (AD). As a direct consequence, delineating how Cu(II)
can be bound to amyloid-β (Aβ) peptide, the amyloidogenic
peptide encountered in AD, is of paramount importance. Two
different forms of [CuII(Aβ)] complexes are present near
physiological pH, usually noted components I and II, the nature of which is still widely debated in the literature, especially for
II. In the present report, the phenomenological pH-dependent study of Cu(II) coordination to Aβ and to ten mutants by EPR, CD,
and NMR techniques is described. Although only indirect insights can be obtained from the study of Cu(II) binding to mutated
peptides, they reveal very useful for better defining Cu(II) coordination sites in the native Aβ peptide. Four components were
identified between pH 6 and 12, namely, components I, II, III and IV, in which the predominant Cu(II) equatorial sites are {NH2,
CO (Asp1Ala2), Nim (His6), Nim (His13 or His14)}, {NH2, N (Asp1Ala2), CO (Ala2Glu3), Nim}, {NH2, N
(Asp1Ala2), N (Ala2Glu3), Nim} and {NH2, N (Asp1Ala2), N (Ala2Glu3), N (Glu3Phe4)}, respectively, in line
with classical pH-induced deprotonation of the peptide backbone encountered in Cu(II) peptidic complexes formation. The
structure proposed for component II is discussed with respect to another coordinationmodel reported in the literature, that is, {CO
(Ala2Glu3), 3 Nim}. Cu(II) binding to the H6R-Aβ andD7N-Aβ peptides, where the familial H6R andD7Nmutations have been
linked to early onset of AD, has also been investigated. In case of the H6Rmutation, some different structural features (compared to
those encountered in the native [CuII(Aβ)] species) have been evidenced and are anticipated to be important for the aggregating
properties of the H6R-Aβ peptide in presence of Cu(II).
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that a third component, where the two His involved in Cu(II)
coordination are the His13 and His14, is also present, this third
component (noted Ic) being more prone to formation of unstruc-
tured aggregates than Ia and Ib.20 Regarding the second component
(II), predominant at higher pH, there are two divergent hypo-
theses.19Mainly on the basis of S-bandEPR andHYSCOREdata on
13C and 15N isotopically labeled peptides, it was proposed that
component II is made of the CO group from the Ala2Glu3
peptide bond and the imidazole rings of the three His.18 In the
second proposition, also deduced fromHYSCORE data on 13C and
15N isotopically labeled peptides15 but from NMR data as well,16
theNH2 terminal, the amidyl function N from the Asp1Ala2
peptide bond, the CO from the Ala2Glu3 peptide bond, and one
among the three imidazole rings of His are the functions predomi-
nantly involved in equatorial Cu(II) binding. Regarding the apical
positions, the debate is still open but involvement of carboxylate
groups has been proposed in the literature.15,16,18
Here, we report a EPR, CD, andNMR study of Cu(II) binding
to the Aβ peptide and to ten mutants that allow discrimination
between the two proposed Cu(II) binding models in II (see
above). Moreover, we describe the pH dependent Cu(II) bind-
ing to this series of peptides from pH 4 to 12. While such a pH
range is not biologically pertinent, study performed outside the
physiological range do help disentangling Cu(II) coordination
features around physiological pH. Indeed, the Cu(II) peptidic
species are generally obtained from each other by successive
deprotonation (protonation) of the peptide when the pH is
increased (decreased).21,22 Moreover, such a wide study is of
interest from a chemical point of view since it provides general
rules for Cu(II) coordination to peptides. We thus characterized
two new components (noted III and IV) at pH higher than 8.
In this study, the impact on Cu(II) binding properties of the
two English (H6R) and TottoriJapanese (D7N) mutations
linked to early onset familial AD were also investigated. In vitro
studies of Aβ40 and Aβ42 peptides incorporating either the H6R
or the D7N mutations have evidenced that the two mutations
alter Aβ assembly at its earliest stages, as well as monomer folding
and oligomerization process. Moreover, it was shown that the
oligomers of the mutated peptides are more toxic to cultured
neuronal cells than the wild type oligomers.23,24 Trace Cu(II)
have not been taken into account in these studies but might
influence the aggregation process. Moreover, His6 intervenes in
Cu(II) binding and Asp7 is a putative Cu ligand in the wild-type
peptide. These are the reasons why it is worth determining how
the H6R and the D7N mutations can modify Cu(II) coordina-
tion in these rare familial forms of AD. Although beyond the
scope of the present phenomenological study, it would be very
important to relate the impact of these mutations on the bio-
logical properties of the peptides with the difference in the Cu(II)
coordination described here.
’RESULTS
1. EPR pH-Dependent Study of Cu(II) Binding to Aβ16
Peptides andMutants.The shorter Aβ16 peptide is used in the
present study. Number of previous works have unambiguously
shown that it represents the minimum Aβ sequence involved in
Cu(II) binding.2527 The pH-dependent EPR signature of Cu-
(II) binding to the Aβ16 peptide is shown in Figure 1 together
with spectra of Cu(II) species obtained with the D1N-Aβ and
E3Q-Aβmutants and the N-terminally acetylated (Ac-Aβ) peptide
at selected pH values. The EPR signatures of the [CuII(Aβ)]
Figure 1. EPR spectra of [CuII(peptide)] complexes as a function of pH. Panel A: Peptide = Aβ16. Panel B: Peptide = D1N-Aβ, E3Q-Aβ, or Ac-Aβ.
Component I is designated by green lines, component II by orange lines, component III by black lines and components IV and IV0 by red and purple
lines, respectively. Plain lines indicate pH values where a component is predominant in solution and dotted lines pH range where a component is present
in solution but not predominant. [CuII(peptide)] = 1mM inD2O. ν = 9.5 GHz, amplitudemodulation = 0.5mT,microwave power = 20mW.T = 110K.
* indicates the presence of a minor species, which is not detected in the EPR spectra of other [CuII(peptide)] species, with g ) = 2.17(8) and A ) = 160
104 cm1 EPR parameters (see Supporting Information for identification of this species).
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complexes are complicated and generally correspond to the super-
imposition of several components simultaneously present in solu-
tion at a given pH.This is particularly obvious at lowpH(near pH4),
at physiological pHwhere two species coexist (the well-described
components I and II, indicated by green and orange colors in
Figure 1, respectively) and at pH near 10. In this latter case,
two among the three coexisting components can be well identi-
fied: the first one is predominant at pH 8.7 (component II)
and the other one is predominant above pH 10.6 (that will be
noted component IV, in red in Figure 1). The third component
(noted III, in black in Figure 1) is present only as a minor
component and is thus difficult to identify. The EPR parameters
determined for these four components (IIV) are given in Table 1.
Regarding the other [CuII(peptide)] complexes (peptide = Ac-Aβ,
D1N-Aβ, E3Q-Aβ, D7N-Aβ, H6A-Aβ, H6R-Aβ, E11Q-Aβ,
H13A-Aβ, and H14A-Aβ) studied here (see Figures S1S3 in
the Supporting Information), none of themwith the exception of
the [CuII(Ac-Aβ)] has significantly different EPR parameters
compared to those of [CuII(Aβ16)] species (Table 1 and see
below for details). Hence, components relative to [CuII(Ac-Aβ)]
will be noted I0IV0. Nevertheless, pKa values corresponding to
transition between the various components depend on the
nature of the peptide involved in Cu(II) binding (Table 1).
Note that the pKa values are defined as the pH values where the
EPR signatures of two components contribute equally to the
EPR intensity and thus have been estimated by considering that
only two components are simultaneously present in solution.
a. Components I and II. Regarding component I, there is now
a consensus that the Cu(II) ion lies in an equatorial binding site
made of the terminal amine NH2 group, the imidazole ring of
His6, the one of His13 or His14 (in equilibrium) and a carbonyl
function,1519 the apical position being likely occupied by a
carboxylate group.15,16,18 Species II, in which the Cu(II) coordina-
tion remains to be elucidated is characterized by EPR parameters
that differ from those of component I by a concomitant decrease
in the g// and A// and are classical for 3N1O or 4N binding site
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(Table 1). The pKa of the I/II transition is approximately 7.8, in
line with previous studies.32,33 In Figure 1, panel B, the EPR pH
dependent signatures of Cu(II) bound to the D1N-Aβmutant is
reminded. While the EPR parameters of components I from
[CuII(Aβ16)] and [CuII(D1N-Aβ)] complexes are very similar,
the pKa(I/II) value is approximately 6.0 in case of the [Cu
II-
(D1N-Aβ)] complexes, thus significantly lower than that of the
[CuII(Aβ16)] complexes. The D1N mutant was previously
studied by the group of Szalai33 and the decrease in the pKa(I/II)
was attributed to the breakage of a H-bond network (due to the
replacement of the Asp1 anionic carboxylate by a neutral group),
which would facilitate the deprotonation of a peptide function
during the process leading to component II. However, in this
pioneer work the peptide function undergoing the deprotonation
was not identified.
Regarding the other Cu(II) complexes studied here, none of
them with the exception of the [CuII(Ac-Aβ)] has significantly
different EPR parameters compared to [CuII(Aβ16)]. This strongly
suggests that none of the mutated residues is essential for creating
the Cu(II) equatorial binding sites and that it can be replaced by an
identical residue but located at another position in the peptide
sequence. Differences between pKa(I/II) values are observed
and the most important ones are detected for the [CuII(H6A-
Aβ)] and [CuII(H6R-Aβ)] complexes, pKa(I/II) values being
approximately 0.5 pH unit below that of [CuII(Aβ16)]. This
suggests that even if His6 has been proposed to be always
equatorially bound to the Cu(II) center in species I,15,17 it can
be replaced by either the His13 or His14 thus leading to the
equatorial coordination of the His13-His14 diad. In such a co-
ordination environment, geometric constraints accounting for
formation of component II at a lower pH than in the native
[CuII(Aβ16)] species may be anticipated. On the contrary, the
H13A or H14A mutations have only a slight impact on the
pKa(I/II) values (Table 1), in line with the equilibrium between
Table 1. EPR Parameters of Components IIV and I0IV0 and of Other [63CuII(peptide)] Complexes for Comparison
I II III IV
peptide g )
a A )
a g )
a A )
a g )
a A )
a g )
a A )
a pKa(I/II)
b pKa(II/III)
b pKa(III/IV)
b
human 2.26(2) 184 2.22(6) 161 2.19(1) 194 2.17(3) 203 7.8 9.3 10.2
D1N-Aβ 2.26(3) 180 2.23(0) 160 2.19(1) 194 2.17(4) 201 6.0 9.0 10.3
D7N-Aβ 2.26(2) 184 2.22(7) 160 2.18(8) 194 2.17(4) 197 7.7 9.1 10.6
E3Q-Aβ 2.26(3) 183 2.22(4) 161 2.19(0) 194 2.17(3) 201 7.6 8.5 9.7
E11Q-Aβ 2.26(5) 184 2.22(5) 161 2.18(7) 194 2.17(0) 202 7.5 9.3 10.1
H6A-Aβ 2.26(8) 185 2.22(8) 164 2.17(2) 202 7.3 9.6
H6R-Aβ 2.26(6) 180 2.22(7) 162 2.17(1) 205 7.2 9.7
H13A-Aβ 2.26(3) 180 2.23(0) 162 2.17(5) 202 7.5 9.5 10.2
H14A-Aβ 2.26(9) 182 2.22(7) 163 2.17(5) 202 7.5 9.6 10.4
DAHK28 2.19 199
GGGGH29 2.23(0) 156 2.19(9) 200 2.17(1) 206
GGGGG29 2.17(1) 206
I0 II0 III0 IV0
Ac-Aβ 2.32(0) 168 2.27(3) 187 2.23(0) 171 2.19(1) 190 5.2 7.5 8.7
GGGTH30 2.20 200
a Parallel spinHamiltonian parameters were obtained directly from the experimental spectra and were calculated from the second and the third hyperfine
lines in order to remove second-order effects. A ) parameters are given in 10
4 cm1. b pKa values are roughly estimated from EPR spectra, and with the
exception of pKa(I/II) that can be estimated accurately, the two others pKa values are given with an uncertainty of (0.3 pH unit.
11195 dx.doi.org/10.1021/ic201739n |Inorg. Chem. 2011, 50, 11192–11201
Inorganic Chemistry ARTICLE
these two His residues for one equatorial binding position pre-
viously proposed.15,17
b. Component III. Component III is hardly distinguishable in
the pH dependent EPR traces of [CuII(Aβ16)], being only
discernible by the fourth hyperfine feature (black line at B =
343 mT in Figure 1, panel A). Indeed, the three other hyperfine
lines are mixed with those of components II and IV and cannot
be well isolated. The reason for such a mixture between com-
ponents II, III, and IV is likely close pKa(II,III) and pKa(III,IV)
values. To better characterize component III, the E3Q mutant is
helpful. Indeed, in the [CuII(E3Q-Aβ)] mutant, component III
is more easily detected, pKa(II/III) and pKa(III/IV) values being
sufficiently different (estimated to 8.5 and 9.7, respectively).
Similar to what was proposed for the D1N-Aβ mutant, we can
hypothesize that the Glu3 carboxylate function stabilizes a
deprotonable function in its protonated form by H-bond inter-
actions, and that in the [CuII(E3Q-Aβ)] complex, the H-bond
network is broken leading to deprotonation of the function at a
lower pKa(II/III) value. It is worth noting that mutation of the
two other carboxylate functions (leading to D7N and E11Q
mutants) do not affect neither the EPR signatures of the cor-
responding Cu(II) complexes nor their pH dependence com-
pared to [CuII(Aβ16)]. Parameters of component III are close to
those observed when the Cu(II) is bound to the ATCUN motif
(encountered in peptide with N-terminal XXH- sequence). In
such species, the Cu(II) is bound via theNH2 terminal, the His
and the two amidyl functions in between these two residues. For
instance, such equatorial Cu(II) coordination is encountered in
the N-terminal binding site of the serum albumin having the
DAHK sequence.28 Nevertheless, some minor differences are
observed that can be attributed to the formation of three adjacent
metallacycles in the ATCUN case, a structural feature that cannot
be observed in the present case due to the position of the His
compared to the NH2 group, the closest His residue being far
from the terminal amine by 5 amino-acids. Such ATCUN type
coordination in component III will be further confirmed by
NMR studies (see below).
It is also worth noticing that component III cannot be de-
tected in the EPR pH-dependent spectra of the [CuII(H6A-Aβ)]
and [CuII(H6R-Aβ)] complexes. This suggests that His6 is more
involved than His13 or His14 in Cu(II) binding in component III.
c. Component IV. The g ) and A ) parameters of component IV
of [CuII(peptide)] complexes, with the exception of the [CuII-
(Ac-Aβ)] are characteristic of a 4N equatorial binding mode,31
where the Cu(II) ion is bound via the terminalNH2 and three
amidyl functions. Indeed, very similar EPR parameters have been
reported for the [CuII(GGGGG)] complex, where the NH2 is
the sole Cu(II) anchoring function and thus where the Cu(II)
equatorial site is completed by amidyl groups from adjacent
peptide bonds.29 Such Cu(II) coordination is often encountered
in peptidic fragments where other potential ligands are replaced
by amidyl functions adjacent to theNH2 anchoring point when
the pH is increased. At high pH, the other possibility is to have a
nitrogen atom from the imidazole ring of an His residues as
the anchoring point and adjacent amidyl functions that entered is
the Cu(II) coordination sphere.22 This is encountered when
the terminalNH2 is not available for Cu(II) binding, for instance
when it is acetylated.30 In this case, the EPR parameters are
different from those observed here in the component IV but
similar to those observed in component IV0 corresponding to
complex [CuII(Ac-Aβ)] at high pH (Figure 1, panel B and
Table 1). This agrees with the involvement of the N-terminal
amine in equatorial Cu(II) coordination in [CuII(Aβ16)] at high
pH. Note that involvement of the terminal NH2 function has
already been identified by EPR and ENDOR experiments per-
formed on labeled [CuII(15N-(Asp1)-Aβ16] species.15 A second
consequence is that, Cu(II) center in component IV is likely
bound by the terminal -NH2 and the three adjacent amidyl func-
tions while in component IV0 by one of the three His and three
adjacent amidyl functions, the His residue(s) involved remaining
to be identified.
d. [CuII(Ac-Aβ)] Species. Acetylation of the terminal amine
lead to a series of new type of components that can be obtained
from component IV0 by successive protonation of the amidyl
functions, leading to a {Nim, 2N, X} equatorial binding site in
III0 and {Nim, N, X, Y} in II0 and {Nim, X, Y, Z} in I0, where
X, Y, and Z can be either His or CO ligands. Further identifica-
tion of the exact nature of components I0IV0 is beyond the
scope of the present paper and is not physiologically relevant for
the understanding of Cu(II) coordination to Aβ. Nevertheless,
an important point to note is that EPR parameters of compo-
nents II0 and III0 are very close to those of components I and II,
respectively and that pKa(II0/III0) is also very close to pKa(I/II)
(Table 1). As a consequence, the pH dependent EPR spectra of
[CuII(Aβ16)] and [CuII(Ac-Aβ)] complexes will be by chance
very similar near physiological pH.Thismay have led tomisinterpreta-
tion of comparative EPR data of [CuII(Aβ16)] and [CuII(Ac-Aβ)]
when recorded only near physiological pH and to the erroneous
conclusion that NH2 is involved in Cu(II) apical position in
component I.34
2. CD pH-Dependent Study of Cu(II) Binding to Aβ16
Peptides and Mutants. EPR is a powerful technique to
determine the Cu(II) binding site but reveals information
concerning only the equatorial plane. As a consequence, CD
can be used to monitor structural modifications that occur
outside from the first coordination shell and in apical position.
pH-dependent CD spectra of four chosen examples of
[CuII(peptide)] complexes that are representative of the four
types of CD signatures obtained in the present study, are
shown in Figure 2 ([CuII(Aβ16)], [CuII(Ac-Aβ)], [CuII(H6A-
Aβ)], [CuII(E3Q-Aβ)]).
a. [CuII(Aβ16)] Type Family. pH dependent CD signatures of
this family is shown in Figure 2, panel A. Weak dd transitions
are observed at λ = 670 and 590 nm, which increase in intensity
upon increasing pH, reaching a maximum at a pH ∼7.5. A new
dd band at λ = 510 nm is observed when the pH is raised above
7.5. In the UV domain, the intensity of the λ = 315 and 285 nm
bands increase from pH approximately 7 and 3, respectively. The
former band has been attributed to amide to Cu(II) charge
transfer transition (LMCT) while the latter to amine to Cu(II)
LMCT. The band detected at λ = 265 nm, which has tentatively
been attributed to imidazole to Cu(II) LMCT,21 increases in
intensity from pH approximately 8.5. pH dependent behavior of
these features indicates that (i) NH2 is bound to Cu(II) from
pH 3 and remains bound to Cu(II) at any higher pH, (ii) amidyl
groups start to bind Cu(II) at pH approximately 7, and (iii)
binding of amidyl functions to Cu(II) enhances the molar
extinction coefficient of the His to Cu(II) LMCT and of the
dd transitions detected at 265 and 590 nm, respectively. The
[CuII(H13A-Aβ)], [CuII(H14A-Aβ)] and [CuII(E11Q-Aβ)]
complexes belong to this family (Supporting Information Figures
S5 and S6) and thus behave very similarly to the [CuII(Aβ16)],
suggesting that (i) both His13 and His14 are not simultaneously
involved in Cu(II) binding in the whole pH range and that
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(ii) carboxylate group from Glu11 is not an essential element of
Cu(II) binding sites.
b. [CuII(Ac-Aβ)]. pH-dependent CD signature of [CuII(Ac-
Aβ)] is unique compared to all the other [CuII(peptide)] com-
plexes studied here (Figure 2, panel B). The continuous increase
of bands at λ = 630, 490, 360, 315, and 265 nm is observed when
the pH is increased. Twomain differences with the [CuII(Aβ16)]
data are the absence of the λ = 285 nm band characteristic of
NH2 to Cu(II) LMCT, in line with acetylation of N-terminal
amine and a significantly higher intensity of the λ = 265 nm band,
especially at high pH, compared to all the others [CuII(peptide)]
complexes, in agreement with the formation of binding sites
centered onHis anchoring residue, as previously proposed on the
basis of the EPR data analysis.
c. [CuII(H6A-Aβ)]/[CuII(H6R-Aβ)] Type Family. These muta-
tions lead to three mains differences in the pH-dependent CD
signatures of the [CuII(peptide)] complexes (Figure 2, panel C
and Supporting Information Figure S5), which are (i) a negative
dd band at λ = 630 nm from pH 3 to approximately 7.5; (ii) a
more pronounced λ = 285 nm band, and (iii) a λ = 265 nm band,
the growth of which begins in the negative part of the CD spectra
from pH 3 to approximately 7.5 and the intensity of which
remains weaker than in the [CuII(Aβ16)] type family complexes
at higher pH. These modifications may be attributed to the
simultaneous involvement of His13 andHis14 in Cu(II) binding,
a feature that is not detected in the [CuII(Aβ16)] type family (see
above), thus leading to an important reshuffling of the peptide
conformation. Sign change in the λ = 265 nm band at pH ∼7.5
may also be interpreted as transition between the His13His14
diad involved in Cu(II) coordination to only one His bound to
Cu(II). These CD data are consistent with the EPR data, since it
confirms that bothHis13 andHis14 can be simultaneously bound to
Cu(II). However, if the EPR traces of both [CuII(H6A-Aβ)] and
[CuII(H6R-Aβ)] complexes are very close to that of the [CuII-
(Aβ16)], their CD signatures differ significantly, in line with
modifications occurring outer from the first coordination shell.
d. [CuII(E3Q-Aβ)] Type Family.The pH dependent CD spectra
of Cu(II) complexes obtained with the triple E3QD7NE11Q
mutants and the D1N, E3Q, and D7N mutants (Figure 2, panel
D and Supporting Information Figures S4 and S6) are slightly
different from that of the [CuII(Aβ16)] type family by having
weaker dd band intensities up to pH 7.5 (especially in the E3Q
and E3QD7NE11Q cases) and then a stronger intensity at λ =
650 nm at higher pH, except for the [CuII(D1N)] complex that
exhibits a weaker intensity. This may reflect involvement of the
Glu3 and Asp7 residues in apical Cu(II) binding or an outer first
Figure 2. Effect of pH on the CD spectra of [CuII(peptide)] complexes, from pH approximately 3 (blue line) to pH approximately 12 (red line). Panel
A: [CuII(Aβ16)]. Panel B: [CuII(Ac-Aβ)]. Panel C: [CuII(H6A-Aβ)]. Panel D: [CuII(E3Q-Aβ16)]. Left insets: pH from approximately 3 to
approximately 7.5. Right insets: pH from approximately 7.5 to approximately 12. [CuII(peptide)] = 0.5 mM, l =1 cm, T = 20 C. Arrows indicate the
formation of relevant bands with pH increase. For exact pH values see Supporting Information, Figures S4S6.
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sphere contribution of the Glu3 and Asp7 residues, for instance
by creating salt bridge with the Arg5 residue. Furthermore, the
CD data obtained here are in line with contribution of the Asp1
residue in Cu(II) apical position even if the different pH-
dependent CD signature of the [CuII(D1N-Aβ)] complex is
mainly due to the low pKa(I/II) value.
e. pKa Determination. Using EPR data it was possible to
evaluate the pKa between various components. As exemplified in
Figure 3 in the case of the [CuII(Aβ16)] complex, this could also
be achieved by simulation of the CD data. Simulations of the pH-
dependent absorbance curves at several selected wavelengths
with a unique set of pKa values were performed and pKa(I/II) =
7.9, pKa(II/III) = 9.3, and pKa(III/IV) = 10.3 values were found.
These results were fully consistent with EPR data suggesting that
no significant pH drift occurs upon freezing the EPR samples. In
the course of simulation, it appears that more than 3 pKa values
were necessary to correctly fit the curves. More precisely, below
pH 6, the intensities of the λ = 620 and 660 nm undergo sig-
nificant increase.The pKa value corresponding to transitionbetween
component I and this newly detected component (noted 0) is
estimated to be 5.8. Regarding the EPR data, it appears that the
EPR signature of component 0 is indiscernible to that of com-
ponent I. Hence, a possible explanation is that this pKa corre-
sponds to the deprotonation of the third Cu(II) unbound His
leading to modification of peptide arrangement but not to direct
change in the equatorial Cu(II) coordination.
3. NMR Studies of Cu(II) Binding to Aβ in Component III
and to H6R-AβMutant in Components I and II. In an attempt
to better characterize the new components III and IV, we used
NMR spectroscopy that was previously revealed to be a powerful
technique to better disentangle Cu(II) binding to Aβ peptides16,32
and to others peptides or proteins.35,36 Indeed the paramagnet-
ism of the Cu(II) ion induces broadening of NMR features that
depends on the proximity of the Cu(II) ion. Hence, it is possible
to map which residues are affected by the presence of Cu(II) and
thus involved in its coordination. 13C NMR spectra of the apo-
Aβ and holo-Aβ (0.3 equiv of Cu(II)) recorded at pH 9.8 (where
component III is predominant) are compared to those of the
apo-Aβ and holo-Aβ (0.1 equiv of Cu(II)) at pH 8.7 (Figure 4).
Cu(II)-induced broadening of the 13C peaks are weaker at pH 9.8
although the Cu(II) stoichiometry is 3-fold higher. Moreover, no
new 13C signals, with the exception of the Cα and Cβ of Lys16,
are affected by the Cu(II) addition at pH 9.8 compared to pH 8.7.
This behavior is attributed to the formation of a “ATCUN” type
Cu(II) binding motif {NH2, 2N, Nim} in component III.
Indeed, it was previously evidenced that in such a coordination
site, Cu(II) exchange between peptides is too slow to affect all
the peptides present in solution. On the contrary, Cu(II) stays
bound to a portion of peptide and then lead to the total dis-
appearance of its NMR signals.28 Thus in the present case, Cu(II)
effect on Aβ NMR peaks corresponding to component III is not
observable. The broadening effect observed is due to the presence
of a small portion of component II (in pH-dependent equilibrium
with component III). As a direct consequence, NMR revealed
inappropriate for the study of components III and IV.
The H6R mutation is a familial mutation that was associated
with early onset of AD.Moreover, significantmodifications of the
pH-dependent CD signature of [CuII(H6R-Aβ)] complexes were
observed compared to that of [CuII(Aβ16)]. These are the
reason why components I and II of the [CuII(H6R-Aβ)] com-
plexes were also studied by 13C NMR. In general, Cu(II) effect
on the 13C NMR spectra of the H6R mutant and on the Aβ16
peptide16 are similar (Supporting Information Figure S7). More
precisely, binding of both His13 and His14 in component I (see
Figure 4. 13C{1H} NMR spectra of 10 mM Aβ peptide in D2O
(bottom spectra) and in presence of 0.1 equiv of Cu(II) (top spectra)
at pH 8.7 (left) and of 0.3 equiv of Cu(II) (top spectra) at pH 9.8 (right).
T = 25 C, ν = 125.8 MHz. Shift of some peaks is due to slight
modification in the pH value induced by Cu(II) addition.
Figure 3. pH-dependent CD absorbance of [CuII(Aβ16)] complex at λ
= 660 (red plain circles), 620 (pink plain squares), 580 nm (purple plain
diamonds), 518 nm (blue plain triangles), and 314 nm (black plain
triangles). Solid lines are the fits of the curves with pKa = 5.8, 7.9, 9.3, and
10.3. [CuII(Aβ16)] = 0.5 mM, l =1 cm, T = 20 C.
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CD part) may induce the binding of the CO function in between
the two His residues, as proposed by calculations.37 However,
such a binding do not change the impact of Cu(II) to the 13C
NMR spectra of H6R-Aβ compared to Aβ16. Indeed, coordina-
tion of CO function fromHis residues was previously detected in
the Aβ16 case and attributed to equilibrium in solution between
{NH2, CO (Asp1), 2NIm} and {NH2, CO (His), 2NIm}.16
The main differences observed on the CO and Cα regions at pH
8.6, where component II is predominant, are shown in Figure 5.
Both the CO functions and Cα atoms from His13 and His 14
residues are more broadened in the case of the H6R mutant.
However, broadening of the CO and Cα
13C atoms from the Ala2
residue, previously attributed to coordination of the amidyl
function from the Asp1Ala2 peptide bond, is still observed.
Thus, this suggests that the deprotonation of the Asp1Ala2
peptide bond also occurs in the H6Rmutant but in this latter case,
it does not induce the binding of the adjacent CO function (from
Ala2 to Glu3). Indeed, CO functions from His residues may
principally be involved in Cu(II) binding.
’DISCUSSION
1. Coordination Sites of Cu(II) in Components IIV. The
proposed equatorial Cu(II) binding sites in components IIV
are shown in Scheme 1. Component I has been proposed by several
groups.1519 In this species, the Cu(II) center is bound via the
terminal amine, two His residues and a CO function mainly
originating from the Asp1Ala2 peptide bond.
While consensus has been recently reached on Cu(II) coor-
dination sphere in component I, this is not the case for component
II. Indeed two models have principally appeared in the last years.
In the first one, Cu(II) is bound via the carbonyl function from
Ala2Glu3 and the imidazole rings of the three His (model
noted 1)17,18 and in the second one, Cu(II) is bound via the
terminal amine, the adjacent amide function from Asp1Ala2,
one out of the three His and the CO function from Ala2Glu3
(model noted 2).15,16 In the present study, new key insights have
been obtained regarding the Cu(II) binding sphere in compo-
nent II. First, an interesting feature is that Cu(II) complexes of
the three H6A, H13A, and H14A mutants have EPR parameters
identical to those of [CuII(Aβ16)], indicating that the simulta-
neous equatorial coordination of the three His to the Cu(II)
center is unlikely. Otherwise, this would imply that in complexes
obtained with the His mutants, the His residues is replaced by a
ligand that would influence the Cu(II) electronic properties in a
very similar way, a possibility that we cannot however fully ruled
out. Second, component III is identified as {NH2, 2N, Nim}
(see below) and thus it is difficult to rationalize why the terminal -
NH2 amine bound to Cu(II) in components I and III, will be
unbound in the intermediate component II. Third, transition
from components III (and to III and IV) is pH driven and thus
should be concomitant to deprotonation of peptide function. In
case of model 1, all the residues that can undergo deprotonation
(i.e., the three His residues) are already deprotonated at pH
below the pKa(I/II) value and hence this model fails to explain
the effect of pH in transition from I to II. Fourthly, contrarily to
model 2, model 1 does not explain the variation in the pKa(I/II)
and pKa(II/III) observed in [Cu
II(D1N-Aβ)] and [CuII(E3Q-Aβ)]
complexes, respectively (see below). Fifthly, intervention of
CO from Ala2Glu3 preferentially to that of another peptide
bond remains unexplained inmodel 1 whereas the deprotonation
of the adjacent Asp1Ala2 amide bond in model 2 justifies the
intervention of the Ala2Glu3 CO function in Cu(II) binding.
Lastly, the EPR parameters of the very simple [CuII(GGGGH)]
complex (see Table 1), containing only one His residues in its
sequence, are virtually identical to those found here for compo-
nents IIIV, indicating that only oneHis can be bound toCu(II)
in components II and III.29
Regarding component III, EPR parameters, as well as NMR
data support an “ATCUN” type Cu(II) site {NH2, 2N, Nim}.
A {NH2, 3N} Cu(II) equatorial site is proposed for compo-
nent IV based on the EPR parameters and the difference with
EPR signature of [CuII(Ac-Aβ)]. These propositions are in
line with those previously reported by Kowalik et al. in their
pioneer work,21 except for component IV that was identified as
{Nim, 3N}. Moreover, in the present study attribution of each
equatorial binding atoms has been proposed, that is, I= {NH2,CO
Scheme 1. Proposed Equatorial Cu(II) Binding Sites of [CuII(Aβ)] as a Function of pH
Figure 5. 13C{1H} NMR spectral regions of 10 mM Aβ16 peptide in
D2O (bottom spectra) and in presence of 0.1 equiv of Cu(II) (top
spectra) at pH 8.7 (panels A and B) and of 5 mM H6R-Aβ peptide in
D2O (bottom spectra) and in presence of 0.05 equiv. of Cu(II) (top
spectra) at pH 8.6 (panels C and D) T = 25 C, ν = 125.8 MHz. Shift of
some peaks is due to slight modification in the pH value induced by
Cu(II) addition.
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(Asp1Ala2), Nim (His6), Nim (His13 or His14)}, II = {NH2,
N (Asp1Ala2), CO (Ala2Glu3), Nim}, III = {NH2, N
(Asp1Ala2), N (Ala2Glu3), Nim}, and IV = {NH2, N
(Asp1Ala2), N (Ala2Glu3), N (Glu3Phe4)}
Regarding involvement of carboxylate groups in Cu(II) apical
position, theCDdata obtained are in linewith previous propositions
that suggest a preferential role of the Asp1 residue.15,16,18 Implica-
tion of theGlu3, Asp7, andGlu11 carboxylate groups in equilibrium
with the one of Asp1 was also suggested for component I.16 The
CD data obtained here agree with this possibility except for the
Glu11 residue, for the involvement of which no evidence was found.
D1N and E3Q mutations induced change in pKa values
between I/II and II/III, respectively (Table 1). More precisely,
D1N mutation decrease the pKa(I/II) value by more than one
pH unit and the E3Qmutation decrease the pKa (II/III) bymore
than 0.5 pH unit (Table 1). As previously pointed out,33 this may
be related to the breakage of H-bond network when carboxylate
functions are modified to amide and subsequent easier deproto-
nation of peptide functions, here identified as the Asp1Ala2
and Ala2Glu3 peptide bonds, respectively. This is illustrated in
Scheme 2,where the interventions of Asp1 andGlu3 are exemplified
on the basis of model 2 for component II.
2. Coordination of Cu(II) to the H6R and D7N Familial
Mutants. Among the various mutants studied here, Cu(II) co-
ordination to the two H6R and D7N familial mutants linked to
early onset of AD were investigated. While, regarding to Cu(II)
coordination, the D7N mutation have no significant impact, the
[CuII(H6R-Aβ)] complexes show differences with [CuII(Aβ16)].
More precisely, the pKa(I/II) is significantly lower (about 0.5 pH
unit) in the former case than in the latter, implying that at
physiological pH the two components I and II will be differently
distributed. More importantly, Cu(II) is differently bound in
both components I and II of [CuII(H6R-Aβ)] and [CuII(Aβ)].
Proposed Cu(II) equatorial binding sites of [CuII(H6R-Aβ)]
complexes are shown in Scheme 3. The most striking difference
with [CuII(Aβ16)] is due to the concomitant involvement of
His13 and His14 in Cu(II) binding in I, leading to outer first
coordination shell effects observed by CD. Such equatorial binding
of the His13-His14 diad (as minor form) in [CuII(Aβ16)] species
compared to coordination of the His6 plus His13 or His14
(as major form) has been recently proposed to be linked to forma-
tion of amorphous aggregates.20 In the [CuII(H6R-Aβ)] species,
only the His13-His14 diad does intervene in Cu(II) equatorial
binding in component I, and thus, the H6R mutation may be
anticipated to be responsible of formation of only amorphous
aggregates. In component II, intervention of CO from His13-
His14 and His14-Gln15 peptide bonds in Cu(II) equatorial
binding may also explained why component III is not detected
in [CuII(H6R-Aβ)] complexes. Indeed, decoordination of the
CO and the adjacent imidazole ring from His13 or His14
(forming a 6-membered metallacycle) residues may be conco-
mitant, thus leading directly to a component IV (identical to the
one obtained in case of the [CuII(Aβ)] species) from component
II. Lastly, the [CuII(H6R-Aβ)] and [CuII(H6A-Aβ)] complexes
have the same spectroscopical signatures implying that nature of
the replacing residue in the H6 mutant is not a key factor.
’CONCLUDING REMARKS
In the present paper, we reported the pH-dependent study of
Cu(II) coordination to the Aβ peptide and to a series of mutants.
While results obtained here are in perfect agreement with the
Cu(II) equatorial binding site previously proposed in the litera-
ture for component I {NH2, CO (Asp1Ala2), 2 Nim}, they
also strongly supports a {NH2, N, CO (Ala2Glu3), Nim}
site in component II. Cu(II) complexes outside the physiological
pH range have also been studied for expanding the number of
spectroscopic references of Cu(II) peptidic species. Among the
various mutants studied, the two familial H6R and D7Nmutants
were investigated and while the D7N mutation does not impact
significantly Cu(II) coordination to Aβ, the H6R one leads to
modification in Cu(II) binding that may also influence the
peptide aggregating properties. During the course of these
studies, the EPR and CD revealed to be complementary spectro-
scopies. Indeed, while EPR is a powerful technique to determine
the Cu(II) equatorial environment, CD was very useful in
disentangling effects outside the first coordination shell and for
instance lead to the detection of a new species near pH 5.5.
’EXPERIMENTAL SECTION
1. Sample Preparation. Studies were performed in H2O or in
D2O. However, for clarity and consistency, we decided to use the
notation pH even when the measurements were made in D2O. pD was
Scheme 2. D1N Mutation Decreases the pKa(I/II) Value by
Precluding the COO 3 3 3HN (Asp1Ala2) Interaction
(7-Membered Metallacycle) while the E3Q Mutation De-
creases the pKa(II/III) Value by Precluding the COO 3 3 3
HN (Ala2Glu3) Interaction (7-Membered Metallacycle)
Scheme 3. Proposed Equatorial Cu(II) Binding Sites of
[CuII(H6R-Aβ)] as a Function of pH
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measured using a classical glass electrode according to pD = pHreading +
0.4, and the pD value was adjusted according to ref 38 to be in ionization
conditions equivalent to those in H2O.
Aβ16 peptide (sequence DAEFRHDSGYEVHHQK and referred to
as Aβ in the following), Ac-Aβ peptide corresponding to the N-termin-
ally acetylated Aβ peptide, the D1N-Aβ (sequence NAEFRHDSGYEV-
HHQK), E3Q-Aβ (sequence DAQFRHDSGYEVHHQK), H6R-Aβ
(sequence DAEFRRDSGYEVHHQK), H6A-Aβ (sequence DAEFRA-
DSGYEVHHQK), D7N-Aβ (sequence DAEFRHNSGYEVHHQK),
E11Q-Aβ (sequence DAEFRHDSGYQVHHQK), H13A-Aβ (sequence
DAEFRHDSGYEVAHQK), H14A-Aβ (sequence DAEFRHDSGYEV-
HAQK), and the triple E3QD7NE11Q-Aβ C-terminally protected Aβ
peptide (sequence DAQFRHNSGYQVHHQK-NH2) were bought from
GeneCust (Dudelange, Luxembourg) with purity grade >98%.
Stock solutions of peptide were prepared by dissolving the powder in
Milli-Q water or in D2O (resulting pH ∼2). Peptide concentration was
then determined by UVvisible absorption of Tyr10 considered as free
tyrosine ((ε276- ε296) = 1410 M
1cm1) and the solution was diluted
down to the appropriate concentration in peptide.
pH was adjusted using NaOH/HCl (H2O) or NaOD/DCl (D2O).
All pH values are given with a ( 0.2 pH unit error.
a. Circular Dicroism (CD) Samples. Stock solution of peptide was
diluted down to 0.5 mM in pure Milli-Q water; 0.9 equiv of CuII was
added from 0.1 M Cu(SO4) stock solution.
b. Electron Paramagnetic Resonance (EPR) Samples. Stock solution
of peptide was diluted down to 1.0 mM in D2O; 0.9 equivalent of
63CuII
was added from 0.1 M 63Cu(NO3)2 stock solution. Samples were frozen
in quartz tube, with addition of 10% glycerol as a cryoprotectant.
c. Nuclear Magnetic Resonance (NMR) Samples. Stock solution of
H6R-Aβ peptide was diluted to about 5 mM in D2O. Substoichiometric
quantity (∼0.05 equiv) of CuII from Cu(SO4) in D2O was added. CuII
to H6R-Aβ ratio was reduced to a minimum in the free peptide solution
by working at 10 mM peptide concentration without buffer that is the
primary source of paramagnetic contamination. Indeed a too high CuII
to Aβ ratio would induce an uncontrolled broadening of NMR signals, a
problem that may contributes to the loss of signals in the apo-peptide
solution in previous studies.39,40 Substoichiometric CuII ratio (0.05
equiv of CuII per Aβ peptide) was used. Indeed, this ratio is large enough
to induce selective broadening of specific residues of all the peptides
present in solution (because of fast exchange of CuII between peptides).
2. Spectroscopic Measurements. a. Circular Dichroism (CD).
CD spectra were recorded on a JASCO circular dichroism spectrometer
at 20 C. Data were collected with a 1 nm sampling interval and 2 scans
were averaged and a baseline spectrum was subtracted for each spectrum.
b. Electron Paramagnetic Resonance (EPR). EPR data were recorded
using an Elexsys E 500 Bruker spectrometer, operating at a microwave
frequency of approximately 9.5 GHz. All spectra were recorded using a
microwave power of 20 mW across a sweep width of 150 mT (centered
at 310 mT) with a modulation amplitude of 0.5 mT. Experiments were
carried out at 110 K using a liquid nitrogen cryostat.
c. Nuclear Magnetic Resonance (RNMR). 1D 1H and 13C experiments
and 2D experiments were recorded on a Bruker Avance 500 spectro-
meter equipped with a 5 mm triple resonance inverse Z-gradient probe
(TBI 1H, 31P, BB) and a Bruker Avance 600 spectrometer equipped with
a 5 mm triple resonance inverse (TCI 1H, 13C, 15N) Z-gradient
cryoprobe, respectively. All chemical shifts are relative to tetramethylsi-
lane. 1D-NMR and 2D-NMR spectra were collected at 298 and 288 K in
pure D2O, respectively. Accumulation lasts c.a. Sixteen hours for the
13C{1H} NMR experiments and 24 h for the 2D 1H1H TOCSY,
1H13C HSQC, and 1H13C HMBC experiments.
All the 1H and 13C signals were assigned on the basis of chemical
shifts, spinspin coupling constants, splitting patterns and signal intensities,
and by using 1H1H TOCSY, 1H13C HSQC, and 1H13C HMBC
experiments.
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bS Supporting Information. pH-dependent EPR and CD
spectra of [CuII(peptide] complexes, 13C NMR spectra of H6R-
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http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*E-mail: christelle.hureau@lcc-toulouse.fr. Phone: (+33) 5 61 33
31 62. Fax: (+33) 5 61 55 30 03.
Author Contributions
†These authors contributed equally to this work.
’ACKNOWLEDGMENT
Authors thank the ANR (Agence Nationale de la Re-
cherche), ANR Grant Neurometals NT09-488591. We thank
Dr. L. Fremond for earlier results obtained on Cu(II) binding
to H13A-Aβ and H14A-Aβ, Drs. L. Sabater, G. La Penna
and P. Dorlet for fruitful discussions. Charles-Louis Serpen-
tini is acknowledged for its participation in recording the
CD data.
’REFERENCES
(1) Holtzman, D. M.; Morris, J. C.; Goate, A. M. Sci. Transl. Med.
2011, 3, 77sr1.
(2) Castellani, R. J.; Smith, M. A. J. Pathol. 2011, 224, 147–152.
(3) Hardy, J.; Selkoe, D. J. Science 2002, 298, 789–791.
(4) Maccioni, R. B.; Mu~noz, J. P.; Barbeito, L. Arch. Med. Res. 2001,
32, 367–381.
(5) Simon, A. M.; Frechilla, D.; del Rio, J. Rev. Neurol. 2010, 50,
667–675.
(6) Cappai, R.; Barnham, K. J. Neurochem. Res. 2008, 33, 526–532.
(7) Adlard, P. A.; Bush, A. I. J. Alzheimer Dis. 2006, 10, 145–163.
(8) Bush, A. I. Trends Neurosci. 2003, 26, 207–214.
(9) Cuajungco, M. P.; Faget, K. Y. Brain Res. Rev. 2003, 41, 44–56.
(10) Faller, P.; Hureau, C. Dalton Trans. 2009, 1080–1094.
(11) Hureau, C.; Faller, P. Biochimie 2009, 91, 1212–1217.
(12) Kozlowski, H.; Janicka-Klos, A.; Brasun, J.; Gaggelli, E.; Valensin,
D.; Valensin, G. Coord. Chem. Rev. 2009, 253, 2665–2685.
(13) Molina-Holgado, F.; Hider, R. C.; Gaeta, A.; Williams, R.;
Francis, P. Biometals 2007, 20, 639–654.
(14) Smith, D. G.; Cappai, R.; Barnham, K. J. Biochim. Biophys. Acta
2007, 1768, 1976–1990.
(15) Dorlet, P.; Gambarelli, S.; Faller, P.; Hureau, C. Angew. Chem.,
Int. Ed. 2009, 48, 9273–9276.
(16) Hureau, C.; Coppel, Y.; Dorlet, P.; Solari, P. L.; Sayen, S.; Guillon,
E.; Sabater, L.; Faller, P. Angew. Chem., Int. Ed. 2009, 48, 9522–9525.
(17) Drew, S. C.; Noble, C. J.; Masters, C. L.; Hanson, G. R.;
Barnham, K. J. J. Am. Chem. Soc. 2009, 131, 1195–1207.
(18) Drew, S. C.; Masters, C. L.; Barnham, K. J. J. Am. Chem. Soc.
2009, 131, 8760–8761.
(19) Drew, S. C.; Barnham, K. J. Acc. Chem. Res. 2011, DOI:
10.1021/ar200014u.
(20) Shin, B.-k.; Saxena, S. J. Phys. Chem. A 2011, 115, 9590–9602.
(21) Kowalik-Jankowska, T.; Ruta, M.; Wisniewska, K.; Lankiewicz,
L. J. Inorg. Biochem. 2003, 95, 270–282.
(22) Kozlowski, H.; Bal, W.; Dyba, M.; Kowalik-Jankowska, T.
Coord. Chem. Rev. 1999, 184, 319–346.
(23) Ono, K.; Condron, M. M.; Teplow, D. B. J. Biol. Chem. 2010,
285, 23186–23197.
11201 dx.doi.org/10.1021/ic201739n |Inorg. Chem. 2011, 50, 11192–11201
Inorganic Chemistry ARTICLE
(24) Hori, Y.; Hashimoto, T.; Wakutani, Y.; Urakami, K.; Nakashima,
K.; Condron, M. M.; Tsubuki, S.; Saido, T. C.; Teplow, D. B.; Iwatsubo,
T. J. Biol. Chem. 2007, 282, 4916–4923.
(25) Karr, J. W.; Kaupp, L. J.; Szalai, V. A. J. Am. Chem. Soc. 2004,
126, 13534–13538.
(26) Minicozzi, V.; Stellato, F.; Comai, M.; Dalla Serra, M.; Potrich, C.;
Meyer-Klaucke, W.; Morante, S. J. Biol. Chem. 2008, 283, 10784–10792.
(27) Syme, C. D.; Nadal, R. C.; Rigby, S. E.; Viles, J. H. J. Biol. Chem.
2004, 279, 18169–18177.
(28) Hureau, C.; Eury, H.; Guillot, R.; Bijani, C.; Sayen, S.; Solari, P. L.;
Guillon, E.; Faller, P.; Dorlet, P. Chem.—Eur. J. 2011, 17, 10151–10160.
(29) Varnagy, K.; Szabo, J.; Sovago, I.; Malandrinos, G.; Nick, H.;
Sanna, D.; Micera, G. J. Chem. Soc., Dalton Trans. 2000, 467–472.
(30) Hureau, C.; Charlet, L.; Dorlet, P.; Gonnet, F.; Spadini, L.;
Anxolabehere-Mallart, E.; Girerd, J.-J. J. Biol. Inorg. Chem. 2006, 11,
735–744.
(31) Peisach, J.; Blumberg, W. E. Arch. Biochem. Biophys. 1974, 165,
691–708.
(32) Eury, H.; Bijani, C.; Faller, P.; Hureau, C. Angew. Chem., Int. Ed.
2011, 50, 901–905.
(33) Karr, J. W.; Szalai, V. A. J. Am. Chem. Soc. 2007, 129, 3796–3797.
(34) Sarell, C. J.; Syme, C. D.; Rigby, S. E.; Viles, J. H. Biochemistry
2009, 48, 4388–4402.
(35) Rasia, R. M.; Bertoncini, C. W.; Marsh, D.; Hoyer, W.; Cherny,
D.; Zweckstetter, M.; Griesinger, C.; Jovin, T.M.; Fernandez, C. O. Proc.
Natl. Acad. Sci. U.S.A. 2005, 102, 4294–4299.
(36) Gaggelli, E.; Bernardi, F.; Molteni, E.; Pogni, R.; Valensin, D.;
Valensin, G.; Remelli, M.; Luczkowski, M.; Kozlowski, H. J. Am. Chem.
Soc. 2005, 127, 996–1006.
(37) Raffa, D. F.; Gomez-Balderas, R.; Brunelle, F.; Rickard, G. A.;
Rauk, A. J. Biol. Inorg. Chem. 2005, 10, 887–903.
(38) Delgado, R.; Da Silva, J. J. R. F.; Amorim, M. T. S.; Cabral,
M. F.; Chaves, S.; Costa, J. Anal. Chim. Acta 1991, 245, 271–282.
(39) Danielsson, J.; Pierattelli, R.; Banci, L.; Graslund, A. FEBS
J. 2007, 274, 46–59.
(40) Hou, L.; Zagorski, M. G. J. Am. Chem. Soc. 2006, 128, 9260–9261.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41
Copper coordination to native N-terminally 
modified versus full-length amyloid-β: second 
sphere effects determine the species present at 
physiological pH 
 
Bruno Alies, Christian Bijani, Stephanie Sayen,  
Emmanuel Guillon, Peter Faller, Christelle Hureau  
 
Inorganic Chemistry 
Accepted 
 
 
 
 
  
The following article is summarized in the previous chapter. It is a comprehensive 
study about Cu coordination to the deleterious N-terminal truncated Aβ peptides. 
 
 
 
 
 
 
 
 
 42
1 Copper Coordination to Native N‑Terminally Modified versus Full-
2 Length Amyloid-β: Second-Sphere Effects Determine the Species
3 Present at Physiological pH
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11 ABSTRACT: Alzheimer’s disease is characterized by senile
12 plaques in which metallic ions (copper, zinc, and iron) are
13 colocalized with amyloid peptides of different sequences in
14 aggregated forms. In addition to the full-length peptides (Aβ1-
15 40/42), N-terminally truncated Aβ3-40/42 forms and their
16 pyroglutamate counterparts, Aβp3-40/42, have been proposed
17 to play key features in the aggregation process, leading to the
18 senile plaques. Furthermore, they have been shown to be more
19 toxic than the full-length Aβ, which made them central targets
20 for therapeutic approaches. In order to better disentangle the
21 possible role of metallic ions in the aggregation process,
22 copper(II) coordination to the full-length amyloid peptides has
23 been extensively studied in the last years. However, regarding
24 the N-terminally modified forms at position 3, very little is known. Therefore, copper(I) and copper(II) coordination to those
25 peptides have been investigated in the present report using a variety of complementary techniques and as a function of the pH.
26 Copper(I) coordination is not affected by the N-terminal modifications. In contrast, copper(II) coordination is different from
27 that previously reported for the full-length peptide. In the case of the pyroglutamate form, this is due to preclusion of N-terminal
28 amine binding. In the case of the N-terminally truncated form, alteration in copper(II) coordination is caused by second-sphere
29 effects that impact the first binding shell and the pH-dependent repartition of the various [Cu(peptide)] complexes. Such
30 second-sphere effects are anticipated to apply to a variety of metal ions and peptides, and their importance on changing the first
31 binding shell has not been fully recognized yet.
32 ■ INTRODUCTION
33 Amyloid-β (Aβ) is mainly a 40/42 amino acid residue peptide
34 that is normally present under physiological conditions,
35 especially in the brain. Despite a wide number of studies, its
36 biological function is still under debate.1 Aβ is well-known to be
37 the main component of senile plaque, a typical feature that
38 occurs in the brain of Alzheimer’s disease (AD) patients.2
39 According to the amyloid cascade hypothesis, aggregation of
40 the monomeric Aβ into the fibrils detected in the senile plaque
41 plays a causal role in AD.3 The amyloid cascade contains several
42 aggregation stages (oligomers, protofibrils, and fibrils), and
43 aggregation intermediates (often called oligomers) have been
44 proposed to instigate further pathological events, including the
45 formation of intracellular neurofibrillary tangles, another
46 hallmark of AD, and disruption of synaptic connections,
47 which would lead ultimately to neuronal cell death and
48 dementia.3−5 They are now considered to be more toxic than
49 the senile plaques or higher molecular weight aggregates,5−7 via
50various events including the production of reactive oxygen
51species (ROS), which have also been implicated in the
52pathological process. Metal ions such as copper, iron, and
53zinc are found at hundreds of micromolars in senile plaques.8,9
54Their effects on Aβ aggregation and their involvement in the
55generation of ROS, two key features in the amyloid cascade,
56underline an important role of metallic ions in AD.10−12
57In order to gain insight into the role of metallic ions in AD,
58coordination of copper to Aβ1-40/42 has been widely studied.
59It was shown that copper(II)13−15 and copper(I)16 bind to the
60first 16 amino acid residues and, hence, the C-terminally
61truncated Aβ1-16 peptide is widely accepted as a valuable
62model of copper binding to monomeric Aβ1-40/42. Copper-
63(II) binds Aβ with an apparent Kd in the low nanomolar range
64(at pH 7.4),17−19 and copper coordination is pH-dependent.
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65 Near physiological pH, [CuII(Aβ)] species are found under two
66 kinds of coordination modes (called “components” I and
67 II),20,21 in which the copper(II) geometry is square-planar.
68 Components I and II have been characterized using electron
69 paramagnetic resonance (EPR), including studies on copper(II)
70 binding to specifically labelled Aβ peptides,22−24 circular
71 dichroism (CD),25 and nuclear magnetic resonance
72 (NMR).15,26 The four copper(II) equatorial ligands in
73 component I are NH2 from the N-terminal Asp1, CO from
74 the Asp1−Ala2 peptide bond, and two nitrogen atoms from the
75 His rings of His6 and His13 or His14, with the latter two being
76 in dynamical exchange for the fourth copper(II) equatorial
77 position. In component II, the four ligands are the NH2
78 terminal amine that remains coordinated, the deprotoned N−
79 amide group from the Asp1−Ala2 bond that replaces the
80 corresponding CO group, the adjacent CO group from the
81 Ala2−Glu3 peptide bond, and a side chain from one His (His6,
82 His13, or His14 in dynamical exchange).
83 Recently, the species obtained at higher pH, i.e., components
84 III and IV, have been characterized as well.27 Component III
85 equatorial ligands consist of −NH2 (Asp1), two adjacent
86 deprotonated amides N− (from Asp1−Ala2 and Ala2−Glu3
87 peptide bonds), and one His. Component IV involves the N-
88 terminal NH2 (Asp1) and three adjacent deprotonated amides
89 N− (from Asp1−Ala2, Ala2−Glu3, and Glu3−Phe4 peptide
90 bonds). Hence, the Roman numbers refer to the number of
91 deprotonated amide function(s) involved in copper(II) binding
92 (from I to IV for components involving from 0 to 3
93 deprotonated amide functions).
94 Regarding copper(I) coordination to the monomeric Aβ
95 peptide, a consensual proposition has recently emerged in the
96 literature: the copper(I) center is linearly bound by two side
97 chains of His residues,16,28 with equilibrium between the three
98 possible pairs of His, His6−His13, His6−His14, and His13−
99 His14, with the latter one being proposed as the predominant
100 species.29,30
101 Aβ1-40/42 and familial mutants are not the only forms of
102 interest. N-Terminally modified peptides such as the Aβ3-40/
103 42 truncated forms, the sequence of which begins by glutamate
104 3, and the pyroglumate Aβp3-40/42 counterpart have been
105 found in AD brains in high amount (up to 25% of Aβ in
106 plaques are pyroglutamate forms31,32) and have been
107 extensively studied in the last years for several reasons. First,
108 they have been shown to be more toxic than the full-length
109 Aβ1-40/42,33−37 possibly via modification of the amyloid
110 plaque morphology.38 Second, the N-term cyclization in Aβp3-
111 40/42 slows down peptide degradation.39 Third, the
112 aggregation process of Aβ1-40/42 could change because of
113 seeding effects of the pyroglutamate forms.40−42
114 Considering the role of copper ions in Aβ aggregation and
115 ROS production processes linked to AD, it seems interesting to
116 investigate the coordination chemistry of copper(I) and
117 copper(II) to those N-terminally modified forms Aβ3-40/42
118 and Aβp3-40/42. So far, only one EPR study on the
119 coordination chemistry copper(II) binding to models of Aβ3-
120 40/42 and Aβp3-40/42, i.e., Aβ3-16 and Aβp3-16, was
121 published.43 On the basis of similar EPR parameters
122 determined for the two [CuII(Aβ3-16)] and [CuII(Aβp3-16)]
123 species, the authors suggested that copper(II) coordination to
124 the Aβ3-16 and Aβp3-16 peptides are similar but with different
125 pH dependence regarding the repartition of components I and
126 II. As in [CuII(Aβp3-16)], copper(II) coordination via the
127 terminal amine is precluded by the pyroglutamate ring; they
128thus proposed that the N-terminal amine is not directly
129involved in copper(II) binding in the [CuII(Aβ3-16)]
130complexes either. This result seems highly questionable because
131it has been shown in many studies and on several different Aβ
132peptide sequences that when the N-terminal amine is available,
133it takes part of the coordination sphere of copper(II) regardless
134of the pH values.25,27
135In order to get a better description of copper(II)
136coordination to Aβ3-16 and Aβp3-16 peptides and possibly
137to disentangle the role of the −NH2 terminus in copper(II)
138binding in such Aβ-modified forms, we have used EPR but also
139extended the analysis with complementary methods, i.e., 13C
140NMR, CD, and X-ray absorption near-edge structure
141(XANES). In addition to these new pieces of data on
142copper(II), we have determined copper(I) coordination by
143
1H NMR, and to complete the study, we have evaluated the
144copper(II) and copper(I) affinity for both N-terminally
145modified peptides. This complete set of analyses provided the
146first results on copper(I) and new insights into the coordination
147of copper(II) to such N-terminally modified peptides.
148■ EXPERIMENTAL SECTION
149Copper Solutions. Copper(II) used was from CuSO4·5H2O and
150purchased from Sigma. A stock solution of copper(II) (∼1 M) was
151prepared in D2O. [Cu
I(MeCN)4](BF4) (MeCN = methyl cyanide)
152was bought from Sigma-Aldrich and kept under an inert atmosphere
153until use. A copper(I) stock solution (0.16 M) was prepared in MeCN.
154Ferrozine [5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine-4,4″-disulfonic
155acid monosodium salt hydrate] was bought from Alfa-Aesar. A 0.1
156M stock solution was prepared in water.
157HEPES buffer (sodium salt of 2-[4-(2-hydroxyethyl)piperazin-1-
158yl]ethanesulfonic acid) was bought from Fluka (bioluminescence
159grade).
160A phosphate buffer was prepared from K2HPO4 and KH2PO4
161bought from Sigma-Aldrich.
162Peptides. Aβ1-16 peptide (sequence DAEFRHDSGYEVHHQK),
163Ac-Aβ peptide corresponding to the N-terminally acetylated Aβ1-16
164peptide, Aβ3-16 (sequence EFRHDSGYEVHHQK), and Aβp3-16
165corresponding to the N-terminally pyroglumate form of the Aβ3-16
166peptide (sequence (pEFRHDSGYEVHHQK) were bought from
167GeneCust (Dudelange, Luxembourg) with purity grade >98%
168Cu(peptide) Sample Preparation. Studies were performed in
169H2O or D2O. However, for clarity and consistency, we decided to use
170the notation pH even when the measurements were made in D2O.
171The pD was measured using a classical glass electrode according to pD
172= pH* + 0.4, and the apparent pH value was adjusted according to ref
17344, pH = (pD − 0.32)/1.044, or equivalently to ref 45, pH =
1740.929pH* + 0.41, to be in ionization conditions equivalent to those in
175H2O.
176Stock solutions of peptide were prepared by dissolving the powder
177in Milli-Q water or D2O (resulting pH ∼ 2). The peptide
178concentration was then determined by UV−vis absorption of Tyr10
179considered as free tyrosine (ε276 − ε296 = 1410 M−1 cm−1), and the
180solution was diluted to the appropriate concentration in peptide. The
181pH was adjusted using NaOH/HCl (H2O) or NaOD/DCl (D2O). All
182pH values are given with a ±0.2 pH unit error.
183Circular Dichroism (CD) Samples. A stock solution of peptide was
184diluted to 0.5 mM in pure Milli-Q water. A total of 0.9 equiv of CuII
185was added from a 0.1 M Cu(SO4) stock solution.
186Electron Paramagnetic Resonance (EPR) Samples. A stock
187solution of peptide was diluted to 1.0 mM in D2O. A total of 0.9
188equiv of 63CuII was added from a 0.1 M 63Cu(NO3)2 stock solution.
189Samples were frozen in quartz tubes after the addition of 10% glycerol
190as a cryoprotectant.
191Nuclear Magnetic Resonance (NMR) Samples. For NMR
192copper(II) experiments, a stock solution of Aβ3-16 or Aβp3-16
193peptide was diluted to about 10 mM in D2O. A substoichiometric
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194 quantity (ca. 0.02 equiv at pH 6 or 0.3 equiv at pH 8.6 for the Aβ3-16
195 peptide and 0.05 equiv at pH 7 for the for the Aβp3-16 peptide) of
196 copper(II) from Cu(SO4) in D2O was added. Indeed, a too high
197 copper(II)-to-Aβ ratio would induce an uncontrolled broadening of
198 NMR signals because of paramagnetism of the copper(II). Never-
199 theless, this ratio needs to be enough to induce selective broadening of
200 specific residues of all of the peptides present in solution [via exchange
201 of copper(II) between peptides].
202 For NMR copper(I) experiments, copper(I) was produced in situ,
203 by the direct addition (1.5 equiv) of a fresh-made Na2S2O3 stock
204 solution (0.1 M) into an NMR tube previously degassed with water-
205 saturated argon containing the peptides and copper(II), both at 1 mM
206 concentration. The NMR tube was sealed under argon, measured as
207 soon as possible to prevent possible oxidation. In such conditions, no
208 significant pH drift due to the addition of Na2S2O3 was measured.
209 UV−Vis Samples. For ferrozine titration experiments, copper(I)
210 stock solutions (5 mM) were prepared in an argon-degassed HEPES
211 buffer [0.1 M, pH 7.4, containing 5% (v/v) MeCN] and degassed with
212 water-saturated argon just before use. UV−vis monitoring of the stock
213 solution under argon was performed to ensure that under these
214 conditions no dismutation occurred. Less than 2% of copper(II) was
215 detected, a content that can be neglected in analysis of the titration
216 curve.
217 CD. CD spectra were recorded at 20 °C on a Jasco J-815 CD
218 spectrometer, with a Peltier PTC423 temperature controller. Data
219were collected with a 1 nm sampling interval, and two scans were
220averaged and a baseline spectrum was subtracted for each spectrum.
221EPR. EPR data were recorded using an Elexsys E 500 Bruker
222spectrometer, operating at a microwave frequency of approximately 9.5
223GHz. All spectra were recorded using a microwave power of 20 mW
224across a sweep width of 150 mT (centered at 310 mT) with a
225modulation amplitude of 0.5 mT. Experiments were carried out at 110
226K using a liquid-nitrogen cryostat.
227NMR. 1D 1H and 13C NMR experiments and 2D experiments were
228recorded on a Bruker Avance 500 spectrometer equipped with a 5-mm
229triple-resonance inverse Z-gradient probe (TBI 1H, 31P, BB). All
230chemical shifts are relative to tetramethylsilane. 1D and 2D NMR
231spectra were collected at 298 K in pure D2O, respectively.
232Accumulation lasted ca. 16 h for the 13C{1H} NMR experiments
233and 24 h for the 2D 1H−1H TOCSY, 1H−13C HSQC, and 1H−13C
234HMBC experiments.
235All of the 1H and 13C NMR signals were assigned on the basis of
236chemical shifts, spin−spin coupling constants, splitting patterns, and
237signal intensities and by using 1H−1H TOCSY, 1H−13C HSQC, and
238
1H−13C HMBC experiments.
239XANES. Measurements were carried out at the SOLEIL
240Synchrotron Facility (St. Aubin, France), which was operating with
241a ring current of 400 mA. Cu K-edge XANES spectra were collected
242on the SAMBA beamline using a Si(220) double crystal mono-
243chromator and two large silicon mirrors for high-energy harmonics
244rejection. The liquid samples were injected in special sample holders
Figure 1. pH dependence of copper(II) coordination to Aβ3-16 (panel A) and Aβ1-16 (inset in panel A) and to Aβp3-16 (panel B) and Ac-Aβ1-16
(insert panel B) from acidic (blue) to basic (red) pH values. Panel C: Zoom on the UV band of [Cu(Aβ3-16)] between pH 9 and 12 and pH
dependence of the UV band at 296 nm detected by CD (inset in panel C). Panel D: pH dependence of the UV band at 293 nm detected by UV−vis
for Aβ1-16 (blue) and Aβ3-16 (red) peptides and of the corresponding copper(II) complexes. Insets in panel D are the UV−vis spectrum of Aβ3-16
and [Cu(Aβ3-16)]. [CuII(peptide)] = 0.45 mM (panels A−C), [CuII(peptide)] = 0.3 mM (panel D), and l = 1 cm.
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245 and cooled down to 20−30 K using a helium-flow cryostat. The
246 spectra were collected in fluorescence mode by measuring the Cu Kα
247 fluorescence with a seven-element germanium detector (Canberra).
248 Three scans of 25 min each were averaged. Data from each detector
249 channel were inspected for glitches or dropouts before inclusion in the
250 final average. Energy calibration was achieved by recording a copper
251 foil for the Cu edge and assigning the first inflection point of the
252 absorption spectrum to 8980.3 eV. XANES spectra were background-
253 corrected by linear regression through the preedge region and a
254 polynomial through the postedge region and normalized to the edge
255 jump. No significant photoreduction of the samples occurs during the
256 measurements.
257 ■ RESULTS
258 Structural Data on [Cu(Aβ3-16)] and [Cu(Aβp3-16)].
259 pH Dependence on the CD Study of [CuII(Aβ3-16)] and
260 [CuII(Aβp3-16)]. CD is a powerful tool to sense structural
261 changes due to metal-ion coordination to peptide. In the case
262 of copper(II) complexes, the d−d and charge-transfer
263 transitions can be studied between 450 to 750 nm and between
264 250 and 400 nm, respectively.46 CD is thus sensitive to
265 structural changes in the first copper(II) coordination sphere
266 but also to modifications beyond the first shell.47 pH-
267 dependent CD spectra were recorded for the four [CuII(Aβ1-
268 16)], [CuII(Aβ3-16)], [CuII(Ac-Aβ1-16)], and [CuII(Aβp3-
f1 269 16)] complexes (Figure 1A,B). All four studied complexes
270 show different signatures, underlining different first and second
271 coordination shells. Nevertheless, general trends can be
272 observed. In all of the complexes, the intensity of the
273 deprotonated amide-to-copper(II) ligand-to-metal charge-
274 transfer (LMCT) transitions increases from pH ∼ 6, indicating
275 participation of the deprotonated amide in copper(II) binding
276 above this pH value. Furthermore, the d−d transition bands
277 evolve from approximately 650 nm at low pH to 500 nm at
278 high pH. This hypsochromic shift indicates a copper(II)
279 environment that gets enriched in nitrogen atoms (compared
280 to oxygen atoms) at higher pH, in line with successive amide
281 backbone deprotonation and subsequent copper(II) binding
282 with a pH increase. Another important feature is the strong
283 similarity between [CuII(Aβ1-16)] and [CuII(Aβ3-16)] on the
284 one side and [CuII(Ac-Aβ1-16)] and [CuII(Aβp3-16)] on the
285 other side (compare parts A and B of Figure 1 and parameters
t1 286 listed in Table 1). Thus, two families can be made: [CuII(Aβ1-
287 16)]-like families obtained when the peptide possesses a free
288 −NH2 terminus (Figure 1A) and [CuII(Ac-Aβ1-16)]-like
289 families when the peptide has the −NH2 terminus blocked
290 (Figure 1B). Two clear spectral differences between the two
291 families can be observed: (i) A negative band at ∼280 nm
292 attributed to NH2-to-copper(II) LMCT appears only in the
293 former family. This indicates the involvement of the −NH2
294 terminal amine in copper(II) binding regardless of the pH.
295 Such a CD feature is not observed in the latter family in line
296 with a −NH2 terminal amine, which is blocked either via
297 acetylation (Ac-Aβ1-16) or via pyroglutamate formation
298 (Aβp3-16). (ii) On the [CuII(Ac-Aβ1-16)] and [CuII(Aβp3-
299 16)] spectra, an intense positive CD band is observed at ∼645
300 nm, while on [CuII(Aβ1-16)] and [CuII(Aβ3-16)] spectra, such
301 a band is not detected. These two main differences strongly
302 suggest two highly different copper(II) sites between
303 [CuII(Aβ1-16)] and [CuII(Aβ3-16)], on the one hand, and
304 [CuII(Ac-Aβ1-16)] and [CuII(Aβp3-16)], on the other hand,
305 regardless of the pH range. Such strong dissimilarities are
306 reminiscent of first-coordination-shell effects. In a more
307 thorough analysis, minor differences, indicative of second- T
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308 sphere effects, are observed between the CD spectra of
309 [CuII(Aβ1-16)] and [CuII(Aβ3-16)] complexes. For instance,
310 d−d transitions are slightly different, with positive CD bands
311 detected in the [CuII(Aβ1-16)] spectrum and only negative CD
312 bands in the case of the [CuII(Aβ3-16)] complex. Also the two
313 −NH2-to-copper(II) and deprotonated amide-to-copper(II)
314 LMCT bands are detected near 315 and 285 nm, respectively,
315 in the case of the [CuII(Aβ1-16)] complex, while the same
316 bands shift from 330 to 310 nm and from 285 to 275 nm with
317 an increase of the pH (pKa = 9.8; Figure 1C) in the case of the
318 [CuII(Aβ3-16)] complex. This pKa value is close to that
319 expected for deprotonation of the Tyr10 residue, and thus to
320 examine whether Tyr10 deprotonation is at the origin of such a
321 band shift in the case of the Aβ3-16 peptide, UV−vis pH
322 titration was performed for both peptides (Aβ1-16 and Aβ3-16)
323 and corresponding copper(II) complexes (Figure 1D).
324 Deprotonation of the Tyr residue is close between the apo-
325 and holopeptide and between the two peptides (pKa = 10.7 ±
326 0.1). Hence, the shift in the N−-to-copper(II) LMCT band
327 observed near pH 9.8 only detected for the [CuII(Aβ3-16)]
328 species is not linked to deprotonation of the Tyr residue,
329 indicating a difference in the second-sphere environment
330 between [CuII(Aβ3-16)] and [CuII(Aβ1-16)] that does not
331 persist above pH 9.8. Indeed above this pH value, both
332 complexes exhibit the same N−-to-copper(II) LMCT at 315
333 nm (Figure 1A,C). In addition, it appears that no Tyr10
334 coordination to copper(II) is observed either in the case of the
335 [CuII(Aβ1-16)] complex, as previously reported,15,24,25,48,49 or
336 in the case of the [CuII(Aβ3-16)] complex, in line with the
337 absence of tyrosinate-to-copper(II) LMCT transition detected
338 near 400 nm.50
339 pH Dependence on the EPR Study of [CuII(Aβ3-16)] and
340 [CuII(Aβp3-16)]. EPR has been widely used to gain insight into
341 copper(II) coordination because different copper(II) environ-
342 ments and geometries lead to different EPR parameters.46 In
343 particular, EPR parameters are correlated to the number,
344 chemical nature, and charge of the equatorial ligands.51 The pH
345 dependence of the EPR fingerprints of the four [Cu(Aβ1-16)],
346 [Cu(Aβ3-16)], [Cu(Ac-Aβ3-16)], and [Cu(Aβp3-16)] com-
347 plexes have been studied over a wide pH range (3−12; Figure
348 S1 in the Supporting Information). This allowed determination
349 of the speciation, i.e., the different types of coordination
350 environments and their relative abundance as a function of the
351 pH. With respect to the previous work,27 the different
352 components encountered in [Cu(Aβ1-16)] and [Cu(Aβ3-
353 16)] (respectively [Cu(Ac-Aβ)] and [Cu(Aβp3-16)]) were
354 denoted as I−IV (respectively I′−IV′). According to the two
f2 355 families observed by CD, we have regrouped in Figure 2A the
356 EPR spectra of [Cu(Aβ1-16)] (black) and [Cu(Aβ3-16)]
357 (gray) and in Figure 2B the EPR spectra of [Cu(Ac-Aβ1-16)]
358 (black) and [Cu(Aβp3-16)] (gray), where the spectra are
359 compared at some selected pH values. In Figure 2A, the two
360 lower traces display the EPR signatures of the two components
361 I (blue) and II (green) in a 1:1 ratio of [Cu(Aβ1-16)] (black,
362 pH 7.8) and [Cu(Aβ3-16)] (gray, pH 7.0). The EPR signatures
363 are very similar, in line with the same type of first-sphere
364 copper(II) coordination in the two peptides for both
365 components I and II. The EPR parameters (Table 1) of
366 components I and II are consistent with a 3N1O coordination
367 mode, as previously discussed in the case of the Aβ1-16
368 peptide.13,17,21,25 The middle trace [Cu(Aβ3-16)] (yellow, pH
369 8.7) is attributed to component III, a component that is hardly
370 detected in the case of [Cu(Aβ1-16)]27 because of the
371simultaneous presence of components II and IV. The two
372upper traces [Cu(Aβ1-16)] (black, pH 11.6) and [Cu(Aβ3-
37316)] (gray, pH 12.5) show the signature of component IV
374(red) of both complexes. EPR parameters of components III
375and IV are consistent with a 4N coordination sphere. In Figure
3762B, EPR spectra of [Cu(Ac-Aβ3-16)] (black) and [Cu(Aβp3-
37716)] (gray) are compared at different pH values. The two
378complexes display the same EPR signatures at similar pH
379values. Three different components are observed. The high
380similarities between the EPR fingerprints of [Cu(Ac-Aβ3-16)]
381and [Cu(Aβp3-16)] suggest that the coordination of copper-
382(II) will be similar in both peptides whatever the pH. Hence,
383the four components observed from pH 5 are denoted as I′−
384IV′, corresponding to complexes with 0 to 3 deprotonated
385amides bound to copper(II), with respect to previous work.27
386Together with the EPR parameters, the pKa values between two
387successive components are reported in Table 1. From these pKa
388values, it is possible to evaluate the relative proportion of the
389different components at a given pH. For the physiological pH
3907.4, in the case of [Cu(Aβ1-16)] having a pKa(I/II) = 7.7,
27 the
391major component is I with a weak contribution of component
392II. In contrast, for [Cu(Aβ3-16)] with a pKa(I/II) = 7.0
393[evaluated from the 50:50 proportion of components I and II at
394pH 7.0 (Figure 2A)] and a pKa(II/III) = 7.5 [evaluated from
395the 50:50 proportion of components II and III (Figure S2 in
396the Supporting Information)], the main component is II with a
397significant contribution of component III. Consequently, the
398type of copper(II) coordination at physiological pH is
399significantly different between the two peptides. For [Cu-
400(Aβp3-16)] species with pKa(II′/III′) = 7.6 [evaluated from the
40150:50 proportion of components II′ and III′ (Figure S2 in the
402Supporting Information)], II′ is the major component at pH
4037.4 with a large contribution of component III′, as is also the
404case for the [Cu(Aβp3-16)] complex. This underlines the fact
405that, for those two latter species, the EPR parameters and pH
406dependence are highly similar, indicating, as expected, that the
407influence of modification on the N-term is weak regarding
408copper(II) coordination.
409In ref 27 and in this work, parallel spin Hamiltonian
410parameters were obtained directly from the experimental
411spectra and were calculated from the second and third
412hyperfine lines in order to remove second-order effects. Errors
413on the hyperfine couplings are ±5 × 10−4 cm−1 and on the pKa
414values ±0.2.
415
13C NMR Study of [CuII(Aβ3-16)] and [CuII(Aβp3-16)]. In
416order to identify ligands involved in copper(II) coordination in
Figure 2. EPR spectra of copper(II) peptide complexes at selected pH
values. Panel A: [Cu(Aβ1-16)] (black); [Cu(Aβ3-16)] (gray). Right
panel B: [Cu(AcAβ1-16)] (black); [Cu(Aβp3-16)] (gray). [Cu-
(peptide)] = 1 mM in D2O, ν = 9.5 GHz, amplitude modulation = 0.5
mT, microwave power = 20 mW, and T = 110 K.
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417 the different species of [CuII(Aβ3-16)] and [CuII(Aβp3-16)],
418 the NMR data (1H, 13C, and 2D NMR experiments) of the
419 corresponding peptide in the absence and presence of
420 substoichiometric copper(II) amounts at several pH values
f3f4 421 were recorded (Figures 3 and 4 and S3−S12 in the Supporting
422 Information). Because copper(II) is paramagnetic and its
423 binding to Aβ peptides is dynamic, a small stoichiometry of
424 copper(II) will induce specific broadening of the NMR signals
425 of residues involved in copper(II) coordination.47 Nevertheless,
426 because of the dynamics in solution, 13C NMR can hardly
427 distinguish the transient ligands from more stable ligands (i.e.,
428
13C NMR signals of COO− and aromatic rings of His are both
429 highly affected by the presence of copper(II) because they are
430 likely involved in copper(II) exchange between peptides; see,
431 for instance, Figures S3, S4, and S10 in the Supporting
432 Information, panels B and F, respectively).26 Such transient
433 ligands may also be involved in the formation of Cu(Aβ)2
434 species, as recently suggested by Pedersen and co-workers,52
435 although in a our previous NMR study of copper binding to
436Aβ1-16, we found no direct evidence for the formation of such
437species in a significant amount.26
438In addition to that, NMR analysis of copper(II) binding to
439the peptides is limited to components with less than two
440deprotonated amide ligands (i.e., components I, II, and II′).
441Indeed, copper(II) coordination involving two or more
442deprotonated amide groups results in a too slow copper(II)
443exchange and the copper(II) paramagnetic effect broadens the
444signal of bound peptide beyond detection. Then only the signal
445of a copper(II)-unbound peptide or copper(II) bound to
446peptide in another detectable component remains.27,53
447Figure 3A shows the 13C NMR spectrum of the Cα area of
448Aβ3-16 peptide in the absence and presence of 0.02%
449copper(II) at pH 6.0. The two signals most strongly affected
450belong to Lys16 and Glu3. The signal of Cα from Glu3
451undergoes a large broadening, which is in line with the −NH2
452terminus bound to copper(II). The broadening of the Cα signal
453from Lys16 is attributed to binding of the free COO− C
454terminus, as observed earlier for Aβ1-16.26 However, this may
455not be relevant for the full-length peptide because the Aβ1-16
456C terminus was not protected. Hence, the involvement of the
457−NH2 terminal amine in copper(II) binding by the Aβ3-16
458peptide is confirmed by the NMR experiments, as were
459previously reported for the Aβ1-16 and murine counter-
460parts.26,54
461In order to figure out copper(II) coordination in component
462II, 13C NMR was performed at higher pH. There is no pH
463where component II is exclusively present. Thus, pH 8.6 was
464chosen because only components II and III are present, but
465component III cannot be detected by 13C NMR, in line with
466the presence of two deprotonated amide groups in the
467copper(II) binding site (see above). Hence, only changes due
468to component II are observed. Cα from Glu3 remains largely
469affected, indicating that the N-terminal NH2 stays coordinated
470to the copper(II) in component II. The main change between
471pH 6.0 and 8.6 is the broadening of Cα from Phe4, which is
472attributed to deprotonation of the NH group from the Glu3−
473Phe4 peptide bond and its coordination to copper(II). At pH
4748.6, the Cα and CO from His (Figure S4 in the Supporting
475Information, panels A and C) are broadened by copper(II)
476addition, and on the Cα/Hα correlation peak (Figure S5 in the
477Supporting Information), His6 is preferentially affected
478compared to the other two His residues, in line with the CO
479group of His6 involved in copper(II) binding.
Figure 3. Cα region of the 13C NMR spectrum of Aβ3-16 peptide in
the absence (black) or presence (gray) of 0.02 equiv of CuII at pH 6.0
(panel A) and of 0.3 equiv of CuII at pH 8.6 (panel B). The signals
affected by copper(II) addition are indicated by dotted lines. [Aβ3-16]
= 10 mM, T = 25 °C, and ν = 125.8 MHz.
Figure 4. Cα (panel A) and CO (panel B) regions of 13C NMR spectra of the Aβp3-16 peptide in the absence (black) or presence of 0.05 equiv of
CuII (gray) at pH 7.0. The signals affected by copper(II) addition are indicated by dotted lines. [Aβp3-16] = 10 mM, T = 25 °C, and ν = 125.8 MHz.
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480 At both pH values, the Cδ/Hδ and Cε/Hε of the His rings
481 are also affected (Figures S3 and S4, panel F, and S8 and S9 in
482 the Supporting Information), indicating His involvement in
483 copper(II) binding in both components. Thus, taking into
484 account the EPR and CD results, the experimental data are best
485 explained by the following equatorial coordination site of
486 copper(II) when linked to the Aβ3-16 peptide: component I
487 {NH2; CO; 2Im (His)} and component II {NH2; N
− (Glu3−
488 Phe4); Im (His6); CO (His6)}. On the basis of what was
489 proposed on the [Cu(Aβ1-16)] species,21 the CO function in
490 component I of [Cu(Aβ3-16)] might come from the Glu3
491 amino acid residue. Indeed, this will induce the formation of a
492 stable five-coordinated metallacycle with the −NH2 terminal
493 amine. In contrast, while in component II of the [Cu(Aβ1-16)]
494 complex, the Glu3 CO group adjacent to the Asp1−Ala2
495 deprotonated amide was proposed to be involved in copper(II)
496 binding,22,26 in the case of [Cu(Aβ3-16)], the CO group is
497 proposed to be that of His6 based on its selective broadening
498 detected by NMR. It has to be noted that, based only on the
499 size of the metallacycle formed, the {Im (His6), CO (His6)}
500 binding is less favorable than that of {N− (Glu3), CO (Arg5)}.
501 Thus, the binding of CO (His6) instead of CO (Arg5) may be
502 linked to the peculiar nature of the Arg5 side chain (bulky and
503 charged).
504 In Figure 4, the two panels display the 13C NMR spectra of
505 Aβp3-16 at pH 7.0 with (gray) and without (black) copper(II)
506 with focus on the CONH (left) and Cα (right) areas. Attempts
507 to record the NMR data at higher pH were unfruitful because
508 broadening was not specific enough, in line with copper(II)
509 bound by two or more deprotonated amide groups in
510 components III′ and IV′. In contrast to component II of
511 [Cu(Aβ3-16)] (Figure 3B, bottom), Phe4 is not affected in the
512 case of the Aβp3-16 peptide, in line with copper(II)
513 coordination to the N-term part (including the deprotonated
514 amide of the Glu3−Phe4 bond) that is precluded by the
515 presence of the pyroglutamate cycle. As a general trend, peaks
516 from the His residues are strongly affected by added copper(II)
517 (Figures S10−S12 in the Supporting Information), as
518 exemplified by Cα and CO (Figure 4). In general, His13 and
519 His14 are more affected than His6. As in component II′, there
520 is one deprotonated amide group bound to the copper(II)
521 center (see above); this might be explained by the preferential
522 involvement of the deprotonated amide from the His13−His14
523 peptide bond rather than the His6−Asp7 bond, with the
524 involvement of the deprotonated amide group from Arg5−His6
525being discarded on the basis of previous results on copper(II)
526binding to Aβ1-16.26,54 Such a His13−N−−His14 tripodal
527copper(II) binding has also been proposed using theoretical
528calculations55,56 and is in line with potentiometric studies of
529copper(II) binding to Ac-Y10A-Aβ8-16 peptides.57 Cα and CO
530from Asp7 and Glu11 are also affected by copper(II).
531Nevertheless, it seems that such a broadening is due to
532COO− coordination to copper(II) because the side chain is
533more strongly affected than the backbone carbon and hydrogen
534atoms. This indicates a possible implication of Asp7 and Glu11
535in copper(II) binding via COO−. As was previously observed,
536Cα from Lys16 is affected because of COO− binding.
537According to results obtained by other techniques, the most
538likely ligands of copper(II) in component II′ of [Cu(Aβp3-16)]
539are {N− (His13−His14); Im (His13); Im (His14); Im (His6);
540COO− (Asp7, Glu11)}.
541XANES Study of [CuII(Aβ3-16)] and [CuII(Aβp3-16)].
542 f5XANES spectra were recorded for [Cu(Aβ3-16)] and [Cu-
543 f5(Aβp3-16)] species at selected pH values (Figures 5 and S13 in
544the Supporting Information). In line with previous measure-
545ments by CD, EPR, and NMR, pH-dependent spectral
546modifications were observed because of copper(II) coordina-
547tion changes with the pH for both complexes. More
548particularly, in the case of [Cu(Aβ3-16)], component III can
549be predominantly detected at pH 8.8, a situation that was not
550encountered for the [Cu(Aβ1-16)] species studied in the
551past.27 The XANES signature of component III was compared
552to that of the well-described [Cu(DAHK)] peptide, where
553DAHK represents the N-terminal sequence of the human
554serum albumin.53 In this latter species, the copper(II) site is
555made of the N-terminal amine, the side chain of the His
556residues, and the two deprotonated amides in between,53,58 and
557such copper(II) coordination is predominant over a wide pH
558range.59 It is worth noting that the XANES spectrum of
559[Cu(Aβ3-16)] at pH 8.8 (component III) and its derivative
560(parts A and B in Figure 5, respectively) are very similar to
561those reported for [Cu(DAHK)] at pH 7.4.53 This supports a
562similar type of first coordination sphere for copper(II) in
563[Cu(Aβ3-16)], i.e., the −NH2, one N−, and one imidazole ring
564of His, in line with the studies described above.
565
1H NMR Study of [CuI(Aβ3-16)] and [CuI(Aβp3-16)]. To
566complete the structural data on copper binding to the N-
567terminally truncated Aβ peptides, we have performed 1H NMR
568studies of [CuI(Aβ3-16)] and [CuI(Aβp3-16)] species. In
569 f6Figure 6, 1H NMR spectra of the Aβ3-16 and Aβp3-16 peptides
Figure 5. XANES spectra (A) and derivatives of the XANES spectra (B) of [Cu(Aβ3-16)] (red, pH 6.0; green, pH 7.7; blue, pH 8.8) and
[Cu(DAHK)] (purple) complexes. Conditions: [Cu(peptide)] = 2 mM in H2O and T = 20 K, except for [Cu(DAHK)] (see ref 21 for conditions).
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570 in the presence of 0.9 equiv of CuI are compared to that
571 obtained in the case of the reference Aβ1-16 peptide.29 Similar
572 effects of copper(I) addition on the apopeptide signature are
573 observed for the three peptides, i.e., a shift of the two aromatic
574 protons from the three His. In the case of Hε (see the
575 Supporting Information for nomenclature details), a downshift
576 is observed that is more important for two of the three His
577 signals (Figure 6). Concomitantly, those latter signals are more
578 broadened. In the case of Hδ, the changes observed are more
579 subtle and more difficult to analyze.29 In addition to
580 modifications on the aromatic domain, some changes are also
581 observed in the aliphatic region for the three peptides (Figure
582 S14 in the Supporting Information) mainly involving Gly9 to
583Val12 residues, modifications that can be attributed in the case
584of the Aβ1-16 peptide to the folding imposed by copper(I)
585coordination to the His13−His14 dyad.30 Copper(I) coordi-
586nation to Aβ1-16 was proposed to be dynamic including the
587different species in equilibrium.29 The major form was
588copper(I) binding to His13 and His14 (His13−CuI−His14)
589in a linear fashion.16,28 This form was in equilibrium with two
590minor forms, i.e., His6−CuI−His13 and His6−CuI−His14. The
591shifts and broadening of the NMR signals due to copper(I)
592addition to either Aβ3-16 or Aβp3-16 peptide are highly similar
593to what was observed for Aβ1-16, strongly indicating that the
594copper(I) coordination site is the same in the three peptides.
595Thus, truncation or pyroglutamate formation at the N-terminus
596does not affect copper(I) binding. This confirms that the N-
597terminal amine is not involved in copper(I) binding.
598Affinity Measurements on [CuII(Aβ3-16)] and [CuII(Aβp3-
59916)]. In addition to structural insight, affinity for copper(II) and
600copper(I) is an important parameter to evaluate because it
601determines whether Aβ peptide is able to bind copper ions in a
602biological environment, in the presence of competitive ligands.
603In order to evaluate the affinities of copper(II) for the Aβ3-
60416 and Aβp3-16 and the Aβ1-16 and Ac-Aβ counterparts,
605competition experiments with a well-known copper(II)
606chelator, i.e., glycine amino acid, have been performed and
607 f7followed by CD (Figure 7). The CD data were reproduced by
608considering the formation of a 1:1 Cu−peptide complex,
609leading to determination of the apparent affinity constant as a
610function of the Gly concentration. Then, the conditional affinity
611is deduced from the following equation, where the conditional
612affinity value is the affinity at a given (pH, T) couple.
Figure 6. 1H NMR spectra of Aβ1-16 (A), Aβ3-16 (B), and Aβp3-16
(C) peptides (black) and in the presence of 0.9 equiv of CuI (gray) in
a phosphate buffer of 0.2 M and pH 6.7. [peptide] = 1 mM.
Figure 7. Gly-induced decrease of a [Cu(peptide)] LMCT band in CD spectra, together with the corresponding simulated curve: (A) [Cu(Aβ1-
16)], λ = 315 nm; (B) [Cu(Aβ3-16)], λ = 282 nm; (C) [Cu(Ac-Aβ)], λ = 280 nm; (D) [Cu(Aβ1-16)], λ = 280 nm. [Cu(peptide)] = 0.5 mM,
[HEPES] = 100 mM, and pH 7.4.
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613 Competition with the HEPES buffer has also been included but
614 is negligible compared to competition with Gly, except for very
615 low Gly concentration. HEPES data are from ref 60; Gly data
616 are from the NIST database and ref 61.
t2 617 Values thus obtained are reported in Table 2 and, for the
618 Aβ1-16 peptide, are in line with most recent values reported in
619 the literature.18,48 Aβp3-16 and Ac-Aβ peptides have very
620 similar affinities for the copper(II) ion, indicating that the way
621 that the free N-terminal is blocked has only a minor impact on
622 copper(II) coordination. In contrast, the affinity of the Aβ3-16
623 peptide is about 3 times weaker than that of the Aβ1-16
624 peptide. These relative affinity values have also been obtained
625 by competition between Aβ1-16 and Aβ3-16 or Aβp3-16,
626 followed by CD and fluorescence (see the Supporting
627Information). Acetylation or pyroglutamate formation on the
628N-terminal amine leads to a decrease in the affinity by 2 orders
629of magnitude, in line with the previous data obtained by
630calorimetric titration.48,62
631Affinity Measurements on [CuI(Aβ3-16)] and [CuI(Aβp3-
63216)]. In a recent study of copper(I) binding to Aβ1-16, we have
633established that ferrozine is a copper(I) chromophore of
634moderate affinity and is thus suitable for competition
635experiments with Aβ peptides.63 The copper(I) affinities of
636Aβ3-16 and Aβp3-16 peptides determined using this method
637are given in Table 2 and compared to those of Aβ1-16 and Ac-
638Aβ1-16 peptides. These four values are very close, indicating
639that the copper(I) site is maintained in the different peptides in
640line with the data obtained by NMR and the involvement of
641His residues only.
642■ DISCUSSION
643Copper(I) Coordination to N-Terminally Modified Aβ
644Peptides. Regarding copper(I) coordination to the Aβ1-16,
645Ac-Aβ1-16, Aβ3-16, and Aβp3-16 peptides, no significant
646structural and thermodynamic change is observed between the
647peptides in line with the involvement of only His side chains in
648copper(I) binding that are conserved in the four peptides.
649Copper(II) Coordination to N-Terminally Truncated
650Aβ Peptides. The proposed copper(II) binding to the Aβ3-16
651 s1peptide as a function of the pH is described in Scheme 1. It is
652worth noting that, as previously described in the case of
653[Cu(Aβ1-16)], several species are in equilibrium at a given pH
654value26 and consequently only the main form is drawn in
655Scheme 1. The involvement of the −NH2 terminal of Aβ3-16 is
656supported by the 13C NMR data in both components I and II,
657where a strong paramagnetic relaxation enhancement effect is
658observed for the signals of the Aβ3-16 N-terminal region. On
659the basis of previous data on [Cu(Aβ1-16)] and on the data
660obtained here, equatorial copper(II) coordination is completed
661by the CO group from the Glu3−Phe4 bond and the side chain
662of two His residues in component I. In component II, a strong
663broadening effect on Phe4 Cα was detected in line with binding
664of the amidyl from the Glu3−Phe4 peptide bond. Also,
665coordination of the CO from the His6−Asp7 bond occurs
Table 2. Conditional Affinity Constants of [CuII(peptide)]
and [CuI(peptide)] Species (0.1 M HEPES, pH 7.4) and
Corresponding Standard Deviation Constants
peptide
copper(II) affinity (×1010
M−1)
copper(I) affinity (×106
M−1) ref
Aβ1-16 1.1 ± 0.1 7.5 ± 1.0 63
Aβ3-16 0.33 ± 0.02 9.2 ± 0.9
Aβp3-16 0.008 ± 0.001 6.5 ± 0.5
Ac-Aβ1-16 0.01 ± 0.001 12 ± 1.3 63
Scheme 1. Proposed [Cu(Aβ3-16)] (A) and [Cu(Aβp3-16)] (B) Complexes as a Function of the pH
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666 concomitant with decoordination of the second His side chain.
667 This was mainly proposed on the basis of different spectral CD
668 signatures compared to the parent [Cu(Aβ1-16)] complex
669 ruling out the formation of two adjacent metallacycles, as in the
670 [Cu(Aβ1-16)] case. Such CO (His 6) binding is likely
671 unfavored on a thermodynamic point of view and may explain
672 why component II evolves toward component III with a very
673 low pKa value compared to other Aβ mutants and is thus very
674 minor in solution. In component III, the {−NH2, 2N−, and
675 His} binding set is deduced from the NMR, EPR, and XANES
676 measurements, and thus deprotonation of the peptide bond
677 His6−Asp7 is proposed. The presence of two distant
678 metallacycles is proposed from the positions of the CD,
679 −NH2-to-copper(II) and N−-to-copper(II) LMCT bands that
680 are different compared to those of the [Cu(Aβ1-16)] complex,
681 where two adjacent metallacycles were observed. Hence,
682 components II and III are slightly different between [Cu-
683 (Aβ1-16)] and [Cu(Aβ3-16)]. Indeed, in the former case, two
684 adjacent metallacycles were proposed between −NH2(Asp1)−
685 CuII−N−(Asp1−Ala2) and N−(Asp1−Ala2)−CuII−CO(Ala2−
686 Glu3) (component II) or N−(Asp1−Ala2)−CuII−CO(Ala2−
687 Glu3) (component III), while in the latter case, two remote
688 metallacycles are proposed between −NH2(Glu3)−CuII−
689 N−(Glu3−Phe4) and Im(His6)−CuII−CO(His6−Asp7) (com-
690 ponent II) or Im(His6)−CuII−N−(His6−Asp7) (component
691 III). Such a trend is quite unusual because, in general, the
692 formation of metallacycles centered on two different (N-term
693 and His) sites is disfavored compared to the formation of
694 several metallacycles centered on either the N-term or the side
695 chain of His residues,57 with the best anchoring site being
696 strongly dependent on the peptide sequence and distance
697 between the N-term and His.64−66 Such a difference might
698 originate from the presence of Arg5 that precludes the
699 formation of the second adjacent metallacycle in the present
700 case (see below). In component IV, the copper(II) site is
701 strongly reshuffled, leading to a copper(II) bound to the N-
702 terminal amine and the three adjacent deprotonated amide
703 groups, as observed in the case of the [Cu(Aβ1-16)] complex,
704 in line with a shift of the position of the LMCT bands in CD
705 toward the position observed in [Cu(Aβ1-16)] for three
706 adjacent metallacycles. Decoordination of the anchoring His at
707 high pH may be the driving force of such a reorganization. Such
708 His decoordination in favor of a third amide coordination at
709 high pH is reminiscent of what was previously reported for
710 other His-containing peptides, when the His residues lies in the
711 fourth position or beyond from the N-terminal anchoring site
712 (reviewed in ref 67). This is particularly true for the simplest
713 GGGH peptide68 and the Aβ one.27
714 Copper(II) Coordination to Pyroglutamate Forms of
715 Aβ Peptides. For copper(II) binding to the Aβp3-16 peptides,
716 as expected from preclusion of the NH2 terminal binding, His
717 act(s) as anchoring residues for copper(II). In component II′,
718 all of the available data converge toward a copper(II) binding
719 site made by two imidazole rings from His, a deprotonated
720 amidyl function, and either a carboxylate function or an
721 imidazole ring from the third His residue, where the former
722 proposition is favored based on the drastic broadening
723 observed by NMR on the Asp7 and Glu11 side chains. In
724 component III′, detected at higher pH, EPR data are in line
725 with deprotonation of a second amidyl function, leading to a
726 copper(II) binding site made by one (anchoring) imidazole
727 ring from His, two deprotonated amidyl functions, and a
728 carbonyle or a carboxylate function or an imidazole ring from
729the second His residue. On the basis of the similarity of the
730EPR data reporting copper(II) binding to the Ac-GGGTH-
731NH2 peptide in component III′,69 in which the copper(II) site
732was one imidazole ring from His, two deprotonated amidyl
733functions, and a carbonyle function, the former possibility is
734favored. In component IV′, a third amidyl function replaces the
735carbonyl one, leading to a {His, 3N−} copper(II) binding site.
736Copper(II) Coordination to N-Terminally Modified Aβ
737Peptides: First-Coordination-Sphere Effects. The results
738obtained here by multiple complementary techniques (NMR,
739CD, XANES, and EPR) on copper(I) and copper(II) binding
740to Aβ3-16 and Aβp3-16 agree in terms of the nature of the
741different components observed as a function of the pH.
742According to these results, pH-dependent copper(II) coordi-
743nation models are proposed in Scheme 1. For copper(II), the
744N-terminal amine plays a crucial role in line with its
745participation in copper(II) anchoring. Indeed, the absence of
746the free N-terminal amine reduces the copper(II) affinity, and
747the copper(II) site is located around the His residues only. This
748is the reason why the spectroscopic features of [Cu(Aβ3-16)]
749compare well with [Cu(Aβ1-16)], on the one hand, and
750[Cu(Aβp3-16)] with [Cu(Ac-Aβ1-16)], on the other hand.
751The two major CD differences between the two peptide groups
752is the shape of d−d and −NH2 LMCT bands. The same
753distinction can be made regarding the EPR data obtained as a
754function of the pH. However, the EPR results alone can be
755misleading, especially in the absence of the attribution of all
756components as a function of the pH. This was the case for
757Drew et al.,43 who concluded that copper(II) binds to Aβ3-16
758and Aβp3-16 peptides in a similar way because of similar EPR
759parameters. They only detected the EPR signatures of two
760components for both Aβ3-16 and Aβp3-16 peptides, a “low-
761pH” component predominant at pH 6.3 (Aβ3-16) and pH 6.9
762(Aβp3-16), and a “high-pH” component predominant at pH
7638.5 (Aβ3-16) and above pH 9 (Aβp3-16).43 Including their
764EPR data in Table 1 clearly shows that for the [Cu(Aβ3-16)]
765complex their “low-pH” component corresponds to component
766I and their “high-pH” form to component III. This is in line
767with a component II that never predominates in solution and is
768thus difficult to detect properly. Similarly, for the [Cu(Aβp3-
76916)] species, their “low-pH” form corresponds to component
770II′ and their “high-pH” form to component IV′. As can be seen
771in Table 1, components I and II′, on the one hand, and III and
772IV′, on the other hand, have comparable EPR parameters,
773hence the ill-interpretation of the EPR data in ref43. Thus, the
774full component assignments over a large pH range and the use
775of complementary methods such as CD and NMR are crucial to
776correctly assigning the components because the same EPR
777parameters do not imply the same copper(II) coordination
778sphere.
779Copper(II) affinities for the different peptide studies here are
780in line with the coordination site proposed based on
781spectroscopic data. Indeed, copper(II) binding to the N-
782terminal amine of Aβ3-16 (and Aβ1-16) is also in agreement
783with the significant drop of the copper(II) affinity due to free
784N-terminal amine blocked in the case of Ac-Aβ1-16 and Aβp3-
78516 peptides. It is also worth noting that the copper(II) affinity
786for Aβ3-16 is slightly weaker than that for the Aβ1-16 peptide,
787while copper(II) coordination to the two peptides at pH 7.4 is
788different. Indeed, at pH 7.4, the main component in [Cu(Aβ1-
78916)] is I, including one metallacycle, whereas the main
790component in [Cu(Aβ3-16)] is II, including two metallacycles.
791Thus, the affinity measurements indicate that the formation of a
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792 second metallacyle is not favorable in terms of the copper(II)
793 affinity. Such a similar trend has been recently observed for
794 Cu(peptide) model systems encompassing two or three
795 metallacycles.70
796 Copper(II) Coordination to N-Terminally Modified Aβ
797 Peptides: Effects beyond the First Coordination Sphere.
798 The four complexes [Cu(Aβ1-16)], [Cu(Aβ3-16)], [Cu(Ac-
799 Aβ1-16)], and [Cu(Aβp3-16)] successively switch from
800 component I/I′ to IV/IV′ via an additional amidyl binding
801 for each further species. However, the pKa values between two
802 successive components are significantly different in the case of
803 the [Cu(Aβ1-16)] and [Cu(Aβ3-16)] complexes (Table 1),
804 while they are close in the case of [Cu(Ac-Aβ1-16)] and
805 [Cu(Aβp3-16)]. In the latter case, this could be explained by
806 the fact that a free N-terminal is not available for copper(II)
807 coordination, leading to the same set of ligands for both Aβp3-
808 16 and AcAβ. In contrast, the high variation in the pKa(I/II)
809 values between the [Cu(Aβ1-16)] and [Cu(Aβ3-16)] com-
s2 810 plexes can be rationalized by second-sphere effects (Scheme 2)
811 in line with the pKa(I/II) value previously determined for the
812 mutants D1N and E3Q, respectively.27,71 The key step between
813 component I/II is deprotonation of the NH amide backbone. If
814 the −NH function is stabilized by its involvement in
815 intramolecular interaction such as hydrogen bonding, then
816 the pKa value between two successive components will be
817 higher. This is typically the case for pKa(I/II) values within the
818 series of [Cu(D1N-Aβ1-16)], [Cu(Aβ3-16)], and [Cu(Aβ1-
819 16)] species in which pKa(I/II) is ∼6.2,27,71 ∼7.0, and ∼7.7,
820 respectively. The highest stabilization of component I is
821 observed for the [Cu(Aβ1-16)] complex, where the NH is
822 stabilized by the hydrogen bond from COO− of Asp1 forming a
823 seven-membered ring. In [Cu(Aβ3-16)], a more moderate
824 stabilization occurs because of the formation of an an eight-
825 membered metallacycle (compared to seven-membered). No
826 stabilization is detected in [Cu(D1N-Aβ1-16)] because the
827 lone pair NH2 of Asn1 is mainly delocalized on the adjacent
828 carbonyl and can thus not be involved in hydrogen-bond
829 interaction.
830 The Arg5 residue, while not directly involved in copper(II)
831 coordination, seems to play a crucial role in copper(II) binding
832 to [Cu(Aβ1-16)] by precluding the formation of a second
833 metallacycle adjacent to the first −NH2−CuII−N− cycle, in
834 contrast to what was previously observed in the case of
835[Cu(Aβ1-16)]. Similar Arg5 effects were observed in the
836comparative study of copper(II) binding to the human and to
837its R5G mutant because replacement of Arg5 by Gly induces
838deprotonation of the Gly5−His6 peptide bond instead of the
839Asp1−Ala2 bond in the human case.54 Also, Arg indirect
840effects, i.e., effects not related to binding of the side chain of
841Arg to Cu, were encountered in other studies. For instance, the
842copper(II) binding site of angiotensin II (sequence DRVYIH),
843initially observed around His6, moves to the N-term part with
844deprotonation of the D1−R2 and R2−V3 bonds at high pH.72
845This is reminiscent of what was observed here between
846components III and IV, where the metal center site has been
847reshuffled at high pH with deprotonation of the F4−R5 and
848R5−H6 bonds. Also, in sequence with specific nickel(II)
849peptide bond hydrolysis, Arg was shown to increase particularly
850the hydrolytic activity compared to other amino acids.65 In the
851present case, the exact origin of such an Arg5 effect needs
852further investigation to be correctly depicted.
853■ CONCLUDING REMARKS
854The present study has revealed the copper(I) and copper(II)
855binding spheres to the two biologically relevant truncated forms
856of the Alzheimer peptide Aβ, i.e., Aβ3-16 and Aβp3-16. The
857application of a multispectroscopic approach (NMR, EPR, CD,
858and XANES) including affinity studies was crucial to decipher-
859ing the different components of the [Cu(peptide)] complexes
860and to identifying the most likely ligands in the component
861present at pH close to the physiological value. It turned out
862that, when available, the free N-terminal amine is the main
863anchor for copper(II) binding, as observed in the [Cu(Aβ1-
86416)] with [Cu(Aβ3-16)] complexes. When the N-terminal
865amine is blocked, as observed in the [Cu(Ac-Aβ1-16)] and
866[Cu(Aβp3-16)] complexes, His will take over the anchoring
867role. In addition to that feature, the present data also reveal an
868important role of the second-sphere environment because pH-
869dependent copper(II) coordination to Aβ1-16 and Aβ3-16 is
870significantly different. Hence, at physiological pH, the main
871coordination sites are altered in Aβ3-16 compared to Aβ1-16,
872with component I or II being predominant in the latter or
873former case, respectively. This also implies that Aβ modification
874of residues not directly involved in copper(II) binding does
875change the copper(II) binding site and can thus impact the
876aggregation and ROS production properties of the [Cu-
Scheme 2. Proposed Interaction To Rationalize the Different Species pKa(I/II) Values Determined between the [Cu(peptide)]
Complexesa
aIn red, the N−H that undergoes deprotonation in component II (upper scheme) and the residue proposed to be involved with it.
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877 (peptide)] complexes. Such a scenario might be of particular
878 interest in the case of familial AD in which Aβ mutation has
879 been reported. A well-known copper(II) coordination chem-
880 istry to these important N-terminally modified Aβ forms is a
881 prerequisite for further studies on aggregation and toxicity.
882 Such studies are currently in progress in our group.
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Le processus d’agrégation, dans lequel des peptides passent d’une forme 
monomérique à un assemblage complexe, apparait dans de nombreuses maladies comme celle 
d’Alzheimer. Divers éléments suggèrent que les ions métalliques tels que le Zn(II) et Cu(II) 
sont impliqués dans ce phénomène. Afin de mieux comprendre l’implication des ions 
métalliques sur l’agrégation de peptides, nous nous sommes intéressés à des peptides 
modèles. Ces modèles nous ont permis de mettre au jour, l’importance du mode de 
coordination des ions métalliques et ses différents impacts sur l’agrégation. Ce chapitre 
résume les trois articles qui suivent.  
III- Agrégation 
III. 1- Problématiques 
 Comment les ions métalliques Cu(II) et Zn(II) influencent-t-ils le processus 
d’agrégation ? Autrement dit, quels sont les caractéristiques déterminantes de l’interaction 
peptide-metal et quelles sont les conséquences engendrées sur la structuration du peptide ? 
Comment ces ions métalliques peuvent modifier l’agrégation ? 
 Afin de répondre à ces différentes questions, nous nous sommes intéressés à différents 
peptides modèles nommés Aβ11-28 et Aβ14-23 avec un intérêt plus prononcé pour le premier 
d’entre eux. La séquence de ces peptides est issue du peptide Amyloïde-β (Aβ1-42), élément 
clé de la maladie d’Alzheimer. Bien que certains de ces peptides tronqués soit retrouvés in 
vivo,1 le but de ces recherches n’est pas de mimer un type particulier d’interaction métal-
peptide, mais plutôt de comprendre les processus clés et généralisables du lien entre métaux, 
peptide et agrégation. En effet, cette problématique dépasse largement le cadre de la maladie 
d’Alzheimer. Les mêmes acteurs interviennent dans d’autres maladies,2 telles que Parkinson, 
Creutzfeld-Jakob, SLA (Sclérose Latérale Amyotrophique) ou encore dans le diabète de type 
II3 (voir tableau 1). L’agrégation ou plutôt l’auto-assemblage de peptides via l’utilisation 
d’ions métalliques comme modulateur est aussi un des sujets d'intérêt pour les bio/nano 
technologies. Une meilleure connaissance fondamentale de ce sujet d’étude (Lien entre 
Peptide – Métaux – Agrégation) couvre donc un large domaine de connaissances et 
d’applications.  
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Proteine / Peptide Maladie Associée 
Amyloïde-β Alzheimer 
α-syncleine Parkinson 
Superoxide Dismutase SLA 
Amylin Diabète de type 2 
Prion Creutzfeldt-Jakob 
Tableau 1 : Exemple de peptide ou de protéine dont l’agrégation 
est impliquée dans une maladie. 
 
Revenons maintenant au choix des peptides, il est basé sur les deux points essentiels : 
- Possibilité de lier des ions métalliques 
- Tendance à l’agrégation 
Cela est rendu possible grâce la conservation de la partie de séquence du peptide Aβ qui 
contient :  
- Des ligands potentiels (comme Histidine et aussi, N-term, C-term, squelette peptiques, 
Aspartate, Glutamate) 
- Un fort regroupement de résidus hydrophobes (Phenylalanine, Leucine, Alanine…) 
Les séquences des peptides Aβ1-42, Aβ11-28, Aβ11-23, Aβ14-23 possédant les 
caractéristiques précédemment énoncées, vous sont présentées ci-dessous. 
 
Aβ1-42   NH2-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-COOH 
Aβ11-28                            NH2-EVHHQKLVFFAEDVGSNK-COOH 
Aβ14-23                                    NH2-HQKLVFFAED-COOH 
 
Figure 1 : Séquences de peptides (utilisant le code à une lettre) qui souligne leur origine 
commune, les ligands potentiels et les chaines latérales hydrophobes. Ligands azotés en bleu ; 
ligands oxygénés en rouge ;  chaines latérales hydrophobes en gras. 
 
 Dans le choix des peptides modèles, on note clairement deux parties, la partie N-term 
avec des ligands des métaux et la partie C-term avec le « noyau » hydrophobe du peptide Aβ 
(LVFFA). Maintenant que nous avons nos modèles, comment étudier l’effet du Cu(II) et du 
Zn(II) sur l’agrégation de ses peptides ? 
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III. 2- Méthodes et Principes : 
 Différentes techniques permettent d’observer l’agrégation et donc l’influence des ions 
métalliques sur celle-ci. Chacune d’entre-elles possède ses spécificités, ses avantages et ses 
limites. 
a- Mécanisme de l’agrégation 
 Le mécanisme de l’agrégation est généralement décrit par trois phases successives : la 
nucléation, l’élongation et le plateau. La nucléation est décrite comme l’étape cinétiquement 
déterminante et correspond à la formation de noyaux (= oligomères). Lorsque le seuil critique 
de taille d’agrégat (noyaux) est atteint, l’élongation commence, elle est caractérisée par 
l’empilement en feuillet-β de peptides. Ces empilements forment ainsi les fibres. Enfin, quand 
le nombre de peptides vient à manquer pour continuer l’empilement, on arrive au plateau. La 
formation de fibre s’arrête.4 La forme de cette cinétique (avec x = le temps et y = quantité de 
fibres) est une sigmoïde. La cinétique est généralement suivie par fluorescence de la 
Thioflavine T (voir ci-dessous). Un paramètre caractéristique de cette sigmoïde est le t1/2, il 
correspond au temps nécessaire pour atteindre la moitié de la valeur maximale.5
b- Agrégation : fibrillaire ou amorphe ?  
 Le terme d’agrégation sera utilisé de manière indifférenciée pour désigner tout type 
d’agrégats, qu’il s’agisse agrégats amyloïde ou amorphes. Une amyloïde est constituée d’un 
empilement de peptides organisés en feuillets-β. Au contraire, un agrégat amorphe n’aura pas 
de structure tridimensionnelle bien définie. De plus, celui-ci est généralement plus enclin à 
devenir insoluble (précipitation) qu’un agrégat amyloïde. 
c- Fluorescence et ThT 
 La fluorescence est une technique intrinsèquement sensible, encore faut-il avoir un 
fluorophore adéquat. La Thioflavine T (ThT) est une molécule qui a la propriété de changer sa 
fluorescence (λexc et λemi differents) et d’exacerber sa fluorescence en présence de fibres (voir 
figure 2 et structure en annexe). Aussi, suivre la fluorescence de la ThT, c’est suivre 
l’agrégation amyloïde du peptide. Ses avantages : elle permet la quantification, le suivi 
cinétique et présente une forte spécificité pour les fibres amyloïde (elle interagit peu avec les 
agrégats amorphes). Comme la ThT peut être utilisée à faible concentration, son influence sur 
la formation de fibres est minimisée. Ses inconvénients : la fluorescence de la ThT peut être 
quenchée par Cu(II) et l’interaction de la ThT avec les fibres reste mal décrite. 
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Figure 2 : Spectre de 3D de la Fluorescence de la ThT (x: λemi ; y: λexc ; z: intensité) en 
l’absence (intensité env. x1000) à gauche, et en présence de fibres à droite. Conditions : 
[ThT] =100µM;  [HEPES] = 100mM; T = 20°C.   
d- Absorbance et turbidité 
 La turbidité mesure le trouble d’une solution. Le suivi de l’absorbance à une longueur 
d’onde fixée où l’échantillon ne présente pas absorption électronique. Aussi, « l’absorbance » 
mesuré est dû à la diffusion de lumière, est donc comparable à une mesure de turbidité. Sa 
mesure permet de suivre l’agrégation. Cette mesure est plutôt représentative de l’état global 
d’agrégation que spécifique de l’agrégation amorphe ou fibrillaire.  
e- MET et fibres 
 La Microscopie Electronique à Transmission (MET), à la différence de la microscopie 
optique, permet de visualiser des objets de l’ordre du nanomètre. Dans notre utilisation, la 
coloration négative à l’acétate d’uranyle révèle les assemblages de peptides. Cette technique  
sert à distinguer les différents types d’agrégats rencontrés (amorphe / fibrillaire).     
f- XANES et ions metalliques 
 La spectroscopie de structure près du front d'absorption de rayons X (ou XANES en 
anglais pour X-ray Absorption Near Edge Structure) est principalement réalisée sur 
synchrotron. Le spectre obtenu correspond à l’absorption dans le domaine des rayons X de 
l’élément considéré sur une courte plage d’énergie (contrairement à l’EXAFS). Celle-ci peut 
être utilisée comme une signature contenant des informations sur la nature de l’élément, son 
degré d’oxydation ainsi que sa coordination. Dans notre cas, les éléments étudiés seront des 
complexes peptidiques de Cu ou de Zn.  
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Il est nécessaire d’utiliser différentes techniques et de coupler les résultats provenant 
de celles-ci afin d’obtenir une image globale. 
 
III. 3- Expérience  
a- Importance de la monomérisation 
 Ci-dessous, la figure 3 représente tout l’intérêt de partir du même état initial pour 
étudier le processus d'agrégation. En effet, le suivi par fluorescence de la ThT montre que 
deux différents lots (carré et cercle noir) d’un même peptide en l’absence d’ions métalliques 
(apo) dans les mêmes conditions ne présentent pas la même agrégation. L’hypothèse est la 
suivante, la différence entre ces deux lots provient de deux états de pré-agrégation différents. 
Le lot « carré noir » contient plus de pré-agrégats que le lot « cercle noir ». Aussi, dans les 
conditions de l’expérience un lot agrège spontanément alors que l’autre est stable. Pour pallier 
ce problème, ces deux lots sont soumis à une pré-incubation à pH 12 afin de monomériser les 
pré-agrégats présents. Le point isoélectrique de ces peptide étant autour de pH ~6, 
l’augmentation de pH augmente la charge négative sur le peptide ce qui permet la dissociation 
des pré-agrégats. La même expérience est alors reconduite dans les mêmes conditions que 
précédemment et les deux lots (carré et rond blanc) se comportent alors de manière identique.  
 
 
Figure 3 : Fluorescence de la ThT au cours du temps de apo-Aβ11-28 provenant de différents 
lots (carré et rond) avec (blanc vide) et sans (noir plein) préincubation à pH 12. 
Conditions : [Aβ11-28] = 300µM, [Hepes] =  100mM pH 7,4, [ThT] = 10µM.  
 
 Cette expérience démontre l’importance de l’état initial dans le cas de l’agrégation. 
Afin d’éviter de considérer ce paramètre majeur, toutes les expériences suivantes seront 
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réalisées à partir de solutions de peptides pré-incubées à pH 12, dosées par UV-vis, diluées à 
1.2 mM, aliquotées, congelées à l’azote liquide et enfin placées à -20°C. 
b- Effet du Cu(II) et Zn(II) sur Aβ11-28 et Aβ14-23 
 Etudions maintenant les différents peptides en présence des ions Cu(II) et Zn(II) à 
l’aide des techniques annoncées ci-dessus. La figure 4 nous présente une étude comparative 
du comportement de Aβ11-28 et Aβ14-23 en présence des deux ions métalliques d’intérêt par 
fluorescence de la ThT, turbidité et MET. Dans la figure 4, on constate des comportements 
similaires entre Aβ11-28 et Aβ14-23 : 
- L’apo-peptide n’agrège pas sur la durée de l’expérience 
- Le Zn(II) déclenche l’agrégation 
 Malgré ces comportements similaires, on notera des différences sur la vitesse et sur 
l’intensité d’agrégation induite par le Zn (t1/2 (Aβ11-28) >> t1/2 (Aβ14-23) ).  
Il est aussi très intéressant de remarquer les comportements diamétralement opposés 
de Aβ11-28 et de Aβ14-23 vis-à-vis du Cu(II). Alors que le Cu(II) inhibe l’agrégation du 
peptide Aβ11-28, il la déclenche sur Aβ14-23. On notera sur le Aβ14-23 que la fluorescence 
de la ThT est quenchée par le Cu(II) car les autres techniques montrent la présence de 
l’agrégation induite par le Cu(II). Deux idées se détachent de cette figure: 
L’agrégation induite par les ions métalliques dépend, d’une part, de la séquence du peptide 
(Aβ11-28 ≠ Aβ14-23) et d’autre part, de l’ion métallique (Cu(II) ≠ Zn(II)). La coordination 
permet-t-elle de faire le lien ? Afin d’en savoir plus, nous nous sommes intéressés de plus près 
aux types de coordinations.  
c- Coordination du Cu(II), Aβ11-28 vs Aβ14-23 
La séquence du Aβ11-28 contient un motif ATCUN (Amino Terminal Cu and Ni 
binding). Le motif ATCUN est défini par la séquence suivante : NH2-XXH-R (avec X≠P). On 
le retrouve dans différents types d’Albumines et dans d’autres peptides.6 Ce motif est 
caractérisé par sa propriété à lier un ion Cu(II) ou un ion Ni(II) avec une forte affinité. La 
coordination au métal se fait via quatre atomes d’azote provenant de l’amine terminale (NH2), 
les deux amides déprotonés suivant (N-) et du Nδ de l’Histidine en troisième position. 
Lorsque le Cu est lié, la partie du N-terminale est alors enroulée autour du Cu. Le Cu-
ATCUN a des caractéristiques précises dans des nombreuses spectroscopies (UV-vis ; 
RPE…). Il a été montré que la coordination du Cu(II) par le Aβ11-28 se fait via le motif 
ATCUN.7
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Figure 4 : Fluorescence de la ThT (dessus), turbidité (milieu) au cours du temps et MET 
(dessous) après incubation, des peptides Aβ11-28 (gauche) et Aβ14-23 (droite) en absence 
(cercle bleu) ou en présence de 0.9 équivalent de Zn(II) (noir, carré) ou de Cu(II) (rouge, 
losange). Condition : [peptide] = 300µM; [Hepes] = 100mM pH 7,4 ; [ThT] = 10µM 
seulement pour la fluorescence.  
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Dans le cas du Aβ14-23, le motif ATCUN n’est pas présent. La coordination sera donc 
nécessairement différente. Bien que la géométrie précise des ligands reste floue, les données 
structurales suggèrent l’implication de l’histidine en N-term, bidentate avec l'amine NH2 
terminale et l’imidazole. Il est donc très probable que le Cu soit lié via deux peptides Aβ14-
23.  
 La nature de la coordination semble bel et bien être à la source des différents 
comportements d’agrégation vis-à-vis de la présence de Cu(II). En effet, la coordination du 
Cu sur le Aβ11-28 via le motif ATCUN entraine 
l’enroulement du N-terminal, réduisant le nombre de 
liaisons hydrogène possibles et donc l’agrégation. Au 
contraire, dans le cas du peptide Aβ14-23, l’implication 
de deux peptides « recrutés » pour lier le Cu, augmentera 
fortement la possibilité de créer des liaisons hydrogènes 
entre eux. Cet effet aura donc tendance à l’accentuer 
l’agrégation (voir schéma ci-contre). 
 
Schéma 1 : Effet de la coordination du Cu(II) sur l’agrégation de Aβ11-28 et Aβ14-23. A la 
différence du Aβ14-23, la coordination du Cu(II) par le Aβ11-28 provoque un enroulement du 
peptide autour du Cu, réduisant le nombre de liaisons hydrogène possibles et donc 
l’agrégation 
 
d- Coordination du Zn(II) au Aβ11-28 
 Quel soit le peptide, le Zn(II) semble promouvoir l’agrégation (voir figure 4). Quel 
rôle joue la coordination dans ce phénomène ? Afin de répondre à cette question, l’interaction 
Zn(II) – Aβ11-28 a été étudiée en détail.  
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Figure 5 : A gauche, fluorescence de la ThT au cours du temps de Aβ11-28 en présence de 
Zn(II) à différentes stœchiométries (0éq bleu foncé ; 0.1éq bleu clair ; 0.3éq rose ; 0.5éq vert ; 
0.7éq orange ; 0.9éq rouge). A droite, le XANES au seuil du Zn de Aβ11-28 en présence de 1 
(noir) ou 0.5 (gris) équivalent de Zn(II) avant (ligne en pointillés) ou après l’agrégation (ligne 
continue). En cartouche, l’agrandissement de la zone autour de 9.67 keV. 
Conditions : Fluorescence de la ThT : [Aβ11-28] =  300 µM; [Zn(II)] = 0-270 µM ; [HEPES] 
= 100 mM, pH 7,4 ; [ThT] = 10 µM ; XANES : [Aβ11-28] = 2.4 mM ; [Zn(II)] = 1.2 or 2.2 
mM; [HEPES] = 50 mM, pH 7,0. 
 
La figure 5, panneau de gauche, nous présente la fluorescence de la ThT du Aβ11-28 à 
différentes stœchiométries. On y remarque que la vitesse ainsi que l’intensité de l’agrégation 
ne sont pas proportionnelles à la stœchiométrie en Zn(II). Ces deux paramètres sont 
maximisés pour un ratio Zn(II)/Aβ11-28 = 0.5. Le panneau de droite nous montre la signature 
en spectroscopie XANES du peptide Aβ11-28 en présence de 0.5 ou 1 équivalent de Zn(II) 
avant et après l’agrégation. On constate tout d’abord que la coordination du Zn(II) ne semble 
pas changer au cours de l’agrégation (la ligne en pointillés et la ligne continue sont 
identiques). Par contre, la stœchiométrie du Zn(II) semble avoir un rôle sur coordination du 
Zn(II). En effet, l’agrandissement au seuil du Zn montre une différence entre le ratio 0.5 (en 
gris) et 1 (en noir). De plus, les spectres XANES enregistrés pour des stœchiométries 
inférieures à 0.5 équivalent sont comparables à celui à 0.5 équivalent, tandis que les spectres 
de stœchiométries supérieures à 0.5 sont comparables à celui à 1 équivalent. 
 Ces deux éléments distincts convergent vers la même idée : la formation d’un dimère 
Zn-(Aβ11-28)2. La formation de ce dimère serait donc à l’origine de l’effet accélérateur du 
Zn(II) sur l’agrégation des différents peptides. Qu’en est-il des ligands impliqués dans la 
formation de ce possible dimère ? 
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 Rien de tel que la RMN pour nous apporter des informations structurales manquantes. 
Ci-dessous, la figure 6 de gauche, présente le spectre RMN 1H centré sur les protons 
aromatiques, de Aβ11-28 et de tetra-peptide modèles de séquence NH2-EVXX-NH2 
(Aβ11-14) avec et sans Zn(II). Lorsque le Zn(II) est ajouté à Aβ11-28, il provoque le 
déplacement préférentiel de deux protons d’une histidine. Le but est d’identifier l’histidine 
mise en jeu dans la coordination du Zn(II). Ce déplacement est aussi visible sur le spectre des 
peptides EVHH (C) et EVRH (B) mais pas sur celui de EVHG (A). Cela suggère fortement 
l’implication de l’histidine 14 dans la coordination du Zn(II). De plus, les protons Hβ du 
Glu11 de Aβ11-28 et du Glu de EVHH sont affectés par la présence de Zn(II) (non montré).  
Basé sur ces indices, nous avons proposé un modèle de la coordination du Zn(II) par 
deux peptides Aβ11-28, avec comme ligands le COO- du Glu11 et l’imidazole de l’His14. La 
possibilité d’autres ligands par exemple une molécule d’eau n’est pas exclue (l’analyse des 
données d’EXAFS privilégie un Zn pentacoordiné plutôt que tetracoordiné). Ce modèle est 
présenté dans la figure 6 de droite, où l’on suppose l’induction de feuillets-β parallèles par la 
coordination du Zn(II) au COO- du Glu11 et au noyau imidazole de l'His14, expliquant ainsi 
la tendance à l’agrégation du Aβ11-28 en présence de Zn(II). 
 
                 
 
Figure 6 : (A gauche) 1H RMN, avec (gris) et sans Zn(II) (noir) de peptides EVHG (A), 
EVRH (B), EVHH (C), and Aβ11-28 (D). Conditions: [peptide] = 300 μM; [Zn(II)] = 270 
μM; [Tris-D11] = 100 mM, pH 7,5. (A droite) Modèle proposé pour le complexe 
Zn(Aβ11-28). 
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 Résumons les points précédents, la coordination du Zn(II) contrairement à celle du 
Cu(II) induit la formation d'un dimère,  via les résidus Glu11 et His14, à l’origine de 
l’agrégation rapide induite par le Zn(II) à pH 7,4. Qu’en est-il à d’autres pH ? Comment 
évoluent l’agrégation et la coordination ? 
e- Effet du pH 
Ci-dessous, la figure 7 décrit la dépendance de l’agrégation de Aβ11-28 en fonction du 
pH en présence de 0.5 équivalent de Zn(II). Les paramètres de l’étude sont les vitesses (t1/2) et 
les intensités des plateaux déterminés par la fluorescence de la ThT et par turbidité. La figure 
7 du dessus nous présente une expérience typique au cours du temps à un pH donné. On peut 
y extraire les t1/2 et les intensités des plateaux (flèches et ligne horizontale) provenant de la 
mesure en simultané à la fois de la turbidité et la fluorescence de la ThT. Cette expérience a 
été répétée sur une plage de pH autour du pH physiologique (i.e 7,4). Les paramètres 
d’intensité (plateau d’intensité) et de vitesse (t1/2) en fonction du pH sont regroupés dans la 
figure 7 du milieu et dans la figure 7 du dessous, respectivement. 
  Dans la figure du milieu et du dessous, on note tout d’abord que les comportements 
vis-à-vis du pH détectés par les deux méthodes sont clairement différents. En effet, dans la 
figure du milieu, alors que l’intensité du plateau en turbidité est très dépendante du pH, 
l’intensité du plateau en fluorescence est relativement constante quel que soit le pH. On 
trouve la tendance inverse si on s’intéresse aux t1/2 (figure 7 du dessous). Le t1/2 en 
fluorescence de la ThT augmente avec le pH, alors que le t1/2 en turbidité est rapide et 
constant. 
 Ainsi, nous sommes donc en présence de deux phénomènes distincts. D’une part, la 
précipitation mesurée par la turbidité apparait toujours rapidement quelque soit le pH, 
néanmoins la quantité de précipité (ou l’intensité du plateau en turbidité) est très dépendante 
de celui-ci (maximum pour ~ pH 7,3). D’autre part, la vitesse de formation des fibres 
amyloïde mesurée par la fluorescence de la ThT ralentit avec l’augmentation du pH alors que 
l’intensité maximum atteinte varie peu en fonction du pH.  
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 La précipitation d’un composé dans 
l’eau se produit généralement lorsque celui-ci 
devient globalement neutre. Le point 
isoélectrique (pI) est le pH auquel un 
composé devient globalement neutre. Dans le 
cas du Aβ11-28, sa charge globale évolue de 
0 à pH 6,3, -1 à pH 7,3, à -2 à pH 8.4. Si l’on 
considère la formation du dimère 
Zn(Aβ11-28)2 avec la coordination proposée 
ci-dessus, la charge globale attendue sera de 
+2 à pH 6,3, 0 à pH 7,3, à -2 à pH 8,4. La 
charge globale du Zn.(Aβ11-28)2 est donc 
bien en accord avec l’allure du plateau de 
turbidité en fonction du pH et permet 
d’expliquer celui-ci.  
 
Figure 7  ci-contre : (Dessus) Fluorescence de 
la ThT (échelle de gauche rouge, carré rouge) 
et turbidité (échelle de droite bleu, ligne bleu) 
au cours du temps de Aβ11-28 en présence de 
0.5éq de Zn(II) à pH 7,0. La ligne noire 
indique l’intensité du plateau, les flèches noires correspondent au temps nécessaire pour 
atteindre la moitié de l’intensité maximale. (Milieu) Intensité des plateaux de la fluorescence 
de la ThT (échelle de gauche rouge, carré rouge) et de turbidité (échelle de droite bleu, cercle 
bleu) en fonction du pH de Aβ11-28 avec 0.5 éq Zn(II). (Dessous) t1/2 de la fluorescence de la 
ThT (carré rouge) et de la turbidité (cercle bleu) de Aβ11-28 avec 0.5 éq de Zn(II) en fonction 
du pH. Conditions : [Aβ11-28] = 300 µM ; [Zn(II)] =150µM ; [Tampon] = 100 mM ; MES 
pour pH 5,5-6, PIPES pour pH 6-7, HEPES pour pH 7-8, POPSO pour pH 8-8,5. 
 
La vitesse de formation des fibres dépend du pH (Figure 8 du dessous). Afin de mieux 
comprendre ce phénomène, nous avons suivi la coordination du Zn(II) au peptide Aβ11-28 à 
différents pH par XANES et RMN (figure 8). Dans les spectres XANES (Figure 8 de gauche) 
présentés ci-dessous, on constate que l’allure de seuils de Zn0.5-Aβ11-28 à pH 6,5 et à pH 7,5 
sont identiques mais diffèrents de celui à pH 8,5. Cela suggère fortement un changement de la 
coordination du Zn(II) au Aβ11-28 entre pH 7,5 et pH 8,5. Le pKa de l’amine terminal étant 
précisément dans cette gamme, sa coordination au Zn(II) est possible. Afin de vérifier cette 
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hypothèse, nous avons étudié par spectroscopie 1H RMN le déplacement du signal du proton 
Hα-Cα-NH2 lors de l’ajout de Zn(II) (Fig. 8 de droite). L’expérience montre qu’à partir de pH 
7,7, un déplacement spécifique de cette résonnance apparait (le signal de His14 est aussi 
déplacé sur toute la gamme de pH étudié, données non montrées). Ce déplacement s’accentue 
avec l’augmentation du pH. En accord avec le XANES, ce déplacement indique la 
coordination de l’amine terminale à un pH supérieur à 7,7. De plus, on voit par RMN que 
l’His14 et le Glu11 ne semblent pas se décoordiner du Zn(II) (non montré) à plus haut pH, le 
NH2 semble donc plutôt s’ajouter aux autres ligands que de s’y substituer.  
 
Figure 8 : (A gauche) Agrandissement au seuil du Zn des spectres XANES de Aβ11-
28 en présence de 0.5 équivalent de Zn(II) à différents pH. En cartouche, le spectre XANES 
complet de Aβ11-28 en présence de 0.5 équivalent de Zn(II) à pH 7,5. L’astérisque pointe un 
artéfact dû au détecteur. Condition : [Aβ11-28] = 2mM ; [Zn(II)] = 1mM ; [Tampon] = 50mM 
(A droite) 1H RMN de Aβ11-28 en l’absence (noir, tracé du bas) et en présence de Zn(II) 
(gris, tracé du haut) à pH 9,1 (A), pH 8,0 (B), pH 7,7 (C), pH 7,3 (D). L’astérisque pointe le 
H-Cα de Val12, fortement affecté par l’ajout de Zn(II) dû à sa proximité avec le Glu11. Les 
traits en pointillés indiquent le déplacement du proton du H-Cα-NH2 dû à l’addition de Zn(II). 
Condition : [Aβ11-28] = 300µM ; [Zn(II)] = 270µM ; [Tris D11] = 100mM. 
 
Afin étudier l’impact de la coordination du NH2 terminal sur l’agrégation, l’équipe de 
G. LaPenna a réalisé des calculs de dynamique moléculaire sur deux modèles. Le premier 
modèle Zn(Ab11-28)2, noté I,  dans lequel le Zn est coordiné par 2 COO- des Glu11 et 2 
noyau imidazole des His14 coorespond au peptide Aβ11-28 en présence de Zn(II) à bas pH. 
Le second modèle Zn(Ab11-28)2, noté II, dans lequel le Zn est coordiné par 1 COO- (Glu11) 2 
NH2 et 2 noyaux imidazole (His14) (la modélisation montre que le départ d’un carboxylate est 
nécessaire à l’arrivé des deux NH2). Les deux modèles choisis présentent une conformation 
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initiale en feuillets-β comme retrouvée dans les agrégats d’Aβ. La modélisation montre que la 
conformation en feuillets-β est plus stable dans le modèle I que dans le modèle II, et que par 
conséquent, l’arrivé du NH2 déstabilise la conformation initiale en feuillet-β. Ces résultats 
sont en accord avec l’observation de la réduction de la vitesse d’agrégation avec 
l’augmentation de pH (Schéma 2, ci-dessous).  
Plusieurs des aspects énoncés ci-dessus peuvent être résumés dans le schéma 2 ci-
dessous. Il représente les différences de coordination induit par le métal (Cu ≠ Zn sur Aβ11-
28) ou par les peptides (Zn.Aβ11-28 pH 7,4 ≠ Zn.Aβ11-28 pH 8,5 et Cu.Aβ11-28 ≠ 
Cu.Aβ14-23) ainsi que l’influence de cette coordination sur la tendance à l’agrégation. 
 
Schéma 2 : Coordination schématique du Cu(II) et du Zn(II) sur Aβ14-23 et Aβ11-28 ainsi 
que l’effet de celle-ci sur l’agrégation. A la différence du Aβ14-23, la coordination du Cu(II) 
par le Aβ11-28 provoque l’inhibition de l’agrégation (voir schéma 1). Le Zn(II) accélère 
l’agrégation chez le Aβ11-28 comme le Aβ14-23. A haut pH, la coordination du Zn(II) au 
Aβ11-28 change, ce qui contribue au ralentissement de l’agrégation.  
f- Dynamique 
On sait que le Aβ présente une affinité modérée pour le Zn(II) avec un Kd de l’ordre 
du µM.8 Une affinité similaire est attendue pour Aβ11-28 (même type de ligands disponible). 
On peut alors se poser plusieurs questions : Le Zn(II) est-il en échange entre les peptides ? 
Est-il labile après l’agrégation ? Que se passe-t-il si on le retire ? Afin de répondre à ces 
questions, nous avons mené les expériences suivantes. 
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Figure 9 : Fluorescence de la ThT (à gauche) et turbidité (à droite) au cours du temps 
(// indique la cassure dans l’échelle du temps) de Aβ11-28 en absence (ligne continu) ou en 
présence de 0.5 équivalent de Zn(II) (lignes en pointillés). L’ajout d’ETDA est indiqué par les 
flèches. Conditions : [Aβ11-28] = 300µM ; [Zn(II)] = 150µM ; [HEPES] = 100mM ; [ThT] = 
10µM ; [EDTA] = 750µM. 
 
Ci-dessus, la figure 9 présente le suivi cinétique par la fluorescence de la ThT et 
turbidité de Aβ11-28 avec et sans Zn(II) sur une longue période. On constate que même en 
l’absence de Zn(II), Aβ11-28 peut agréger si l’on est suffisamment patient (voir aussi Fig. 5). 
On remarque aussi que l’apoAβ11-28 forme un type d'agrégats différent de celui 
formé par Aβ11-28 en présence de Zn(II). En effet, dans l’agrégation de apoAβ11-28, on 
observe une fluorescence de la ThT moins intense (~5-10 fois) qu’avec Zn0.5-Aβ11-28 (voir 
Figure 5 et Figure 9 de gauche). De plus, aucune turbidité des agrégats n’est détectée avec 
ApoAβ11-28 (contrairement à Zn0.5-Aβ11-28, figure 9 de droite).  Les fibres apoAβ11-28 
sont aussi moins denses que celles de Zn0.5-Aβ11-28 (voir Fig. 10, panneau de gauche et de 
droite). Il y a donc deux types d’agrégats. Ils se distinguent par l’intensité en fluorescence 
(Zn0.5Aβ11-28 > apoAβ11-28) et la présence de turbidité (Zn0.5Aβ11-28 >> apoAβ11-28 ~ 0).  
Que se passe-t-il lorsqu’on retire le Zn(II) des agrégats Zn0.5Aβ11-28 ? L’ajout 
d’EDTA sur Zn0.5-Aβ11-28 provoque un changement du type d'agrégat. D’agrégat de type Zn, 
on passe à des agrégats de type Apo (voir Figure 9 et Figure 10).  
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 Figure 10 : Image de TEM de Zn0.5-Aβ11-28 (gauche), Zn0.5-Aβ11-28 + EDTA 
(milieu) et apoAβ11-28 après un jour d’incubation. Conditions : [Aβ11-28] = 300µM ; 
[Zn(II)] = 150µM ; [HEPES] = 100mM ; [ThT] = 10µM ; [EDTA] = 750µM. 
 
Plus intéressant encore, le moment de l’ajout de l’EDTA n’a pas d’importance (de t = 
2 min jusqu'à plusieurs heures). L’addition d’EDTA sur Aβ11-28 en présence de Zn(II) 
provoque une formation très rapide d’agrégats de type apo et ce même si l’EDTA est ajouté 
avant l’augmentation de la fluorescence de la ThT (pendant la phase de nucléation) de Zn0.5-
Aβ11-28 (données non montrées). La formation d’agrégats de type Apo via l’exposition au 
Zn(II) et puis à l’EDTA est ainsi beaucoup plus rapide que la formation d’agrégat de type 
Apo avec seulement du Aβ11-28. Cela signifie que lorsque l’Aβ11-28 est en présence de 
Zn(II) même de manière très temporaire, le Zn(II) pourra induire une modification (comme 
par exemple la formation d’un dimère) « durable », modification qui accélère l’agrégation 
même en absence de Zn(II) (voir schéma 3). 
 
 
 Schéma 3 : Aβ11-28 de la forme monomérique aux agrégats de type « apo » ou « Zn » 
 
Le Zn(II) coordiné sur Aβ11-28, même après agrégation semble donc labile 
(accessible à la chélation), mais via ce chélateur (EDTA), la quantification n’est pas possible. 
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Aussi, nous avons eu recours au PAR (voir structure en annexe), qui est un chélateur du 
Zn(II). PAR et le Zn(PAR)2 n’ont pas la même absorption ce qui rend  possible le suivi de la 
chélation du Zn(II). Dans la figure 11 de gauche, le Zn0.5Aβ11-28 préalablement agrégé est 
ajouté à une solution de PAR. On constate que très vite (t1/2 < 1min) et totalement, le Zn(II) 
est chélaté par le PAR. Ainsi, même lorsque que le Zn est co-agrégé au Aβ11-28 et donc sous 
forme solide, il est accessible en solution. La figure 10 de droite montre la 1H RMN dans la 
zone des aromatiques de Aβ11-28 en présence de différents équivalents de Zn(II). On notera 
que les déplacements sur Hε et Hδ de l'His14 (~7.75ppm et ~6.9ppm) augmentent avec les 
équivalents en Zn(II), et qu’un ajout sub-stœchiométrique provoque le déplacement du signal 
de tout l’échantillon. Cela caractérise un échange rapide du Zn(II) avec l’ensemble des 
molécules d’Aβ11-28. Ces deux expériences montrent l’échange rapide du Zn(II) que ce soit 
entre peptides en solution ou entre peptides agrégés et peptides en solution. 
   
        
 Figure 11 : (A gauche) Suivi UV-vis de l’addition Zn0.5-Aβ11-28 pre-agrégé à la 
solution de PAR. Condition : [PAR] = 300 μM ; pré-agrégé [Zn0.5-Aβ11-28] = 160μM ; 
[HEPES] = 100mM, pH 7,4. (A droite) 1H RMN de Aβ11-28 en absence et présence de 
différentes stœchiométries de Zn(II). Conditions : [Aβ11-28] = 300μM ; [Zn(II)] = 0-300µM ; 
[Tris D11]=100mM. 
 
  Une autre expérience intéressante est l’effet de « l’ensemencement » (ou seeding en 
anglais). L’ensemencement consiste à ajouter des agrégats ou des fibres  préformés pour 
déclencher l’agrégation, agrégation qui suit alors normalement la nature de la matrice imposée 
par la « graine » (comparable à une cristallisation). La figure 12 montre l’ajout de Zn0.5-Aβ11-
28 pré-agrégé à une solution d’apoAβ11-28. On observe un déclenchement immédiat de 
l’agrégation. Cette agrégation n’est pas une agrégation de type Zn mais de type Apo. En effet, 
les caractéristiques spectroscopiques, à savoir, une fluorescence de la ThT faible et pas de 
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turbidité, sont celles d’une agrégation de type « apo ». Ce comportement peut être expliqué, 
par l’échange du Zn(II) entre les peptides (voir schéma 4). 
 
 
 Figure 12 : Fluorescence de la ThT (à gauche) et turbidité (à droite) au cours du temps, 
suivant l'agrégation de Aβ11-28 en absence (ligne continue) ou en présence d’un ajout 
Zn0.5-Aβ11-28 pré-agrégé (ligne pointillée) indiqué par les flèches. Conditions : [Aβ11-28] = 
300µM ; [Zn0.5-Aβ11-28] = 22.5μM ; [HEPES] = 100mM ; [ThT] = 10µM. 
 
 
 
 Schéma 4 : L’échange dynamique du Zn(II) induit une agrégation de type « apo » 
plutôt que de type « Zn ». Ici, le complexe Zn(II)-Aβ11-28 est considéré comme un catalyseur 
de l’agrégation d’apoAβ11-28 
 
III. 4- Conclusion : 
 Par ces expériences, nous avons montré que : 
- L’agrégation d’un peptide induite par les ions métalliques Cu et Zn dépend du peptide et des 
ions métalliques. 
 Ces deux paramètres sont reliés par la coordination de l’ion métallique au peptide.  
-Le Zn(II) accélère l’agrégation de l’Aβ11-28 via la formation d’un dimère impliquant les 
Glu11 et His14. L’augmentation du pH change cette coordination (implication du NH2 
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terminal) et contribue au ralentissement de la cinétique d’agrégation. La charge globale du 
dimère Zn(Aβ11-28)2 conditionne la précipitation.   
- La coordination du Zn(II) au Aβ11-28 est dynamique, même lorsque le Zn est co-précipité, 
l’échange entre agrégats solides et peptides en solution est très rapide. La coordination du 
Zn(II) même transitoire ou temporaire, induit des modifications (formation de dimères) non 
réversibles par le retrait du Zn. Ces modifications accélèrent fortement et durablement 
l’agrégation même en l’absence de Zn(II). 
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Abstract Metal ions such as zinc and copper can have dra-
matic effects on the aggregation kinetics of and the structures
formed by several amyloidogenic peptides/proteins. Depend-
ing on the identity of the amyloidogenic peptide/protein and the
conditions, Zn(II) and Cu(II) can promote or inhibit fibril for-
mation, and in some cases these metal ions have opposite
effects. To better understand this modulation of peptide
aggregation by metal ions, the impact of Zn(II) binding to three
amyloidogenic peptides (Ab14-23, Ab11-23, and Ab11-28) on
the formation and structure of amyloid-type fibrils was
investigated. Zn(II) was able to accelerate fibril formation for
all three peptides as measured by thioflavin T fluorescence and
transmission electron microscopy. The effects of Zn(II) on
Ab11-23 and Ab11-28 aggregation were very different com-
pared with the effects of Cu(II), showing that these promoting
effects were metal-specific. X-ray absorption spectroscopy
suggested that the Zn(II) binding to Ab11-23 and Ab11-28 is
very different from Cu(II) binding, but that the binding is
similar in the case of Ab14-23. A model is proposed in which
the different coordination chemistry of Zn(II) compared with
Cu(II) explains the metal-specific effect on aggregation and the
difference between peptides Ab14-23 and Ab11-23/Ab11-28.
Keywords Amyloid  Zinc  Copper  Aggregation 
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Abbreviations
Ab Amyloid b
ESRF European Synchrotron Radiation Facility
EXAFS Extended X-ray absorption fine structure
Hepes 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic
acid
POPSO Piperazine-1,4-bis-(2-hydroxy-propane-sulfonic
acid) dihydrate
ThT Thioflavin T
XAS X-ray absorption spectroscopy
Introduction
Amyloid fibrils formed by the assembly of peptides or
proteins are widely studied owing to their roles in several
disorders, including neurodegenerative diseases [1, 2]. The
assembly of these peptides/proteins can be modulated by a
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variety of cofactors. Metal ions are one cofactor, and in
particular, Cu, Zn, and Fe ions are reported to be involved
in several neurodegenerative diseases [3–5]. The binding of
these metal ions to several peptide/proteins has been pro-
posed. It has been shown that metal ion binding can
modulate the kinetics and the structure of several amyloi-
dogenic peptides/proteins [6–13]. Although the importance
of metal ions in the formation of peptide/protein aggregates
has been recognized, little is known on the underlying
molecular mechanisms. Fundamental insight into amyloid
fibril formation has been gained with short model peptides
(for reviews see [14–16]). This strategy has also been
applied for studying fundamental questions of metal-ion-
assisted aggregation [17–23].
Here, three model peptides were used deriving from
amyloid b (Ab) peptide (Fig. 1), which plays a central role
in Alzheimer’s disease. However, the aim was not to model
the metal binding to full-length Ab, as it is known that
residues 1–10 play an important role (for recent references
see [24–27]); the aim was to gain general insights into the
role of metal binding in peptide aggregation. The peptides
chosen are able to make amyloid-type fibrils and contain
two important features: a hydrophobic core (amino acids
17–21), thought to be involved in initiation of the aggre-
gation process [28], and a metal binding site due to the one
or two His residues, which are well known to be anchors
for metal binding [21, 22, 29]. The same peptides were
used in our previous study, in which we were able to gain
interesting insights into the influence of Cu(II) binding on
the formation and structure of aggregates [29]. It was found
that Cu(II) bound to Ab11-28 and Ab11-23 as a mononu-
clear complex, which inhibited but did not abolish fibril
formation (Fig. 2). In contrast Cu(II) bound to Ab14-23
increased fibril formation by bridging two peptides (Fig. 2).
The present study focuses on the modulating effect of
Zn(II) on the model peptides Ab11-28, Ab11-23, and
Ab14-23. Aggregation kinetics and structural methods
were employed to better understand the mechanism of
Zn(II)-induced aggregation.
Materials and methods
Ab11-23/Ab11-28/Ab14-23 sample preparation
The peptides Ab11-23 (sequence Glu-Val-His-His-Gln-
Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp), Ab11-28 (sequence
Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-
Val-Gly-Ser-Asn-Lys), and Ab14-23 (sequence His-Gln-
Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp) were purchased from
either GeneCust (Dudelange, Luxembourg) or GenScript
(Piscataway, NJ, USA). The stock solutions of peptides
were prepared by first dissolving the peptides in pure
water (resistivity 18 MX cm-1), which resulted in a final
pH 2. Then the solution pH was adjusted to 12 by adding
NaOH, to monomerize the peptides. These stock solutions
were stored at 253 K. The peptide concentrations were
determined by using the molar extinction coefficient
e = 390 M-1 cm-1 of the two Phe at 258 nm [30]. (As
Phe does not absorb at 275 nm, the absorbance at that
wavelength was subtracted to remove contributions from
the buffer or baseline shifts.). The stock solution of Zn(II)
was prepared with ZnSO4H2O (Strem Chemicals) in
water. Aggregation of peptides in the presence of Zn(II)
was performed by dissolving peptides from stock solution in a
100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(Hepes) buffer pH 7.4 (the pH was checked at the end of
the experiment). We chose to perform ‘‘equimolar’’
experiments with 0.9 equiv of Zn(II) to be sure to avoid
any effects of excess Zn(II). All of the experiments mea-
suring either turbidimetry or fluorescence intensity were
A
β
11-28: NH3+-EVHHQKLVFFAEDVGSNK-COO - 
A 11-23: NH3+-EVHHQKLVFFAED-COO -
Aβ14-23:         NH3+-HQKLVFFAED-COO -
β
Fig. 1 Sequences of Ab11-28, Ab11-23, and Ab14-23
β β
Fig. 2 The modulation of Cu(II) and Zn(II) (black circles) on the
peptides Ab14-23 (white rod) and Ab11-23/Ab11-28 aggregation
(gray rod). Black sticks represent H-bonds in the b-sheets and the
thickness of the arrows symbolizes the aggregation rate. For Ab14-23,
Cu(II) and Zn(II) accelerate fibril formation by bridging the peptides.
Zn(II) has a more important effect than Cu(II), which may be due to
the more flexible coordination geometry. For Ab11-23/Ab11-28,
Zn(II) accelerates fibril formation owing to the bridging of two
peptides. In contrast, Cu(II) does not bridge and hence decreases fibril
formation owing to the peptides wrapping around Cu(II) in the
ATCUN motif and the consequent lower number of H-bonds
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realized at room temperature. The kinetic data were
obtained at least five times, including from different pep-
tide batches (from different sources, see above) and dif-
ferent preparations. There were variations in the kinetics,
but the effects of the metal ions and different peptides were
always the same. The data shown are representative mea-
surements. In the X-ray absorption spectroscopy (XAS)
measurements, 1 mM peptide and 0.9 mM Zn(II) in
100 mM POPSO at pH 8.6 were used. The first sample
(t = 0 h) was withdrawn immediately after mixing and
transferred to the sample holder and frozen in liquid
nitrogen. The second sample was incubated for 24 h at
room temperature before being transferred to and frozen in
the sample holder.
Turbimetry
Turbidity measurements were done by measuring the
absorbance at 350 nm with an Agilent 8453 spectrometer
connected to a personal computer (UV–vis ChemStation,
revision A.10.01), in a 1 cm path length quartz cuvette or
in a 96-well quartz microplate (Hellma) with an flx-Xenius
spectrophotometer (SAFAS) connected to a personal
computer. Peptide concentrations were 300 lM in 100 mM
Hepes pH 7.4 if not otherwise stated.
Fluorescence spectroscopy
Fluorescence spectra were measured using an flx-Xenius
spectrophotometer (SAFAS) or a Fluostar Optima (BMG)
connected to a personal computer. Thioflavin T (ThT),
peptides, and Zn(II) were mixed in 100 mM Hepes buffer
pH 7.4 and placed in a 96-well microplate. The time course
of ThT fluorescence was then measured (excitation
437 nm, emission 485 nm, bandwidth for emission and
excitation 10 nm). The final concentrations of peptides and
ThT were 300 and 10 lM, respectively.
If a sigmoidal type of kinetic trace was obtained, the
data were fitted with the program KaleidaGraph to the
formula F(t) = F0 ? A/{1 ? exp[-k(t - t1/2)]}, where
k is the elongation rate, A the amplitude, t1/2 the time point
when half the maximal intensity is reached, and F0 the
baseline before aggregation [31].
Electronic microscopy
Five microliter of peptide samples incubated for 17–24 h
was applied on electron microscopy grids, washed with
5 lL of Milli-Q water, and negatively stained with an
aqueous solution (5 lL) of uranyl acetate (1% w/w).
Samples were air-dried and examined with a JEOL 1011
transmission electron microscope operating at an acceler-
ating voltage of 100 kV.
X-ray absorption spectroscopy
XAS measurements were carried out at the European Syn-
chrotron Radiation Facility (ESRF; Grenoble, France), which
was operating with a ring current of 150–200 mA. Zn K-edge
XAS spectra were collected on the BM30B (FAME) beamline
using a Si(220) N2 cryo-cooled double-crystal monochroma-
tor [32, 33]. The spectra were measured in fluorescence mode
by measuring the Zn Ka fluorescence with a 30-element solid-
state Ge detector (Canberra) in liquid cells in a He cryostat.
The temperature was kept at 10 K during data collection to
prevent sample damage. Three scans of 45 min each were
averaged. Data from each detector channel were inspected for
glitches or dropouts before inclusion in the final average.
Energy calibration was achieved by measuring a Zn foil for the
Zn edge and assigning the first inflection point of the Zn foil
spectrum to 9,659 eV. Data analysis was performed using the
MAX (multiplatform applications for X-ray absorption
spectroscopy) package, including Cherokee for the data
extraction and Roundmidnight for the shell fitting [34]. X-ray
absorption near-edge structure spectra were background-
corrected by a linear regression through the pre-edge region
and a polynomial through the postedge region and normalized
to the edge jump. For the extraction of the extended X-ray
absorption fine structure (EXAFS) part, E0 was defined at the
half-height of the absorption edge step. The v(k) functions
were extracted from the data with a linear pre-edge back-
ground, a polynomial atomic-absorption background, and
were normalized using the Lengeler–Eisenberg method [35].
The k2-weighted EXAFS spectra were Fourier-transformed
over the k range 2.4–11.9 A˚-1 using a Kaiser–Bessel window
with a smoothness s parameter of 2.5 (k is the photoelectron
wave number). In this work, all Fourier transforms were cal-
culated and presented without phase correction. The peak
corresponding to the first coordination shell was then isolated
and back-Fourier-transformed into k space to determine the
mean coordination number, N, the bond length, R, and the
Debye–Waller factor, r2, by a fitting procedure realized in the
framework of single scattering using the standard EXAFS
formula:
v kð Þ ¼ S20
X
i
Ni
R2i
Ai kð Þe2r2i k2 e2Ri=kðkÞ sin 2kRi þ Ui kð Þð Þ
 
:
The S0
2 value was taken as 1 and kept constant. Fits
were performed on the Fourier-filtered spectra over the
R ? DR range 0.8–2.3 A˚. Theoretical amplitude and phase
shift functions were calculated with the ab initio code
FEFF 7.0 [36] using bis(salicylhydrazide)sulfatozinc(II)
monohydrate [37] as a structure model from the Cambridge
Structural Database (http://www.ccdc.cam.ac.uk/products/
csd). The estimated errors for distances and coordination
numbers are ±0.02 A˚ and ±20%, respectively.
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Results
During our investigation with the peptides Ab11-23, Ab11-
28, and Ab14-23, we realized that the aggregation kinetics
followed by ThT (an amyloid-specific fluorescent dye)
fluorescence were dependent on the batch (Fig. 3) [38].
This is likely due to a small portion of preaggregated
peptide, the quantity or structure of which is batch-
dependent. As aggregation can be seeded by a small
amount of preaggregated peptide, a very small amount of
preaggregated peptide is sufficient for a large kinetic dif-
ference. In contrast, in the presence of 0.9 equiv of Zn(II),
the aggregation kinetics were more uniform between the
batches, indicating that the effect of Zn binding prevails
over the seeding effect (not shown). Thus, the peptides
were incubated at pH 12, a well-established treatment to
monomerize full-length Ab1-40/Ab1-42 peptide. After this
treatment, the apo form of the model peptides (Ab11-23,
Ab11-28, Ab14-23) aggregated more slowly and more
uniformly between batches. Thus, for the rest of the study
all peptides were incubated at pH 12 to have more homo-
geneous samples. However, even without the incubation at
pH 12, the differences between the different peptides and
metal ions were qualitatively the same.
As in our previous study we did not use the pH 12
treatment. The measurements of apo Ab11-23/Ab11-28/
Ab14-23 and Cu-Ab11-23/Cu-Ab11-28/Cu-Ab14-23 were
reperformed to be able to compare them directly with the
measurements for Zn [29]. As shown in Fig. 4, for all three
peptides, Ab11-23, Ab11-28, and Ab14-23, Zn had a
dramatic effect on the ThT fluorescence traces. In general,
Zn accelerated and increased ThT fluorescence over time.
Comparison with Cu(II) and apo forms showed an impor-
tant metal-specific effect.
The ThT fluorescence intensity increased instanta-
neously for Zn-Ab14-23, more slowly for Zn-Ab11-28,
and even more slowly for Zn-Ab11-23. The latter two
showed a sigmoidal curve, which is typical for amyloid
fibril formation. These curves can be fitted with an
aggregation model including a nucleation and elongation
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Fig. 3 Representative thioflavin T (ThT) fluorescence of apo-Ab11-
28 (two different batches, circles and squares) with (filled symbols)
and without (open symbols) preincubation at pH 12. The solid line
represents a fit (see ‘‘Materials and methods’’ for details). The
conditions were as follows: 300 lM Ab11-28, 100 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) pH 7.4,
10 lM ThT
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Fig. 4 Metal-specific aggregation: representative kinetic data of ThT
fluorescence of Ab11-28 (top), Ab11-23 (middle), and Ab14-23
(bottom) in the presence of Zn(II) (squares) and Cu(II) (triangles) and
without metal ions (circles). The conditions were as follows: 300 lM
peptides, 270 lM metal ions, 100 mM Hepes pH 7.4, 10 lM ThT.
The solid line represents a fit (see ‘‘Materials and methods’’ for
details)
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process (for a recent review see [39]). In terms of the
fluorescence intensity after reaching the plateau, Zn-Ab11-
28 had higher intensity than Zn-Ab14-23 and Zn-Ab11-23,
showing that the Zn-induced aggregation in amyloid-type
structures is peptide-dependent.
In parallel, turbidity was measured. In contrast to ThT
fluorescence, turbidity assesses the general state of aggre-
gation (amount and size, but not specific for fibrils). Tur-
bidity increased rapidly for all three peptides after addition
of Zn (Fig. 5, top). The turbidity of Zn-Ab11-28 was the
highest, whereas the turbidities of the other two peptides
were similar. The turbidity of Zn-Ab11-28 and that of Zn-
Ab11-23 (but not Zn-Ab14-23) showed several phases.
The changes were small but reproducible, and the same
features occurred in Zn-Ab11-28 and Zn-Ab11-23, but the
turbidity change for the latter was slower. Several phases
can be distinguished. This indicates that the aggregation for
Zn-Ab11-28 and Zn-Ab11-23 occurs in several steps and
that the increase in ThT fluorescence is not associated with
the first events.
Transmission electron microscopy images were collected
at the beginning (just after mixing; 0 h) and after reaching
the plateau (24 h) (Fig. 6). Zn-Ab11-28 and Zn-Ab11-23
showed aggregates at the beginning, but they were rather
amorphous and little fibrils were observed. At the end,
clearly fibrillar aggregates can be observed (Fig. 6). This is
in line with the turbidity and ThT measurements, as turbidity
measures better the degree of aggregation and ThT is more
specific for fibrillar aggregates. Zn-Ab11-28 showed more
fibrils than Zn-Ab11-23, in line with the ThT measurements.
In the case of Zn-Ab14-23, similar fibrillar structures were
observed at 0 and 24 h, in line with the very fast increase of
turbidity and ThT fluorescence (Fig. 6).
To gain insight into the coordination of Zn to the three
different peptides during aggregation, XAS was employed.
To have an intense signal, a higher concentration of Zn–
peptides was used (approximately 1 mM). The pH was
adjusted to 8.6 to slow down the faster aggregation due to
higher concentrations. As such we were able to measure XAS
spectra at a time point before the ThT fluorescence increased
and on the plateau for Zn-Ab11-28 (see the electronic sup-
plementary material for details of pH and concentration
dependence). The X-ray absorption near-edge structures are
shown in Fig. 7. All spectra were in agreement with a
hexacoordinated Zn(II), which was confirmed by EXAFS
(see below), although a pentacoordination cannot be com-
pletely ruled out [40]. Moreover, for all three peptides,
Zn-Ab14-23, Zn-Ab11-23, and Zn-Ab11-28, no significant
difference between the time point at the beginning and after
24 h could be detected, indicating that the type of Zn(II)
binding site does not change much during aggregation. The
XAS spectra are very similar for Zn-Ab11-23 and Zn-Ab11-
28, indicating that they have the same binding site and hence
amino acids 24–28 do not play an important role in Zn(II)
coordination. In contrast, the spectrum of Zn(II)-Ab14-23
differs, supporting the role of amino acids 11–13 in Zn(II)
binding of the Ab11-23/Ab11-28 peptides.
These conclusions are supported by the EXAFS data
(Table 1; see also the electronic supplementary material).
The Zn(II) coordination showed no significant changes
between the beginning of the aggregation (time point 0 h)
and after 24 h. For all Zn–peptides at different time points,
the best fit suggested about four atoms at a distance of
1.96 ± 0.4 A˚ and about two atoms at a distance of
2.05 ± 0.04 A˚. The shorter distance is more in line with
carboxylate ligands (from Asp, Glu, or the C terminus) and
the longer distance with nitrogen ligands (His or N-termi-
nal amine) [40]. This suggests that in Zn-Ab14-23 Zn is
bound by the N-terminal His via both the amine and the
imidazol group. In the case of Zn-Ab11-23/Zn-Ab11-28,
the two nitrogen ligands are more likely to be the two His.
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Fig. 5 Representative kinetic data of ThT fluorescence (top) and
turbidity (bottom) of Zn-Ab11-28, Zn-Ab11-23, and Zn-Ab14-23.
The conditions were as follows 300 lM peptides, 270 lM Zn(II),
100 mM Hepes pH 7.4. The solid line represents a fit (see ‘‘Materials
and methods’’ for details)
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Discussion
In general, Zn drastically increased the formation of fibrils
and the aggregation intensity for all three peptides, Ab14-
23, Ab11-23, and Ab11-28. Moreover, the impact of Zn on
the fibrils was metal-specific as Cu(II) behaves very dif-
ferently. Cu(II) inhibited the formation of fibrils by Ab11-
23 and Ab11-28. In contrast, Cu(II) slightly increased the
formation of fibrils by Ab14-23, but to a much lower extent
when compared with Zn(II).
In the case of Ab14-23, the fibril-inducing effect of Cu
has been assigned to the bridging coordination of Cu(II) at
the end of the peptides leading to a stabilization of the
aggregates [29] with Cu(II) bound to the N-terminal His
and to C-terminal caboxylates. The XAS data are in line
with Zn binding to the same ligands as Cu (NH2 and
imidazole of N-terminal His and carboxylates near the C
terminus). However, the Zn(II) coordination geometry is
more flexible compared with that of Cu(II) as distorted
four, five, and six ligand coordinations are well tolerated
(Fig. 2). Indeed the XAS data suggest a hexacoordinated
Zn(II) in Ab14-23. In contrast Cu(II)-Ab14-23 is more
square-planar [29]. As such, the aggregation-increasing
effect of Zn(II) binding [compared with Cu(II)] can be
explained by the more flexible coordination chemistry,
which imposes a lower constraint on the aggregation
process.
Ab11-28 and Ab11-23 have very similar binding modes
for either Zn(II) or Cu(II) (see earlier and [29]). Cu(II)
binds in the well-defined ATCUN motif, by the His,
N-terminal amine, and two amidyl as is typical for peptides
with the sequence H2N-Xxx-Xxx-His-R [41]. The XAS
data suggest that Zn(II) is hexacoordinated in Ab11-23/
Ab11-28, likely including the two His side chains, and
hence Zn(II) coordinates differently to the N-terminal
portion of Ab11-23/Ab11-28. This is also supported by
studies reported in the literature of Zn binding to the
peptides Asp-Ala-His and Gly-Gly-His showing that Zn
did not bind to amidyl, but bound to the His side chain and
N-terminal amine and/or carboxylate [42].
This implies that Zn(II) is able to bridge two Ab11-23/
Ab11-28 peptides and hence promote the formation of
amyloid-type structures like in the case of Ab14-23
(Fig. 2). In contrast, Cu(II) bound to the ATCUN motif has
Fig. 6 Representative
transmission electron
microscopy images of
Zn-Ab11-28 (top), Zn-Ab11-23
(middle) and Zn-Ab14-23
(bottom) at 0 h (left) and after
24 h (right)
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all ligands on the same Ab11-23/Ab11-28 peptide.
Therefore, Cu(II) is not able to bridge two Ab11-23/Ab11-
28 peptides, which could explain the non-promoting effect
of Cu(II) on the amyloid formation of Ab11-23/Ab11-28.
Another important physico-chemical parameter to con-
sider in aggregation is the charge. Aggregation is faster
when the net charge approaches 0 [43, 44]. As Zn(II) and
Cu(II) have ?2 charges, their binding can change the net
charge. Moreover, depending on the binding site, protons
can be released and hence for the equally charged Cu(II)
and Zn(II), their binding to a peptide at different sites can
result in different net charge. Ab14-23 at physiological pH
has a charge of about -1. Zn(II) binding and Cu(II)
binding are supposed to displace only the N-terminal pro-
ton. This leads to an overall charge of 0 for Zn(II)-Ab14-23
or Cu(II)-Ab14-23. This is supposed to contribute to the
accelerated fibril formation. However, as the effects of Zn
and Cu are different, the effect on charge of metal ion
binding does not explain everything and structural effects
(see above) are likely to contribute as well. In the case of
Ab11-23/Ab11-28, Cu(II) and Zn(II) do not bind to the
same site. Cu(II) replaces about three protons (ATCUN
motif), and therefore the negative charge increases from
-2 for apo-Ab11-23 to -3 for Cu(II)-Ab11-23 and from -1
for apo-Ab11-28 to -2 for Cu(II)-Ab11-28. In contrast, Zn is
thought to replace only one proton (no binding to amidyl),
and the negative charge decreases from -2 for apo-Ab11-23
to -1 for Zn(II)-Ab11-23 and from -1 for apo-Ab11-28 to 0
for Zn(II)-Ab11-28. This suggests that changes in overall
charge play a role in the effects of metal ion binding to
amyloidogenic peptides.
It is interesting to note that at least for Ab11-23 and Ab11-
28, turbidity evolves much faster than ThT fluorescence,
indicating that first non-ThT-positive aggregates are formed,
which later transform to ThT-positive amyloid-like aggre-
gates. During the transformation, the turbidity intensity does
not change much, suggesting a transformation of aggregates.
In conclusion, Zn(II) is able to accelerate fibril forma-
tion for all three peptides. The different coordination
chemistry of Zn(II) versus Cu(II) can explain the metal-
specific effect on aggregation and the difference between
the peptides Ab14-23 and Ab11-23/Ab11-28. These
insights could provide mechanistic hypotheses on how Zn
can promote and Cu inhibit fibril formation of certain
amyloidogenic peptides/proteins [12, 13] (like Ab11-23
and Ab11-28) or how in certain cases both metals promote
amyloid formation [7, 10].
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Fig. 7 X-ray absorption near edge structure of Ab14-23 (1a, 1b),
Zn-Ab11-23 (2a, 2b), and Zn-Ab11-28 (3a, 3b) just after Zn addition
(1a, 2a, 3a) and after 24 h incubation (1b, 2b, 3b). The conditions were as
follows: 1 mM peptide, 0.9 mM Zn(II), 100 mM POPSO pH 8.6
Table 1 Structural data of the
first coordination shell obtained
from R-space fits of extended
X-ray absorption fine structure
spectra; N number of neighbors,
R absorber–neighbour distance,
r2 Debye–Waller factor;
uncertainties in coordination
numbers are estimated
to ± 20%, in R to ± 0.02 A˚,
and in r2 to ± 0.001 A˚2
a R factor is the overall
goodness of fit
Scattered/backscattered N R (A˚) r2 (A˚2) R factora (%) DE0 (eV)
ZnAb14-23 (0 h) Zn-N/O 4.46 1.93 0.0078 0.38 2.74
2.43 2.08 0.0025 5.75
ZnAb14-23 (24 h) Zn-N/O 4.31 2.00 0.0077 0.51 3.09
2.47 2.04 0.0044 2.47
ZnAb11-23 (0 h) Zn-N/O 4.31 1.95 0.0011 0.35 1.88
2.47 2.09 0.0075 4.37
ZnAb11-23 (24 h) Zn-N/O 4.45 1.93 0.0046 0.53 2.26
2.41 2.05 0.0080 1.43
ZnAb11-28 (0 h) Zn-N/O 4.39 1.95 0.0078 0.87 0.79
2.38 2.01 0.0056 1.16
ZnAb11-28 (24 h) Zn-N/O 4.47 1.92 0.0069 0.36 0.36
2.39 2.08 0.0058 2.88
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ABSTRACT: Self-assembly of amyloidogenic peptides and
their metal complexes are of multiple interest including their
association with several neurological diseases. Therefore, a
better understanding of the role of metal ions in the
aggregation process is of broad interest. We report pH-
dependent structural and aggregation studies on ZnII binding
to the amyloidogenic peptide Ab11-28. The results suggest
that coordination of the N-terminal amine to ZnII is
responsible for the inhibition of amyloid formation and the
overall charge for amorphous aggregates.
■ INTRODUCTION
The supramolecular assembly of peptides and proteins into
amyloid fibrils is intensively studied owing to their important
biological roles including different neurological diseases
(Alzheimer’s, Parkinson's, etc.)1−3 and because amyloids are
of interest in material science.4,5 Amyloids are made of peptides
or proteins that adopt fibrils based on the cross-β-structure, in
which the peptide backbone is orthogonal to the fibril axis.4,6,7
They are normally formed by a two-step process of slow
nucleation, followed by a typically fast, autocatalytic surface
growth, leading to a sigmoid curve for amyloid formation.8
The binding of metal ions such as zinc, copper, and iron to
amyloidogenic peptides modulates the aggregation behav-
ior9−14 and results in fibrils with embedded metal ions.15−20
The use of small peptides to model the aggregation of native
peptides or to gain general insight into the mechanisms was
very helpful in the understanding of amyloid formation4,21−23
and the role of metal ions.24−30 Smaller model peptides are
often easier to handle and have higher reproducibility in terms
of aggregation behavior.
In the past, we investigated the effect of ZnII and CuII binding
on three different amyloidogenic model peptides and found
metal- and peptide-specific effects related to the coordination
chemistry of the metal ions.31,32 One of these peptides, Ab11-
28, showed suitable properties in terms of mechanistic studies
for ZnII-induced aggregation. Ab11-28 is derived from amyloid-
β (Aβ) peptide, which plays a crucial role in Alzheimer’s
disease. Although Ab11-28 is missing the N- and C-terminal
parts and, hence, is clearly different from Aβ in terms of
aggregation and metal binding,33 it preserves two important
features for metal-induced amyloid formation. These are the
two His residues (His13 and His14) known to anchor ZnII and
the hydrophobic core (amino acid residues spanning from 17 to
21, sequence LVFFA). Moreover, truncated Aβ peptides
starting at position 11 (i.e., Aβ11-x) have been found in
human amyloid plaques and are thus physiologically relevant.34
Therefore, the amyloidogenic Ab11-28 peptide can serve as a
model system to gain general insight into metal-induced
amyloid formation.
Further studies on ZnII binding to the peptide Ab11-28 at pH
7.4 showed the importance of dynamical ZnII binding for
aggregation and suggested that the formation of a transitory
complex of two Ab11-28 bound to ZnII (i.e., ZnII(Ab11-28)2)
via His14 and the carboxylate of Glu11 is most prone to fibril
formation.35
In order to gain insight into the relationships between the
structure of ZnII binding and the aggregation behavior, we
studied the pH dependence of ZnII binding to Ab11-28 upon
aggregation.
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■ RESULTS AND DISCUSSION
pH Dependence of ZnII0.5-Ab11-28 Aggregation. Our
previous studies indicated that ZnII(Ab11-28)2 is the building
block of aggregation into amyloids.31,35 Changing the pH of
metallopeptides like ZnII(Ab11-28)2 will influence two
important parameters concerning aggregation: (i) the overall
charge of a peptide is pH-dependent, and aggregation is
classically faster when the overall charge approaches zero
(Table 1).36,37 (ii) Metal binding is often pH-dependent, and
hence the structure of the metal−peptide complex can change.
The aggregation of Ab11-28 with 0.5 equiv of ZnII was
followed by thioflavin T (ThT) fluorescence and turbidimetry
at different pH values. ThT is a specific fluorescence dye for
amyloid-type aggregates, while turbidity measures more
amorphous aggregates because it depends mostly on the
amount and size of aggregates.
Figure 1 (top) shows the time courses of the ThT
fluorescence and turbidity of Ab11-28 with 0.5 equiv of ZnII
at pH 7. For either measurement, the overall curve has a
sigmoidal form, and hence a t1/2 and a plateau intensity can be
estimated as indicated. t1/2 of turbidity is shorter than t1/2 from
ThT, indicating that first amorphous-type aggregates are
formed, which are subsequently transformed into amyloid-
type aggregates.
The pH dependence of Ab11-28 with 0.5 equiv of ZnII
revealed very different ThT fluorescence and turbidity features
(Figure 1, middle and bottom), indicating that aggregates and
amyloid formation are not directly correlated. The main kinetic
phase of ThT fluorescence was faster with lower pH (Figure 1,
bottom), but the plateau reached at the end was similar (Figure
1, middle). This indicates that the same amount of amyloid was
formed over the present pH range, but the formation was faster
at low pH. In contrast, the turbidity increased rapidly in a
nonsigmoidal manner and ThT fluorescence preceded (at the
pH where it could be well measured, i.e., ≥ pH 7). The kinetics
was not very sensitive to the pH (Figure 1, bottom). This
suggests that amorphous, unstructured aggregates are formed
before amyloids and likely a transformation occurred. The
turbidity plateau reached was pH-dependent (Figure 1,
middle). It was maximal around pH 7.4, i.e., increased from
pH 8.4 to 7.4, and then decreased by a further lowering of the
pH to 6.
To gain insight into the structural changes responsible for the
pH dependence of turbididy and ThT fluorescence, NMR and
X-ray absorption spectroscopies (XAS) were applied.
NMR. The effect of the addition of ZnII to Ab11-28 was
studied by 1H NMR at several pH values (Figure 2).
Measurements were done immediately after ZnII addition in
order to minimize aggregation. ZnII-induced line broadening
and shifts for some specific resonances (Figures 2 and S2 in the
Supporting Information), indicating the specific binding of ZnII
to the affected residues. Figure 2, left panel, shows the aromatic
region, including His13, His14, Phe19, and Phe20. ZnII
addition at different pH values lead to line broadening and to
shifts of H−Cδ and H−Cε of His14. In contrast, the H−Cδ
and H−Cε resonances of His13 were only little affected,
showing a slight broadening and a slight chemical shift. The
resonances of the two Phe are not affected at all, indicating no
binding to or near the Phe. This indicates that over the pH
range studied, His14, but not His13, is bound to ZnII.
The resonance of H−Cα of Glu11 in the apo-Ab11-28
underwent a large shift over the pH range 7−9, in line with
deprotonation of the N-terminal amine (Glu11). A pKa of 7.8 is
Table 1. Expected Charge of Ab11-28 and ZnII1(Ab11-28)2
pH Ab11-28 ZnII1-(Ab11-28)2
8.4 −2 −2
7.3 −1 0
6.3 0 +2
Figure 1. (Top) Time course of turbidity (blue, right scale) and ThT
fluorescence (red squares, raw data; red line, fitted data; left scale) of
Ab11-28 with 0.5 equiv of ZnII at pH 7.0. The black line indicates the
intensity of the plateau. t1/2 values are given by the fit. (Middle) pH
dependence of the plateau intensity reached in ThT fluorescence (red
squares, raw data; red line, linear fit; left scale) and in turbidity (blue
circles, raw data; blue line, trendline; right scale) by Ab11-28 with 0.5
equiv of ZnII aggregation. Raw data are from five independent
measurements. (Bottom) pH dependence of t1/2 to reach the plateau
in fluorescence (red square, raw data; red line, trendline) and in
turbidity (blue circle) by Ab11-28 with 0.5 equiv of ZnII aggregation.
Raw data are from five independent measurements.
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estimated, a typical value for N-terminal amines in peptides
(Figure S3 in the Supporting Information). The addition of
ZnII showed a pH-dependent feature; at higher pH, the
resonances shifted and were largely broadened; in contrast, at
lower pH, no shift was induced and only a little broadening
occurred (Figures 2 and S3 in the Supporting Information).
This is interpreted in the sense that at higher pH the
deprotonated NH2 of the N-terminal Glu is a ligand to Zn
II but
not at lower pH, where NH3
+ is present. The smaller
broadening at lower pH is ascribed to the binding of ZnII to
the COO− of Glu11 (in line with ref 38).
These results suggest that ZnII binding occurs to Glu11 and
His14. In order to confirm this, we used the shorter,
nonaggregating peptide Ab11-14 (Glu-Val-His-His-NH2), and
as expected, the same resonances were affected by the addition
of ZnII in a way very similar to that in the longer Ab11-28 (see
above). Moreover, the same pH dependence was observed (see
Figure S4 in the Supporting Information) and hence supports
the binding of ZnII by NH2 of Glu11 at higher pH.
XAS. X-ray absorption near-edge structure (XANES) spectra
give an indication of the dominant zinc species in a given
sample. Thus, XANES was used to probe the pH dependence
of ZnII coordination to Ab11-28 (Figure 3). The Zn K-edge
spectra for the two Ab11-28 with 0.5 equiv of ZnII at pH 6.5
and 7.5 were similar, indicating that no major difference in zinc
speciation occurred between these two pH values. On the
contrary, the sample at pH 8.5 exhibited a different shape.
Indeed, based qualitatively on the shapes of the main white-line
peak at ∼9665 eV and oscillations on the high energy side of
the white-line peak, the solution at pH 8.5 had distinctly a
different spectrum compared with those at lower pH. The
white-line peak was enlarged with pH, especially between pH
7.5 and 8.5, the peak at 9670 eV was shifted to a higher energy
(∼9672 eV), and the peak at 9678 eV (dotted line)
disappeared. These differences indicate a change in coordina-
tion between pH 7.5 and 8.5 in line with the NMR data (see
above).
Previous studies suggested that the dimer ZnII(Ab11-28)2 is
the building block, which first forms nonamyloid aggregates
(the presence of turbidity but no ThT fluorescence) and then
converts to amyloid fibril (increasing ThT fluorescence).
Moreover, ZnII was bound by COO− from two Glu11 and
two imidazole of His14 from each peptide38,39 (see the inset in
Figure 4A). As pointed out by a reviewer, the binding of ZnII to
Glu11 and His14 is not consistent with a β-sheet structure of
this portion of the peptide because the two side chains point in
opposite directions. This resembles the structure from solid-
state NMR of Aβ1-42, in which the N-terminal part 1−16 is
disordered and the β-sheet structure starts around position
17.40,41 The structural data obtained above suggest that the ZnII
binding in ZnII(Ab11-28)2 is pH-dependent in the region of pH
6−8.5. Two forms exist with an apparent pKa of about 7.8, the
low pH form binds His14 and COO− of Glu11, and in the high
pH form, the N-terminal amine binds additionally to His14.
Whether COO− is still bound cannot be determined.
The pKa of N-terminal amine binding to Zn
II correlates very
well with the kinetics of the fibril formation measured by ThT
(Figure 1, bottom) and hence suggests that the binding of the
N-terminal amine changes the peptide structure to a less
aggregation-prone conformation. An explanation would be that
additional binding of N-terminal NH2 to Zn
II coordinated by
COO− from Glu11 and His14 of the two peptides might inhibit
the alignment of the two portions from amino acids 15−28 in a
Figure 2. 1H NMR of apo-Ab11-28 (lower trace) and ZnII-Ab11-28 (upper trace) at pH 9.1 (A), 8.0 (B), 7.7 (C), and 7.3 (D) in the regions of H−
Cδ and H−Cε of His13 and 14 (left) and H−Cα of Glu11 (right). Dotted lines represent the affected H−Cδ and H−Cε of His14 by Ab11-28 (left)
and H−Cα of Glu11 (right). H−Cα of Glu11 shifts strongly because of protonation of NH2. The asterisk indicates the H−Cα attributed to Val 12.
Conditions: 300 μM Ab11-28, 270 μM Zn2+, Tris-d11 100 mM.
Figure 3. Zoom on XANES of Ab11-28 with 0.5 equiv of ZnII at pH
6.5, 7.5, and 8.5. The asterisk indicates an artifact of the detector
(inset: complete XANES of Ab11-28 with 0.5 equiv of ZnII at pH 7.5).
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parallel β-sheet as needed for an amyloid structure. It might
also reduce dimerization because the monomeric ZnII1(Ab11-
28)1 is stabilized because of the tripodal binding of NH2,
COO− from Glu11, and His14.
Modeling. To gain deeper insight into the possible
structural changes of the ZnII site at different pH values and
of the implications of structural changes on the peptide
structure and aggregation, we investigated two semiempirical
models of the dimeric ZnII(Ab11−28)2 with NH3+-Ab11-28
and NH2-Ab11-28, respectively, as ligands.
First, ZnII(Ab11-28)2 with two NH3
+-Ab11-28, in which zinc
is bound to both His14 residues via the Nδ atoms, as suggested
by ref 38, and to both COO− groups of Glu11, was constructed
and simulated in the vacuum at T = 50 K for 5 ps. This
corresponds to ZnII(Ab11-28)2 at pH 6.5, called model 1
hereafter. Then, a second model, ZnII(Ab11-28)2 with two
NH2-Ab11-28, in which the two N atoms of the two Glu11
residues are included in the zinc coordination sphere
corresponding to ZnII(Ab11-28)2 at pH 8.5 was simulated in
the same conditions (model 2 hereafter).
The result of model 1 is very similar to the structure reported
by Kozin and co-workers (Figure 4a in ref 38), although in their
peptide, the NH2 of Glu11 is acetylated. Thus, a significant
difference in our model 1 is that the N termini are positively
charged and one is in hydrogen-bond distance to COO−
(Figure 4a).
Once the N termini are deprotonated and the approach of
N(Glu 11) toward ZnII is forced (model 2), one of the COO−
groups of Glu11 is expelled away from the zinc coordination
sphere. This event produces a pentacoordinated ZnII (ligands 2
His, 2 NH2, and 1 COO
−; Figure 4B), which is stable for the
simulated time.
The root-mean-square deviation (rmsd) of backbone heavy
atoms in the two models measured for residues 11−16 with
respect to the initial extended β-sheet conformation (almost the
backbone structure proposed by Luhrs et al.40) is smaller for
model 1 (low pH) than for model 2 (high pH) (the two 5-ps-
range curves in Figure 5). This indicates a distortion of the β-
sheet alignment between the two peptides in the high-pH
Figure 4. Final configurations (t = 5 ps) for models 1 (low pH, panel A) and 2 (high pH, panel B) for TB-MD at T = 50 K. Residues 17−28
(displayed as ribbons only) are represented with the positions of the empirical models. Residues 11−16 are represented as sticks, and ZnII is
represented as a sphere. Bonds involving ZnII are displayed for interatomic distances within 2.2 Å. Atomic radii are arbitrary, and the color scheme is
gray for C, red for O, blue for N, and silver for Cu. The VMD program was used for this and the following molecular drawings. A schematic view of
the first coordination sphere for the two structures is given in the upper left corner.
Figure 5. rmsd for heavy backbone atoms along with different
trajectories. The first noisy line represents the span of values obtained
within the MC-RW of residues 11−13. Square points represent the
values along with the manipulations of empirical models (see the text
for details). The two lines along with the 5-ps trajectories are the
values for the TB-MD at T = 50 K. The first 5-ps part is for model 1,
and the second 5-ps part is for model 2.
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model, induced by the NH2(Glu 11)−ZnII bond. This
observation is in line with a lower propensity to aggregate.
It is interesting to note that the turbidity does not correlate
with the changes of ZnII coordination observed because the
intensity was highest around pH 7.4 (Figure 1, middle) and the
kinetics is much less pH-dependent than it is for ThT (Figure
1, bottom). This can be explained by the overall net charge,
which is an important parameter of aggregation because
classically proteins precipitate better the closer the pH is to
the isoelectric point (pI). The overall expected charges of
ZnII1(Ab11-28)2 is around 0 at pH 7.4 (Table 1) and thus very
well with the profile of turbidity measurements (see Figure 1,
middle), where a bell-like curve in aggregation/precipitation
dependent on the pH was found with a peak around pH 7.4.
In conclusion, the very different pH dependences of ThT
fluorescence (related to amyloids) and turbidity (global
aggregation state) can be explained. The precipitation of
ZnII1(Ab11-28)2 leading to high turbidity is governed by the
global charge of ZnII1(Ab11−28)2, whereas the amyloid
formation is governed by the pH-dependent structure of the
zinc(II) peptide complex.
■ MATERIALS AND METHODS
Ab11-28 Sample Preparation. The peptide Ab11-28 (sequence
Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-
Asn-Lys) was purchased from GenScript Corp. (Piscataway, NJ). The
stock solutions of Ab11-28 (∼1.2 mM) have been prepared by
dissolving the peptide in Milli-Q water (resistivity = 18 MΩ cm−1) or
in D2O for an NMR stock solution, which resulted in a final pH of 2.
The pH of the solution was then adjusted to pH 12 by the addition of
NaOH (or NaOD for NMR) stock solutions, in order to monomerize
the peptides. These stock solutions were stored at 253 K. The peptide
concentrations were determined by using the molar extinction
coefficient ε = 390 M−1 cm−1 of the two phenylalanines at 258
nm.30 Because phenylalanine does not absorb at 275 nm, the
absorption at that wavelength was subtracted in order to remove
contributions from the buffer or baseline drifts. A ZnII stock solution
was prepared with ZnIISO4 monohydrate (Strem Chemicals) in water
or in D2O for NMR experiments. Aggregation of peptides in the
presence of ZnII has been performed by dissolving peptides from a
stock solution into a 100 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid buffer at pH 7.4, 100 mM piperazine-N,N′-bis(2-
ethanesulfonic acid) for pH 7.0 and 6.5, 2-(N-morpholino)-
ethanesulfonic acid for pH 6.0, or piperazine-1,4-bis(2-hydroxypropa-
nesulfonic acid) for pH 8.0 and 8.4 and was controlled at the end of
the experiment. All of the experiments measuring either turbidity or
fluorescence intensity have been performed at 298 K. The experiments
were repeated at least five times in different preparations.
UV−Vis Spectroscopy. UV−vis spectra were recorded on an
Agilent 8453 UV−visible spectrometer. Measurements were per-
formed at room temperature.
Turbimetry. Turbidity measurements were done by measuring the
absorbance at 350 nm with a FLUOstar Optima (BMG Labtech) in a
quartz microplate (96-well, Hellma). The final concentrations of
Ab11-28 and ThT are 300 and 10 μM, respectively.
Fluorescence Spectroscopy. Fluorescence spectra were meas-
ured by using a FLUOstar Optima (BMG Labtech). ThT, Ab11-28,
and ZnII were mixed in a 100 mM buffer and placed in a 96-well
microplate. The time course of ThT fluorescence was then measured
(excitation, 440 nm; emission, 490 nm; bandwidth for emission and
excitation, 10 nm). The final concentrations of Ab11-28 and ThT were
300 and 10 μM, respectively.
The sigmoidal ThT curve was fitted with the program KaleidaGraph
to the formula F(t) = F0 + A/{1 + exp[−k(t − t1/2)]}, where k is the
elongation rate, A the amplitude, t1/2 the time point when half the
maximal intensity is reached, and F0 the baseline before aggregation.
42
XAS. XANES measurements were carried out at the SOLEIL
Synchrotron Facility (St. Aubin, France), which was operating with a
ring current of 400 mA. ZnII K-edge XAS spectra were collected on the
SAMBA beamline. The measurements were performed using a Si(220)
water-cooled double-crystal monochromator and two large silicon
mirrors for high-energy harmonics rejection. Energy calibration was
achieved by measuring a copper foil and assigning the first inflection
point of the absorption spectrum to 8979 eV. The spectra were
measured in fluorescence mode by measuring the ZnII Kα fluorescence
with a 7-element germanium detector. The liquid samples were
injected in special sample holders and cooled down to 20−30 K using
a helium-flow cryostat. XANES spectra were background-corrected by
a linear regression through the preedge region and a polynomial
through the postedge region and normalized to the edge jump.
NMR. NMR experiments were realized on a Avance 500 Bruker
NMR spectrometer. Several solutions of the buffer deuterated
tris(hydroxymethyl)aminomethane (D11-TRIS) at different pH values
were prepared by solubilization of the TRIS powder in D2O and
acidification with D2SO4. Ab11-28 samples were freshly prepared from
a D2O stock solution (see the Ab11-28 Sample Preparation section).
Ab11-28 (final TRIS concentration of 300 μM) was added to several
TRIS solutions at a given pH (final concentration of 100 mM). The
solutions were mixed, the pH was measured (to take into account the
increase of the pH due to the Ab11-28 solution), and the resulting
solution was added to the NMR tube. The residual water signal was
suppressed by a presaturation procedure. ZnII was directly added to
the NMR tube, and measurements were performed as quickly as
possible (less than 1 min 30 s) in order to minimize the aggregation
process during spectrum acquisition. The assignment of the
resonances at pH 7.4 was published earlier,35 and titration between
pH 7 and 9 in small pH steps allowed the assignment of the
resonances over this pH range (see Figure S4 in the Supporting
Information).
Calculations. The first two monomers in the structure reported in
ref 40 (PDB id2BEG) were used as templates for building the initial
Ab11-28 dimer. The φ and ψ dihedral angles of each residue are, in
this structure, approaching the pair of values φ = −120°/ψ = 120°
typical of a parallel β-sheet. A ZnII ion was docked within the Nd
atoms of His14, by using a dummy counterion model,43 and the two
His14 side chains were adapted to bind the ZnII ion in an approximate
tetrahedral coordination. A short molecular dynamics (MD) trajectory
(20 ps) of this model in the vacuum and at T = 50 K was performed,
keeping the N, CA, and C atoms of residues 17−28 fixed in space, in
order to adapt the ZnII-bound 11−16 region to the extended β-strand
proposed by Luhrs et al.40
All of the manipulations of the empirical models were performed
with the NAMD44 and VMD45 packages, with external forces
implemented via the PLUMED46 plugins. In order to build structures
with the two Glu11 side chains in the ZnII coordination sphere already
occupied by the two His14 side chains, a Monte Carlo random walk
(MC-RW) for the dihedral angles involving heavy atoms in the two
11−13 regions was performed. This random walk47 samples almost
every configuration with nonoverlapping atoms, with residues 14−28
fixed in space. Among the collected configurations, the first
configuration with one ZnIIOe(Glu 11) distance (in both Glu11
residues) within 3 Å was extracted. This configuration was then moved
into the closest energy minimum and assumed as the starting model
for a semiempirical calculation based on the tight-binding (TB)
approximation.48 The system was truncated to the ZnII complex of
Ab(11−16)−CO−NH−CH3. The density functional TB code DFTB
+49 was used with the set of parameters developed for organic ZnII
compounds.50 After 300 steps of energy minimization, a 5-ps-long MD
simulation at T = 50 K was performed with the C, O, and N atoms in
the two −CO−NH−CH3 C-terminal groups (mimicking the Lys16−
Leu17 linkage) fixed in space. A time step of 1 fs was used with no
thermal bath (approximately constant energy or Born−Oppenheimer
MD simulation). The result is model 1.
The approach of the two N termini of Glu11 toward ZnII (model 2)
was performed by the removal of one proton for each N terminus in
the last DFTB configuration. External harmonic forces acting on the
Inorganic Chemistry Article
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ZnII−N(Glu 11) distances were added to the empirical model. By
increasing the equilibrium distance for the harmonic force in steps of
0.5 Å, the N(Glu 11)−Zn(II) distance decreased from 4.5 to 2 Å,
ending to a model where both N(Glu 11) atoms are at bonding
distance with ZnII. The final configuration obtained with this
procedure was used as the starting point for a second DFTB
simulation, again at T = 50 K for 5 ps. The result is model 2.
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ABSTRACT: Supramolecular assembly of peptides and proteins into amyloid fibrils is of
multifold interest, going from materials science to physiopathology. The binding of metal
ions to amyloidogenic peptides is associated with several amyloid diseases, and amyloids
with incorporated metal ions are of interest in nanotechnology. Understanding the
mechanisms of amyloid formation and the role of metal ions can improve strategies
toward the prevention of this process and enable potential applications in nano-
technology. Here, studies on ZnII binding to the amyloidogenic peptide Aβ11-28 are reported. ZnII modulates the Aβ11-28
aggregation, in terms of kinetics and fibril structures. Structural studies suggest that Aβ11-28 binds ZnII by amino acid residues
Glu11 and His14 and that ZnII is rapidly exchanged between peptides. Structural and aggregation data indicate that ZnII binding
induces the formation of the dimeric ZnII1(Aβ11-28)2 species, which is the building block of fibrillar aggregates and explains why
ZnII binding accelerates Aβ11-28 aggregation. Moreover, transient ZnII binding, even briefly, was enough to promote fibril
formation, but the final structure resembled that of apo-Aβ11-28 amyloids. Also, seeding experiments, i.e., the addition of fibrillar
ZnII1(Aβ11-28)2 to the apo-Aβ11-28 peptide, induced aggregation but not propagation of the Zn
II
1(Aβ11-28)2-type fibrils. This
can be explained by the dynamic ZnII binding between soluble and aggregated Aβ11-28. As a consequence, dynamic ZnII binding
has a strong impact on the aggregation behavior of the Aβ11-28 peptide and might be a relevant and so far little regarded
parameter in other systems of metal ions and amyloidogenic peptides.
1. INTRODUCTION
The supramolecular assembly of peptides and proteins into
amyloid fibrils is intensively studied not only because of their
important biological roles in several diseases1,2 but also because
nonpathological roles have been identified.3 Moreover,
amyloids are of interest in nanostructure fabrication and
biotechnology.4,5 Amyloids refer to peptides and proteins that
adopt fibrils based on the cross-β structure, in which the peptide
backbone is orthogonal to the fibril axis.4,6,7 They normally form
by a two-step process with a slow nucleation phase, followed by a
typically fast, autocatalytic surface growth, leading to a sigmoid
curve characteristic of amyloid formation, often monitored by
thioflavin T (ThT) fluorescence.8 Binding of metal ions to
amyloidogenic peptides is of biological relevance in several cases,
including Prion diseases, Alzheimer’s disease, Parkinson's disease,
amyotrophic lateral scleroses, and type II diabetes, in which
specific amyloidogenic peptides or proteins interact with metal
ions such as Zn, Cu, Fe, etc.,9−16 and for which compounds are
developed to suppress the effect of the metal ion.16−21 Also,
for biotechnological application or in nanoscience, amyloid fibrils
with embedded metal ions are of interest because they can
undergo electron-transfer reactions or can serve as catalytic
centers.22−27
Truncated peptides have been used to model the aggregation of
native peptides or to gain general insight into the mechanisms of
the aggregating process as well as for nanostructure fabrication.28
Also, de novo designed peptides were very useful for under-
standing aggregation and for obtaining nanostructures of the
amyloid type.4,29,30 The interaction of small or truncated
amyloidogenic peptides with various metal ions has been studied
in the past.31−37 Recently, we investigated the impacts of
stoichiometric ZnII and CuII binding on three different amylo-
idogenic model peptides including Aβ11-28 and found metal- and
peptide-specific effects related to the coordination chemistry of the
metal ions.38,39 Aβ11-28 is derived from amyloid-β (Aβ) peptide,
which plays a central role in Alzheimer’s disease. Although Aβ11-
28 is missing the N- and C-terminal parts and, hence, is clearly
different from Aβ in terms of aggregation and metal binding, it
retains two important features for metal-induced amyloid
formation. These are the hydrophobic core (amino acid residues
spanning from 17 to 21, sequence LVFFA) and the two His
residues (His13 and His14) known to anchor the ZnII ion. Thus,
this amyloidogenic Aβ11-28 peptide can serve as a model system
to gain general insight into metal-induced amyloid formation but
does not mimic the special case of native Aβ (although native
truncated forms starting from amino acid 11 have been identified
in AD40).
So far, studies of the effect of metal binding on amyloid
formation have focused on the addition of metal ions at the
beginning of the aggregation process with the idea that they
bind very rapidly41,42 and stay bound. Only one case is reported
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where transient copper(II) binding to β-2 microglobulin in a
2:1 ratio was sufficient to promote amyloid formation.
Copper(II) binding to the natively structured protein β-2
microglobulin induced a conformational change to form an
oligomerization-prone structure by exposing a previously buried
region. The structural conversion is CuII-dependent, while the
subsequent formation of amyloids is not. The transient copper(II)
binding required for conformational change was on the hour time
scale.14,43
Transient metal ion binding might be of biological relevance
because in several biological environments metal-ion concen-
trations can fluctuate at different time scales; i.e., binding can be
dynamic. A well-known example is the ZnII ion in certain
glutamatergic neurons, in which ZnII is released in high amounts
(up to 300 μM) in the synaptic cleft and taken up in a few
seconds.44,45 Thus, we investigated also dynamical aspects of ZnII
binding to the Aβ11-28 model peptide during aggregation, and the
results suggest that dynamics can play an important role in the
aggregating process and might be of biological relevance.
2. RESULTS
2.1. Aggregation Dependence of the ZnII to Aβ11-28
Ratio. The stoichiometry between metal ions and amyloido-
genic peptides can influence the aggregation behavior because
of the formation of different types of complexes. Here, the
aggregation kinetics were followed by ThT fluorescence and
turbidity as a function of the ZnII to Aβ11-28 ratio (Figure 1).
ThT is a specific fluorescence dye for amyloid-type aggregates,
while turbidity measures all types of aggregates. The ZnII to
Aβ11-28 stoichiometry had a pronounced impact on the
aggregation behavior, and different changes in the ThT fluores-
cence and turbidity were observed (Figure 1). The turbidity
increased rapidly upon ZnII addition to Aβ11-28. ZnII addition
to the buffer only (no peptide) did not show turbidity, hence
ruling out that turbidity is due to ZnII precipitation. Increasing
the equivalent of ZnII per Aβ11-28 from 0 to 0.9 led to faster
kinetics and a higher plateau, a behavior that has often been
observed for amyloidogenic peptides (Figure 1, right panel). In
contrast, ThT traces did not parallel the one measured by
turbidity. The increase in ThT fluorescence was slower and
showed the typical sigmoid curve for amyloid-type aggregation
due to a nucleation and elongation mechanism.8 The fastest
curve with the most intense plateau was observed for
approximately 0.5 equiv of ZnII per Aβ11-28; below and above
this stoichiometry, the kinetics and intensity were slower and
smaller, respectively (Figure 1, left panel). Turbidity evolved
much faster than ThT fluorescence for all ZnII to Aβ11-28
stoichiometries. This indicates that in a first stage ThT-negative
amorphous aggregates were formed, which later evolved toward
ThT-positive amyloid-like aggregates. During this change, the
turbidity intensity stayed more or less constant, suggesting a
transformation of the aggregates. This indicates that from 0 to
0.9 equiv of ZnII per Aβ11-28 global aggregation is accelerated
and increased, while for fibril formation, 0.5 equiv is the
optimum. This can be explained in the most straightforward
manner by assuming that a dimeric complex with one ZnII bound
to two Aβ11-28 peptides, i.e. ZnII1(Aβ11-28)2, is the building
block of the fibrillar-type aggregate. The further addition of ZnII
enhanced the formation of aggregates but diminished the fibrillar
content, likely by precipitating the ZnII1(Aβ11-28)2 complex via
ZnII bridging of two ZnII1(Aβ11-28)2 moieties.
It is important to note that after longer incubation apo-Aβ11-28
aggregated as well (Figure 1, insets) but with different character-
istics. Apo-Aβ11-28 reached a plateau of ThT fluorescence
approximately 5 times lower than the one observed in the case
of ZnII0.5-Aβ11-28 and did not show any detectable increase in
the turbidity. This strongly indicates that apo-Aβ11-28 forms a
different type of amyloid compared to ZnII0.5-Aβ11-28. Indeed,
transmission electron microscopy (TEM) showed a dense
scaffold of fibrillar aggregates for ZnII0.5-Aβ11-28, whereas apo-
Aβ11-28 formed more isolated fibrillar aggregates (Figure 2).
2.2. Effect of Ethylenediaminetetraacetic Acid (EDTA)
on ZnII0.5-Aβ11-28. In order to see whether Zn
II is involved
in the different phases of the aggregation process and if the
effect of ZnII binding on Aβ11-28 is reversible, we added the
very strong ZnII chelator EDTA (dissociation constant of
approximately 10−13 M at pH 7.4 compared to approximately
10−6 M for Aβ peptide and truncated forms similar to Aβ11-
2846,47) at different time points. EDTA has been shown to be
useful to reverse the effect of ZnII on amyloid formation, like in
the case of Aβ1-42, where it abolished completely the inhibitory
effect of ZnII on fibril formation.48 First, as a control, EDTA
(5 equiv per ZnII ion) was added just before ZnII and, as expected,
the Aβ11-28 aggregation behavior was very similar to that of
apo-Aβ11-28, indicating that the ZnIIEDTA complex does not
interfere with aggregation. Very interestingly, adding EDTA at any
time point after the ZnII addition (2 min to 3 h; see Figure S1 in
the Supporting Information) did not completely reverse the
aggregation profile back to the level of the nonaggregated
apo-Aβ11-28 in ThT fluorescence (Figure 3). In other words,
Figure 1. Time-course measurements of ThT fluorescence (left) and turbidity (right) of Aβ11-28 peptide in the presence of ZnII, with ZnII to Aβ11-
28 ratios ranging from 0 to 0.9. Conditions: [Aβ11-28] = 300 μM; [ZnII] = 0−270 μM; [HEPES buffer] = 100 mM, pH 7.4; [ThT] = 10 μM. Insets:
time-course measurements of ThT fluorescence (left) and turbidity (right) of Aβ11-28 peptide without ZnII (i.e., apo-Aβ11-28) over a longer period.
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the addition of EDTA does not totally reverse the system, and hence
even transient ZnII binding is sufficient to induce aggregation.
In Figure 3, we are reminded of the fact that apo-Aβ11-28 did
not undergo any increase in ThT fluorescence (left panel) or
turbidity (right panel) over several hours, while ZnII0.5-Aβ11-28
showed the typical sigmoid behavior in ThT fluorescence and a
turbidity increase from the beginning. The addition of EDTA to
the ZnII0.5-Aβ11-28 mixture led to an immediate drop of the
turbidity back to the nonaggregated apo-Aβ11-28 level (Figure
3, right). Interestingly, ThT fluorescence did not drop as fast as
the turbidity (and sometimes even continued to increase for a
while before dropping; data not shown; Figure S1 in the
Supporting Information) nor did it drop back to the level of
nonaggregated apo-Aβ11-28. At the end, the plateau reached a
level similar to that of aggregated apo-Aβ11-28 (compare the
left panel in Figure 3 and the inset of the left panel in Figure 1).
On the basis of the formation of two types of aggregates, i.e.,
ZnII0.5-Aβ11-28, which exhibits an intense turbidity and high
ThT fluorescence, and apo-Aβ11-28, which shows a low ThT
fluorescence intensity and no detectible turbidity, the addition
of EDTA to ZnII0.5-Aβ11-28 resulted in the formation of apo-
Aβ11-28-type aggregates, which was much faster compared to
that of apo-Aβ11-28 only. This is in line with TEM data (Figure
2), which showed similar types of aggregates for apo-Aβ11-28
and ZnII0.5-Aβ11-28 plus EDTA (more isolated fibrillar-type
structures), but different from ZnII-Aβ11-28 (more dense).
The addition of EDTA to ZnII0.5-Aβ11-28 at different time
points did not change the overall feature; i.e., shorter or longer
transient ZnII binding modulated the aggregation behavior
compared to apo-Aβ11-28 in any case (see Figure S1 in the
Supporting Information). There were variations in the kinetics
and intensity of the drop of ThT fluorescence, but in all
experiments, the decrease of ThT fluorescence was slower than
that of turbidity. Moreover, at the end, the fluorescence intensity
was similar to that of the aggregated apo-Aβ11-28 peptide
(Figure 1, left inset) but was reached much faster (Figure S1 in
the Supporting Information). This indicates that ZnII is able to
nucleate the amyloid formation of apo-Aβ11-28, even when it
binds only transiently.
Aβ11-28, after ZnII and EDTA treatments, aggregates faster
than without such treatments. Thus EDTA does not reverse
ZnII0.5-Aβ11-28 back to nonaggregated apo-Aβ11-28 (Figure 3).
This indicates that, after ZnII removal by EDTA, apo-Aβ11-28 is in
a different state (likely an oligomeric form) and is more prone to
aggregation than monomeric apo-Aβ11-28 (Scheme 1).
To see the effect of ZnII addition to aggregated apo-Aβ11-28
(formed via EDTA-treated ZnII0.5-Aβ11-28), Zn
II was added again
at a concentration equal to that of EDTA, leading to ZnIIEDTA
and ZnII0.5-Aβ11-28 species. ThT fluorescence increased again
with a sigmoidal curve similar to that observed in the case of ZnII
addition to monomeric apo-Aβ11-28 (Figure 4). This can be most
straightforwardly explained assuming that ZnII induces aggregation
of a portion of the soluble apo-Aβ11-28 peptide. Because of
equilibrium between the aggregated and soluble states in amyloids,
aggregated apo-Aβ11-28 is solubilized into monomeric Aβ11-28,
leading to further ZnII-induced aggregation. Thus, the aggregated
apo-Aβ11-28 is transformed into aggregated ZnII0.5-Aβ11-28
(Scheme 1).
2.3. Seeding Experiment and Labile ZnII Binding. Because
the previous experiments indicated that two structural different
aggregates are formed for apo- and ZnII0.5-Aβ11-28, we tested if
aggregated ZnII0.5-Aβ11-28 can seed apo-Aβ11-28. Indeed, after
seeding of soluble apo-Aβ11-28 with 7.5% preaggregated
ZnII0.5-Aβ11-28, ThT fluorescence immediately started to
increase and reached a plateau of intensity similar to that of
apo-Aβ11-28 (Figure 5, left). No increase in the turbidity was
detected (Figure 5, right). This indicates that indeed ZnII0.5-
Aβ11-28 can nucleate aggregation of apo-Aβ11-28, but the
aggregates formed are of the apo-type, so it is a triggering rather
Figure 3. Time course of ThT fluorescence (left) and turbidity (right) of apo-Aβ11-28 and ZnII0.5-Aβ11-28 without (solid) and with the addition of
EDTA at the time point indicated by the arrow (dashed). Conditions: [Aβ11-28] = 300 μM; [ZnII] = 0 or 150 μM; [EDTA] = 750 μM; [HEPES
buffer] = 100 mM, pH 7.4; [ThT] = 10 μM.
Figure 2. TEM images of ZnII0.5-Aβ11-28 (left), Zn
II
0.5-Aβ11-28 + EDTA (middle), and apo-Aβ11-28 (right) after 1 day of incubation. Conditions:
[Aβ11-28] = 300 μM; [ZnII] = 0 or 150 μM; [EDTA] = 750 μM; [HEPES buffer] = 100 mM, pH 7.4; [ThT] = 10 μM.
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than a seeding effect because the structure of the seed is not
propagated (Scheme 2).
The model shown in Scheme 2 is based on a fast exchange of
ZnII between peptides. NMR experiments with several amyloid-
type peptides indicated that exchange of ZnII between the
peptides is faster than that on the NMR time scale (approximately
milliseconds).49−51 This is also the case for the Aβ11-28
peptide because the substoichiometric addition of ZnII affects
the resonances of the entire sample (see below and Figure S2 in
the Supporting Information). To see if the predicted fast
exchange is also possible for the aggregated ZnII0.5-Aβ11-28, the
ZnII-sensitive chelator 4-(2-pyridylazo)resorcinol (PAR) was
used (Figure 6). PAR forms the ZnII complex [ZnII(PAR)2],
which absorbs at λ = 490 nm with ε = 73 × 103 M−1 cm−1, while
PAR alone absorbs at λ = 413 nm (ε = 33 × 103 M−1 cm−1).52
PAR was able to retrieve ZnII very rapidly and quantitatively
(half-time faster than 1 min), indicating indeed that ZnII in
aggregated ZnII0.5-Aβ11-28 is very labile and suggesting that Zn
II
exchange between aggregated and soluble Aβ11-28 is also quite
rapid. Hence, ZnII in aggregates could have an impact on the
aggregation of soluble apo-Aβ11-28 via fast ZnII exchange
reactions.
2.4. X-ray Absorption Spectroscopy (XAS). In order to
obtain structural information about ZnII binding to Aβ11-28,
X-ray absorption near-edge structure (XANES) was used. XANES
experiments with 0.5 and 1.0 equiv of ZnII per Aβ11-28 peptide
were performed at the beginning and at the end of the aggrega-
tion process (Figure 7). All of the spectra are in line with
a mononuclear ZnII site and resemble most proteins
with tetracoordinated ZnII including two His residues.53,54
Figure 4. Time course of ThT fluorescence of ZnII0.5-Aβ11-28 (solid)
and of ZnII0.5-Aβ11-28 with the addition of EDTA after ∼10 min and
of ZnII after ∼190 min (dashed). Conditions: [Aβ11-28] = 300 μM;
[ZnII] = 150 and 900 μM (after 190 min); [EDTA] = 750 μM;
[HEPES buffer] = 100 mM, pH 7.4; [ThT] = 10 μM.
Figure 5. Time course of ThT fluorescence (left) and turbidity (right) of apo-Aβ11-28 without (solid) and with the addition of 7.5% preaggregated
ZnII0.5-Aβ11-28 (dashed). Conditions: [Aβ11-28] = 300 μM; [Zn
II
0.5-Aβ11-28] = 22.5 μM added after 90 min (indicated by an arrow); [HEPES
buffer] = 100 mM, pH 7.4; [ThT] = 10 μM. The addition of preaggregated ZnII0.5-Aβ11-28 is indicated by an arrow.
Scheme 2. Model for the Triggering of apo-Aβ11-28
(Triangles) with Amyloid-Type Aggregates of ZnII0.5-Aβ11-
28 (ZnII, Red Circles; Peptides, Rectangular Sticks; See Also
Scheme 1)a
aThe structure of ZnII0.5-Aβ11-28 is not propagated like in a “seeding”
process, but ZnII triggers aggregation of monomeric apo-Aβ11-28 to
amyloid-type apo-Aβ11-28 (round sticks) because of its fast exchange
between the different forms of Aβ11-28 (see also Scheme 1).
Scheme 1. Monomeric Aβ11-28 Peptide (Triangles) Binding
ZnII (Red Circles) and Forming ZnII1(Aβ11-28)2
a
aZnII1(Aβ11-28)2 rapidly form amorphous-type aggregates (triangles)
with high turbidity and very little ThT fluorescence, which then evolve
into amyloid-type aggregates (rectangular sticks). The addition of
EDTA (open rings) does not reverse the system to monomeric
Aβ11-28 (triangles) but induces a form with a different conformation
(ellipses) more prone to aggregate into apo-Aβ11-28 amyloid-type
fibrils (round sticks).
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No difference between the beginning and end of the aggregation
was observed, indicating that the coordination sphere does not
change much during aggregation. The spectra were slightly
different compared to previous measurements of ZnII1-Aβ11-28 at
pH 8.6, indicating a pH-dependent ZnII coordination.38
The measurements at different stoichiometries, i.e., ZnII0.25-
Aβ11-28, ZnII0.5-Aβ11-28, and Zn
II
1-Aβ11-28, supported the
formation of the dimeric ZnII1(Aβ11-28)2 species because
Aβ11-28 species with 0.25 and 0.5 equiv of ZnII were identical,
but with 1 equiv, features were dampened. This points to a
more homogeneous coordination site of the first 0.5 equiv of
ZnII, in contrast to a more heterogeneous binding of the second
0.5 equiv of ZnII. This is in line with formation of the dimeric
ZnII1(Aβ11-28)2 complex as a building block.
2.5. NMR. As shown by XANES, ZnII coordination does
not change significantly during aggregation, suggesting that ZnII
binding in the soluble state, as can be probed by NMR, is also
relevant for the aggregated state. Hence, the effect of the ZnII
addition of the Aβ11-28 peptide was monitored by NMR
(Figures 8 and S2−S4 in the Supporting Information). ZnII
induced line broadening and chemical shifts of some specific
resonances. Figure 8 shows the aromatic region of the 1H NMR
spectra of the Aβ11-28 peptide in the absence and presence of
1 equiv of ZnII, including the two His and two Phe residues.
ZnII addition leads to line broadening and a shift of only one of
the two Hδ and only one of the two Hε of His13 or His14. The
other Hδ and Hε resonances are only weakly affected, likely
because of perturbation by ZnII binding to the neighboring His.
The resonances of the two Phe residues are not affected at all,
indicating no binding to or near the Phe residues. The other
affected residues were Glu11 and Val12 (see Figures S3 and S4
in the Supporting Information). This is attributed to the
involvement of Glu11 in ZnII binding, with Val12 being affected
because of its vicinity to Glu11.
Because Aβ11-28 aggregation precluded the attribution of
the resonances by longer NMR measurements (2D and 13C
experiments), we used model peptides corresponding to the
ZnII-binding region Glu-Val-His-His (EVHH-NH2). Upon Zn
II
addition to the EVHH peptide, although with slight differences,
the ZnII effect observed on the Aβ11-28 spectrum was
reproduced, i.e., one of the His is much more affected than
the other one (Figure 8C,D). The addition of ZnII to the
EVHG peptide lacking the His14 residue did not perturb
significantly the NMR spectrum, with the remaining His13
being only weakly affected (Figure 8A). This indicates that the
ZnII binding His is His14. This was confirmed by the study of
the EVRH peptide lacking His13, in which His14 is affected
similarly to the His14 from Aβ11-28 (Figure 8B,D). This
allowed assignment of the highly affected His of Aβ11-28 to
His14. Moreover, a comparison between the EVHH and Aβ11-
28 spectra in the Glu11 Hβ and Hγ regions with and without
ZnII established the implication of Glu11 in ZnII binding
(Figure S4 in the Supporting Information). This agrees with
the recent work of Kozin and collaborators, who proposed
binding of ZnII to COO− of Glu11 and to His14 in the peptide
Ac-Glu-Val-His-His-NH2 with an apparent Kd in the lower
micromolar range.47,55 In conclusion, ZnII binds preferentially
to Glu11 (COO−) and His14 in Aβ11-28 (Scheme 3). These
structural features are fully in line with the possible formation
of a dimeric ZnII1(Aβ11-28)2 species, as indicated by the
aggregation experiments (see above).
3. DISCUSSION
The structural studies described above suggest that ZnII binds
to Glu11 (COO−) and His14 and that a dimeric ZnII1(Aβ11-
28)2 can be formed in line with recent studies on Ac-EVHH-
NH2.
47,55 These dimers are likely to be formed transiently and
dynamically and aggregated further to larger aggregates.
Figure 6. UV−vis monitoring of the addition of preaggregated ZnII0.5-
Aβ11-28 to PAR. [PAR] = 300 μM; preaggregated [ZnII0.5-Aβ11-28] =
160 μM; [ZnII] = 80 μM; [HEPES] = 100 mM, pH 7.4.
Figure 7. XANES spectra of ZnII0.5-Aβ11-28 (gray, 0.5) and Zn
II
1-
Aβ11-28 (black, 1) before (dashed) and after (solid) aggregation at
pH 7. Inset: magnification of the zone around 9.67 keV. [Aβ11-28] =
2.4 mM; [ZnII] = 1.2 or 2.2 mM; [HEPES] = 50 mM, pH 7.0.
Figure 8. 1H NMR of apo- (lower black trace) and ZnII peptides
(upper gray trace) of EVHG (A), EVRH (B), EVHH (C), and Aβ11-
28 (D). Conditions: [peptide] = 300 μM; [ZnII] = 270 μM; [Tris-d11] =
100 mM, pH 7.5.
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Amyloid-type fibrils are most rapidly and most intensively
formed at 0.5 ZnII per Aβ11-28 ratio, suggesting that the dimer
ZnII1(Aβ11-28)2 is the building block of fibrils. This is
supported by considering the overall charge. Classically, proteins
precipitate and often aggregate into amyloids better when the net
charge is smaller. At pH 7.4, apo-Aβ11-28 has a charge of 1−.
The ZnII(Aβ11-28) complex is thus expected to have 1+ charge,
while ZnII1(Aβ11-28)2 has an expected charge of 0 and thus fits
better with the faster aggregation. Further ZnII addition
decreased fibril formation but increased the turbidity, likely
because of binding of ZnII between the ZnII1(Aβ11-28)2 units
and subsequent distortion of the amyloid-like aggregation of the
ZnII1(Aβ11-28)2 units with the formation of more amorphous-
like aggregates.
A very important finding is that ZnII binding is very dynamic
and ZnII exchange between soluble and aggregated Aβ11-28 is
rapid, which has a crucial impact on the aggregation behavior
(Schemes 1 and 2). Apo-Aβ11-28 aggregates into amyloid-type
fibrils with moderate ThT fluorescence and very little turbidity
because the fibrils are not clumped together (Scheme 1, process 1a).
ZnII binding to apo-Aβ11-28 is rapid (Scheme 1, process 2) and
forms at least transiently a dimeric ZnII1(Aβ11-28)2 complex,
which forms amorphous-type aggregates (Scheme 1, process 3)
with intense turbidity but no ThT fluorescence. These aggregates
evolve toward amyloid-type fibrils (high ThT fluorescence),
forming dense meshes (therefore, high turbidity). If ZnII is added
to preaggregated apo-Aβ11-28, the same process likely occurs
(Scheme 1, processes 2−4) and soluble apo-Aβ11-28 is
repopulated by the dissolution of aggregated apo-Aβ11-28
(process 1b). In contrast, when EDTA is added to ZnII-Aβ11-
28 aggregates (process 5), apo-Aβ11-28 aggregates are formed
but not via the reversed pathway (processes 4 to 2). Instead
another pathway is taken (Scheme 1, processes 5−7). This is
supported by the findings that the turbidity is dropping faster
than ThT fluorescence, indicating an intermediate state and that
formation of apo-Aβ11-28 is much faster than expected from a
reversible pathway.
As a consequence, transiently adding ZnII to apo-Aβ11-28
results in fibrils like the ones formed by apo-Aβ11-28 only but
dramatically accelerates formation. Transient ZnII binding over
different time periods shows the effect, but a period of transient
ZnII binding of less than 1 min is sufficient to accelerate the
formation of apo-Aβ11-28 aggregates. This clearly shows that
transient ZnII binding in the second time scale can have a
nucleation effect on the aggregation of apo-Aβ11-28. Moreover,
transient ZnII binding accelerates the formation of apo-Aβ11-28
at substoichiometric amounts (Figure 1), showing that
relatively low concentrations of ZnII can have an important
effect on aggregation. The dynamic exchange of ZnII binding to
Aβ11-28 did not only involve soluble Aβ11-28 because
aggregated ZnII-Aβ11-28 was also able to take part in the
exchange. The observation that the addition of a small fraction
of preaggregated ZnII0.5-Aβ11-28 to soluble apo-Aβ11-28
(“seeding experiment”) forms apo-type aggregates and not
ZnII-type aggregates is in line with nucleation due to ZnII
exchange (see above).
These new findings about the very dynamic ZnII exchange
between different forms of Aβ11-28 might also apply to other
systems with metal ion and amyloidogenic peptide interactions
and have the following important impacts:
i. Transient Labile Metal Pools. Fast transient ZnII
binding might be very relevant for certain biological systems, in
particular for the Aβ peptide and ZnII in Alzheimer’s disease. In
certain synapses, ZnII is ejected in the synaptic cleft and taken
up on the second time scale44,45 and plays the role of a
neuromodulator. This ZnII has been shown to be involved in the
formation of Aβ deposits, and the distribution of histological
stainable ZnII resembles the area most prone to amyloid deposit in
Alzheimer’s disease.56 Moreover, in vitro ZnII is able to induce Aβ
aggregation in milliseconds.41 A similar transient increase of the
metal-ion concentration in certain synaptic clefts has been
proposed for copper.57−59 Another example is the release of
ZnII from pancreatic islet β cells into the blood, which includes
locally high ZnII concentrations next to the release before dilution
out in the blood.15,16
ii. Trace Metal Ions. It has been observed, for different
metal−amyloidogenic interactions, that trace amounts (large
substoichiometric) of metal ions can have a strong impact on
aggregation.60−63 This has classically been assigned to the
induction of a stable metal−peptide nucleus with a further
elongation phase consisting of apo-peptide addition to the
nucleus. The dynamic exchange found here sheds more light on
the mechanism: substoichimetric amounts of metal ions will
not be bound to a portion of the peptide in a stable 1:1
complex but can be exchanged and thus bound transiently to
the entire pool of peptides. Hence, metal ions induce nucleation
of a much higher peptide concentration compared to its concen-
tration,and this in a relatively short time.
iii. Binding Constant. For several biological relevant
systems of metal−peptide interactions (Aβ, prion, α-synuclein,
amylin, etc.), the binding affinity for metal ions is much weaker
than that for classical metalloproteins (see, e.g., refs 12, 23, and
64−67), and hence sometimes the biological relevance of metal
binding to these peptides has been questioned. However, in
light of the present findings, a strong affinity is not required
because a substoichiometric amount of transiently bound metal
ions is sufficient for having a high impact on the aggregation
behavior.
iv. Metal-Ion Source. The dynamic exchange of ZnII
binding to Aβ11-28 did not only involve the soluble Aβ11-28
because aggregated ZnII-Aβ11-28 was also able to take part in
the exchange. This means that metal−peptide aggregates can
provide metal ions for transient binding to soluble apo peptide.
This might be particularly relevant for Aβ, where amyloid
Scheme 3. Model of the ZnII1(Aβ11-28)2 Complex
a
aShown are Glu11, Val12, His13, and His14. Gln15 to Lys28 are
represented as arrows. ZnII is bound by Glu11 (COO−) and His14 of
Aβ11-28. Other ligands are possible (e.g., H2O).
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plaques contain a high amount of metal ions available for metal
binding by external chelators.46,68 Moreover, metal ions could
also originate from other biomolecules containing labile-bound
metal ions, like metallothioneins.69
In conclusion, modulators of amyloid formation can interact
differently, i.e., covalently, by coordination, or by weak interactions.
For the latter two, transient binding is possible. Binding of metal
ions has been reported for quite a lot of amyloidogenic proteins/
peptides, and in several cases, they seem to be biologically relevant.
So far, not that much attention has been paid to dynamic exchange
reactions, in particular related to aggregation species. The studies of
our model system revealed that dynamic metal exchange reactions
between soluble and aggregated peptides are an important mech-
anism that can strongly impact the aggregation behavior.
4. MATERIALS AND METHODS
Aβ11-28 Sample Preparation. The peptide Aβ11-28 (sequence
Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-
Asn-Lys) was purchased from GenScript Corp. (Piscataway, NJ). The
stock solutions of Aβ11-28 (∼1.2 mM) have been prepared by
dissolving the peptide in Milli-Q water (resistivity = 18 MΩ cm−1) or
in D2O for an NMR stock solution, which resulted in a final pH of 2.
The pH of the solution was then adjusted to pH 12 by adding NaOH
(or NaOD for NMR) stock solutions, in order to monomerize the
peptides. These stock solutions were stored at 253 K. The peptide
concentrations were determined by using the molar extinction
coefficient ε = 390 M−1 cm−1 of the two phenylalanines at 258 nm.30
Because phenylalanine does not absorb at 275 nm, absorption at that
wavelength was subtracted in order to remove contributions from the
buffer or baseline drifts. A ZnII stock solution was prepared with
ZnIISO4 monohydrate (Strem Chemicals) in water or in D2O for NMR
experiment. Aggregation of peptides in the presence of ZnII has been
performed by dissolving peptides from a stock solution in a 100 mM
4-(2-hydroxyethyl)-1-piperazylethanesulfonic acid (HEPES) buffer at
pH 7.4 and was controlled at the end of the experiment.
All of the experiments measuring either turbidimetry or fluorescence
intensity have been realized at 298 K. The experiments were repeated at
least five times in different preparations. There were variations in the
kinetics, but the trends shown were always the same. Data shown are
representative measurements.
In the XANES measurements, the first sample (t = 0 h) was
withdrawn immediately after mixing, transferred to the sample holder,
and frozen in liquid nitrogen. The second sample was incubated for 15 h
at room temperature before transferring to and freezing in the sample
holder.
EDTA. An EDTA solution at 100 mM is prepared from ethylene-
diaminetetraacetic acid disodium salt (Sigma-Aldrich).
Tetrapeptides. EVHH-NH2, EVHG-NH2, and EVRH-NH2 pep-
tides (N-terminal amine; C-terminal amide) were purchased from
GenScript Corp. (Piscataway, NJ). The stock solutions were prepared
by dissolving the peptides in D2O. The peptide concentrations were
determined by CuII titration (see ref 32).
4-(2-Pyridylazo)resorcinol (PAR) Measurement. PAR was
purchased from Sigma-Aldrich. UV−vis measurements were done in
a 1 mm quartz cuvette in the presence of a HEPES buffer at pH 7.4
(100 mM).70
UV−Vis Spectroscopy. UV−vis spectra were recorded on an
Agilent 8453 UV−vis spectrometer. Measurements were performed at
room temperature.
Turbidimetry. Turbidity measurements were done by measuring
the absorbance at 350 nm with a FLUOstar Optima (BMG Labtech)
in a quartz microplate (96-well, Hellma).
Fluorescence Spectroscopy. Fluorescence spectra were meas-
ured by using a FLUOstar Optima (BMG Labtech). ThT (Acros),
Aβ11-28, and ZnII were mixed in a 100 mM HEPES buffer at pH 7.4
and placed in 96-well microplate. The time course of ThT fluorescence
was then measured (excitation, 440 nm; emission, 490 nm; bandwidth
for emission and excitation, 10 nm). The final concentrations of Aβ11-
28 and ThT were 300 and 10 μM, respectively.
TEM. Peptide samples (15 μL) incubated for 17 h were applied on
EM grids, washed with 15 μL of Milli-Q water, and negatively stained
with an aqueous solution (15 μL) of uranyl acetate (1% w/w).
Samples were air-dried and examined with a JEOL 1011 transmission
electron microscope operating at an accelerating voltage of 100 kV or
on a HU12A transmission electron microscope (75 kV). Conditions:
[Aβ11-28] = 300 μM; [ZnII2+] = 0 or 150 μM; [EDTA] = 750 μM;
[HEPES buffer] = 100 mM, pH 7.4; [ThT] = 10 μM. EDTA was
added after 1 day of incubation and 10 min before grid deposition.
XAS. XANES measurements were carried out at the SOLEIL
Synchrotron Facility (St. Aubin, France), which was operating with a
ring current of 400 mA. ZnII K-edge XAS spectra were collected on the
MARS beamline.71 The measurements were performed using a Si(220)
water-cooled double-crystal monochromator and two large silicon
mirrors for high-energy harmonics rejection. Energy calibration was
achieved by measuring a copper foil and assigning the first inflection
point of the absorption spectrum to 8979 eV. The spectra were
measured in fluorescence mode by measuring the ZnII Kα fluorescence
with a silicon drift detector (SII Nanotechnology). The liquid samples
were injected into special sample holders and cooled to 20−30 K using a
helium-flow cryostat. XANES spectra were background-corrected by a
linear regression through the preedge region and a polynomial through
the postedge region and normalized to the edge jump.
NMR. NMR experiments were realized on a Avance 500 Bruker
NMR spectrometer. Aβ11-28 samples were freshly prepared from a
D2O stock solution (see the Aβ11-28 Sample Preparation section). The
pH value of Aβ11-28 (300 μM) and a deuterated tris(hydroxymethyl)-
aminomethane (Tris) buffer (100 mM) was adjusted to 7.5. The
residual water signal was suppressed by a presaturation procedure. ZnII
was directly added to the NMR tube, and measurement was performed
as quickly as possible (less than 1 min 30 s) in order to minimize the
aggregation process during spectrum acquisition. EVHH-NH2, EVHG-
NH2, and EVRH-NH2 samples were prepared by diluting stock
solutions (see the Tetrapeptide section) to 300 μM in a deuterated
Tris buffer (100 mM); the pH value was adjusted to 7.4.
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Main Findings 
 
 The aim of our work was to get a better knowledge about Aβ – metal ions interactions, 
which are a wide and wild field of research. We decided to mainly focus on two aspects: Cu 
coordination to altered Aβ sequence and role of metal ions on aggregation by the means of 
models peptides. Our main findings are stated below in their two respective parts. 
 
Coordination 
 
We have determined: 
- the coordination of Cu(II)- and Cu(I)-Aβ species and their pH dependence; 
- the importance of the N-terminal amine function in Cu(II) coordination and the dramatic 
effect of its absence on coordination and affinity;  
- the major impacts of non-coordinating residues on the Cu(II) coordination, i.e. the 
importance of second-sphere effects on the first Cu(II) coordination sphere;   
- The high dependence of Cu(II) coordination on slight Aβ sequence modifications.  
 
Aggregation 
 
We have demonstrated that: 
- aggregation is peptides and metal ions dependent; these two parameters are linked to a 
specific coordination; 
- Zn binding to Aβ11-28 accelerates aggregation via the formation of dimeric species 
where the Zn ion bridges two peptides;  
- a pH increase changes Zn coordination and thus contributes to slowdown the aggregation 
process and that the total charge of Zn(Aβ11-28)2 controls the complex precipitation; 
- Zn binding is dynamic and Zn is in exchange within the peptide pool;  
- Transiently Zn binding can induce non-reversible modifications even if Zn is later taken 
off. These modifications dramatically accelerate the peptide aggregation.  
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V- Perspectives 
 
As explained in the introduction part, AD, metal ions and Aβ seems to be closely 
interconnected. Our approach was original, in the sense that we perform fundamental 
research on a highly applied issue (AD). From my point of view, understanding fundamental 
aspects are prior and required to develop efficient therapeutic tools. In this line, we explored 
“basic” aspects of metal ions and peptides:  
- their coordination to a series of Aβ peptides;  
- their role in aggregation of amyloidogenic peptides originating from Aβ .  
Having acquired this fundamental knowledge, we can try to find concepts which can 
be applied to AD and further (as in material science or in catalysis). The following 
paragraphs are (d/r)eflections from findings to others interesting aspects uncovered in this 
manuscript. 
V.1- Coordination 
 In the present work, we focused on Cu coordination to Aβ. Using complementary 
techniques and relevant mutants, we demonstrated the intricacy of simple Cu-peptides 
complexes. Metals exchange’s in the peptide pool is fast and metal coordination on the same 
peptide might exhibit different types of coordination in equilibrium. This clearly contrasts 
with proteins, which have mostly one well defined metal-binding site and do not exchange 
their metal ions. Two parameters control this versatile behaviour: affinity and folding. The 
higher the affinity is, the slower the exchange rate is. In addition, a better folding induces a 
lowering of the number of conformations and thus makes less coordination modes available, 
classically resulting in one strong binding site. So, unstructured peptides like Aβ, with 
moderate Cu affinity, have the “ideal” profile to be tricky to study! Indeed, even a 
modification of non-coordinating residue, may lead to a strong shift of the equilibrium (see 
for instance the D1N mutation) or give rise to different coordination modes (see for instance, 
the Aβ3-16 truncation). In addition, a modification in the first Cu(II) coordination shell (for 
instance, acetylation of the N-terminal amine function) can go unnoticed if only one 
spectroscopic technique is used and/or if the pH range of study is too narrow. 
Zn is also of paramount importance in AD. Therefore, studies of Zn coordination to 
Aβ and its modified forms are worthy. Our preliminary results (not shown) indicate that Zn 
coordination also differs with the peptide sequence and the pH (around physiological values). 
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 In our Cu(II) coordination studies, we have demonstrated that the majority of sequence 
alterations in Aβ linked to an early onset of AD or to higher toxic species, also induce strong 
modifications in Cu(II) coordination. This supports an active role of Cu-Aβ interactions in 
AD. Nevertheless, in order to know if such modified forms are more toxic via a higher ROS 
production, it would be worthy to quantify and compare Aβ and modified Aβ on Cu induced 
ROS production.  
Contrasting with the plethora of existing methods to quantify ROS (Ascorbate 
consumption, Coumarin fluorescence, Resorufin production, Nitro blue tetrazolium reduction, 
DMPO spin trap…), general features of the Cu-peptide ROS production are still poorly 
understood. Yet, coordination seems to be related to ROS production since ROS are produced 
by redox cycle of the metal ions and thus depend on its coordination. With regards to 
parameters such as affinity, metal ions (oxidized and reduced forms) coordination spheres, it 
seems possible to predict ROS production. However, our preliminary experiments prove that 
it is not so simple! Anyway, a better understanding of such process will be, in fundamental 
aspects interesting and challenging, and could also be used to applied research, as for instance 
the search of drugs. Imagine a ROS hyper-active compound (peptidic complexes or not); it 
may be a good anti-cancer drug candidate, even better if specific. 
 
V.2- Aggregation 
 In this part of our studies, we tried to understand “basic” features of peptide 
aggregation modulated by metal ions. Interactions of metals ions - peptides are diverse and 
depend of both metal ions and peptide sequence. Metal ions can induce dimerisation and thus 
promote aggregation (see for instance Cu and Aβ14-23) or in contrast preclude aggregation 
process by binding in a fashion which destabilizes the β-sheet formation (Cu and Aβ11-28). 
pH and total charge are also key parameters. On one hand, pH may influence the metal 
coordination and thus modulate aggregation. On the other hand, the total charge of metal-ions 
peptide complexe, which is also pH dependent, controls the precipitation.  
Another interesting finding was the importance of the metal ions dynamic exchange. 
Indeed, temporary metal binding may induce change (i.e. induce dimerisation) which 
influences the aggregation even if the metal ion is removed rapidly. Since exchange is fast, a 
trace of the metal ions is sufficient to interact with the whole pool of peptide and, in our case, 
to force it to aggregate. Moreover, Zn from solid aggregates is rapidly and fully available to 
peptide from the bulk solution meaning that amyloid plaques may act as pool of ions metal. In 
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the synaptic cleft, Zn is released and then taken up; this could be enough to induce 
modification on surrounding Aβ. We have demonstrated this effect on Aβ11-28, but it would 
be highly interesting to observe it on the native Aβ1-40 peptide. Affinity is usually use as a 
proof of biological interaction, but if the affinity is too high, exchange via free Zn becomes 
slow. The affinity of Aβ for metal ions is rather moderate and lower for Zn compared to Cu. 
This dynamic exchange allowed by the moderate affinity may be a key point of Aβ 
aggregation in AD, in line with the fact that Zn is more competent to enhance full-length Aβ 
aggregation than Cu. 
 Measurements of aggregation of deleterious modified Aβ peptides will be also worthy 
to reveal if their toxicity originates from aggregation tendency mediated or not by metal ions 
rather than by metal ions induced ROS production.  
Aggregation is generally follows by Thioflavin T (ThT) fluorescence. Such 
measurements are adequate to monitor fibrils formation. However, fibrils seem not to be the 
harmful species. Scientific consensus supports that aggregation intermediate species (called 
oligomers) are the most toxic species. To the best of our knowledge, those species has been 
poorly characterised (mainly by TEM). Indeed, with fluorophore such ThT, we are blind to 
species of interest. Did you ever try to find something you don’t know in the dark? Sounds 
pretty hard, doesn’t it? FRET technique could be a major help in oligomer’s detection. Indeed, 
mixtures of fibrils specific and unspecific fluorophores enabled to FRET together may light 
on “oligomers”. This could be great step forward in the AD field that could let us dream of an 
early diagnostic of AD.  
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Structure  
 
 
Optically active compound : 
 
 
                     
 
                   Thioflavin T                                                                         PAR  
                                                                                                     4-(2-pyridylazo)resorcinol 
 
 
 
 
Buffer : 
 
                                                            
   
  
MES PIPES HEPES POPSO 
pKa = 6.1 pKa = 6.8 pKa = 7.5 pKa = 7.8 
    
2-(N-Morpholino) 1,4-Piperazinediethane   4-(2-Hydroxyethyl)piperazine- Piperazine-1,4-bis(2-hydroxy
ethanesulfonic acid sulfonic acid 1-ethanesulfonic acid propanesulfonic acid)
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The following article is a review which focuses on peptide sample preparation and 
common methods used to study peptide – metal ions interactions. I critically reviewed this 
article and contributed to Figures 1, 3, 8 and Table 2. 
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concerning  sample  preparation  etc.  It is  not  addressed  to specialists  of these  techniques  as  the  physical
principles of  the  techniques  are  nor  given.  First,  a general  overview  is given  about  sample  preparation  and
treatment, with  focus  on  the metal  ions  Zn(II),  Cu(I/II) and  Fe(II/III)  and  the  peptides  amyloid-  (but also
-synuclein, prion  etc.).  Then  the  methods  NMR,  EPR,  electrochemistry,  optical  spectroscopy,  isothermal
titration calorimetry,  FTIR,  X-ray  absorption  and  mass  spectrometry  are  treated.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The aim of this article is to give an overview on the most current
different techniques, which are applied for studying the interaction
of metal ions (mostly, Cu(I/II), Zn(II) and Fe(II/III) ions) with amy-
loidogenic peptides, in particular amyloid- (A), but also prion,
-synuclein etc. The aim is to concentrate on the following ques-
tions:
- what kind of information can be obtained by each techniques, and
what are the advantages and limits;
-  what are the metal and amyloid peptide specific particularities
which should be taken into account for proper sample handling
and  application to the technique.
There is no space to give explanation about the physical prin-
ciple of the methods. Here we refer to more specialized articles.
Moreover, we focus on the most common methods which are par-
ticular dedicated to the metal ions. We  did not treat other very
important techniques, in which the impact of metal ions is less
important and can be found in other non metal specific reviews on
amyloids (e.g. transmission electron microscopy) or in which we
feel not competent enough.
2.  Samples preparation
2.1.  Metal ions and buffers
Zn(II),  Cu(II) and Fe(III): Zn(II), Cu(II) and Fe(III) are the oxidation
states stable on air and in aqueous solution. Classical salts used are
chlorides, sulfates etc. Best is to take salts which are not hygroscopic
and contain a defined amount of water, in order to have a precise
quantity by weighting.
The  solubility of Zn(II), Cu(II) and Fe(III) around physiological pH
is not very high due to the formation of hydroxides and subsequent
precipitation (solubility constants Ksp for Fe(OH)3 = 6 × 10−38;
Zn(OH)2 = 4.5 × 10−17; Cu(OH)2 = 1.6 × 10−19). Thus the solubility is
pH dependent and salts are more soluble at low pH. Concentrated
stock solution (mM  range) of Zn(II), Cu(II) and Fe(III) should be pre-
pared at low pH (for 1 M stock solutions the volume change due to
the dissolution of the salt has to be taken into account, in contrast
for 100 mM stock solution this can be neglected). The pH is directly
low when salts are dissolved in pure water, due to the Lewis acidity
of the metal ions.
Reduced  forms Cu(I) and Fe(II): Generally, salts of Cu(I) are less
soluble as salts of Cu(II), whereas Fe(II) salts are better soluble than
Fe(III). Dissolved Cu(I) and Fe(II) salts are normally not stable on
air. Thus stock solutions have to be prepared under inert gas (Ar
or N2) by using degassed aqueous solution (freeze/thaw cycles are
appropriate). In the case of Fe(II), Fe(NH4)2(SO4)2 is the only redox
stable Fe(II) salt. For Cu(I) the complexes [Cu(I)(MeCN)4]+ (counte-
rion BF4−, ClO4− or PF6−) can be used.
For Cu(I) an additional problem is that Cu(I) disproportionates
in Cu(0) and Cu(II) in aqueous solutions. Thus Cu(I) has to be sta-
bilized, often done by adding a portion of MeCN (classically at
least 10%). The presence of MeCN has to be taken into account
for further analyses of the sample. Another possibility is to add
thiols, like DTT, EtSH or glutathione. Glutathione has the advan-
tage to be the biological reducing agent likely natively involved in
Cu(I) coordination/stabilization, and other thiols can be argued to
be models for glutathione. In contrast, due to their strong affin-
ity, the thiols have a strong impact on the apparent metal-binding
affinity of peptides/proteins. Moreover, Cu(I)-thiolates are not sta-
ble under aerobic conditions as Cu(I) oxidizes to Cu(II), which in
turn is rereduced to Cu(I) by thiol oxidation to disulfides. This has
the advantage that thiols play two roles, impeding disproportion-
ation and oxidation. The drawback is that thiols are consumed and
disulfides formed, but under inert atmosphere this is very limited.
Apart  from adding thiols which are good ligands and reducing
agents, other reducing agents which have lower affinity for metal
ions can be added, like dithionite, NaBH4, ascorbate etc. Dithionite
works well to keep Fe(II) and Cu(I) reduced and seems not to inter-
fere strongly with metal-binding to A. Dithionite reacts directly
with molecular oxygen and hence eats up dissolved oxygen. How-
ever, the reaction produces radicals which can attack the sample.
Moreover HSO3− and HSO4− is formed which can acidify the solu-
tion. Thus a strong buffer has to be used and the pH checked at
the end of the experiment. Ascorbate does not react directly with
molecular oxygen and is a weaker reductant.
2.2. Buffers
Important factors about the choice of buffers are [1]:
Interaction of buffer with metal ions: All buffers can have inter-
action as the base of the buffers has an unpaired electron (often
amine) which is able to coordinate metal ions. So there are two pos-
sibilities, either take a buffer with little interaction, so that it can
be neglected (this is mostly the case for the Good’s buffer, Hepes,
Pipes, Popso etc.) or take a buffer for which the interaction with the
metal ions is well defined, so that it can be corrected (for instance
Cu(II) with glycine or Hepes). In the former case, a problem can be
that in such buffers metal ions are not stable (at higher concentra-
tion) due to the formation of hydroxides. This is less the case for
buffers with a stronger interaction (see Table 1).
Precipitation: This is the case for phosphate, Cu3(PO4)2,
Zn3(PO4)2 and Fe3(PO4)2 complexes are very insoluble (solubility
product constants Ksp = 1.4 × 10−37, 9.0 × 10−33, and 1.0 × 10−36,
respectively) and hence precipitation could occur, which may inval-
idate the results. This is pH dependent due to the pH dependent
concentration of PO43−.
Temperature  dependence of pH: The pKa of the buffers are tem-
perature dependent, i.e. by changing the temperature the pH of the
buffer will change. This dependence differs between the different
buffers, e.g. it is high for Tris and small for Hepes. This is important
P. Faller et al. / Coordination Chemistry Reviews 256 (2012) 2381– 2396 2383
Table 1
Buffers and metal ions.
Buffer Properties with Mn+ Pros Cons
Phosphate Forms unsoluble complexes with several
metal ions
No 1H signal in NMR, covers large pH
range
Cu3(PO4)2 and Zn3(PO4)2 complexes are
very insoluble
Tris  Binds well metal ions, keep them in
solution
Keeps Mn+ in solution cheap d11-Tris
available  for NMR
Complexes of Mn+ not well defined. Strong
temperature dependence of pKa
Hepes Low interaction Cu–Hepes (1:1) complex well defined
[5]. Zn(II) Hepes interaction can often
be neglected. Small temperature
dependence  of pKa
Hepes can form radicals (reducing agent)
CAPSO,  POPSO, PIPES, MES Low interaction Weak Mn+ binding Interaction not well defined
for temperature dependent studies and also in techniques using
samples in the frozen state (classically in EPR, XAS, etc.).
A  specific case is phosphate buffer, because the change in pH
upon freezing depends on the presence of sodium (like in PBS).
With sodium, phosphate shows an important decrease in pH (up
to 3 units) upon freezing. In contrast, the Hepes buffer shows only
a moderate change (−0.4 units) and the Tris buffer can increase up
to 2 pH units [2].
Side  reaction: Buffers can make side reactions. A non negligible
one is that Hepes is a weak reducing agent and can form radicals.
Hepes was reported to reduce Cu(II), if a Cu(I) stabilizing ligand is
present [3]. However, no redox reactions of Cu(II)–A occurred in
Hepes over 2 h [4].
Techniques specific issues: In 1H NMR  the choice of buffer is lim-
ited as for buffers with 1H the deuterated form has to be used,
at least in the more common case where a large excess of buffer
compared to the peptide is used. The only cheap deuterated buffer
is Tris, others are very expensive. Alternative is phosphate, which
contains no 1H.
2.3.  Peptides
A  very detailed review on methods concerning A handling
without metal ions has been published recently [6].
Peptide sources: Chemical synthesis or recombinant peptides are
commercially available. Chemically synthesized peptides contain
counter ions, classically trifluoroacetate (TFA) from HPLC purifica-
tion. The number of counter ions can be calculated from the charge
of the peptide at pH ∼ 2 and has to be taken into account when the
peptide is quantified by weight. For A, the charge at pH 2 is about
+7 (N-terminal amine, 3 His, 2 Lys, 1 Arg, but the carboxylates are
mostly protonated) and hence ∼7 counterions are present. More-
over, the purification at pH around 2 (e.g. due to presence of 0.1%
TFA) and subsequent freeze drying results in peptide, in which the
His and carboxylates are mostly protonated. If such a peptide is
dissolved in water at higher concentrations (mM),  the resulting pH
will be quite low. Even when the peptide is dissolved in high con-
centration of buffer, the pH can drop significantly, so pH should be
checked for such preparations.
For  longer very amyloidogenic peptides like A1–42, but also
A1–40 there are differences between batches in term of their state
of aggregation. Differences in batches and between chemically syn-
thesized and recombinant A are often encountered (Fig. 1). Often
recombinant A is less preaggregated and hence aggregates slower
and often in a more reproducible way.
Monomerization: Several treatments have been described to
break preaggregates (or seeds), either using solvents (mostly hexa-
fluoro-isopropanol (HFIP) shown to be better than DMSO [7]),
formic acid, chaotropic agents (urea, guanidinium hydrochloride)
or incubation at high pH [8] (Fig. 1). However, it seems difficult
to obtain completely monomerized A following these methods.
To minimize the presence of preaggregates, the sample should
be passed over a size-exclusion column and the monomer peak
collected  [9]. Also ultracentrifugation has been reported to remove
preaggregated A [10].
Aggregation:  Apart from the presence of preaggregates/seeds,
there  are a lot of other factors having an effect on aggregation,
including pH, temperature, presence of trace amounts of metal ions,
agitation and contact with air (e.g. by shaking, bubbles etc.), contact
with other surfaces (like wells, tubes, etc.) [9].
Model peptides: Model peptides are used because they are
cheaper and/or easier to handle. Normally they are shorter peptides
and the idea is that they contain the relevant part of the sequence.
As the name says model peptides are models, so they will never
be identical to the native peptide. So experiments have to be done
showing that the model peptide keeps the property of interest. For
instance, it has been well established that A1–16 contains the
principle metal binding site, at least for Cu(II), Cu(I), Zn(II) and Fe(II)
[11–13]. Similarly, this is the case of -synuclein, the main metal
ion binding sites are in the N-terminal portion (amino acids 1–60)
or for prion, it is the octarepeat region (amino acids 60–91), where
Cu(II) and Zn(II) are predominantly bound [14]. In several cases, the
ligands are present in the model peptide, but they do not form amy-
loid fibrils, so they are good models for studying the interaction of
the metal ions in the monomeric complex, but not for studying the
aggregation.
Dosage of apo-peptides by weight: If the peptide is dry and the
number and type of counterions known (see above), this can be very
accurate, but often this is not the case and it is better to confirm by
another method.
Dosage  of apo-peptides UV-absorption: Most of the peptides can
be dosed by the absorption of the aromatic amino acids via UV spec-
troscopy. Often the extinction is known or can be calculated upon
the amino acid composition. In case of an unstructured peptide this
Fig. 1. Aggregation followed by thioflavin T fluorescence of the peptide A11–28 at
pH 7.4. Two different batches (square and circles) are shown in red (before incuba-
tion  at pH 12) and blue (after incubation at pH 12) (Conditions: 100 mM Hepes, pH
7.4, 300 M A11–28).
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Fig. 2. Schematic absorption spectra of a peptide containing one or more Tyr (but no Trp) like A. The maximum of the Tyr absorption in such a peptide is around 275 nm
and no absorption occurs above 295 nm.  If there is little light scattering, it can be corrected for by subtracting the value at 295 nm (i.e. use the ε275–ε295 = 1410 M−1 cm−1).
is quite accurate, but the absorption of an amino acid can change
depending on the structure, in particular in a more hydrophobic
environment. However, changes in intensity do rarely exceed 10%,
keeping such an approach still relatively correct. A problem which
can occur with these often amyloidogenic peptides, is the presence
of aggregates and therefore light scattering. Thus the sample is not
homogeneous anymore, which has to be taken into account. As such
the peptide concentration is overestimated. If light scattering is not
too intense, the light scattering can be corrected for by substracting
the OD where the peptide does not absorb, but light scattering is
similar. For instance A has one Tyr and hence absorbs at 275 nm
with an extinction coefficient of 1400 M−1 cm−1 (see Fig. 2).
The interference of light scattering is particularly important for
very amyloidogenic peptides like A42. A42 is much more solu-
ble at higher pH (pI around 5–6), and hence dosage can be made at
high pH. However, the tyrosine becomes deprotonated at around
pH 10, and the tyrosinate has a different absorption, the band is
moved to the red with a maximum at 293 nm and an extinction
coefficient of 2400 M−1 cm−1 (Fig. 3). If one want to dose the pep-
tide at high pH, one has to make sure that tyrosine is completely
deprotonated, so a pH clearly above 11, i.e. ∼13 should be used and
use ε293–ε360 = 2400 M−1 cm.Classical protein tests like BCA, Brad-
ford Lowry etc. can be also used. They are normally quite accurate
if the calibration is made with the same peptide. In contrast if the
calibration is made with another protein like BSA the concentration
is less accurate. (For instance in our hands BCA test was  off by up
to a factor of two when using BSA for amyloid- dosage.) Another
Fig. 3. pH titration of Tyr in A1–16 (300 M).  From tyrosine band (red) to tyrosi-
nate  band (blue).
issue is the aggregation state, which is likely to change the reac-
tivity toward the different chemicals used in these tests.There are
other methods, like amino acid analysis which is very accurate.
Dosage  in the presence of metal ions: UV–Vis is not always valu-
able as metals bound to the peptide can absorb as well in the region
of the aromatic amino acids. This is the case of Cu(II)-bound to
A and prion. In contrast Zn(II) binding does not induce absorp-
tion and hence dosage based on the absorption of aromatic amino
acids is possible given that the metal does not induce aggregation
and hence light scattering. A possibility to circumvent this, is to
lower the pH to 2, as metal are released and do not contribute to
absorption anymore.
3.  Isothermal titration calorimetry (ITC)
Isothermal titration calorimetry (ITC) is a method giving access
to the thermodynamic parameters of an interaction, like metal ion
binding to a protein. It measures directly the enthalpy of a reac-
tion and delivers a model-based binding stoichiometry as well as
the dissociation constant. Thus three parameters (stoichiometry,
affinity constant and enthalpy) are needed for the fit per metal
binding site. Thus, and this is in particular important in the case
of more than one binding site, it is important to have independent
measurements of stoichiometry and/or affinity constant.
A  first prerequisite for such measurements is that the system
reaches equilibrium after each titration step, that means that the
binding event, e.g. of a metal ion to a peptide is completed before
the next titration step is started. Moreover, it is important to note
that the heat measured, and as a consequence the thermodynamic
parameters (K and H), stem from all the reactions occurring,
including dilution, precipitation, oxidation, degradation etc. dur-
ing the titration of a metal ion to a macromolecule. For instance
in the case of Cu(II)-binding to A, the reaction is not limited to
Cu(II) and A as the starting reagents and the complex Cu(II)–A
is the final product (Fig. 4). At the beginning A and Cu(II) are
hydrated and Cu(II) does often bind to the buffer. Upon binding
of Cu(II) to A, the water and buffer bound to Cu(II) are (at least
partially) released. Moreover, if Cu(II) replaces protons from the
A, they will be bound by the buffer. Thus, the measured heat can
stem from (1) breaking bonds from Cu(II) to water and/or buffer
interactions, (2) bond formation of Cu(II) with peptide, (3) concur-
rent changes in hydration upon Cu(II)–peptide complex formation,
(4) deprotonation of peptide, (5) proton(s) binding to buffer, if pro-
ton(s) are displaced upon Cu(II)-binding to A, and (6) structural
changes of the peptide due to Cu(II)-binding. Thus, the thermo-
dynamic parameters obtained are apparent. Or in other words,
the thermodynamic parameters obtained include all the processes
associated. For an excellent recent review going more into details
on ITC and metal ions see Wilcox and colleagues [15]. There is the
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Fig. 4. Possible processes associated to addition of metal ion (Mn+) to a peptide (black line) in an aqueous buffered solution. The buffer is present in protonated and
deprotonated form. B and B–H depicts a deprotonated and protonated base, respectively, which is able to bind the metal ion.
possibility to have access to the thermodynamic parameters of the
pure metal-binding to peptide, if all the associated processes are
well known. For instance, if metal-binding to a peptide includes
a displacement of protons, the measured H includes the H of
the proton-binding to the buffer and the metal-binding. Thus, if
the number of displaced protons and the H of buffer protonation
are known, the H of the metal-binding to peptide can be cor-
rected. Similarly, one could correct for metal–buffer interaction,
however in practice this is often not very easy as the interaction
of metal ions with buffers are often ill defined and/or conflict-
ing.
The number of protons displaced upon metal-binding can be
determined by using exactly the same condition but different
buffers with known H. Then, the difference in H is only due
to proton-binding to the buffer (see [16] for a recent example on
metal-peptides).
Determination of an apparent dissociation constant is lim-
ited in ITC to a range between 1 mM and 10 nM. This is
deduced from a parameter c = n·[M]/Kd (with n = binding stoi-
chiometry, [M]  = concentration of macromolecule, e.g. peptide;
Kd = dissociation constant), which should be ideally between 5 and
500. This means if the Kd is too low, very little concentration should
be used to fulfill the requirement for c, but then the concentration
are too low to yield measurable enthalpy.
A way around that is the use of a competing ligand, i.e. metal-
ion bound to competing ligand is titrated to a peptide. As such the
measured Kd drops to the difference between the Kd of peptide and
Kd of competing ligand, and hence the parameter c can be moved
to the ideal region. In this case, in order to deduce the thermody-
namic parameter of the metal ion interaction with the peptide in
the absence of the competing ligand, one has to correct them. For
that the H, stoichiometry and Kd of the metal ions competing
ligand interaction has to be known.
ITC has been mainly applied for Zn(II) and Cu(II)-binding to
A [17–19], prion [20–22] and some other amyloid like iAPP [23],
mainly by titrating Cu(II) or Zn(II) in a buffer to the peptide. Thus the
thermodynamic parameters obtained are apparent, without cor-
rection for buffer interaction etc. Simon and colleagues [24,25] used
the glycine as a competing ligand to study Cu(II)-binding to A, and
were able to obtain a Kd after correcting for the glycine. In this case
the buffer does not interfere with the determination of the Kd, and
the deduced Kd corresponds to the Kd of Cu(II)-binding to A at
the measured pH in the absence of buffer. However, a prerequi-
site for this analysis is that no ternary complexes are formed. Very
recently, Trapaidze et al. [16] extended the methodology of Simon
and colleagues to two  model peptides. By measuring at different
glycine concentrations and with different buffers they were able to
correct not only the Kd, but also H (corrected for H of glycine
and displaced protons). Thus they obtained formally Kd and H of
Cu-binding to peptide in pure water at pH 7.4. Moreover, with this
method the formation of a ternary complex peptide–Cu–glycine
was evidenced and the Kd of glycine binding to Cu–peptide could
be determined.
4.  Electron paramagnetic resonance (EPR)
Electron paramagnetic resonance (EPR) is a powerful technique
to study species with unpaired electrons. In bioinorganic chemistry,
it is widely applied to transition metals and radicals encountered
during catalytic reactions. In the case of the interaction of metals
with amyloidogenic peptides, the relevant ions and redox states are
essentially Cu(I), Cu(II), Zn(II), Fe(II) and Fe(III). Among those, Cu(I)
and Zn(II) are diamagnetic and cannot be studied by this technique.
Fe(II) can be either diamagnetic (low spin state S = 0) or paramag-
netic (high-spin state S = 2). The paramagnetic state can in principle
be studied by EPR, however the zero-field splitting (ZFS) effect for
such integer spin prevent the use of conventional EPR (signals can in
principles be obtained with parallel detection mode EPR or high-
field EPR if the Zeeman effect can become competitive with the
ZFS). Fe(III) and Cu(II) have half-integer spin-states and are rou-
tinely studied by conventional EPR and more advanced techniques.
In the case of amyloid peptides, most EPR studies have focused on
the coordination of the Cu(II) ion and this will be the case of interest
in the remaining of this section.
The electronic configuration of the Cu(II) ion is 3d9 and there-
fore it has an unpaired electron, leading to an electron spin S = 1/2.
When there are no strong geometrical constraints, which is the
case in peptide systems for Cu(II), the metal center is in a distorted
octahedral geometry due to the Jahn–Teller effect (elongated octa-
hedron or usually pentacoordinated square base pyramid) and the
unpaired electron is in the orbital dx2−y2 . This orbital extends in the
equatorial plane and therefore the equatorial ligands are those most
easily studied, the potential axial ligands being only very weakly
coupled to the metal ion. In frozen solution, the observed spectrum
is anisotropic with axial symmetry. The Zeeman effect gives rise
to two resonances at g// and g⊥ and ligand field theory indicates
that g// and g⊥ are both greater than ge (g-value of the free elec-
tron) and g// is greater than g⊥. Moreover, the nuclear spin for the
two natural isotopes 63Cu(II) and 65Cu(II) (natural proportion 69%
and 31%, respectively) is I = 3/2 leading to hyperfine coupling. This
interaction is highly anisotropic with the stronger component along
g//, leading to a splitting in four distinct lines while the perpendic-
ular component of the Cu(II) hyperfine coupling is generally not
resolved on the EPR spectra in frozen solution. Furthermore inter-
actions so-called “super-hyperfine” between the electron spin of
the Cu(II) ion and the nuclear spins of the atoms of the ligands
(mainly nitrogens and protons) are also present. They are usu-
ally partially resolved on the EPR spectrum, in particular for the
g⊥ region. The analysis of the hyperfine coupling is very impor-
tant for chemists and biologists because it provides information on
the distribution of spin density (electronic structure) and structure
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(distances obtained through dipolar interactions) of the complex
studied.
In the case of Cu(II), the values of g// and A// are very sensitive
to the nature of the equatorial ligands. In the 1970s, Peisach and
Blumberg have published empirical diagrams that give insights into
the coordination sphere of the cupric ion [26]. Practically in our
case, a change from O ligands to N ligands induce a decrease of
the g// value while the A// increases. The specific values indicate
the relative number of O and N ligands. This has been used to pro-
pose the binding modes of Cu(II) with proteins and peptides such
as prion protein [27–29], A [30–33,18,34], -synuclein [35–37].
To get insights into the structure of the binding site in greater
details, the careful study of the interaction with the atoms from
the ligands has to be made, that is the super-hyperfine interac-
tions. The best way to disentangle and analyze the superhyperfine
interactions is to use isotopic labeling in conjunction with the EPR
experiments. Indeed, different isotopes of the same element often
have different nuclear spins (1H I = 1/2 vs. 2H I = 1; 14N I = 1 vs. 15N
I = 1/2, 12C I = 0 vs. 13C I = 1/2) resulting in different patterns in the
spectra. Specific isotopic labeling can therefore directly attributes
the nucleus responsible for the interaction observed. The superhy-
perfine interaction can be resolved, at least partially, on the EPR
spectrum. It is sometimes convenient to record the spectrum at
lower frequency (S-band or L-band vs. X-band) to improve the res-
olution. Studies on prion peptides and A-peptides are example
of this [27,38,39]. When the (super)hyperfine couplings are not
directly measurable on the EPR spectrum or their analysis is too
complex, other EPR methods such as ENDOR (electron nuclear dou-
ble resonance), ESEEM (electron spin echo envelope modulation)
or HYSCORE (hyperfine sublevels correlation) are used to obtain
direct measurements of hyperfine couplings. These two techniques
are complementary, the ENDOR being particularly suitable for
strong couplings (typically the nitrogen atoms directly coordi-
nated to Cu(II)) and high frequency resonances while the ESEEM
is most successful for weak couplings and low frequency ranges
(coupled deuterons, non-coordinated nitrogen from His, amides,
etc.). In addition to measure the hyperfine couplings unresolved
in EPR spectra, these techniques also allow the determination of
the nature of the coupled nuclei (H, N, etc.) because they are sensi-
tive to the Larmor frequency, characteristic of a given nucleus. This
information is not available in the EPR spectra. An important and
recurring case in the Cu(II) complexes is the ligation of a His residue
by the imidazole ring of the side chain which is a very good ligand
for Cu(II). The coupling of the nitrogen atom linked directly to the
Cu(II) is too strong to be detected by ESEEM, but can be measured
by ENDOR. In contrast, the remote nitrogen atom of the imidazole
ring has a very weak coupling, which gives a characteristic signal in
ESEEM and HYSCORE. At X-band for which the exact cancellation
condition (|aiso| = 2n) is achieved for this nucleus, the spectrum
obtained for 3-pulse ESEEM consists of three narrow peaks in the
range 0–2 MHz  corresponding to the quadrupole transitions and
a broad peak around 4 MHz  (Fig. 5). When multiple equivalent
nitrogen nuclei are coupled to Cu(II) (coordination of several His
residues in equatorial position) so-called combination peaks are
observed at frequencies sum of the three basic frequencies, there-
fore it is possible to distinguish between single or simultaneous
His binding in equatorial position. Although theoretically possi-
ble, it is more difficult to determine without ambiguities the exact
number of residues coordinated simultaneously when several of
them are involved. Detection of coordinating His is quite systematic
in Cu(II)–amyloid peptide studies [27,38,40–43]. Another nitrogen
atom routinely detected in ESEEM and HYSCORE in Cu-peptide
complexes is the one from a peptide bond when the carbonyl is
a ligand to the Cu(II) ion. This coupling has been described for
example in the case of the octarepeat domain of the prion pro-
tein [27] and observed also in the case of the A peptide. Labeling
Fig. 5. Frequency domain of a 3-pulse ESEEM experiment for an equatorial His
bound  Cu(II) complex. The nitrogen nucleus sublevels are presented on the right
within the exact cancellation condition. In the center, the scheme of the Cu–His
complex  indicates which N nucleus is detected by which technique at X-band.
with 13C can also be used to detect couplings with carbon atoms.
This has been applied for example to study the involvement of
the Asp1 residue of the A peptide in the coordination of Cu(II)
[38,42,44].
All these measurements are best applied when there is no mix-
ture of species in the sample. However, in the case of amyloid
peptides it is usual that there is a strong pH dependence in the
complexes that can be formed with Cu(II). This leads to a mixture
of species at physiological pH which plagues the analysis of the data
since working on difference spectra can prove not to be obvious in
particular with pulse techniques. One way to work around this is to
study the predominance diagram for the complexes as a function
of pH and poise the sample at those pHs for which the complex of
interest are predominant, when possible. With respect to sample
preparation, a typical volume to work with at X-band is 100–150 L
of sample, the concentration of which can range from tens of M
up to 1 mM.  For the usual case of aqueous samples, 10% of glycerol
should be added to the samples to enhance the glass property of the
solvent and improve the detection/resolution of the EPR spectrum.
Isotopic labeled samples should be prepared in parallel to unlabeled
samples under the same conditions to allow direct comparisons.
With  the development of new pulse-sequences, the avail-
ability of different frequencies, the technical improvements on
spectrometers and the rather straightforward isotopic label-
ing possible on peptides synthesized chemically, EPR remains
a method of choice and a powerful technique to study the
coordination of paramagnetic transition metals to amyloid pep-
tides.
5. Nuclear magnetic resonance (NMR)
NMR spectroscopy provides detailed information at the atomic
level about the structure and dynamics of metal–peptide interac-
tions in solution.
The  peptide concentration is usually in the range from 0.05 to
2 mM for 1H NMR  spectroscopy. The higher concentration limit is
imposed by peptide aggregation that will broaden the NMR  signals.
Higher aggregates cannot not be measured by solution NMR,
due too slow tumbling and poor solubility. However, during the
last years solid state NMR  provided important insights into the
structure of aggregated amyloidogenic peptides, on their interac-
tion with metal ions [45] and on the interaction of metal–peptide
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with lipids [46]. In contrast to solution NMR, solid state NMR  needs
site specific labeling and is more demanding in sample prepara-
tion and measurements. We  do not considered solid state NMR
as a routine technique and we refer to a recent review for more
details [47]. Peptide–peptide aggregation phenomena or oligomer
formation, possibly mediated by metal binding, can be studied by
translational diffusion coefficient measurement (DOSY NMR). The
lower concentration depends on the NMR  spectrometer used. The
signal to noise ratio and the spectral dispersion both increase with
the magnetic field strength. Today NMR  spectrometers can operate
at 1H NMR  frequency up to 1 GHz but 500 MHz  may  be sufficient
in many cases. Spectrometer equipped with cryogenic probe can
allow for reduction of the protein concentration by approximately
a factor of four compare to conventional probes. NMR  experiments
on 13C and/or 15N nuclei notably with the usual 2-D or even 3-
D correlation experiments (HSQC, HNCO, HNCA, etc.) can also be
interesting or necessary. For low concentrated samples, the pep-
tides need to be enriched with the magnetically active isotopes.
For highly soluble peptides (short model peptides for example),
13C NMR  can be perform at natural abundance. The solvent is usu-
ally 90% H2O/10% D2O or 100% D2O. In the later case, labile protons
(NH, OH, etc.) are deuterated and are no more observable. Some-
times DMSO-d6 has been chosen but its use is subject of extensive
debate about its biological relevance. Buffer choice for NMR  is lim-
ited to deuterated buffers or buffers that contain no 1H (see above).
The pH should be adjusted with deuterated salts for 100% D2O (DCl
and NaOD).
Peptide–metal ion complexes are dynamic systems and there-
fore the time scale at which the components of the protein–metal
ion complex exchange between free and bound forms is an impor-
tant factor that needs to be addressed [48]. The time scale of
the experimental method (chemical shift, relaxation time or dif-
fusion coefficient monitoring for example) has to be comparable
to the time scale of the dynamic process studied (usually on the
micro to milli-second time scale). For a system in slow exchange
on the chemical shift time scale (in general terms this would be
a peptide–metal ion system with high binding affinity and low
dissociation constant, Kd = M or lower), resolved signals might
be expected for the free and bound states. For a system in fast
exchange, the observed NMR  responses are the mole fraction
weighted average of the NMR  parameters of the free and bound
states. At the intermediate chemical exchange rate regime with
respect to the chemical shift time scale, resonance broadenings are
observed. Investigation of the dynamic processes can be done by
recording NMR  experiment at different temperatures. Temperature
changes will influence the dynamics, i.e. increase exchange rates
(kon and koff), but will also have an influence on the equilibrium
populations (Kd) [49].
5.1.  Diamagnetic Zn(II) and Cu(I)
The binding of diamagnetic metal ions is usually investigated
through the chemical shift variations upon metal binding (chemical
shift mapping). The titration experiments where the concentration
of the metal ion is increased gradually can be used to estimate the
binding constant and the rate constant of the complex formation
[50]. (Caution has to be taken about a stable pH, as metal ion solu-
tions are often acid (see above) and hence addition of concentrated
metal ion solution may  drop the pH and could lead to chemical shift
variations).
The chemical shift variations are mostly due to conformational
changes caused by the metal binding and from the electric field
induced by the charge of the metal ion. Amino acid residues whose
resonances are perturbed upon metal ion addition are involved in
the metal coordination and/or are close to the metal binding site
(Fig. 6). This is particularly true for flexible unstructured peptides.
Fig. 6. Simulation of a 1H NMR  spectrum of one proton in a ligand close to a Zn-
binding  site, where 30% of the ligand is bound to diamagnetic Zn(II) and 70% is not
bound to Zn. Under slow exchange (bottom) the resonance of Zn-bound and Zn-
free ligand is detected with the ratio of 0.3–0.7. Under fast exchange (top) only one
resonance is observed, in between the shifts of free and Zn-bound ligand (bottom)
and  with a shift reflecting the % of Zn(II) load. Intermediate exchange broadens the
resonances.
For peptide with ordered organization, small chemical shift vari-
ations far from the metal binding site can result from an overall
change of the peptide structure following metal binding. In this case
of well defined peptide framework, the three dimensional structure
can be studied by 1H nuclear Overhauser enhancements (NOEs)
that give information about inter-proton distances.
However, most of the times exchange between the metal-free
and metal-bound peptide is fast compared to the chemical shift
differences between the two  form (kex  ) so that only single
exchange-averaged signals are observed making precise geometric
structure less straightforward (Fig. 6). In these cases the coordi-
nation environment of the metal can be monitored by following
changes to the NMR  spectrum upon metal ion concentration. Fur-
thermore, a peptide may  have a number of different coexisting
binding sites in fast exchange among themselves, making it difficult
to localize and identify the different binding sites.
Sometimes non-selective broadening of basically all the
observed signals, including those of the non-coordinating amino
acid residues, occurred even at a small proportion of metal
ion. This phenomenon refers to the presence of several com-
plexes, which are in relatively intermediate mutual exchange
(with respect to the chemical shift time scale) with each other
and with the free ion. Global line broadening can also indicate
the formation of peptide–peptide aggregates mediated by metal
binding. If these aggregates are insoluble, an overall signal inten-
sity decrease will be observed. For oxygen sensitive Cu(I), line
broadenings can also result from the presence of contaminating
paramagnetic Cu(II). Local resonance broadening can also be due
to protonation–deprotonation equilibrium influenced by the metal
binding.
63Cu(II) (or 65Cu(II)) and 67Zn(II) nuclei are too insensitive to be
studied by NMR  at the peptide concentration. Substitutions with
more sensitive nuclei like 113Cd (or 111Cd) and 109Ag can be done
in order to obtain information at the metal level about the type and
number of the bound ligands.
The metal ion binding can also change locally the flexibility
of the peptide. NMR  spectroscopy can provide information about
the backbone dynamics on the pico to milli-second time scale.
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Dynamics information on the peptide backbone are retrieved from
15N R1 and R2 relaxation rates and 1H–15N NOEs and side chain
dynamics can be studied using relaxation rates of 13C, 1H or 2H
(15N, 13C and 2H sample labeling necessary) [51].
5.2. Paramagnetic Cu(II) and Fe(II)
The binding of paramagnetic metal ions to peptide has a pro-
nounced effect on the NMR  spectra of the peptide. The reason for
this pronounced effect is the presence of unpaired electrons that
strongly interact with surrounding peptide nuclei. The unpaired
electrons can affect the chemical shift and/or the relaxation rates
of the nearby nuclei. The paramagnetic contribution to the nucleus
chemical shift are the Fermi contact shift (through bond effect: the
paramagnetic equivalent of scalar couplings) and pseudocontact
shift (through space effect due to dipolar interactions with unpaired
electrons). Contact shifts are restricted to nuclei in the immedi-
ate vicinity of the paramagnetic center. Pseudocontact shifts (PCS)
depend on the anisotropy of the magnetic susceptibility tensor.
PCSs depend also on the distance (with an inverse-three power) and
on the spherical position of the nuclei with respect to the metal ion.
PCS are usually very small for Cu(II) (less than ±10 ppm), contact
shift can be more important (up to ±50 ppm). For Fe(II), the situ-
ation is more complex as the electron spin quantum number can
take different values depending of the complex nature (from S = 0
(diamagnetic, see above) to S = 2). For Fe(II) with S = 2, paramagnetic
contribution to the chemical shift are usually more important than
for Cu(II). Fast exchange between bound and free paramagnetic
metal ion lead to much reduced weighted average paramagnetic
contribution to the chemical shift that depend on the metal bound
fraction [52]. Intermediate exchange cases are more complicated
to study [52].
Paramagnetic relaxation enhancements (PRE) depend on the
electron spin quantum number, the electron spin relaxation time,
the gyromagnetic ratio of the nuclear spin and the distance (with
an inverse-sixth power) from the paramagnetic center. PRE decays
much more rapidly with increasing distance from the paramagnetic
metal than the PCS. However paramagnetic metal ions are generally
at the center of a “blind” sphere in which the NMR  signals are too
broad to be detected, due to the paramagnetic enhancement of the
transverse relaxation rates R2. However, the R2 rates are difficult
to interpret quantitatively [53]. Measuring spin-lattice relaxation
R1 is usually preferable for obtaining structural information on the
metal ion peptide complex [54]. The line broadening effects are less
severe for low gyromagnetic nuclei as 13C or 15N (compared to 1H)
making NMR  detection of these nuclei advantageous for the iden-
tification of residue in the proximity of the paramagnetic center
[55]. Again exchange rate between bound and free paramagnetic
metal ion is an important factor to evaluate (Fig. 7). Slow exchange
rate level off the paramagnetic contribution to the nuclear relax-
ation rates necessitating adding higher amount of the metal ion
[49]. For fast exchange rate, paramagnetic nuclear relaxation rates
depend on the metal-bound fraction and on the distances between
the paramagnetic center and the corresponding peptide residues
(Fig. 7). Selective line broadening effects can be use to locate the
metal binding sites even in the presence on several lowly popu-
lated states in fast exchange [53]. Localization of metal ion binding
sites can also be done by using the paramagnetic longitudinal relax-
ation rates R1p that are exclusively dependent on: (i) metal bound
complex molar fraction; (ii) the kinetic off rate (koff) and (iii) metal
bound proton relaxation rates T1b [49]. T1b strongly depends on the
Cu(II) proton distances and it is shortening with the metal–nucleus
distance. Cu(II) has a long electron spin relaxation time but a small
electron spin quantum number (S = 1/2) [56]. Cu(II) can induce
important line broadening effects that supply direct qualitative evi-
dence for residues involved in binding. Cu(II) is also known to affect
Fig. 7. Simulation of a 1H NMR  spectrum of one proton in a ligand close to the Cu(II)).
10%  of the ligand is bound to paramagnetic Cu(II) and 90% is not bound to Cu(II).
Under  slow exchange (bottom) the resonance of Cu(II)-bound state is broadened
beyond  detection due to PRE; the Cu(II)-free ligand is detected. Under fast exchange
(top)  only one resonance is observed, in between the shifts of free and Zn-bound
ligand  (bottom) and with a shift reflecting the % of Cu(II) load (i.e. with 10% Cu(II)
load  the shift is small). The average resonance also broadens due to the propor-
tional  averaging of the R2 relaxation rates of the free and bound states. Intermediate
exchange  broadens also the signal with a very small shift.
the paramagnetic longitudinal relaxation rates R1p through dipolar
interaction and so R1p can provide metal-nucleus distance infor-
mation [52]. Fe(II) has much shorter spin electron spin relaxation
times than Cu(II) resulting in nearly no effect on R1 relaxation rates
[56]. However Fe(II) can induce more important broadening effects
than Cu(II) due to more important Curie relaxation contributions
[56].
6. Electrochemistry, cyclic voltammetry
Among the various electrochemical techniques available, cyclic
voltammetry is commonly used and will be detailed below. It is
based on the detection of the variation of current intensity (i) as a
function of an applied potential (E) that depends linearly with time
(t).
6.1. Experimental setup
Cyclic  voltammetry (CV) measurements are performed in three-
electrodes electrochemical cells combining the working electrode
(WE), the reference electrode (ref) and the counter electrode (CE).
The controlled electrical variable is the potential of the working
electrode. It is measured between the WE  and the reference elec-
trode and the current circulates between the WE  and the CE. In
aqueous medium, well-suited reference electrodes are SCE (Sat-
urated Calomel Electrode) or Ag/AgCl electrodes. The CE has to
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conduct the current and has not to interfere with the bulk solu-
tion. In general, it is a Pt wire. The electron transfer of interest
takes place at the WE,  the nature of which is crucial for an ideal
detection of the electrochemical process. Carbon-based electrodes
(glassy carbon GC, graphite), Pt and Au electrodes are the most com-
mon  working electrodes. In the particular case of small peptides
complexes, good experimental CV traces have been reported with
GC electrodes (for recent examples, see Refs. [28,57–59]). Careful
polishing of the WE  before each CV record is strictly required in case
of peptidic complexes and an insufficiently well-polished electrode
may preclude the correct measurement of the CV traces. Electrodes
are fixed in the electrochemical cell and the solution is not stirred
to ensure diffusion controlled current transport required for the CV
analysis. The measured current is the sum of two contributions: the
faradic current (if) corresponding to the electron transfer of inter-
est and the capacitive current depending on the electrochemical
setup. Thus ideally, the current recorded in absence of the studied
species (capacitive current (ic)) should be subtracted from the total
current to obtain only the faradic contribution.
Supporting electrolyte is required in order to ensure a correct
conductivity. In case of aqueous solution, the supporting elec-
trolyte can be either the buffer itself or NaCl. Considering its
electroactive domain, i.e. the potential range inside which the mea-
surement can be performed, phosphate buffer may  be the best
choice. Indeed, other commonly used buffer such as Hepes or
Tris contain amine functions that can be easily oxidized and thus
restricts the electroactive domain. However, due to precipitation
issues with phosphate (see above) it should be used with cautious
and the metal ions should not be added to the buffer without prior
addition of the peptidic ligand.
In case of peptidic species, residues like Cys, Met, Tyr and Trp
may also contribute to restrict the electroactive domain due to their
oxidation at “low” potential (i.e. at pH 7.4 approx. 0.9 vs. NHE for Cys
[60], 1.4 vs. NHE for Met  [60], 1.0 V vs. NHE for Tyr, pH 7.4 [61] and
1.1 V vs. NHE for Trp pH 7.4 [62]). In most cases, the electrochemical
cell containing the solution of interest should be flushed with argon
to prevent from any O2 contribution.
6.2.  Useful insights obtained from CV
6.2.1. Electrochemical reaction
Case of fast electron transfer: This case is encountered when the
electron transfer is sufficiently fast compared to the electrochem-
ical diffusion rate, given by
√
FvD/RT , where v is the scan rate
and D the diffusion coefficient of the studied species, F being the
Faraday constant, R the perfect gas constant and T the tempera-
ture). A direct consequence is that, depending on the scan rate,
a system can be considered slow or fast. Experimentally a sys-
tem will considered fast if (in the scan rate range used, classically
between 50 mV  s−1 and 500 mV  s−1) the faradic current if varies lin-
early with
√
v, the maximum intensity in the anodic scan iap equals
the maximum intensity in the reverse (cathodic) scan icp, and the
difference between the potential at the two maximum of intensity
Ep = |Ecp − Eap| = 2.22RT/F = 57 mV at 25 ◦C for a mono-electronic
transfer.
In  that present case, thermodynamic equilibrium is reached
at any potential point in the scan and concentrations of oxidant
and reductant at the electrode are given by the Nernst Law. Two
parameters can then be deduced from the CV trace: (1) the E1/2 =
(1/2)(Ecp + Eap), which is the apparent standard potential in the
recording conditions (pH, T, ionic strength etc.) used for the mea-
surement and (2) the diffusion coefficient D obtained according to
ip = 0.446FSC0
√
D
√
Fv/RT ,  where C0 is the concentration of the
studied species in the bulk. From this last equation it clearly appears
that the intensity of the recorded current will decrease with the
Scheme 1. Square scheme mechanism showing an ECEC mechanism between
unbound  Cu(II)/Cu(I) and peptide-bound Cu(II)/Cu(I) redox couples (oval). If the
chemical reaction(s) is (are) equilibrated and if the electron transfer is slow when
the Cu(I/II) is bound to the peptide then electron transfer via unbound Cu(I/II) may
occur predominantly.
decrease in the diffusion coefficient of the molecule and thus with
the increase in its size. This is the reason why proteins cannot be
studied by classical voltammetry. Instead Protein Film Voltamme-
try investigations where the protein is attached to the electrode
surface are performed (see Ref. [63] for an example and Ref. [64]
for a review).
Case of slow electron transfer: In such conditions, the kinetics of
the electron transfer are rate determining and the electrochemical
equilibrium is not reached. As a direct consequence the oxidant and
reductant concentrations are not given by the Nernst Law but by the
Butler–Volmer law allowing access to the kinetics of the electron
transfer described by two  parameters (see Refs. [65,66] for more
details).
6.2.2. Chemically coupled electrochemical reactions
More complicated CV traces can be observed when chemical
reaction (C) interferes with the electrochemical reaction (E). If
the rate of the chemical reaction is fast compared with the scan
rate, insights into the chemical reaction can be obtained. In case
of Cu(I)/Cu(II) redox couples, structural rearrangement is often
observed between Cu(I) and Cu(II) redox states. This will give rise to
an ECEC square-scheme mechanism that can be probed by varying
the scan rate [67,68]. Another process (ECE) has also been recently
proposed for Cu–A species [57]. These mechanisms are very intri-
cate and detailed analysis can be found in Refs. [57,67,68].
Two  important cases of coupled chemical–electrochemical reac-
tions is given below in case of Cu(I/II) peptidic species.
1. Square  scheme between unbound Cu(I/II) and coordinated Cu(I/II):
In  case of low Cu(I/II) affinity for the peptide and in case of
slow  electron transfer inside the Cu(I/II)–peptide species, the
electron  transfer can occur via unbound Cu(I/II) for which the
electron  transfer is fast (Scheme 1). As a consequence, data
should  be recorded in excess of peptide to minimize contribution
of  unbound Cu(I/II) in the electron transfer process.
2. O2 reduction catalysis: An interesting EC mechanism in case
of  Cu(I/II)–peptide species is O2 (or H2O2) catalytic reduction
[69,70] (Scheme 2) due to their proposed involvement in reac-
tive  oxygen species production [71]. If Cu(I/II)–peptide species
catalyze  O2 reduction, then the catalytic reduction will be cen-
tered  on the reduction peak of the Cu(II)-peptidic species and a
more intense cathodic current should be observed, the intensity
of  which increases with increase in O2 concentration and the
shape  of which depends on O2 diffusion rate to the electrode.
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Scheme 2. Catalytic reduction of dioxygen (C) by Cu(I) species electrochemically
generated  at the electrode (E). Intensity and shape of the reduction wave depends
on  O2 concentration at the electrode and of O2 diffusion rate to the electrode.
7. Optical methods: (UV–Vis, circular dichroism and
fluorescence)
7.1.  Fluorescence
Intrinsic fluorescence: Intrinsic fluorescence can be well mea-
sured on tryptophan and tyrosin (phenylalanine is more difficult
due to the lower intensity). For instance A contains one tyro-
sine and no tryptophan, which makes the system relatively simple,
as fluorescence originates from the single Tyr only. This fluores-
cence has been used to measure coordination of Cu(II), as Cu(II)
like other paramagnetic ions (e.g. Fe(III)) quenches the fluorescence
quite strongly. Based on this approach binding affinities have been
measured [32,18,72]. Similar approach was performed on prion
protein with tryptophan and tyrosine for -synuclein [62,73]. Flu-
orescence changes on addition of diamagnetic metal ions (Cu(I),
Zn(II), Al(III)) are not easy to detect due to the absence of the para-
magnetic effect. Hence a conformational change is needed to affect
fluorescence, which is often less pronounced. Thus Zn-binding to
A was reported to increase or decrease fluorescence. We  never
observed a robust fluorescence change of Zn(II) on A1–16, under
non aggregating conditions. As tyrosine fluorescence changes with
aggregation [74] and Zn(II) induces aggregation, observed fluo-
rescence changes might be due to aggregation and hence only
indirectly to Zn-binding [4] (Table 2).
Covalent linked fluorophores: There are several fluorophore
tagged peptides commercially available or kits to produce them,
mostly with a classical fluorophore, like rhodamine, often cova-
lently bound to the N-terminal amine or to a cysteine [75]. As
the N-terminus is often involved in metal-binding (like in A, 
Table 2
Fluorophores.
Name/wavelength ex emi
Intrinsic
Tyrosine 270–280 300–320
Tryptophan 280–290 310–360
Extrinsic
Thioflavin T 440–450 480–490
ANS 350–380 495–515
Bis-ANS 385–400 485–500
Nile Red 540–580 620–660
Covalent linked
TRITC  – tetramethyl-rhodamine-isothiocyanate 535–545 565–575
FITC – fluorescein isothiocynate 490–500 515–525
synuclein), a C-terminal tagged peptide might be more suitable. In
any case, controls have to be performed in order to show that the
linked fluorophore does not interfere (too much) with the prop-
erties of the peptide. This is in particular difficult in aggregation
studies as small changes can have a considerable impact on the
aggregation behavior [75].
Fluorophore labeled amyloidogenic peptides allows the mon-
itoring of the peptide at very low concentrations and to follow
the aggregation by different fluorescence based methods, e.g. a
change in intensity or shift of the emission upon aggregation, fluo-
rescence anisotropy [76] or fluorescence correlation spectroscopy
[77]. Another very valuable technique is FRET, which detects the
proximity of two  fluorophores and hence can be used to evidence
interaction of two molecules, like a metallo-peptide with a poten-
tial binding partner.
Extrinsic  fluorescence: Several extrinsic fluorophores are avail-
able to monitor the formation of amyloids, including thioflavin T
(ThT), ANS, bis-ANS, Nile-Red, etc. [78,79] The most widely used
is ThT [80]. In principle there is a risk that paramagnetic ions, like
Cu(II), Fe(III), etc. quench the ThT fluorescence, and hence change
in ThT fluorescence cannot be correlated directly with the aggre-
gation state. This was  for instance the case for the model peptide
A14–23 [81]. In the case of Cu(II)-binding to A aggregates, no
such quenching was  observed at least if Cu(II) was not added in a
large excess. Thus ThT is a valuable tool to monitor amyloid in the
presence Cu(II). ThT is also suitable for the in real-time observation
of fibrillation in solution in solution [82]. Care has to be taken when
organic molecules (in particular potential aggregation inhibitors)
are present, as they might interfere with ThT-binding assay rather
than inhibiting the aggregation [83].
7.2. UV–Vis spectroscopy
UV–Vis  is mainly used to measure concentrations of peptides
(see above). Moreover, metal-binding can be studied via the charge
transfer (CT) and the d–d bands. Cu(II) has d–d bands in the visible,
which give information about the type of coordination sphere [84].
Zn(II) and Cu(I) do not have d–d bands and even the charge transfer
bands of O and N (His, amine etc.) are often too high in energy to
be observed. In contrast thiolates bound to Zn(II) and Cu(I) give
rise to ligand to metal CT band in the UV (around 225 nm and 250,
respectively).
However, very often the CT and d–d band are better resolved in
circular dichroism and hence this technique is preferred (see next
Section 7.3 and Fig. 8).
7.3.  Circular dichroism
Secondary  structure: Classically circular dichroism is used to
obtain information about the secondary structure of proteins. The
spectrum of the peptide bands (around 190–230 nm) depends on
the content of -helix, -sheet, turns and random coil. CD is par-
ticularly sensitive to -helix and is often used to detect structural
changes to the mostly  sheet structure found in amyloids. It seems
to be tempting to use CD to monitor secondary structural changes
induced by metal binding. However, attention has to be paid on the
fact that metal-binding to proteins can have charge transfer bands
in the same region, and this band are also CD active. In other words,
in the case a charge transfer band is in the same region (like if Cu(II)
binds to His, or Zn(II) to Cys), then changes upon Cu(II)-binding are
the sum of secondary structure change and charge transfer bands
and hence no clear statement about secondary structure can be
made. This is the case of Cu(II)–A and Cu(II)–prion, both of them
employ His residues to bind Cu(II). However, in the absence of CT
bands in this region, like for Zn-binding to A or prion, changes in
secondary structure can be unambiguously made.
P. Faller et al. / Coordination Chemistry Reviews 256 (2012) 2381– 2396 2391
Fig. 8. Circular dichroism (red) and absorption spectrum (blue) of the visible region
of Cu(II)-Glu-Val-His-Gly (solid) and Cu(II)-Gly-Gly-His-Gly (dashed) (Conditions:
1.8  mM Cu(II), 2 mM peptide, Hepes 100 mM,  pH 7.4). Although the absorption spec-
trum of the d–d bands of the two Cu(II) peptides are very similar, the circular
dichroism  spectra differ a lot. This is an example of the possible higher sensitiv-
ity  toward subtle and/or second coordination sphere changes of circular dichroism
compared  to absorption.
Charge transfer and d–d bands: The other interesting use of CD
is to measure the charge transfer and d–d bands. Cu(II) shows d–d
bands in the visible and often CT bands in the UV. In contrast Cu(I)
and Zn(II) have no d–d and only CT bands connected to Cys (in
proteins) are low enough in energy to be detected. These bands are
also detected in UV–Vis absorption, but the advantage of CD is often
the better resolution (as band can be positive and negative) and
that they are often sensitive to the structural environment (Fig. 8).
Several charge transfer bands for certain ligand–Cu(II) interaction
have been assigned, like the amide to Cu(II) charge transfer band
around 315 nm [31]. This helped for instance to deduce the ligands
in Cu(II)-binding to A or prion [31,85].
Also the d–d bands of Cu(II) are quite sensitive to structural
changes even in the second coordination sphere. Although this is
not well understood [86], it allows the use of CD signals as signa-
tures for certain type of Cu(II) environment. As such, CD spectrum
of the d–d bands were used to evidence differences in the second
sphere of Cu(II) in certain mutants in A [34].
8. Infrared (IR) spectroscopy
Infrared  (IR) spectroscopy is a well-established technique for
the investigation of the structural properties of molecules and was
extensively used for the study of amyloid structures. Although the
theory of infrared spectroscopy is thoroughly worked out, its sci-
entific basis is undergoing a current boost, with the application of
this analytical technique in biology and biomedicine and the devel-
opment of new time and space resolved techniques. The analysis of
the IR data is based on the presence of specific vibrational marker
modes of reactant, intermediate or product states. The outcome or
kinetics of a studied reaction can then be interpreted by inspec-
tion of the transitions of these marker modes. When, in comparing
the experimentally observed vibrational mode pattern with predic-
tions from quantum chemical calculations a full correspondence
is possible, the three-dimensional structure is derivable. Current
quantum chemical calculation routines, such as density functional
theory (DFT), allow for the estimation of the electronic ground state
structure of medium-sized molecules.
Different experimental setups can be used in order to obtain
absorption data. Experiments in transition mode can be realized by
stabilizing two windows with a spacer. The strong absorbance of
water at the same position as the amide I band, however, makes it
necessary  to work with very thin cells of 10 m path only and to
subtract the solvents contribution. Alternatively experiments with
difference spectroscopic approaches are possible. Here the differ-
ence between two  states is measured in one cell and the solvent
absorption is omitted. Most studies, however, are performed in
reflection mode and more specifically by attenuated total reflec-
tion (ATR). The samples are deposited as a film or as a solid on the
crystal and the samples are monitored by the infrared beam. ATR
cells have been optimized in a way  that only a few microliters of
sample are necessary.
Most  infrared studies in the field use the spectral range between
1700 and 1600 cm−1 that includes the coordinates of the (C O)
vibration (amide I) [87,88]. The exact position of the amide I band
is dependent on the hydrogen bonding strength and is thus spe-
cific for the secondary structure of the peptide. In order to obtain
the exact position of each structural element the amide I signal is
fitted on the basis of a second derivative method or a Fourier self
deconvolution [89]. The technique has an error of up to 10% and
is highly complementary to CD spectroscopy and X-ray [90]. The
amide signal analysis contributed to the understanding of the struc-
tures of the amyloid fibrils and more specifically on the ‘-sheet
core structure’. Vibrational spectroscopy was extensively used for
the study of the aggregation process in the absence of metal ions
[91–96].
Linear IR dichroism and polarization studies gives information
on the orientation of a functional group, here for example the C O
vibration of the peptide backbone [97,98]. Oriented fibrils have
been studied by this technique and two kinds of -sheets were
detected [99]. Isotopic substitution reveals the involvement of cer-
tain nuclei in the vibrational motions and the labeling of the C O
group gave further insight in the structure of the amyloid fibril and
a six-residue parallel -sheet over the F22-V27 region of the pep-
tide were deduced [100]. The antiparallel -sheet structure was
reported for the toxic peptide [101].
The combination of microscopic techniques and infrared spec-
troscopy added the possibility to study surfaces and tissues at
molecular resolution and has led to the development of infrared
imaging [102]. Chemical, biochemical and biomedical information
can be combined with spatial information. Imaging has become one
of the main applications of synchrotron light based infrared spec-
troscopies [103]. In vivo and in vitro studies with this technique
confirmed the correlation of the antiparallel -sheet structure with
toxicity [104].
Site-specific information can be obtained for vibrational marker
modes that involve nuclear motions of specific molecular side
group and the analysis completed by isotope labeling. Labeling
may also be performed by H/D exchange of the solvent, supporting
among others the attribution of NH or COOH vibrational modes. The
side chain contributions of individual amino acids have been exam-
ined by a number of infrared spectroscopists [105,106] and are well
established in the mid  infrared spectral range. Few studies are avail-
able on individual amino acids since most of the signal is buried in
the strong amid absorptions. The role of individual amino acids in
the aggregation process is followed on the basis of the perturbation
of the amide I signal [107]. The analysis of the contribution of spe-
cific amino acids in the interaction of Cu(II) with the amyloid -16
was recently presented in function of pH. At pH 7.4 two forms exist,
called components I and II. Components I and II are predominant at
pH 6.5 and 9, respectively. Combined with isotopic labeling of the
amino acids involved in the coordination sphere, the data pointed
toward the coordination of Cu(II) via the carboxylate of Asp1 for
components I and II in a pseudo-bridging monovalent fashion. At
low pH (i.e. component I), His6 bound Cu(II) via N while His13
and His14 are bound via N. At high pH (i.e. component II), direct
evidence was given on the coordination of Cu(II) via the N atom
of  His6 [108].
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Exciting developments have been performed in the field of
two-dimensional infrared (2D-IR) spectroscopy in recent years.
This spectroscopic tool combines structural and ultrafast time
resolution. The idea is based on the transferability of the con-
cepts of multidimensional nuclear magnetic resonance (NMR)
spectroscopy to IR spectroscopy which was postulated already in
the earliest publications on 2D-NMR [109]. The first 2D-IR spec-
trum was measured about 12 years ago [110]. Despite the fact,
that multidimensional optical techniques are analogs of their NMR
counterparts, the time resolution is significantly improved: from
ms in NMR  to fs in IR. This technique provides a unique view into the
structure, dynamics, and fluctuating environments of molecules,
such as signatures of conformational and hydrogen-bonding fluc-
tuations, protein folding, and chemical-exchange processes.
Since  vibrational spectra of large molecules are complex and
congested, the use of a vibrational marker for 2D-IR is essen-
tial. Stretching modes with a large transition dipole such as C O,
Amide-I, Amide-II, O H, and N H, are often used in 2D-IR mea-
surements. In addition, isotope labeling can be used to support
the analysis [111–113]. The interpretation is made on the basis
of theoretical tools and simulation protocols, based on different
approaches, including for example vibrational-exciton Hamiltoni-
ans [114] or united residue models [112,115].
The application of 2D spectroscopy to amyloid research is thus
sensible toward the structural evolution of the aggregates and
the dynamics of hydrogen bonding [112,116–119]. The technique
revealed that some amino acids form nearly linear chains within
the fibrils. The rigidity of the fibrils has been analyzed and a
fast dynamics and the role of water molecules incorporated dur-
ing the fibrillization process demonstrated. The inhomogeneously
broadened -sheet peak and strong coupling to random coil con-
formations in 2D IR spectra reveal that the -sheet fibers have a
large structural distribution.
9.  X-ray absorption spectroscopy (XAS)
9.1. Information obtained from XAS
In general, X-ray absorption spectroscopy gives information
about the binding site of the metal, i.e. the first coordination shell
and if good signal to noise also second or further shell. Thus it gives
information about the number and type of ligand, the geometry
and metal–ligand distance. The spectrum obtained is an average
over all centers, i.e. in the case of heterogeneous sites or several
distinct sites; the spectrum obtained is the average over the sites.
One of the advantages of X-ray absorption (XAS) is that it can be
applied to all the metals in their different redox states. This is in
particular interesting for elements where less other methods are
available, i.e. Zn(II) and Cu(I). XAS gives information about the oxi-
dation state, so Cu(II) and Cu(I) could be distinguished, see e.g.
[120], as well as Fe(II) and Fe(III). XAS can be divided into two zones,
X-ray absorption near edge structure (XANES) and extended X-ray
absorption fine structure (EXAFS), which can give complementary
information.
XANES: fingerprint of the metal ion coordination sphere, that
means XANES can qualitatively used to compare coordination’s
spheres as differences in the XANES suggest a different sphere. In
the case of Cu(I) the XANES allows relatively well the distinction
between bi, tri and tetra-coordinated Cu(I). For Cu(I)–A the XANES
was diagnostic for a diagonal coordination [85,121].
For Zn, the shape of the XANES was linked to the tetra-, penta-
and hexa-coordination [122], but the distinctions are not that
straight forward as probably the type of ligand and the exact geom-
etry influences the shape. For instance the use of several truncated
peptide of A, showed that the Zn-binding is in A1–16, as the
XANES  of Zn–A16 resembled more Zn–A than Zn(II)–A17–40
[94]. Another example is that the XANES of the model peptide
A11–28 bound to Zn(II) did not change with its aggregation state,
indicating that the binding sphere is similar in the monomeric and
aggregates state [123].
EXAFS: EXAFS gives very accurate information about the bond-
length (average) between the metal ion and sulfur ligands or
nitrogen/oxygen (the distinction between N and O is very difficult).
Conclusions about the number of ligands can also be made based
on the fact that the bond length increases with an increasing num-
ber of ligands. Compared to XANES, the EXAFS features are smaller
and hence a better signal to noise is required. This means often a
higher concentrated sample or longer acquisition time.
9.2.  Samples preparation and damages induced by the beam
XAS  of Cu(I/II) A has been recorded in the frozen solution (clas-
sically) but also at room temperature. In the frozen state damage
by the beam is expected to be lower. Adding of cryoprotectant like
10% glycerol or ethyleneglycol leads to more homogeneous freez-
ing and often to a better signal to noise. Possible pH changes due
to freezing of the sample should be considered (see above). Dam-
aging the sample at room temperature is expected to be higher,
however, in the liquid phase flow can occur (in particular due to
heating by the beam) which can lead to a renewal of the sample
in the beam. In any case it is important to assess damage of the
sample by the beam. This can be reached by performing several
scans and to see if the spectrum evolves with time. If the spectrum
evolve the sample is not stable and hence best is to move the beam
after each scan to a different place when several accumulation are
performed.
A classical form of beam induced damage is photo reduction or
photo oxidation. In the case of Zn(II) this is not a problem as Zn(II)
is redox inert under the conditions, and indeed XAS on Zn(II)–A
did not suffer from this problem. In contrast, photo reduction is
very common for Cu(II) samples (see Fig. 9) [71,124]. This can be a
problem as the a mixture of Cu(I) and Cu(II) is present, which can
complicate the interpretation [85,125]. Photo oxidation of Cu(I) is
less observed and has not been reported for Cu(I)–A [71,124].
Fig. 9. Photoreduction of Cu(II)–A16: evolution of the edge of X-ray absorption of
Cu(II)–A16 at pH 8.7 for consecutive X-ray scans at the same position of the sample.
First  scan (black) and last scan (blue). The growing of a shoulder around 8983 eV is
observed, typical for the edge of Cu(I). Inset: magnification of the spectrum around
8984 eV.
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10. Mass spectrometry
In  the past decade, mass spectrometry (MS) has become a
powerful analytical tool for studying bioorganic and bioinorganic
molecule. This evolution can be mainly attributed to electrospray
ionization (ESI) and matrix-assisted laser desorption ionization
(MALDI), because of their gentle nature that allowed analysis of
biomolecule – usually fragmented if ionized by electron impact
(EI). MALDI is less applicable for studies of non-covalent interac-
tion, generally lost during ionization, but indirect strategies for
determining metal/peptide coordination mode can be applied and
provide valuable information. Thus mostly ESI Mass spectrome-
try was applied for studying metal–peptide complexes linked to
neurodegenerative diseases as it preserves best noncovalent inter-
actions. In addition, tandem mass spectrometry (MS/MS) could
provide accurate determination of the binding sites involved in
metal coordination.
In  the case of Alzheimer’s disease, the general use of mass spec-
trometry to study A peptide has recently been reviewed [126].
ESI/MS is commonly employed to identify the formation of A com-
plex  with Cu(II) [127,128], Zn(II) [129], Pt(II) [130], Ni(II), Ag(I),
or Fe(III) [131], by mass measurement of whole metal–peptide
complexes. The coordination mode of metal ions with A pep-
tide was thus revealed as being pH-dependent and influencing
A conformation [131,34,132]. Model peptides, mimicking A,
have also been investigated by mass spectrometry to understand
Cu(II)-induced conformational changes [133]. The binding affinity
of palladium complexes – Pd(phen)Cl2, Pd(bipy)Cl2 and Pd(en)Cl2
– to synthetic peptide PrP106–126 of prion protein, involved in
transmissible spongiform encephalopathies, was  easily investi-
gated by ESI/MS [134]. After identification by high resolution mass
spectrometry (HRMS), Pd(bipy)Cl2 was found the most efficient
in inhibiting the toxicity of PrP106–126 toward human SH-SY5Y
cells. While not essential when working in vitro with model pep-
tides, HRMS provides accurate mass measurement (precision of few
ppm) facilitating the identification. -Synuclein, a 140-amino acid
residue presynaptic brain protein involved in Parkinson’s disease,
has also been identified by ESI/MS mass measurement in complex
with Cu(II) [135,136], Fe(II) [137] or Tb(III) [138]. In this case, and
generally for high mass proteins complexed with metal ion, the use
of MALDI/TOF (time-of-flight mass spectrometry) could be a smart
analytical tool as it provides the mass of the monoprotonated ion
[139]. Multiprotonated ions generated during ESI ionization can
overlap the ones with each other, making sometimes the mass spec-
tra confused and difficult to analyze. Moreover, the use of solvent
free mini-ball mill (MBM)  MALDI/TOF facilitates the detection of
hydrophobic peptides, such as A1–42, more difficult to observe
by ESI/MS [140].
For  some complexes, and despite the gentle nature of ESI, the
metal–protein interaction is lost during desolvation and ioniza-
tion because coordination bond is weaker than covalent one. If
Zn(II)–A interaction can be partially preserved during ioniza-
tion and fragmentation [141], recent work has demonstrated that
ESI–MS of Zn(II) peptide systems are subject to Zn(II) deposition in
the ESI emitter. This deposition affects the mass spectral intensities
and is thus a significant obstacle for quantification of Zn(II)-bound
species [142]. No similar process has been described for other metal
ion. Platinum, in complex with peptide, usually exhibits coordi-
nation bonds strong enough for mass determination by ESI, while
coordination bonds with Cu(II) may  have various energies, being or
not preserved during ionization. Whatever the metal–peptide com-
plex, probing protein conformation remains possible even when
metal–peptide interaction is lost during ionization. This has been
recently developed and named as Selective Noncovalent Adduct
Protein Probing Mass Spectrometry (SNAPP-MS) [143]. By utiliz-
ing specific interactions of 18-crown-6-ether (18C6) with lysine
residues,  18C6/-synuclein distribution was  studied and found
dependent on the presence of Al(III), confirming that aluminum
binding induced significant changes in structural reorganization of
-synuclein.
Most often, the determination of the binding site location of
metal coordination is based on nuclear magnetic resonance (NMR)
or circular dichroism (CD) measurements. The use of tandem mass
spectrometry (MS/MS) is one complementary strategy that could
provide valuable information. Briefly, the selected metal–peptide
complex ion (most likely a multicharged ion) is fragmented and
give rise to a set of b and y ions that are dependent on the peptide
sequence (‘b’ and ‘y’ refers to the common Biemann nomenclature
[144], where ‘b’ are N-terminal and ‘y’ are C-terminal fragment
ions). The coordination of the metal with one residue will affect
the mass of the corresponding ion and will be thus identified.
Tandem mass spectrometry can be applied if the metal–peptide
interaction is preserved in the gas phase during fragmenta-
tion, which is usually dependent on the metal complex. For
weak metal peptide interaction, identifying oxidized residue after
metal-catalyzed oxidation (MCO) is a possible strategy for giving
information about the residues involved in the coordination with
the metal ion [145,146]. When metal–peptide interaction is strong
enough, as for Zn(II)–A1–16 complex, ESI–MS/MS could provide
accurate information on the coordination mode. Zn(II) binding sites
of A1–16 were thus identified as Arg5, His6, His13 and His14 [141],
even if MS/MS  spectra exhibited partial set of b and y ions. Both
histidyl residues His6 and His14 from A1–16 were also involved
in Pt(II) coordination, as deduced from ESI–MS/MS spectra [147].
Four major and five minor products were actually identified – after
separation by high performance liquid chromatography (HPLC) –
each one corresponding to one coordination mode involving one
or two platinum complexes. The binding sites were deduced from
ESI–MS/MS spectra of both 3+ and 4+ charged Pt(phen)/A1–16
ions, as presented in Fig. 10 for one of the major products detected.
By comparison between Pt-free and platinated b/y ions, histidyl
residues His6 and His14 were identified as being involved in the
coordination of Pt(phen). The same approach successfully leads to
the determination of the coordination mode of Cu(II), Pd(II), Co(III)
and Pt(II) to a model peptide mimicking the octarepeat region in
the N-terminal domain of the human prion protein [148].
If  necessary, tryptic digestion may  be performed prior to
collision-induced peptide fragmentation analysis. This is needed
for high mass metal–protein complexes for which direct frag-
mentation is difficult to reach and often needs specific mass
spectrometer (such as FT-ICR, i.e. Fourier Transform-Ion Cyclotron
Resonance). Such approach coupled to MALDI/MS–MS revealed for
example that Met1 was  involved as the primary anchoring residue
for Cu(II) in -synuclein [139]. In all cases, tandem mass spectrom-
etry had allowed an unambiguous determination of the residues
involved in the metal coordination.
The development of imaging mass spectrometry (for a gen-
eral review of the technique, see [149]) is becoming of significant
importance as it provides the distribution analysis of metals in
biological tissues, which is of key interest in neurodegenerative
diseases. Laser ablation inductively coupled mass spectrometry
(LA-ICP-MS) has been successfully applied for the determination
of metal distribution in thin tissue sections of human or rodent
brain and has provided quantitative images of detailed regionally
specific element (for a review, see [150]). Time of Flight Secondary
Ion Mass Spectrometry (TOF-SIMS) is also becoming of interest for
studying amyloid peptides [151]. However, these techniques are
not suited for studying metal/peptides interaction as they do not
preserve non covalent bond during ionization.
Mass spectrometry plays an important role in several aspects
of metal–peptide investigation, linked to neurodegenerative dis-
eases. Detailed information on peptide/protein interaction with
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Fig. 10. (A) Fragmentation scheme of one Pt(phen)/A1–16 complex deduced from ESI–MS/MS spectra of both 3+ and 4+ charged ions, including bn/yn ions of Pt-free
fragments and b∗n/y
∗
n ions of platinated fragments. The lowest platinated and Pt-free ions detected are, respectively, b
∗
6/y
∗
3 and b5/y2, showing that histidyl residues His
6 and
His14 are involved in Pt coordination. (B) The binding model proposed for His6/His14 chelation.
Adapted from Ref. [147].
various metal ions, metal-induced conformational changes and
unambiguous MS  assignment of coordination modes and binding
sites are easily achievable, and have allowed the elucidation of fun-
damental issues regarding the amyloid fibril assembly pathway.
For these reasons, the use of mass spectrometry should stay on the
increase in the future and new MS  approaches, combining existing
MS analytical tools with other experimental techniques, should be
developed.
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Reevaluation of Copper(I) Affinity for Amyloid-b Peptides by Competition
with Ferrozine—An Unusual Copper(I) Indicator
Bruno Alies,[a, b] Bertrand Badei,[a, b] Peter Faller,[a, b] and Christelle Hureau*[a, b]
Introduction
Copper is an essential trace element involved in several es-
sential biological functions and is used as cofactor in many
redox proteins. However, Cu dyshomeostasis is responsible
for several diseases. For instance, CuI overload in the cytosol
is the fingerprint of the genetic disorder Wilsons disease
(WD). A disturbed CuI supply is also encountered in the
Menkes syndrome.[1,2] In addition, Cu has been involved in
neurodegenerative diseases, such as Alzheimer disease
(AD),[3–5] in which both CuI and CuII oxidation states have
been proposed to intervene in deleterious processes linked
to the development of the pathology, possibly through the
production of reactive oxygen species (ROS).[6,7]
Some therapeutic approaches rely on the use of Cu chela-
tors. For instance for WD, the chelators should have a high
affinity to sequester CuI and should ideally target the liver
where CuI accumulates.[8] However, to determine directly
CuI binding affinity is often difficult. As a consequence, af-
finities of most of chelators have been obtained by competi-
tion with CuI-specific dyes with known formation constants,
such as the BCS (2,9-dimethyl-4,7-diphenyl-1,10-phenan-
throline disulfonic acid, log b2=19.8)
[9] and BCA (bicincho-
ninic acid, log b2=14.7
[10] or 17.2)[11] reagents (Scheme 1 and
Table 1) that form 1:2 Cu/ligand complexes. No dye with
lower CuI affinities has been studied so far. Herein, we re-
ported on the determination of the apparent formation con-
stant (b2=10
11.6 in Hepes 0.1m, pH 7.4) of the [CuI(Fz)2]
3
species (Fz= ferrozine=5,6-diphenyl-3-(2-pyridyl)-1,2,4-tri-
ACHTUNGTRENNUNGazine-4,4’’-disulfonic acid). This complex shows a visible sig-
nature at 470 nm (e=4320m1 cm1, Scheme 1 and
Table 1).[12]
Secondly, competition with the chromophoric [CuI(Fz)2]
3
complex was applied to determine CuI binding affinity to
amyloid-b (Ab) peptides involved in AD, including the full-
length Ab42 peptide (sequence: DAEFRHDS-
GYEVHHQKLVFFAEDVGSNK GAIIGLMVGGVVIA).
Recently, it was shown that CuI binds to the soluble form of
Ab through two of the three His residues in positions 6, 13,
and 14 with a preference for the His diad His13-His14.[18–22]
In the 1:1 Cu/Ab complex obtained, the metal center is
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Supporting information for this article is available on the WWW
under http://dx.doi.org/10.1002/chem.201102746, including UV/Vis de-
tection (at 470 nm) of reverse titration experiment (Fz into a CuI so-
lution) and UV/Vis monitoring of competition between Ab and
BCA.
Scheme 1. Structures of the BCS, BCA, and Fz ligands.
Abstract: The association constant of
ferrozine (5,6-diphenyl-3-(2-pyridyl)-
1,2,4-triazine-4,4’’-disulfonic acid) with
CuI to form the chromophoric
[CuI(Fz)2]
3 complex was determined
by UV/Vis titration experiments in
Hepes buffer (0.1m, pH 7.4). An asso-
ciation constant close to 1012m2, which
is significantly weaker than those of
the well-known, water-soluble, CuI che-
lators bicinchoninic acid and 2,9-di-
methyl-4,7-diphenyl-1,10-phenantroline
disulfonic acid, was found. The
[CuI(Fz)2]
3 chromophore was used in
UV/Vis competition experiments to de-
termine CuI binding affinity for the
amyloid-b peptide involved in Alz-
heimers disease and for a series of per-
tinent mutants. An association constant
of approximately 107m1 was found;
this is much weaker than that reported
for dithiothreitol and confirms that imi-
dazoles are harder ligands than thio-
lates. Each His mutation (H6A, H13A,
and H14A) impacts the peptide affinity
for CuI. The native human amyloid-b
peptide was found to be a fourfold-
stronger CuI ligand than the murine
peptide, which differs by three point
mutations (R5G, Y10F, and H13R)
from the human one.
Keywords: amyloid-beta peptides ·
binding affinity · chromophores ·
copper · ferrozine
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linearly bound by two imidazole rings from His resi-
dues.[18,20] Another key parameter to determine is the
strength of the CuI–Ab interaction. From our measurements,
an apparent affinity of (1.90.8)107m1 for the Ab42 pep-
tide (in 0.1m Hepes, pH 7.4) was deduced. This result is dis-
cussed with respect to contradictory data obtained very re-
cently by Feaga et al. , who reported a dissociation constant
in the femtomolar range.[23] We also investigated the C-ter-
minally truncated peptide that contains the 16 first amino
acid residues of Ab42 (including the three His ligands),
noted Ab16. The CuI affinity for the corresponding Ab16-
H6A, Ab16-H13A, and Ab16-H14A mutants and the N-ter-
minally protected peptide Ac-Ab16 were studied to confront
affinity data with the actual [CuI(Ab)] structural model pro-
posed on the basis of spectroscopic data. Furthermore, as
mice and rats, whose peptide differs from the human Ab
peptide by three point mutations (R5G, Y10F, and H13R),
do not develop AD, we have also studied CuI binding to the
murine Ab (mAb) peptide and the impact of each point mu-
tation on CuI affinity.
Results and Discussion
Association constant of [CuI(Fz)2]
3 : Fz is a well-known
water-soluble spectrophotometric indicator for FeII and is
widely used to titrate FeII in biological medium or in potable
water.[16,17,24] The use of Fz as a CuI spectrophotometric indi-
cator has been proposed,[12] but has remained unexploited
due to possible interference with FeII concomitants present
in natural media.[25] Herein, such interferences with FeII was
avoided or at least corrected and we could thus investigate
CuI binding to Fz. In a first attempt, competition experi-
ments between Fz and BCA for CuI binding were performed
and revealed that Fz was a significantly weaker CuI ligand
than BCA. However, formation of the ternary [CuI(Fz)-
ACHTUNGTRENNUNG(BCA)]3 species (for which the spectroscopic data are not
known) during the competition experiment precluded any
straightforward quantitative analysis. Moreover, at physio-
logical pH, two different association constants are reported
for the [CuI ACHTUNGTRENNUNG(BCA)2]
3 complex,[10,11] and thus the
[CuI(Fz)2]
3 association constant deduced from competition
experiments would have been a relative value. That is the
reason why the [CuI(Fz)2]
3 association constant was deter-
mined by UV/Vis titration, a technique that led to particu-
larly accurate and independently confirmed results in case
of the parent [FeII(Fz)3]
4 species.[17,26] Indeed in such a way,
only a small error is detected on the order of magnitude of
the constant, because it mainly depends on the concentra-
tion at which the reaction between the metal ion and the
chromophore is equilibrated. In the present case, the ideal
concentrations to observe the equilibrium between CuI and
Fz was below 50 mm, a concentration at which the absorb-
ance of [CuI(Fz)2]
3 is still high enough to be correctly eval-
uated (under the usual working conditions, i.e., a pathlength
of 1 cm). It is worth noting that such a direct titration is not
straightforward for evaluation of the stronger [CuI ACHTUNGTRENNUNG(BCA)2]
3
and [CuI ACHTUNGTRENNUNG(BCS)2]
3 association constants. Two kinds of titra-
tion experiments were performed: either CuI was added into
a Fz solution (direct titration) or Fz was added into a CuI
solution (reverse titration) and all the titrations were repeat-
ed at least three times with [Fz]=30 or 50 mm (direct titra-
tion) or [CuI]=15 or 25 mm (reverse titration). In the former
case (Figure 1a), it was possible to monitor both the absorp-
tion band at 470 nm, the increase of which corresponds to
the formation of the [CuI(Fz)2]
3 complex, and the absorp-
tion band near 290 nm, which was slightly modified by the
addition of CuI. Addition of CuI led to the increase of the
470 nm absorption band that followed the titration curve
shown in Figure 1b. In the UV region, addition of CuI (up
to half of the Fz concentration) led to the formation of a
new absorption band at a higher wavelength. Concomitantly
three isosbestic points were detected; this indicates that two
chromophores, identified as [Fz] and [CuI(Fz)2]
3, are in
equilibrium in solution. At higher CuI amounts, the UV
band slightly increased and was still weakly shifted toward a
higher wavelength. This is due to the formation of a third
chromophore, which may be the [CuI(Fz)] species. The as-
sociation constants (b2) deduced from direct measurement is
(3.71.5)1011 and from the reverse measurement (2.5
Table 1. Formation constants and spectroscopic data of [CuI(L)2]
3 complexes.
Ligand Log b2 Comment Ref lmax [nm] emax [M
1 cm1] Ref
BCS 19.8 from [Cu ACHTUNGTRENNUNG(BCS)2]
2 association constant and redox potential of [Cu ACHTUNGTRENNUNG(BCS)2]
2/3 complexes [9] 483 1300 [9]
22.1 competition with cyanide (pH 6.0) [13] 485 [13]
BCA 14.7 by calorimetry in Hepes (50 mm, NaCl 200 mm, pH 7.5, 25 8C) [10] 562 7700 [10]
17.2 by indirect competition with BCS [11] 562 7900 [14]
11.4 by spectrophotometric titration pH 6.0 [13] 560 [13]
Fz 11.6 by spectrophotometric titration in Hepes (100 mm, pH 7.4) [b] 290 49500 [b]
470 4320 [b]
ACHTUNGTRENNUNG(562)[a] 2600 [b]
470 4320 [12]
ACHTUNGTRENNUNG(562)[a] 3300 [12]
MeCN 4.35 NIST[c]
4.0 kinetics of [CoIII ACHTUNGTRENNUNG(NH3)5X]2+ reduction by CuI (0.11 m NaClO4, 0.033m HClO4, 21 8C) [15]
[a] Data for comparison with [FeII(Fz)3]
4, which exhibits a lmax at 562 nm. e of [Fe
II(Fz)3]
4 at 562 and 470 nm (the maximum of [CuI(Fz)2]
3 absorption)
were determined herein to be 25 000m1 cm1 and 8600m1 cm1, respectively. These values are slightly lower than those previously reported.[12,16, 17]
[b] This work. [c] NIST=National Institute of Standards and Technology database.
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0.5)1011 (see example of titration curve in Figure S1 in the
Supporting Information and the Experimental Section for
detailed calculations). The weak difference observed be-
tween the two kinds of titrations may originate from contri-
butions of the [CuI(Fz)] , which is more important in the re-
verse titration. A b2 value of (3.71.7)1011, which covers
the whole error range, was used in the results described
below. Note that 1) in these experiments, we used [Cu-
ACHTUNGTRENNUNG(MeCN)4]
+ as a starting CuI source. The MeCN concentra-
tion at the break point of the titration curve is approximate-
ly 2.5 mm. Because MeCN is a weak CuI chelator (Table 1),
we ensured in a preliminary study that the MeCN concen-
tration up to 20 mm did not interfere with the determination
of the b2 value. 2) The experiments were performed in
Hepes buffer (0.1m) and as a consequence the b2 value is an
apparent constant. However Hepes, due to its chemical
structure, is anticipated to have only weak CuI binding abili-
ty. Potentiometric determination of absolute constants, as
performed for quinoline ZnII sensors by Fahrni and OHal-
loran,[27] was not tried due to the redox sensitivity of CuI.
Affinity constants of [CuI(Ab)] species : To determine the
CuI binding affinity for Ab peptides, a first attempt was per-
formed by using the known BCA ligand. However, even
after addition of 40 equivalents of Ab16 peptide per CuI, the
UV/Vis signature of the [CuI ACHTUNGTRENNUNG(BCA)2]
3 species did not
evolve enough to determine precisely the binding affinity of
[CuI(Ab)] (Figure S2 in the Supporting Information). That
was the reason why association of CuI with Fz was deter-
mined (see above). In Figure 2, the effect of successive addi-
tion of the Ab16 peptide to a solution of [CuI(Fz)2]
3 is
shown. Addition of the Ab16 peptide led to a significant de-
crease in the 470 nm absorption band characteristic of the
[CuI(Fz)2]
3 complex. Concomitantly a weak increase of the
absorbance is observed at 562 nm; this indicates the forma-
tion of the [FeII(Fz)3]
4 complex and is attributed to the
presence of small amount of Fe in the peptide batch. Analy-
sis of UV/Vis data, according to Equation (4) in the Experi-
mental Section, gave the affinity values of CuI for the vari-
ous Ab peptides that are reported in Table 2. Note that UV/
Vis data have been corrected for contribution of the small
amounts of [FeII(Fz)3]
4 formed during the titration.
An independent method to illustrate the competition be-
tween [CuI(Ab)] and [CuI(Fz)2]
3 species is NMR spectros-
copy. Indeed, it was previously evidenced that CuI binding
to the Ab peptide lead to shifts in the position of the His
resonances (Figure 3 spectra a and b).[19] Addition of two
equivalents of Fz per CuI ion shifts the His resonances to-
wards those of the apo peptide (Figure 3, spectrum c). The
proportion of CuI bound to the Ab peptide can thus be de-
duced from the differences in the peak positions of the His
Figure 1. A) UV/Vis spectra of successive additions of CuI into a Fz solu-
tion: [Fz]=30 mm (Hepes 0.1m pH 7.4), bold traces correspond to [CuI]=
0 mm, 15 mm, and 75 mm. Insets: a) [CuI] from 0 to 15 mm and b) [CuI] from
15 to 75 mm in the UV region. B) Titration curve of successive additions
of CuI into a Fz solution with the absorbance measured at 470 nm: solid
lines correspond to asymptotes for which [CuI]!0 and [CuI]!1. The
theoretical absorbance value obtained for total complexation between
CuI and Fz is given by the [CuI]!1 asymptote. The x value of the inter-
section between the two asymptotes gives access to the Cu/Fz ratio in the
complex formed (dashed line) and the real absorbance value detected
due to an equilibrated reaction corresponds to the intersection of the
dashed line with the titration curve.
Figure 2. UV/Vis spectra of successive additions of Ab16 (ca. 100 mm per
addition) into a solution of [CuI(Fz)2]
3 (55 mm) in Hepes (0.1m, pH 7.4):
Bold traces correspond to [Ab]=0 and 720 mm. The solid arrow indicates
the decrease of the 470 nm absorption band characteristic of the
[CuI(Fz)2]
3 complex. The dashed arrow indicates the increase of the
562 nm absorption band characteristic of the [FeII(Fz)3]
4 complex, the
formation of which is due to the presence of very small amount of Fe in
the peptide batch.
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resonance of the apo-peptide spectrum (Figure 3, spectrum
a) and of the mixture of [CuI(Ab)] and [CuI(Fz)2]
3
(Figure 3, spectrum c) compared with the differences in the
peak positions of the His resonances of the apo-peptide
spectrum and of the [CuI(Ab)] species (Figure 3, spectrum
b). From the NMR data a binding constant of (84)
106m1 was deduced by using Equation (4) in the Experi-
mental Section. This value agrees well with that determined
by UV/Vis titration.
The affinity value obtained herein for the [CuI ACHTUNGTRENNUNG(Ab16)]
complex (7.5106m1) is very different from the one of ap-
proximately 61014m1 obtained recently by Feaga et al.[23]
To better understand the possible origin of such discrepancy,
we tried to reproduce the data obtained by Feaga et al.
However, instead of pure water or N-ethylmorpholine
buffer (20 mm, pH 7.0), we worked in Hepes (0.1m, pH 7.4)
and used a CuI source, instead of reducing CuII by ascorbate.
Under such conditions, we were unable to see any competi-
tion between Ab16 and BCS for CuI binding, contrary to
what was reported by Feaga et al., and we detected only a
weak competition with the weaker chelator BCA (see Fig-
ure S2 in the Supporting Information) for CuI. Our condi-
tions are probably more appropriate because in unbuffered
conditions the pH can shift significantly down to pH<4, pH
values at which CuI decoordination from BCS is anticipated.
The pH shift may originate from 1) successive addition of
Ab16 (the stock solution is usually around pH 2 due to pep-
tide purification in trifluoroacetic acid) and 2) the addition
of ascorbate to reduce the CuII. This is the reason why we
also performed the experiments in unbuffered solutions and
indeed found that addition of Ab and a concomitant pH
shift induce the removal of CuI from BCS. Even though this
explanation may account for the discrepancy between the
values found by Feaga et al. and those determined herein,
this may not be the sole reason. It is worth noting that the
CuI association constant with dithiothreitol (DTT) has been
reported to be weaker than 1015 (b1).
[28,29] On the basis of
the HSAB (hard–soft acid–base) theory, the affinity of
[CuI(Ab)], for which CuI is linked by two imidazole rings in-
stead of thiolate functions when bound to DTT, is expected
to be weaker than that of [CuI ACHTUNGTRENNUNG(DTT)].
The impact of mutations on CuI affinity for Ab was also
investigated to better disentangle CuI binding to Ab pep-
tides (Table 2). The full-length Ab42 peptide is a threefold-
stronger CuI ligand than the truncated Ab16 peptide. This
result may be due to participation of Met35 in CuI coordina-
tion. However, this contradicts XAS data that show no spec-
troscopic differences between CuI bound to monomeric full-
length Ab and truncated Ab16 peptides.[20] Moreover Met35
did not bind to other metal ions associated with AD, includ-
ing the intermediate Lewis acid FeII.[30] Increased CuI affini-
ty for the full-length peptide compared with the truncated
one may originate from contributions of oligomeric species
in the Ab42-peptide sample compared with the monomeric
form in the Ab16-peptide sample. Indeed different CuI coor-
dination spheres in monomeric and oligomeric species have
been recently proposed based on XAS data. Met35 was,
however, not involved in this coordination.[22]
Among the various mutations studied herein, the His re-
placement by an Ala leads to the most important impact ob-
served on CuI binding affinity. The three mutants—Ab16-
H6A, Ab16-H13A, and Ab16-H14A—are all weaker CuI li-
gands than the corresponding Ab16 truncated peptide; this
suggests that all three His residues intervene in CuI coordi-
nation. However, the decrease in the affinity is not drastic,
in line with results that show that the CuI binding site con-
sists of two of the three His residues,[20] with the three possi-
ble couples of His being in equilibrium.[19] More precisely,
the affinity follows the trend Ab16>Ab16-H6A>Ab16-
H14A>Ab16-H13A. This result agrees with the fact that
the diad that is most frequently involved in CuI coordination
is His13-His14.[19,21] However, the H13A mutation has a
more important impact on the affinity than the H14A one;
this suggests that the His6-His13 couple is more involved in
CuI coordination than the His6-His14 couple. We also mea-
sured CuI affinity for the N-terminally protected Ac-Ab16
peptide, and a slightly higher affinity than that of the Ab16
peptide was found. These results suggest that the N terminus
of Ab is not involved in CuI coordination; this agrees with
the spectroscopic data available at present.[19,20] It can be an-
Table 2. Affinity constants of [CuI(L)] species (Hepes 0.1m, pH 7.4) and
corresponding standard-deviation constants calculated by competition
with Fz and a b2 value of 3.710
11.
Ligand Ka [10
6m1] Ligand Ka [10
6m1]
Ab42 198.2[a] – –
Ab16 7.51.0 mAb16 1.90.15
Ab16-H6A 2.70.30 Ab16-R5G 121.2
Ab16-H13A 1.10.17 Ab16-Y10F 9.20.88
Ab16-H14A 2.10.13 Ab16-H13R 0.80.15
Ac-Ab16 121.3 Ab16-R5G-H13R 1.70.20
[a] The high value of the standard deviation is attributed to a possible
heterogeneity of the Ab42 peptide stock solution due to aggregation.
Figure 3. The aromatic region of the NMR spectra of a) Ab16 peptide
([Ab]=200 mm), b) Ab16 peptide ([Ab]=200 mm in presence of 0.9 equiv-
alents of CuI), and c) Ab16 peptide ([Ab]=200 mm in presence of one
equivalent of CuI and two equivalents of Fz, phosphate buffer 40 mm,
pH 7.4). Peaks from [CuI(Fz)2]
3 are represented by *. Dashed lines indi-
cate the position of the His peaks in the apo peptide and arrows indicate
the position of the His peaks in the [CuI(Ab)] complex.
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ticipated that the higher CuI affinity found for Ac-Ab16 is
due to second-sphere effects, in which, for instance, the un-
favorable formation of salt bridges or H bonds between the
NH3+-terminal function and a negatively charged residues
will be precluded by the N-terminal protection.
Lastly, the affinity for CuI of the mAb16 and of the Ab16-
R5G, Ab16-Y10F, Ab16-H13R, Ab16-R5G-H13R mutants
was measured. Contrary to what was observed for CuII bind-
ing, for which a threefold-higher affinity was detected for
the mAb16 peptide compared with the human one,[31,32] the
human Ab16 peptide is a fourfold-stronger CuI-binding
ligand than the mAb16 peptide. Studies of mutants reveals
that the decrease in the CuI affinity for mAb16 compared
with human Ab16 is mainly due to the H13R mutation.
However, it is worth noting that the R5G mutation has an
opposite effect that leads to a slightly higher CuI affinity
either for Ab16 compared with Ab16-R5G or for Ab16-
H13R compared with Ab16-R5G-H13R. This may be attrib-
uted to a better accessibility of the His6 residue when the
bulky and charged Arg amino acid is replaced by the Gly.
Conclusion
The main information deduced from the present study is
that CuI binding to Ab is weaker than CuII binding to Ab ;
the [CuII(Ab)] association constant is in the subnanomolar
range,[3] whereas that of [CuI(Ab)] is in the submicromolar
range. This may be linked to the different binding sites occu-
pied by the two ions: a square planar site composed of
-NH2, two His, and a CO function from the peptide back-
bone for the main CuII species present at physiological
pH,[33–35] and two His in a linear mode for CuI.[19,20] This im-
plies that in the extracellular medium, Cu bound to Ab is
likely in the + II valence state, although this can be modu-
lated by the presence of other CuI and CuII chelators. Never-
theless, CuI bound to Ab can be transiently found during
ROS-production processes; this requires a redox switch be-
tween the + I and + II valence states of the [CuII(Ab)] spe-
cies.[6]
It was previously conjectured that the higher CuII affinity
for mAb compared with human Ab alters the distribution of
CuII bound to human Ab in transgenic murine AD models,
which produce both human and mAb peptides in contrast to
AD cases that produce only human Ab.[31] For CuI, such al-
teration is not anticipated because CuI affinity for the mAb
peptide is about a fourth of that of human Ab.
Last but not the least, the affinity range of chromophoric
CuI complexes has been enlarged by the determination of a
significantly weaker association constant for the [CuI(Fz)2]
3
species compared with those already reported in the litera-
ture for [CuI ACHTUNGTRENNUNG(BCA)2]
3 and [CuI ACHTUNGTRENNUNG(BCS)2]
3 (Table 1). A wider
affinity range allows determination of CuI affinity of biologi-
cally relevant molecules, such as a-synuclein or prion pro-
teins, and of synthetic chelators by straightforward UV/Vis
competition experiments.
Experimental Section
Chemicals : The monosodium salt hydrate of Fz was bought from Alfa-
Aesar. A stock solution (0.1m) was prepared in water. BCS and the diso-
dium salt of BCA were bought from Sigma-Aldrich. A stock solution
(0.1m) was prepared in water. Hepes buffer (sodium salt of 2-(4-(2-hy-
droxyethyl)piperazin-1-yl)ethanesulfonic acid) were bought from Fluka
(bioluminescence grade). [CuACHTUNGTRENNUNG(MeCN)4] ACHTUNGTRENNUNG(BF4) was bought from Sigma–Al-
drich and kept under inert atmosphere until used. A CuI stock solution
(0.2m) was prepared in MeCN. For titration experiments, CuI stock solu-
tions (10 or 5 mm) were prepared in Ar-degassed Hepes (0.1m, pH 7.4,
containing 10 or 5% v/v MeCN) and degassed with water-saturated Ar
just before use. UV/Vis monitoring of the stock solution under Ar was
performed to ensure that under these conditions no dismutation oc-
curred. Less than 2% of CuII was detected, a content that can be neglect-
ed in the analysis of the titration curve. The Ab16 peptide (sequence
DAEFRHDSGYEVHHQK) was bought from GeneCust (Dudelange,
Luxembourg). The other peptides, that is, the mAb16 peptide (sequence
DAEFGHDSGFEVRHQK), the Ab16-R5G, Ab16-Y10F, Ab16-H13R,
and Ab16-H13R-R5G human mutants (sequences DAEFGHDS-
GYEVHHQK, DAEFRHDSGFEVHHQK, DAEFRHDSGYEVRHQK
and DAEFGHDSGYEVRHQK) as well as the full-length Ab42 (se-
quence DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM-
ACHTUNGTRENNUNGVGGVVIA) peptide were bought from GenScript (Piscataway, USA).
Truncated peptides : A stock solution of peptide (ca. 10 mm) was prepared
by dissolving the powder in milliQ water (resulting pHffi2). The peptide
concentration was then determined by UV/Vis absorption of Tyr10,
which was considered as free tyrosine ((e276–e296)=1410m
1 cm1) for a ty-
rosine-containing peptide, and of two Phe ((e258–e280)=390m
1 cm1) for
the mAb and Y10F peptides. The human Ab42 peptide was prepared by
dissolving the powder in milliQ water and the peptide concentration was
then determined by UV/Vis absorption of Tyr10, which was considered
as free tyrosine ((e293–e360)=2410m
1 cm1) in NaOH (0.1m).
Techniques : UV/Vis spectroscopy : UV/Vis spectra were recorded on a
Hewlett Packard Agilent 8453 UV/Vis spectrometer at 25 8C.
NMR spectroscopy : 1D 1H NMR experiments were recorded on a Bruker
Avance 500 spectrometer equipped with a 5 mm triple resonance inverse
Z-gradient probe (TBI 1H, 31P, BB). Spectra were collected at 298 K in
D2O. All UV/Vis and NMR experiments were performed on Ar-degassed
solutions and in an Ar atmosphere.
Association constants : Regarding [CuI(Fz)2]
3-association-constant deter-
mination, freshly prepared dithionite or ascorbate (10 mm) was added at
the end of the titration experiment to reduce possible [CuII(Fz)2]
2
formed during the experiment. Absorbance values showed only a slight
increase corresponding to the presence of less than 5% [CuII(Fz)2]
2.
This value is sufficiently weak to neglect trace amounts of CuII in the cal-
culation of the [CuI(Fz)2]
3 association constant.
Regarding [CuI(Ab)]-association-constant determination, ascorbate
(10 mm) was added to the stock solution of peptides (ca. 1 equiv of ascor-
bate per peptide) just before use to avoid any possible oxidation of CuI
to CuII during the peptide additions in the competition experiments.
Under these conditions, the pH of the solution does not change. More-
over, it is worth noting that in competition experiments, interference with
ascorbate (or with any other weak chelators) has no impact on the deter-
mination of the association constant. A typical competition experiment
consisted in addition of aliquots of the stock peptide solution into a
[CuI(Fz)2]
3 solution. The equilibration time after each peptide addition
was approximately 2 min, that is, the time requested for homogenization
of the sample and stabilization of the UV/Vis spectrum.
Calculations : The [Cu(Fz)2]
3 formation constant was determined accord-
ing to Equation (2).
b2 ¼
Cu Fzð Þ2½ 
Cu½  Fz½ 2 ð1Þ
See Table 3 for the reaction considered. Two kinds of titrations were per-
formed: CuI into a solution of Fz of a known concentration (direct titra-
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tion) or Fz into a CuI solution of a known concentration (reverse titra-
tion). C0= [Cu
+]0, C1= [Fz]0, a=x/C1 (direct titration) or x/C0 (reverse ti-
tration), and x is the [Cu(Fz)2)]
3 concentration determined by UV/Vis
absorption. When C0!1 (in case of direct titration) or C1!1 (in case
of reverse titration), a!1 and then it is possible to deduce
e([Cu(Fz)2]
3). When C1=2C0, the conditions of Equation (2) are fulfil-
led:
b2 ¼
a
4 C0ð Þ2 1 að Þ3
; a ¼ x
C0
ð2Þ
Determination of the [Cu(Ab)] formation constant : Competition experi-
ments between [Cu(Fz)2]
+ and Ab are described by Table 4 and Equa-
tion (3) and (4):
KAba ¼ b2C0
1 aFzð Þ
aFz
C1
C0
 2aFz
 2
C2
C0
 1þ aFz
  ð4Þ
for which aFz is determined by UV/Vis (470 nm) or NMR spectroscopy.
C0=50 mm, C1=105 mm, and C2 was varied from 100 mm to 1 mm (ca. five
to ten C2 values were used). The affinity constant of Cu
I towards Ab was
determined by solving Equation (4) for each C2 concentration used in
one experiment (with the Kaleidagraph software). Data given in Table 2
correspond to the mean value and the standard deviation obtained for
the different C2 values.
Contribution to the absorbance at 470 nm from [Fe(Fz)3)]
4 was calculat-
ed by solving Equations (5) and (6) with the e values reported in Table 1.
A470nm ¼ e470nmFe Fe Fzð Þ3½  þ e470nmCu Cu Fzð Þ2½  ð5Þ
A562nm ¼ e562nmFe Fe Fzð Þ3½  þ e562nmCu Cu Fzð Þ2½  ð6Þ
Acknowledgements
The authors thank the ANR (Agence
Nationale de la Recherche) for finan-
cial support (ANR Grant Neurometals
NT09–488591). Dr. C. Bijani (Labora-
toire de Chimie de Coordination) is
acknowledged for recording the NMR
data.
[1] V. Lalioti, G. Muruais, Y. Tsuchiya, D. Pulido, I. V. Sandoval, Front.
Biosci. 2009, 14, 4878.
[2] B. Sarkar, Chem. Rev. 1999, 99, 2535.
[3] P. Faller, C. Hureau, Dalton Trans. 2009, 1080 and references there-
in.
[4] E. Gaggelli, H. Kozlowski, D. Valensin, G. Valensin, Chem. Rev.
2006, 106, 1995.
[5] K. J. Barnham, A. I. Bush, Curr. Opin. Chem. Biol. 2008, 12, 222.
[6] C. Hureau, P. Faller, Biochimie 2009, 91, 1212.
[7] D. G. Smith, R. Cappai, K. J. Barnham, Biochim. Biophys. Acta Bio-
membr. 2007, 1768, 1976.
[8] A. M. Pujol, M. Cuillel, O. Renaudet, C. Lebrun, P. Charbonnier, D.
Cassio, C. Gateau, D. Pascal, E. Mintz, P. Delangle, J. Am. Chem.
Soc. 2011, 133, 286–296.
[9] Z. Xiao, F. Loughlin, G. N.
George, G. J. Howlett, A. G.
Wedd, J. Am. Chem. Soc. 2004,
126, 3081 and refrences therein.
[10] L. A. Yatsunyk, A. C. Rose-
nzweig, J. Biol. Chem. 2007, 282,
8622.
[11] Z. Xiao, P. S. Donnelly, M. Zim-
mermann, A. G. Wedd, Inorg.
Chem. 2008, 47, 4338.
[12] S. K. Kundra, M. Katyal, R. P.
Singh, Anal. Chem. 1974, 46,
1605.
[13] R. Miras, I. Morin, O. Jacquin, M.
Cuillel, F. Guillain, E. Mintz, J.
Biol. Inorg. Chem. 2008, 13, 195.
[14] K. Y. Djoko, Z. Xiao, D. L. Huff-
man, A. G. Wedd, Inorg. Chem.
2007, 46, 4560.
[15] P. Kamau, R. B. Jordan, Inorg.
Chem. 2001, 40, 3879.
[16] L. Stookey, Anal. Chem. 1970, 42, 779.
[17] C. R. Gibbs, Anal. Chem. 1976, 48, 1197.
[18] R. A. Himes, G. Y. Park, G. S. Siluvai, N. J. Blackburn, K. D. Karlin,
Angew. Chem. 2008, 120, 9224; Angew. Chem. Int. Ed. 2008, 47,
9084.
[19] C. Hureau, V. Balland, Y. Coppel, P. L. Solari, E. Fonda, P. Faller, J.
Biol. Inorg. Chem. 2009, 14, 995.
[20] J. Shearer, V. A. Szalai, J. Am. Chem. Soc. 2008, 130, 17826.
[21] S. Furlan, C. Hureau, P. Faller, G. La Penna, J. Phys. Chem. B 2010,
114, 15119.
[22] J. Shearer, P. E. Callan, T. Tran, V. A. Szalai, Chem. Commun. 2010,
46, 9137.
[23] H. A. Feaga, R. C. Maduka, M. N. Foster, V. A. Szalai, Inorg. Chem.
2011, 50, 1614.
[24] V. V. S. Eswara Dutt, A. Eskander-Hanna, H. A. Mottola, Anal.
Chem. 1976, 48, 1207.
[25] A. C. I. Anusiem, G. B. Ojo, Anal. Chem. 1978, 50, 531.
[26] J. C. Thompsen, H. A. Mottola, Anal. Chem. 1984, 56, 755.
[27] C. J. Fahrni, T. V. OHalloran, J. Am. Chem. Soc. 1999, 121, 11448.
[28] Z. Xiao, J. Brose, S. Schimo, S. M. Ackland, S. La Fontaine, A. G.
Wedd, J. Biol. Chem. 2011, 286, 11047.
[29] A. Krezel, W. Les´niak, M. Jez˙owska-Bojczuk, P. Młynarz, J. BrasuÇ,
H. Kozłowski, W. Bal, J. Inorg. Biochem. 2001, 84, 77.
Table 3.
Cu+ + 2Fz Q [Cu(Fz)2)]3
C0 C1 0 initial
C1<2C0 C0x; 0<x<0.5C1<C0 C12x x equilibrium: 0<x<0.5C1<C0
C1 ACHTUNGTRENNUNG(C0/C1a) C1ACHTUNGTRENNUNG(12a) C1a 0<a<0.5; a=x/C1
C1>2C0 C0x ; 0<x<C0<0.5C1 C12x x equilibrium: 0<x<C0<0.5C1
C0 ACHTUNGTRENNUNG(1a) C0ACHTUNGTRENNUNG(C1/C02a) C0a 0<a<1; a=x/C0
Table 4.
Cu+ + 2Fz Q [Cu(Fz)2]3
C0 C1 0 initial
C0xFzxAb C12xFz xFz C1>2C0 (0<xFz<C0)
C0(1aFzaAb) C0(C1/C02aFz) C0aFz equilibrium is described by 0<a<1; aFz=xFz/C0
Cu+ + Ab Q [Cu(Ab)]
C0 C2 0 initial
C0xFzxAb C2xAb xAb C2>C0 (0<xAb<C0)
C0(1aFzaAb) C0(C2/C0aAb) C0aAb equilibrium is described by 0<a<1; aAb=xAb/C0
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Abstract. 
Cu(II) binding to the amyloid-β peptide has been proposed to be a key event in the cascade 
leading to Alzheimer disease. As a direct consequence, the strength of the Cu(II) to Aβ 
interaction, i.e. the Cu(II) affinity of Aβ,  is a very important parameter to determine. Because Aβ 
peptide contain one Tyr fluorophore in its sequence and because Cu(II) does quench Tyr 
fluorescence, fluorescence measurements appear to be a straightforward way to obtain this 
parameter. However, this proved to be wrong, mainly due to data misinterpretation in some 
previous studies that leads to a conflicting situation. In the present paper, we have investigated in 
details a large new set of fluorescence data that were analyzed with a new method taking into 
account the presence of two Cu(II) sites and the inner-filter effect. This leads to re-interpretation 
of the published data and to the determination of a unified affinity value in the 1010 M-1 range. 
   
Introduction. 
 Alzheimer’s disease (AD) is the most prevalent cause of dementia in the elderly 
population, affecting about 40 million people world-wide.1 This clearly underlines the need to 
find more efficient medical treatments for AD. In order to find such drugs, the better 
understanding of the mechanisms, from the origin of the disease to the death of neurons is of 
central interest.   
 The underlying mechanism of AD is not clear, but there is evidence and a relatively wide 
agreement that the so-called amyloid cascade is a key and early event in the development of 
AD.1-4 This hypothesis suggests that the mismetabolism of the amyloid-β (Aβ) peptide is the 
initiating event in AD pathogenesis. The amyloid cascade contains several aggregation stages: 
oligomers, protofibrils and fibrils that are found in the senile plaques, a traditional hallmark of 
AD. Aβ is a 39–43 residue polypeptide encompassing a hydrophilic N-terminal domain (1–28) 
 
and a C-terminal hydrophobic domain (29–39/43). In vivo, the most prevalent forms consist of 40 
(Aβ40) and 42 amino acids (Aβ42). The longer form Aβ42 is more prone to aggregation and 
more toxic to neurons than Aβ40, in agreement with the amyloid cascade hypothesis.1 
 A large body of evidence also indicates that transition metal ions are involved in the 
neurodegenerative process.5, 6 In vivo, in cellulo and in vitro experiments strongly suggest that 
metal ions and in particular Cu ions can indeed intervene in the amyloid cascade process.5, 7-13 
Aggregation intermediates (often called oligomers) are now considered to be more toxic than the 
senile plaques or higher molecular weight aggregates,14-16 via various events including the 
production of Reactive Oxygen Species (ROS). As a consequence, metal ions and the amyloid 
cascade is a central target of anti-AD molecules.17-19 In such a context, a very important 
parameter to know is the affinity of Cu(II) for the Aβ peptide. Indeed, it determines: (i) the 
possibility to have the Cu-Aβ interaction in vivo and (ii) it drives the design of Cu(II) chelator, 
one of the possible therapeutic strategy recently developed.18        
  However, as recently pointed out by some of us in a detailed review,20 the value of Cu(II) 
affinity for the amyloid-β peptide (Aβ) is still a matter of debate. While conditional affinity 
values obtained by potentiometry and isothermal calorimetry (ITC) are in the 109 to 1010 M-1 
range, those obtained by Tyr10 fluorescence lie mainly in the 107 to 108 M-1 range (Table 1). 
Conditional affinity constants describe the effective affinity at a given (pH, T) couple in absence 
of any competitor. Here, unless specified, these data are given for pH 7.4 and 25 °C. Two 
possibilities to explain such important discrepancies are: (i) there is a systematic error in the 
Tyr10 fluorescence or in the potentiometry and ITC experiments (ii) the value found depends on 
the Aβ concentration since Tyr10 fluorescence studies are performed at much lower 
concentrations than the other two types of experiments. In parallel with the concentration issue, 
the nature of the peptide used is different in the two kinds of experiments: short truncated Aβ16 
 
peptide in the latter ones, because relatively high concentration are required for ITC and 
potentiometry measurements and full-length Aβ peptide for fluorescence experiments that 
required lower concentration.  
 Taken into account those considerations, here, we report a new set of Tyr10 fluorescence 
experiments to evaluate the Cu(II) affinity to Aβ. Concentration of Aβ was varied by two orders 
of magnitude to search for possible concentration dependence. We get consistent results over a 
wide range of concentrations, with Aβ16 and Aβ40 peptides of different sources. Also affinity for 
the second Cu(II) site was evaluated.  
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Results. 
  
New analysis of Cu(II)-induced quenching of Tyr10 fluorescence:  The full-length Aβ sequence 
contains only one Tyr residue at position 10 and three Phe residues at position 4, 19 and 20. 
Hence, upon excitation at 275 nm (and emission at 305 nm), the intrinsic fluorescence of the 
peptide is predominantly due to the sole Tyr. Figure 1 and S1 show the effect of Cu(II) addition 
on the Tyr10 fluorescence of Aβ16, considered as a valuable model of Cu(II) binding site in the 
monomeric full-length Aβ (reviewed in ref. 37). Full-length Aβ40 has also been studied (Figure 
S2) but because its aggregation can significantly interfere with fluorescence measurements (see 
Experimental section), Aβ16 has been preferred, especially when high concentrations are used. 
Due to its paramagnetic character, Cu(II) quenches the Tyr10 fluorescence. Intensity of the 
quenching increases with the number of Cu(II) equivalents added and three parts can be 
identified in the Tyr10 fluorescence quenching curve (Figure 1, left): (i) a linear portion between 
0 and 1 Cu(II) equivalent; (ii) a second linear portion with a weaker slope between 1 and 2 Cu(II) 
equivalents and (iii) an exponential decrease above 2 Cu(II) equivalents. While two break points 
at 1 and 2 Cu(II) equivalents can be well-observed on this data set, it appears that in most of 
similar data previously published,27, 28 they are ill-defined. It is mainly due to a low number of 
points in the first part of the curve or to irregularly placed points. In such cases, curves 
reminiscent of the equilibrated formation of the Cu:Aβ 1:1 are observed, leading to the 
conclusion that Cu(II) affinity lies in the range of the Aβ concentration used for the measurement. 
Also the Aβ concentration (classically below 10 µM) and the buffer concentration influence the 
observation of those two break-points. 
 
 
Figure 1. Left panel: Tyr10 fluorescence titration curve showing the three portions of the curve. 
Inset shows the two first portions of the titration curve, with slope change observed at 1 Cu(II) 
equivalent per peptide. F0 corresponds to the fluorescence measured in absence of Cu(II). Central 
panel: Illustration of impact of Aβ and hepes concentrations on the Cu(II)-induced quenching of 
Tyr10 fluorescence. Calculated points using equations 1 to 4, absKa of 1.12 1010 M-1 (see below) 
and the following conditions: [Aβ16] = 10 µM, [hepes] = 100 mM, pH 7.4 (open squares) or 
[Aβ16] = 80 µM, [hepes] = 20 mM, pH 7.4 (solid circles). Right panel: fit (solid line) of the 
former calculated data points (from left panel, open squares) using classical equation for the 
formation of a 1:1 Cu(II):Aβ complex, where one equivalent of Cu(II) is assumed to quench 
integrally the Tyr fuorescence (appKd  = 3.5 10-6 M-1). F0 corresponds to the fluorescence in 
absence of Cu(II).   
  
 
 To better illustrate this issue, calculated curves using the affinity value determined in this 
paper and obtained for two extreme conditions are compared in Figure 1, center. For Aβ  = 10 
µM and [hepes] = 100 mM, the two break points are ill-defined and in such a case, the curve can 
be well-reproduced with classical model for the equilibrated formation of a Cu:Aβ complex, 
 
yielding an appKd of 3.5 10-6 M which leads to a conditional affinity of 2 x 107 M-1 after 
correction for competition with hepes buffer according to constants determined in Ref.36 (Figure 
1, right). This value is close to those reported in Table 1, when the fluorescence experiments have 
been carried out in hepes buffer, a very weak Cu(II) competitor (see Supporting Information).     
  Analysis of the presently obtained data leads to drastically different conclusions: (i)  
linearity of the first portion of the titration curve (Figure 1, left, 0 to 1 Cu(II) equivalent) is due to 
the total (not equilibrated) formation of the Cu(Aβ) complex. Formation of the Cu(Aβ) complex 
leads to a partial quenching of the Tyr10 fluorescence, with approximately 50% of residual 
fluorescence observed in presence of one equivalent of Cu(II). (ii) the linearity of the second 
portion of the curve (1 to 2 Cu(II) equivalents) is due to the total formation of the Cu2(Aβ) 
complex leading to approximately 20% of residual fluorescence. (iii) The trend of the third 
portion of the curve (above 2 Cu(II) equivalents) is due to an inner-filter effect that becomes 
predominant and leads to a complete Tyr10 fluorescence quenching.  
 The inner-filter effect is often omitted in Tyr10 fluorescence experiments, inducing 
misinterpretation of the data. It originates from absorbance of the sample at the excitation (x) and 
emission (y) points (Ii(x,y)), where x and y are the dimensions of the cuvette parallel and 
perpendicular to the excitation beam. It differs from the maximum intensity (Io), according to the 
Beer-Lamber law, , where abs(x) and abs(y) are the absorbance at the 
(x,y) position and the fluorescence of a molecule M defined as . In the present 
case, 
 
and 
 
 
 and the experimental setup is such as x = 0.5 cm and y = 0.05 cm. Taken into account that the 
absorbing species absorb at 275 nm but almost not at 305 nm, the second term abs(y) was 
neglected. Validity of such approximation was checked by addition of the Cu(DAHK) 
chromophore to a solution of a water-soluble non-coordinating fluorophore (i.e. a phenol 
sulfonate) (Figure S3). In the following, fluorescence of Aβ containing species will be considered 
according to Equations 1 and 2 detailed in the Experimental Section. 
        
Glycine as a weak Cu(II) competitor to determine Cu(II) affinity of Aβ. From the Cu(II) 
addition to Aβ peptide experiment, it appears that it is not possible to determine directly the 
conditional Cu(II) affinity for Aβ due to a too strong value and thus a non-equilibrated reaction 
between Cu(II) and Aβ (first part of the titration curve in Figure 1, left). Else, the experiment 
would require using extremely low Aβ concentrations (nM to pM range). This is the reason why 
further experiments were performed in presence of the weak competitor, glycine (Gly). Gly was 
chosen because it proved to be a very-well defined Cu(II) ligand, the formation constants of 
which has been accurately determined.38 More particularly, we have used such competitor in the 
past to evaluate the Cu(II) affinity of GHK and DAHK peptides and obtained results in a close 
agreement with those obtained by other techniques without Gly competitor.39 In this case, the 
affinity value obtained is the apparent affinity, i.e. the affinity in presence of a competitor, which 
thus depends on the competitor concentration according to equation 3 (see Experimental Section).  
     Two kinds of complementary experiments were performed: (i) Gly addition to Cu(Aβ) 
species leading to the recovery of the Tyr10 fluorescence (Figure 2, left) or (ii) Cu(II) addition to 
Aβ in presence of various amounts of Gly (Figure 2, right).      
 
In Figure 2, left, recovery of Tyr10 fluorescence for [Cu(Aβ)] ranging from 20 µM to 
200 µM is reported together with simulation of the curves according to the procedure described 
in the Experimental Section. Also the decrease of the circular dichroism (CD) absorption band at 
315 nm (corresponding to the N- to Cu(II) ligand to metal charge transfer transition in the Cu(Aβ) 
complex) induced by the formation of the achiral Cu-Gly complexes has been reproduced (Figure 
S4). A unique value of 1.12 x 1010 M-1 M has been used to reproduce the five curves, obtained for 
[Cu(Aβ)] ranging from 20 µM to 1 mM. This strongly supports that the affinity value of Cu(II)-
Aβ binding depends neither on Aβ concentration nor on the technique used for the competition 
experiments. This also indicates that formation of a ternary Gly-Cu-Aβ complex is unlikely or 
that the formation constant is very weak.   
 
     
    Figure 2. Left panel:  Gly induced recovery of [Cu(Aβ16)]-Tyr10 fluorescence, [Cu(Aβ16)] = 
20 (a), 50 (b), 80 (c) and 200 µM (d), [hepes] = 100 mM, pH 7.4. Inset shows the data obtained 
for [Cu(Aβ16)] = 200 µM on a larger scale of Gly concentration. Dashed lines represent the 
fitting of the Tyr10 fluorescence recovery according to equations 1 to 4 (see Experimental 
Section), with condK= 1.12 1010 M-1. Note that Tyr10 fluorescence decrease at high Gly 
concentration is due to dilution effects (that are taken into account in the fitting procedure). ΔF = 
F0-F with F0 the fluorescence value in absence of Gly. Central panel: Gly induced recovery of 
[Cu2(Aβ16)]-Tyr10 fluorescence, [Cu2(Aβ16)] = 50 µM, [hepes] = 100 mM, pH 7.4 and the 
corresponding calculated curve (dashed line). Inset: Gly induced recovery of [Cu2(Aβ16)]-Tyr10 
fluorescence on a larger scale of Gly concentrations, including Cu removal from the first site. ΔF 
= F0-F, F0 the fluorescence value in absence of Gly and Fmax is the fluorescence value for [Gly] = 
1 mM. Right panel: Cu(II) induced quenching of Aβ16-Tyr10 fluorescence, [Aβ16] = 80 µM, 
[hepes] = 100 mM, pH 7.4, in presence of various concentration of glycine, [Gly] = 2 (a), 4 (b), 8 
(c) and 16 mM (d). Dashed lines represent the fitting or the Tyr10 fluorescence quenching with 
condK= 1.12 1010 M-1. F0 is the fluorescence value in absence of Cu(II). 
 
 
Affinity of the second Cu(II) binding site. A second Cu(II) binding site has been identified by 
Tyr10 fluorescence quenching (Figure 1, left, second portion of the titration curve). To better 
characterize this second Cu(II) site, CD and EPR measurements were performed (Figure S5). It 
appears that, in line with previous reports,22, 29, 32, 35, 40 it is possible to insert a second Cu(II) site 
into the Aβ16 sequence and that the second Cu(II) binding is sequential.  
By addition of Gly to the Cu2(Aβ) species, Tyr10 fluorescence is recovered in a two-step 
process (Inset in Figure 2, center). The first steep step (up to 1 mM Gly) corresponds to the 
removal of the second Cu(II) ion and the second flatter step to the removal of the first Cu(II) ion. 
Reproduction of the first part of the curve, taking into account that the two Cu(II) ions bind to the 
Aβ sequentially, leads to an affinity constant of approximately 5 x 107- 1 x108 M-1 for the second 
Cu(II) ion, in agreement with that evaluated by ITC measurements, with Aβ peptide used as the 
titrant of a Cu(II) solution.32 This value is also reminiscent of the Cu(II) affinity for Ac-Aβ 
peptide measured by ITC.41  
 
Cu(II)-induced quenching of Tyr10 fluorescence in presence of Gly. Because the two affinity 
constants determined for the first and the second Cu(II) ion differs by more than a factor of 100, 
it is also possible to determine the affinity for the binding of the first Cu(II) to Aβ by monitoring 
the Tyr10 quenching induced by Cu(II) addition to Aβ in presence of Gly. The second Cu(II) site 
can be neglected in presence of the Gly concentration required for having an equilibrated reaction 
between the first Aβ site and the Cu(II). In Figure 2, right, such Cu(II) titration to Aβ has been 
obtained for [Gly] ranging from 2 mM to 16 mM. A unique affinity value was used to reproduce 
the four curves: 1.12 1010 M-1, equal to the value determined by Tyr10 recovery in presence of 
Gly (Figure 2, left).  
 
 
Cu(II) affinity for full-length human and murine Aβ peptides. Similar affinity value is 
anticipated for Cu(II) binding to the full-length Aβ (Aβ40) compared to the truncated Aβ16 
(compared Figure 1 and S1). Because the Cu(II) titration of Tyr10 fluorescence performed on the 
Aβ40 was very similar to that obtained for Aβ16, and because Aβ40 is much more complicated to 
handle and the results less reproducible, Cu(II) affinity for Aβ40 was deduced from competition 
experiment with the Aβ16 lacking the Tyr10 (Y10F-Aβ16 or murine peptide, i.e. the triple R5G-
Y10F-H13R-Aβ16 mutant noted mAβ16). Indeed, such measurements require recording less data 
compared to the titration curve. In the first step, Cu(II) affinity for Y10F-Aβ16 was deduced from 
a competition experiment with Aβ16 (Figure 3, bottom data, plain squares). Addition of Cu(II) to 
Aβ16 leads to a linear decrease of fluorescence (left part of the curve) as observed previously 
(Figure 1, left). Upon addition of the mAβ16 mutant, fluorescence is recovered (right part of the 
curve). Taking into account this effect, the affinity ratio between Aβ16 and mAβ16 peptides can 
be calculated. The same holds for competition between Aβ40 and mAβ16, and Aβ40 and mAβ40. 
Affinity values thus calculated are reported in Table 2. Aβ16 and Y10F mutant have very similar 
affinities while the murine Aβ16 binds Cu(II) three times stronger than the human counterpart, in 
line with previous measurement by competition in circular dichroism (CD).42 Aβ40 is also 
stronger than Aβ16, in line with previous publications reporting measurements on both Aβ16 and 
Aβ40.23, 31 
 
 
 
Figure 3. Competition experiments using Tyr10 fluorescence. In the first part of the curves, the 
fluorescence of Aβ16 (bottom data in solid symbols) or Aβ40 (top data in open symbols) is 
quenched by addition of Cu(II) while in the second part, fluorescence is recovered by addition of 
a competing peptide lacking the Tyr10, i.e. Y10F-Aβ16 (bottom data, plain circles), mAβ16 
(bottom data, plain squares or top data, open circles) or mAβ40 (top data, open squares). Last 
points on the four curves correspond to the Tyr10 fluorescence recovery after addition of two 
equiv. of a strong competitor (DAHK). Initial fluorescence is not recovered due to an increased 
inner filter effect at the end of the experiment compared to the beginning. . [peptide] = 50 µM, 
[hepes] = 100 mM, pH 7.4. F0 is the fluorescence value in absence of Cu(II).   
 
 
Table 2.  Conditional affinity relative to conditional affinity of Aβ16. Errors are indicative and 
come from variation in three independent measurements. Note that a very weak change in 
fluorescence value impacts significantly the condKa ratio.  
peptide Aβ16 Y10F-Aβ16 Aβ40 mAβ16 mAβ40 
condKa/condKa(Aβ16) 1 ~1±0.2 ~2.5±1 ~3±1.5 ~1±0.5 
 
 
Discussion. 
 In the present report, we detail a new method to analyze Cu(II) induced quenching of 
Tyr10 fluorescence data, that can apply to other quencher - fluorophore couples. In a very weak 
coordinating buffer such as hepes, the titration curve is made of the three independent parts 
(Figure 1, left), due to coordination of the first Cu(II) ion, of the second Cu(II) ion and to inner-
filter effect induced by increased absorbance of the sample due to Cu(II) addition and binding to 
the buffer, respectively. These three events are usually ill-defined in the titration curves that can 
then appears as a classical titration curve of an equilibrated reaction (Cu + Aβ ↔ Cu(Aβ)).27, 28 
Contribution of the inner-filter effect has always been underestimated in all previous reports 
using fluorescence. The inner-filter effect becomes predominant after the second Cu(II) ion 
binding to Aβ but also contributes to fluorescence decrease in the first two parts of the titration 
curve, explaining why Cu(II) induces different ratio in Tyr10 fluorescence quenching depending 
on the conditions (compare F/F0 value at one Cu(II) equivalent in Figure 1, center). For instance, 
in our experiments in presence of one Cu(II) equivalent  residual Tyr10 fluorescence was 53 % 
for Aβ16 = 20 µM, 50 % for Aβ16 = 50 µM, 45 % for Aβ16 = 80 µM (data not shown).  
 
 This new analysis leads to Cu(II) affinity of Aβ of about 1010 M-1 similar to those 
obtained by other techniques (compare entry 11 with entries 12-20 in Table 1). If a more 
coordinating buffer such as tris (Figure S6) is used, the Cu(II) induced quenching of Tyr10 
fluorescence gives a titration curve characteristic of an equilibrated reaction. This is due to the 
non-negligible Cu(II) affinity of tris that acts as a weak Cu(II) competitor. Fitting of the titration 
curve and calculation of the conditional affinity from the apparent one should thus gives a correct 
evaluation of Cu(II) affinity of Aβ. However, because complexes formation between Cu(II) and 
tris is still unclear, it is difficult to account for tris competition correctly. Using formation 
constants from ref. 27, the conditional Cu(II) affinity of Aβ is underestimated (Table 1, entries 1, 
3, 7 and 16). Using those from ref. 30 gives results in better agreement with Cu(II) affinity of Aβ 
obtained by other techniques, but there is a strong dependence on tris concentration (Table 1, 
entry 7). As pointed out in a recent review,10 it may originate from tris-Cu formation constants 
that are not fully correct or from the formation of tris-Cu-Aβ ternary species.  
 This is the reason why we performed our experiments with Gly as a weak Cu(II) 
competitor, formation constants of Cu-Gly species being very-well defined.38 Regarding the use 
of Gly as weak competitor, some of us raised a possibility that Gly may form ternary complexes 
with Cu(II) and Aβ, which could explain the discrepancies presented in Table 1 (compare entries 
7b and 9 with entries 10 and 12 to 14).20 The experimental results presented here do not support 
this concept. The fitting of the affinity constant, which was based upon the absence of such 
complex, was successful under a broad range of experimental conditions. Even stronger and more 
direct evidence comes from the CD titration (Figure S5), in which the Gly additions affected only 
the intensity of the spectrum, but not its shape. CD is very sensitive to perturbations of the d-d 
chromophore.43 Thus, we can state that Gly did not bind to the Cu(Aβ) ion in the course of 
titration. 
 
 The competitive titrations using other Aβ analogs are based on a similar assumption, but 
in this case it is less solid, because we have no evidence that the ternary (Aβ)Cu(Aβ'), where Aβ 
and Aβ' are the two peptides in competition, isn't present in solution. The existence of such 
ternary Cu(Aβ)2 species was described as transient species in ref. 44 and later on, reported in ref. 
45 on the basis of NMR relaxation rates as a minor species. Hence we have conjectured that the 
formation of Cu(Aβ)2 was not very significant. 
 We also evaluate the Cu(II) affinity for the second site (5 x 107 M-1 - 108 M-1), which is 
about 100 fold weaker than the first site. Such value involves that hepes in classical concentration 
range (i.e. 0.1 M) can interfere with Cu(II) binding to the second site. This explains why the slope 
of the second part of the titration curve is less pronounced in presence of high hepes 
concentration and weak Aβ concentration (Figure 1, center). This also contributes to the ill-
defined break-point at 2 Cu(II) equivalent in most of the titration curves reported, using classical 
concentration ranges ([Aβ] = 10µM, [hepes] = 100 mM)). Recently, Viles and coworkers29 
proposed that the second Cu(II) site is only observed in the shorter truncated Aβ16 and Aβ28 
peptide or in Aβ42 in presence of alcoholic solvent. This proposition was based on EPR signal 
quantification. Here, by fluorescence, no significant difference in the titration curve measured for 
the full-length Aβ40 and the shorter Aβ16 peptides has been detected, suggesting that the second 
Cu(II) binding site is also present in the Aβ40 peptide. Cu((II) affinity for Aβ lies in the 1010 M-1 
range, close to affinity of other neurodegenerative proteins (reviewed in ref. 20), such as the α-
synuclein involved in Parkinson disease (109 - 1010 M-1)46 and the Prion Protein  (106 M-1 for the 
octarepeat domain occupied with 4 Cu(II) ions and 1010 M-1 for the octarepeat domain occupied 
with 1 Cu(II) ion).20 Affinity is lower than those of Cu proteins (1017 M-1 for the SOD),47 and to a 
lesser extent to those of other biologically relevant peptides, the N-terminal Cu(II) site of Human 
 
Serum Albumin (1012 M-1 48- 1014 M-1 39) and the cell growth factor GHK (1013 M-1).39 Hence, 
affinity of Cu(II) chelators designed in the context of AD should thus lie in a relatively narrow 
range to not disturb the native Cu(II) distribution.  
 
 
Experimental Section. 
Chemicals. 
Sodium 4-hydroxybenzenesulfonate dihydrate (phenol sulfonate) was bought from sigma aldrich. 
Hepes buffer (sodium salt of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), tris (tris 
(hydroxymethyl) aminomethane), popso (piperazine-1, 4-bis-(2-hydroxy-propane-sulfonic acid) 
dihydrate) and pipes (piperazine-N, N’-bis (2-ethanesulfonic acid) buffer were bought from  
Fluka (bioluminescence grade).  
Human and murine Aβ40 peptide (sequences 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV and 
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVV) and the corresponding C-
terminally truncated form at position 16 were bought from GeneCust (Dudelange, Luxembourg) 
with a minimum purity grade of 95%. The Aβ16-Y10F peptide was bought from Genscript 
(Piscataway, USA). 
For truncated peptides: approx. 10 mM stock solution of peptide was prepared by dissolving the 
powder in milliQ water (resulting pH ~ 2). Peptide concentration was then determined by UV-
visible absorption of Tyr10 considered as free tyrosine ((ε276-ε296) = 1410 M-1cm-1) for tyrosine-
containing peptide and by UV-visible of two Phe ((ε258-ε280) = 390 M-1cm-1) for the mAβ and 
Y10F peptides.  
Human Aβ40 peptide was prepared by dissolving the powder in milliQ water and peptide 
concentration was then determined by UV-visible absorption of Tyr10 considered as free tyrosine 
((ε293-ε360) = 2400 M-1cm-1) in NaOH 1 M.  
 
For some titration experiments the Aβ40 peptide was obtained by expression in E. coli and 
purified using HPLC as described before.28 The identity of this peptide was verified by a ESI Q-
ToF Premier mass spectrometer (Waters). Its purity was assessed by HPLC to exceed 98%.  
Techniques.  
UV-Vis spectra were recorded on a Hewlet Packard Agilent 8453 UV-Vis spectrometer at 25°C.  
The circular dichroism (CD) spectra were recorded at 25 °C on a J-815 spectropolarimeter 
(JASCO). Fluorescence measurements were recorded on a on a FluoroMax-4 spectrofluorometer 
in triplicate and representative data are given in the text. In all measurements, after each addition 
of Cu(II) or Gly, the solution was gently mixed up and fluorescence recorded until a stabilization 
of the value. In case of the full-length Aβ peptide, mixing of the solution was challenging even 
for very low concentration (below 10 µM) due to foam formation and maybe aggregation of the 
peptide Thus, it was difficult to obtain correct measurements reproducibly. It was also checked 
that the quenching of Tyr fluorescence was only due to specific Cu interaction with the Aβ 
peptides since no intensity decrease was observed for Cu addition to a non-coordination phenol 
water soluble molecule, except decrease due to inner-filter effect. 
 
Equations. 
For a molecule M, the fluorescence is given by       
where FM is the fluorescence intensity and IaM the absorbed intensity given by: 
 
where Ii is the incident intensity and It the transmitted intensity. 
Because l is very small, it comes that      
then,        
 
and       , 
with       , where 
   and    
Finally, for a molecule M       
In the present case,    
    (Eq. 1), with 
         (Eq. 2) 
 
Fitting procedures. 
The apparent dissociation constant is defined as:  
 
where       
 
Hence, it comes that (ML) is given by: 
    (Eq. 4) 
For each titration curve, an initial value of the conditional affinity is supposed and the apparent 
dissociation constant is calculated according to Eq. 3:  
 
 
 
(Eq. 3) 
where competition with hepes buffer has also been included but is negligible compared to 
competition with Gly, except for very low Gly concentration. 
;36  (hepes data 
from ref. 38, Gly data from the NIST database and ref. 38).  
Then, concentration of Cu, Aβ and Cu(Aβ) species are calculated according to Eq. 4 and the 
resulting fluorescence according to Eq. 1 to 3. Next, the initial conditional affinity value is 
adjusted to improve similarity between the experimental data and the calculated curve.  
The intrinsic fluorescence coefficients  have been evaluated by dependence of the Tyr10 
fluorescence on the fluorophore (Aβ, Cu(Aβ) and Cu2(Aβ)) concentration (Figure S7).  
 
Buffers. 
Another important parameter to control is the nature of the buffer to use for the fluorescence 
experiments. The buffer should not interfere with Cu(II) binding to Aβ and have the maximum 
buffering effect near pH 7.4. The effect of various buffers on fluorescence of the Cu(Aβ16) 
complex was tested (Figure S6). Hepes has been chosen for the following reasons:  
(i) hepes is a weak Cu(II) competitor,  
(ii) Its buffering power lies in the best pH range (pKa = 7.4)  
(iii) Its constant formation with Cu(II) has been evaluated and thus its contribution can be 
corrected.36 
In specific cases, pipes has been used. They are: in the calibration curve of the Cu2(Aβ) species, 
because hepes can compete with the second Cu site, the Tyr10 fluorescence recovery upon buffer 
addition for the initial point and EPR and CD experiments on the second Cu(II) binding. 
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Combined coordination of ZnII and CuI or CuII to the 
amyloid-β peptide has been investigated by XANES, EPR and 
NMR spectroscopies. While ZnII does alter CuII binding to 10 
Aβ, this has no effect on (Aβ)Cu induced ROS production and 
cell toxicity.   
 
 Extracellular amyloid deposits are one of the main 
morphological hallmark of Alzheimer's Disease (AD).1 They are 15 
made of aggregated forms of a 40 to 42 residues peptide called 
amyloid-β (Aβ). In addition, they contain high levels of metal 
ions, mainly Cu and Zn, which are coordinated to the Aβ peptide. 
Aβ aggregation that can be modulated by metal ions is the central 
event of the amyloid cascade, a process proposed to initiate the 20 
AD pathology.2, 3and refs therein Reactive Oxygen Species (ROS) 
production linked to aberrant binding of the redox-active Cu ion 
has also been involved as a deleterious mechanism.4 The Aβ 
peptide possesses multiple binding sites with the N-term amine, 
three His at positions 6, 13 and 14 and four carboxylic acids at 25 
positions 1, 3, 7 and 11. Zn level in the synaptic cleft can reach 
up to 300µM while Cu level is less well determined with reported 
concentrations in the µM to 100µM range (reviewed in ref. 3). 
Hence, for those two reasons studies on simultaneous binding of 
Cu and Zn to Aβ are biologically relevant. In addition, although 30 
Zn is redox-silent, it has recently been proposed5, 6 that it may 
change Cu binding to Aβ and, as a consequence, the associated 
ROS production. In contrast to Prion protein,7-9 the simultaneous 
coordination of Cu and Zn to Aβ has only been scarcely 
investigated. In a pioneering report, Sovago and coworkers 35 
studied the impact of Zn addition on (Aβ)CuII species by 
speciation and EPR on an highly hydrosoluble PEG derivative of 
the Aβ peptide (PEG-Aβ16).5 In contrast, independent Cu and Zn 
binding to Aβ have been extensively studied in the past ten years. 
CuII coordination is pH-dependent and two species noted 40 
components I and II coexist at physiological pH. In I (resp. II), 
CuII is linked to the N-term amine, the adjacent CO group, and 
two His imidazole rings, (resp. N-term amine, the adjacent 
deprotonated amide group, a CO group and one His imidazole 
ring).10 and refs therein CuI lies in a linear geometry between two His 45 
imidazole rings.11, 12 Regarding Zn, the coordination picture is 
less clear, but involvement of at least two His residues, a 
carboxylate group and the N-term amine has been proposed.13, 14 
and refs therein In the present report, we use a set of complementary 
spectroscopies to investigate the concomitant Cu and Zn binding 50 
to Aβ as well as interference of Zn in Cu mediated ROS 
production and cell toxicity.1  
Figure 1. The X-ray absorption near edge structure (XANES) of the 
normalized absorption amplitude versus energy at the Zn (panel A) and 
Cu (panel B) K-edges of (a) (Aβ16)Zn, (b) (Aβ16)ZnCuI, (c) 55 
(Aβ16)ZnCuII, (d) (Aβ16)CuII and (e) (Aβ16)CuI complexes. 
[complexes] = 2 mM, [hepes] = 0.1 M, pH 7.4, T = 20 K. 
 To evaluate the effect of simultaneous Cu and Zn binding to 
Aβ, X-ray absorption spectroscopy is the most powerful 
technique since it permits to record both Zn and CuI or CuII 60 
signatures on the same sample depending on the chosen K-edge.2 
The Zn K-edge is reproduced in Figure 1, panel A. Presence of 
CuI or CuII modifies significantly the Zn XANES signature 
indicating changes in the Zn coordination site upon binding of 
either CuI or CuII. In contrast, the CuI XANES signature is not 65 
perturbed by the presence of Zn (Figure 1, panel B, (e) and (b)). 
This is particularly clear for the pre-edge associated with the 1s 
→ 4p transition characteristic of a CuI coordinence of 2. For CuII, 
the situation is less obvious with a slight modification of the 
XANES signature observed at 9.00 keV. These changes due to Zn 70 
binding are reminiscent of what has been observed for component 
II of the (Aβ)CuII complex.15 These first characterizations 
indicate that: (i) Zn can adopt several geometries, with Cu 
governing Zn coordination in the mixed Cu,Zn complexes. This 
is line with CuII and CuI having affinities higher than Zn affinity 75 
for Aβ.16 (ii) in the (Aβ)ZnCuI complex, change in Zn 
coordination site is due to the requirement of two His residues for 
CuI binding, leaving only one His available for Zn binding which 
was proposed to require at least two His residues.13 The 
unchanged CuI environment is also deduced from NMR 80 
 2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
experiments (Figure 2, panel B) in which the shift of the aromatic 
His resonances is not modified by the presence of Zn, whatever 
the addition order of metal ions to the Aβ peptide (compare (d) 
and (e)). (iii) in the (Aβ)ZnCuII complex, the situation is similar 
excepted that CuII requires more potential Zn ligands, such as for 5 
instance the -NH2 terminal amine. This would explained why the 
(Aβ)ZnCuI and the (Aβ)ZnCuII  signatures are different. In 
addition, Zn also induces a reshuffling of the CuII coordination 
sphere, with a CuII XANES spectrum that evolves towards that of 
component II. This effect is quite weak and can hardly be 10 
observed by XANES.  
 
Figure 2. Panel A: EPR spectra of (Aβ16)CuII complex in presence of 
increasing equiv. of ZnII: (a) without Zn, (b) 0.5 equiv., (c) 1 equiv. and 
(d) 2 equiv. Inset: amplification of the first hyperfines lines of spectra (a) 15 
to (d). [(Aβ16)CuII]= 1mM, [hepes] = 0.1 M, pH 7.4, T = 110 K, mod. 
ampl. 1 mT, microwave power: 20 mW, ν = 9.51 GHz. Panel B: NMR 
spectra of (a) Aβ16 peptide and complexes (b) (Aβ16)CuI, (c) (Aβ16)Zn, 
(d) (Aβ16)ZnCuI where CuI was added to (Aβ16)Zn and (e) (Aβ16)CuIZn 
where Zn was added to (Aβ16)CuI. [complexes]= 1mM, [d11-Tris] = 50 20 
mM pH = 7.4, T = 300 K, ν = 500 MHz. 
In contrast, modifications of the (Aβ)CuII EPR traces upon 
addition of increasing equivalent of Zn are unambiguous (Figure 
2, panel A). Indeed the ratio between the EPR signatures of 
components I and II evolves from 80/203 for the (Aβ)CuII to 25 
55/45 for the (Aβ)ZnCuII and to 40/60 in presence of one 
additional Zn equiv.. Similar trends were previously observed for 
mixed Zn and Cu coordination to the PEG-Aβ16.5, 4 Such 
reorganization of the CuII sphere is in line with the reported 
involvement of at least two His residues in Zn binding.13 In 30 
addition as CuII can change its coordination, Zn succeeds in 
pushing it toward a component II environment, as previously 
deduced for the PEG-Aβ16 by EPR and speciation study.5 Such 
reorganization of the CuII site might induce a change in the redox 
properties of the Cu centre and thus of its ability to produce ROS 35 
and to induce cell damages.  
 In Figure 3, the (Aβ)Cu mediated ROS production is 
monitored by consumption of Ascorbate used here as the CuII 
reductant (panel A) and has been confirmed by classical Amplex 
Red and CCA assays (data not shown). Addition of Zn in the 40 
course of the experiment does not change the Asc consumption. 
Same results are obtained when Zn is initially present and 
incubated with the (Aβ)Cu species. In addition, (Aβ)Cu induced 
cell toxicity is not influenced by the presence of Zn in the media 
(Figure 3, panel B).  45 
Figure 3. Panel A: Consumption of ascorbate by (a) unbound CuII and (b) 
(Aβ40)CuII  without Zn (plain circles) and with Zn (plain squares). 
[Aβ40] = 7 µM, [CuII] = 5 µM, [ZnII] = 5 µM, [Asc] = 100 µM, [PO4] = 
50 mM pH 7.4. Panel C: Cell viability measurements by MTT assay of (a) 
Aβ40, (b) (Aβ40)CuII, (c) (Aβ40)Zn and (d) (Aβ40)ZnCuII, [Aβ40] = 10 50 
µM, [Cu] or [Zn] = 9 µM, [Asc] = 500 µM. 
Conclusions 
 Altogether these data indicate that modification of the CuII 
coordination site induced by the Zn ion is not sufficiently 
important to significantly interfere with (Aβ)Cu ROS production, 55 
in contrast to what was proposed in previous reports.5, 6 More 
importantly, Zn does not influence the (Aβ)Cu induced cell 
Hence, the proposed protective role of Zn (for a recent article, see 
ref. 17) may be related to modulation of Aβ aggregation ability or 
to other mechanisms linked to the AD aetiology and not only to 60 
variation of the (Aβ)Cu cell toxicity associated to ROS 
production. 
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1 Note that for the spectroscopic studies the short truncated Aβ16 peptide 
was used. It is a valuable model of metal ions binding to the full-length 
Aβ40/42 peptides (reviewed in ref. 3). For the ROS production studies 
Aβ40 or Aβ16 were used and give the same results (Aβ16 data are in the 
Supporting Information). For cell studies Aβ40 was used. For simplicity 
purpose, Aβ is used in the text while the nature of the peptide used is 
given in the Figure captions.  
   
2 The order of Zn or Cu addition does not change the XANES signatures 
detected. 
 
3 For quantification of each component, the EPR spectra of the pure 
components I and II were recorded in absence of Zn at pH 6.5 and 8.7, 
respectively and the proportion of I and II were deduced from linear 
combination for [Zn]-dependent spectra.  
 
4 Note that as was previously pointed out in ref. 5, Zn addition to (Aβ)Cu 
complex at [Aβ] = 1mM induces a partial precipitation of the 
corresponding species. With [Aβ] = 0.2mM, no precipitation occurs. As a 
consequence, we have checked that the partial precipitation observed at 
[Aβ] = 1mM did not lead to a change in the spectroscopic signatures of 
the mixed Cu,Zn complexes (See Supporting Information).  
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The synthesis of the H2L2− ligand (N,N′-Bis[(5-sulfonato-2-hydroxy)benzyl]-N,N′-dimethyl-ethane-1,2-
diamine) and characterizations of the corresponding Cu(II) complex [Cu(L)(H2O)]2− (1) by X-ray diffraction,
EPR, UV–Visible and potentiometry are described. At pH 7.4, the affinity of Cu(II) for this ligand is approximately
4×1014 M−1. Coordination of redox active metal ions such as copper or iron to the amyloid-β (Aβ) peptide has
been linked to deleterious processes encountered in the etiology of Alzheimer disease (AD), such as Aβ aggre-
gation and reactive oxygen species (ROS) production. In this context, the ability of the H2L2− to extract Cu(II)
from Cu(Aβ) species where Aβ is the peptide involved in AD, is reported as well as its capacity to redox silence
the Cu(Aβ) induced ROS formation and to prevent Cu(II)‐induced Aβ aggregation. Suchwater soluble sulfonato-
derivatives of Cu(II) chelators are very interesting counterparts for in vitro study of chelators' properties
required to attend further biological applications as therapeutic tools against AD.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Alzheimer disease (AD) is a neurodegenerative disorder charac-
terized by extracellular deposits of amyloid-β (Aβ) peptides,
known as senile plaques. High concentration of metal ions, mainly
Cu, Zn and Fe have been found co-localized with the senile plaques
and deleterious interactions of these ions with soluble and aggregat-
ed forms of Aβ peptide have been associated to the development of
AD [1–5]. Metal ions can modulate the Aβ peptide aggregation lead-
ing to amyloid deposits [6]. Furthermore, redox active Cu and Fe
ions impact the production of reactive oxygen species (ROS) [7,8].
A conceptual view of ROS formation is shown in Scheme 1. A valu-
able approach to fight against AD relies on the design and develop-
ment of Cu chelators that should be strong enough to remove Cu(II)
from Aβ but not from essential metalloproteins. Recently several
groups have conceived such new molecules (see Refs. [9–16] and
for recent reviews, Refs. [17–19]). More particularly, in a pioneering
work, Orvig has developed gluco-conjugated schiff based ligands,
namely H2GL1 (N,N′-Bis[(5-β-D-glucopyranosyloxy-2-hydroxy)ben-
zyl]-N,N′-dimethyl-ethane-1,2-diamine) and H2GL2 (N,N′-Bis[(5-β-
D-glucopyranosyloxy-3-tert-butyl-2-hydroxy)benzyl]-N,N′-dimethyl-
ethane-1,2-diamine) that have shown promising in vitro properties
as therapeutic tools against AD [15]. Herein, we report the study
of a related ligand, H2L2−(N,N′-Bis[(5-sulfonato-2-hydroxy)benzyl]-
N,N′-dimethyl-ethane-1,2-diamine) in which the phenolato groups
are sulfonated, leading to a water-soluble counterpart of the
well-known (Me)2salan (N,N′-Bis[(2-hydroxy)benzyl]-N,N′-dimethyl-
ethane-1,2-diamine). Such water-soluble ligands are perfectly
designed for in vitro biophysical investigations (determination
of Cu(II) affinity, spectroscopic characterizations of the Cu(II)
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complexes…). Furthermore, the properties of the chelating scaffold
are anticipated to vary minimally between the water-soluble and its
parent ligand that should be preferred for further biological
applications. Although sulfonation is the most straightforward way
to obtain water-soluble counterparts, such strategy has still been
poorly investigated in the context of AD.
Ligand H2L2− has been obtained by aMannich reaction according to
Ref. [15]. Reaction with CuCl2 in a methanol/water mixture gave access
to crystals of [Cu(L)(H2O)]2− (1) suitable for X-ray crystallography
study (Fig. 1,1 Table 1 and see details in the Supporting information).
1.1. Physico-chemical properties of 1
Complex 1 has been characterized by EPR (g//=2.23(5) and A//
(63Cu)=190×10−4 cm−1) and UV–Vis (ε390=1200 and ε620=
240 M−1.cm−1) (Fig. 2c). The parameters are comparable to those
of the H2GL1 ligand although the later ones have been determined
in MeOH. [15] The H2L2− ligand and its corresponding Cu complexes
have been studied by potentiometry. The overall acidity constants of
the ligand (β01h) and of the Cu(II) complexes (β11h) are given in
Table 2.2 At pH 7.4, the ligand is mainly obtained as H3L− and the
Cu(II) species as [Cu(L)(H2O)]2− (1) that predominates in a 5-pH
unit range around pH 7.4. From the parameters determined by
potentiometry, a conditional affinity value of 4.4×1014 M−1 is
found at pH 7.4 (Eq. (S3)), 50 times stronger than that reported for
the H2GL1 ligand [15]. We have also performed competition experi-
ments with the DAHK (Asp-Ala-His-Lys) peptide to confirm3 our
value. Indeed, the Cu(II) conditional affinity for DAHK has been eval-
uated by several groups which concur to a value of 4.7×1013 M−1 at
pH 7.4 [20]. Competition between H2L2− and DAHK for Cu(II) was
monitored by EPR and UV–Vis spectroscopies (compare a), b) and
c) in Fig. 2) and showed that H2L2− is about a 7±3 times stronger
Cu(II) ligand than DAHK, leading to a conditional affinity value of
3±1.5×1014 M−1 in full agreement with potentiometric titration.
The ability of ligand H2L2− to remove Cu(II) from Cu(Aβ) species at
physiological pH is expected from the value of the conditional affinity
reported for Aβ (10−10 M) [1]. Competition experiments by EPR and
UV–Vis (compare c) d) and e)) in Fig. 2) confirm that in the presence
of H2L2−, Cu(II) is completely removed from Cu(Aβ) species.
1.2. Prevention of Cu(II)‐induced Aβ aggregation
As anticipated based on previously reported data for the parent
H2GL1 ligand [15], ligand H2L2− prevents Cu(II)-induced aggregation
of the native Aβ40 peptide (Fig. 3) as probed by the well-known
Thioflavine T (ThT) fluorescence experiments, in which an enhanced
ThT fluorescence indicates the formation of fibrillar Aβ aggregates
(see Supporting information for details). Because Aβ aggregation is
highly intricate and versatile by itself, [5] we have performed two se-
ries of measurements with different conditions (pH, peptide source,
etc.). Although Cu(II) provokes different Aβ aggregation profiles in
the two experiments, the H2L2− ligand prevents Cu(II)‐induced Aβ
aggregation whatever the conditions. In the first case (Fig. 3A), it de-
lays the Cu(II)‐induced aggregation of Aβ40 and decreases the quan-
tity of fibrillar aggregates formed. In the second case (Fig. 3B),
addition of the H2L2− ligand to Cu(II) Aβ40 mixture leads to an
aggregation process reminiscent of what is observed in absence of
Cu(II).
1 The Cu(II) ion lies in a distorted square-based pyramid, where the equatorial plan
is made of two nitrogen atoms from the tertiary amines and two oxygen atoms from
the phenolato groups. A water molecule occupies the apical position. This structure dif-
fers from that of Cu(GL2) reported by Orvig and coworkers [15] in line with different
crystal packing effects observed in the two crystals. Indeed, in the present case, com-
plex 1 is obtained as a sodium-bridged dinuclear species (Fig. S1).
2 Attribution of pKa values show that in contrast to what was observed for the H2GL1
ligand, [15] the two phenolic functions are deprotonated before the second tertiary
amine.
3 The difference in the conditional affinity observed at pH 7.4 between the H2L2−
and H2GL1 ligands might be unexpected based only on the electron-withdrawing/
electron-donating properties of both ligands but may have several other origins. In-
deed, this value is a multiple function of β11h and of the ligand basicity. It may reflect
difference in charge distribution and steric effects and may also originate from differ-
ences in the experimental conditions. In particular, in the Orvig's study, [15] the ionic
strength was 0.16 M in NaCl. Although chloride is a weak Cu(II) ligand, in such a 1000-
fold excess, it can interfere in the determination of the βmlh.
Fig. 1. Top: Ligand H2L2−, H2GL1 and H2GL2 for comparison. Bottom: Ellipsoid plot (50% level, H and disorders atoms are omitted for clarity, excepted for the apical water molecule)
of [Cu(L)(H2O)]2− (1).
Table 1
Selected bond lengths and angles for 1.
Bond length (Å) Angle (°)
Cu–O1 1.924 (4) O1–Cu–O2 84.20 (16)
Cu–O2 1.936 (4) O1–Cu–N1 93.29 (18)
Cu–N1 2.017 (5) N1–Cu–N2 87.4 (3)
Cu–N2 2.018 (7) O2–Cu–N2 94.3 (2)
Cu–O9 2.495 (5)
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1.3. Inhibition of Cu(Aβ) ROS production
In contrast to prevention of Cu(II)‐induced Aβ aggregation that
was previously shown by Orvig, [15] no direct measurement of im-
pact of the (Me)2salan scaffold on ROS production by Cu(Aβ) has
been reported in the literature. Ligand H2L2− was therefore probed
for its ability to stop Cu(Aβ) ROS production using recently developed
in vitro tests [9,10]. As ROS production by Cu species requires the
reduction of the air-stable Cu(II) by ascorbate (Asc) (Scheme 1), the
rate of Asc consumption is indicative of the Cu species' ability to pro-
duce ROS. Alternatively, HO● formation is monitored by formation of
the fluorescent 7-OH-CCA dye from 3-CCA (coumarin-3-carboxylic
acid). As illustrated in Fig. 4, “free” Cu(II), i.e. Cu weakly bound to
buffer is the most efficient species in consuming Asc and producing
HO●. Cu(II) coordination to Aβ significantly slows down both pro-
cesses, in line with a sluggish redox cycling of the Cu(Aβ) complex
compared to “free” Cu [21]. Cu(II) coordination to H2L2− lowers Asc
consumption and HO● formation to the background level, in line
with no cathodic process observed down to−0.6 V vs. NHE (normal hy-
drogen electrode) by voltammetry (Fig. S7). Also, when H2L2− is added
to Cu(Aβ) species after incubation, Asc consumption and HO● formation
are reduced to the background level.
The data reported here strongly support that the salan scaffold is
well-appropriate to eliminate deleterious effects related to Cu binding
to Aβ. In cello study on ligandsH2L2− and (Me)2salan is under investiga-
tion in our group to determine whether the in vitro encouraging results
are confirmed in biological conditions.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jinorgbio.2012.05.016.
Fig. 3. Prevention of Cu(II)‐induced Aβ40 aggregation, Panel A: a) [peptide A]=40 μM, [Cu(II)]=20 μM, b) [peptide A]=40 μM, [Cu(II)]=20 μM, [H2L2−]=40 μM; [ThT]=20 μM,
T=37 °C, [Hepes]=20 mM, pH 7.4, NaCl 0.1 M. Panel B: a) [peptide B]=40 μM, [Cu(II)]=20 μM, b) [peptide A]=40 μM, [Cu(II)]=20 μM, [H2L2−]=40 μM, c) [peptide B]=
40 μM; [ThT]=10 μM, T=25 °C, [Pipes]=100 mM, pH 6.5. (For source and preparation of peptides A and B, see Supporting information).
Fig. 2. 63Cu EPR (panel A) and UV–Vis spectra (panel B) of a) [Cu(DAHK)], b) 1 in presence of 5 equiv. of DAHK, c) 1, d) Cu(Aβ) in presence of 1 equiv. of H2L2−, e) Cu(Aβ). [Cu(II)]=
0.9 mM, [ligand]=1 mM. [hepes]=50 mM, pH 7.4. UV–Vis recording conditions: ℓ=1 cm, T=25 °C; EPR recording conditions: ν=9.53 GHz; T=100 K, microwave
power=20 mW, modulation amplitude 0.5 mT.
Table 2
Logarithmic values of the overall acidity constants of the ligand (β01h) and of the over-
all stability constants of Cu(II) complexes (βm1h), standard deviation is indicated in
parenthesis for the last digit. I=0.1 M KNO3, T=25 °C (see speciation diagrams in
Figs. S3 and S4). Attribution of pKa values has been performed by UV–Vis and 1H
NMR titrations (Figs. S5 and S6).
log βmlh[a] L pKa Attribution
log β0l4 34.24 (7) 5.05 (3) Tertiary amine
log β0l3 29.19 (6) 7.79 (3) Phenol
log β0l2 21.40 (4) 9.72 (2) Phenol
log β0l1 11.68 (4) 11.68 (4) Tertiary amine
log β1l2 29.1 (2) –
log β1l1 25.75 (4) –
log β1l0 21.79 (3) 10.7
log β1l-1 11.09 (4) –
[a] βmlh ¼ MmL1Hh½ M½ m L½ 1 H½ h where mM+lL+hH⇌MmL1Hh.
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H2L2−, d) control experiment without Cu(II). Inset: e) in presence of 1.2 equiv. of Aβ peptide and after addition of 1.2 equiv. of H2L2− at t=1000 s. λem=452 nm, [Asc]=
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Résumé 
 
La maladie d'Alzheimer est caractérisée par la présence de plaques amyloïdes qui sont 
constituées d'agrégats de peptides amyloïdes-β (Aβ) et d'ions métalliques. Dans ce contexte, nous nous 
sommes intéressés à l'interaction des ions Cu et Zn avec des formes tronquées de peptides Aβ en se 
concentrant sur deux aspects : la coordination des ions métalliques et son impact sur les propriétés 
d'agrégation du peptide.  
 Dans la première partie, nous avons étudié la coordination du Cu sur des peptides Aβ dont la 
séquence diffère de celle du peptide original. Ces peptides modifiés sont considérés comme plus 
délétères. En combinant l'utilisation de plusieurs techniques spectroscopiques (RPE, DC, RMN...), 
nous avons ainsi: (i) déterminé les différents modes de coordination des Cu(II) et Cu(I) sur ces 
peptides en fonction du pH; (ii) montré l'importance de la fonction N-terminale dans la coordination 
du Cu(II); (iii) mis en évidence le rôle majeur de la seconde sphère sur la coordination des différentes 
espèces Cu(II)-peptides observées en fonction du pH; (iv) démontrer des différences de coordination 
du Cu(II) entre l'Aβ et ses formes modifiées, à mettre en parallèle avec une toxicité différente. 
Dans la seconde partie, notre but a été de mieux de comprendre les mécanismes d'agrégation 
des peptides modulée par les ions métalliques. L'agrégation de peptides est un domaine vaste allant des 
maladies neurodégénératives à la nanotechnologie. Grâce à différents peptides (sous-séquences du Aβ) 
et à plusieurs techniques complémentaires (Fluorescence, Turbidité, MET...), nous avons montré que 
(i) la modulation de l'agrégation par un ion métallique dépend de sa sphère de coordination; (ii) 
l'accélération de l'agrégation du peptide Aβ11-28 induit par le Zn est due à la formation d'un complexe 
dimérique; (iii) la coordination du Zn change en fonction du pH, ce qui modifie la vitesse de 
l'agrégation; (iv) la charge du dimère est déterminante dans la précipitation du complexe peptidique; 
(v) la coordination du Zn au Aβ11-28 est dynamique : la coordination du Zn, même transitoire, induit 
des modifications non réversibles. Ces modifications accélèrent fortement et durablement l’agrégation 
de peptide même en forte sous-stœchiométrie de Zn. 
 
Summary 
 
 Amyloid plaques are a hallmark of Alzheimer’s disease. These plaques are formed by 
amyloid-β (Aβ) aggregates and metal ions. In this context, we studied the interaction of Cu and Zn 
ions with truncated forms of Aβ peptides. We focused on two aspects: Metals coordination and its 
impact on the aggregation of Aβ peptides. 
 In a first part, we studied coordination of Cu on modified Aβ peptides compared to the 
original one. These native modified peptides are considered more deleterious. Using many 
complementary spectroscopies (EPR, CD, NMR...), we have shown that (i) Cu(II) coordination is pH 
dependent; (ii) the importance of N-terminal amine in Cu(II) binding; (iii) the major role played by the 
second sphere in Cu(II) coordination; (iv) Cu Coordination differences between Aβ and its modified 
forms, that might be linked to their different toxicity. 
 In a second part, our aim was to gain insights into peptides aggregation mechanisms 
modulated by metal ions. Aggregation of peptides is a wide field of interest from neurological diseases 
to nanotechnology. Using different peptides (derived from Aβ sequence) and several complementary 
techniques (Fluorescence, Turbitity, TEM...), we have shown that (i) the  aggregation depends on the 
metal ion coordination; (ii) the acceleration of Aβ11-28 aggregation induced by Zn is due to a dimer 
formation; (iii) pH induced changes in Zn coordination contribute to modify the aggregation rate; (iv) 
total charge of the dimer determine the precipitation; (v) Zn coordination to Aβ11-28 is highly 
dynamic: Zn coordination, even transiently, induced non-reversible modifications. These 
modifications dramatically and durably accelerate peptide aggregation even in large sub-
stoichiometric amount of Zn. 
